Interation_Record_ID Interaction_Category MASI-Microbe-ID Microbe-Tax-ID Microbe-Name MASI-Substance-chemicalD Substance-Name Substance-Category Substance-subCategory Substance_Exposure_Details Microbiota_Site Microbe_Change Microbe_Change_Statistics Metabolites Metabolism_Type Metabolism_Enzymes Metabolism_Effect_on_Drug Experiment_System Experiment_Model_Species Model_Condition/Disease Metabolism_Mechanism Outcome Reference_ID_Type Reference_ID PMDBI10001 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD95 Baicalin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Baicalein; oroxylin A Hydrolysis; deglycosylation n.a. Increase Efficacy n.a. n.a. Inflammation; diabetes mellitus; tumor n.a. Increased activity PMID PMID: 26569070; PMID: 22516259; PMID: 24947972; PMID: 24033282 PMDBI10002 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylclic acid Azo reduction n.a. Increase Efficacy; Increase Toxicity In vivo Dog Inflammatory diseases(ulcerative colitis; Crohn’s disease; rheumatoid arthritis) n.a. Increased activity or causing side effects(anorexia and nausea) PMID PMID: 26569070; PMID: 11230497 PMDBI10003 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-oxide bond cleavage n.a. Decrease Efficacy In vivo Dog Peptic ulcer disease n.a. Decreased intestinal absorption and systemic bioavailability PMID PMID: 26569070; PMID: 13481854 PMDBI10004 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. N-oxide bond cleavage n.a. Decrease Efficacy n.a. n.a. Peptic ulcer disease n.a. Decreased intestinal absorption and systemic bioavailability PMID PMID: 26569070; PMID: 13481854 PMDBI10005 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouracil Deamination n.a. Increase Efficacy; Increase Toxicity In vivo BDIX strain rat n.a. n.a. Increased activity or toxicity PMID PMID: 26569070; PMID: 14768038 PMDBI10007 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulindac sulfide; sulinpyrzone sulfide Reduction n.a. Increase Efficacy In vivo Rat Irinotecan-induced diarrhea model n.a. Increased activity PMID PMID: 26569070; PMID: 18927500 PMDBI10008 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulindac sulfide; sulinpyrzone sulfide Reduction n.a. Increase Efficacy In vivo Rat Irinotecan-induced diarrhea model n.a. Increased activity PMID PMID: 26569070; PMID: 18927500 PMDBI10009 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD447 Insulin human Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Peptides Proteolysis n.a. Decrease Efficacy In vivo BALB/c mouse Health n.a. Decreased activity PMID PMID: 26569070; PMID: 21051639 PMDBI10010 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. Loperamide Reduction n.a. Increase Efficacy n.a. n.a. n.a. n.a. Increased activity PMID PMID: 26569070; PMID: 21148486 PMDBI10011 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminonitrazepam Nitroreduction n.a. Increase Toxicity In vivo Mouse Moderate to severe insomnia n.a. Inducing teratogenicity PMID PMID: 26569070; PMID: 21156650 PMDBI10012 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD600 Nitroglycerin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate Denitration n.a. Decrease Efficacy n.a. n.a. Angina pectoris n.a. Decreased activity PMID PMID: 26569070; PMID: 22902524 PMDBI10013 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD279 Dihydroxyphenylalanine (DOPA) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. m-tyramine; m-hydroxylphenylacetic acid Dehydroxylation n.a. Increase Efficacy n.a. n.a. Parkinson’s disease (PD) n.a. Increased activity PMID PMID: 26569070; PMID: 24264989 PMDBI10014 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deconjugation n.a. Decrease Efficacy; Increase Toxicity n.a. n.a. n.a. n.a. Decreased activity; increased side effects(diarrhea; anorexia; weight loss) PMID PMID: 26569070; PMID: 24264990 PMDBI10015 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Lactic acid; 3-hydroxybutanoic acid; cyclohexanecarboxylic acid; 2-hydroxyvaleric acid Hydrolysis; demethylation; hydroxylation/dehydroxylation; β-oxidation n.a. n.a. n.a. Cardiovascular disease n.a. Altering its lipid-lowering activity PMID PMID: 26569070; PMID: 5913083 PMDBI10016 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Benzisoxazole ring scission; Benzisoxazole ring hydroxylation Ring cleavage; hydroxylation Increase Toxicity In vitro Human n.a. n.a. Inducting symptoms of Parkinson’s disease PMID PMID: 26569070; PMID: 6836275 PMDBI10017 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. p-aminphenyl-2-amino-1； 3-propanediol Amine formation; hydrolysis Increase Toxicity n.a. n.a. n.a. n.a. Inducing bone marrow aplasia PMID PMID: 26569070; PMID: 8706020 PMDBI10019 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrodaidzein; equol; O-desmethylanolensin(ODMA） Reduction; phenolic ring opening n.a. Increase Efficacy n.a. n.a. Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity n.a. Increased activity PMID PMID: 26569070 PMDBI10020 Microbes metabolize substances PMDBM15 78352 anaerobic bacterium 'strain 7' PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrodaidzein; equol; O-desmethylanolensin(ODMA） Reduction; phenolic ring opening n.a. Increase Efficacy n.a. n.a. Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity n.a. Increased activity PMID PMID: 26569070 PMDBI10021 Microbes metabolize substances PMDBM72 820 Bacteroides uniformis PMDBD386 Genistein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Production of 5-hydroxyequol Hydrogenation n.a. n.a. n.a. n.a. Obesity; Type 2 diabetes n.a. n.a. PMID PMID: 26569070 PMDBI10022 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Compound K Hydrolysis n.a. Increase Efficacy n.a. n.a. Inflammation; tumor n.a. Increased activity PMID PMID: 26569070 PMDBI10023 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Compound K Hydrolysis n.a. Increase Efficacy n.a. n.a. Inflammation; tumor n.a. Increased activity PMID PMID: 26569070 PMDBI10024 Microbes metabolize substances PMDBM227 n.a. Eubacterium sp. GLH PMDBD408 Glycyrrhizin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 18-β-glycyrrhetinic acid Hydrolysis n.a. Increase Efficacy n.a. n.a. Inflammation n.a. Increased activity PMID PMID: 26569070 PMDBI10025 Microbes metabolize substances PMDBM344 n.a. Pseudocera PMDBD420 Hesperidin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Hesperetin Deglycosylation n.a. Increase Efficacy n.a. n.a. n.a. n.a. Increased activity PMID PMID: 26569070 PMDBI10026 Microbes metabolize substances PMDBM258 573 Klebsiella pneumoniae PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides; lactate, acetate; butyrate Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli) PMID PMID: 26569070 PMDBI10027 Microbes metabolize substances PMDBM199 n.a. Enterococcus faecalis PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides; lactate, acetate; butyrate Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli) PMID PMID: 26569070 PMDBI10028 Microbes metabolize substances PMDBM176 28141 Cronobacter sakazakii PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides; lactate, acetate; butyrate Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli) PMID PMID: 26569070 PMDBI10029 Microbes metabolize substances PMDBM198 37734 Enterococcus casseliflavus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides; lactate, acetate; butyrate Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli) PMID PMID: 26569070 PMDBI10030 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I; levametabol-II; levametabol-III Thiazole ring opening n.a. Increase Efficacy n.a. n.a. Colon cancer n.a. Increased activity PMID PMID: 26569070 PMDBI10031 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I; levametabol-II; levametabol-III Thiazole ring opening n.a. Increase Efficacy n.a. n.a. Colon cancer n.a. Increased activity PMID PMID: 26569070 PMDBI10032 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine; norephedrine; an unknown metabolite Demethylation n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decreased activity PMID PMID: 26569070 PMDBI10033 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine; norephedrine; an unknown metabolite Demethylation n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decreased activity PMID PMID: 26569070 PMDBI10034 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine; norephedrine; an unknown metabolite Demethylation n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decreased activity PMID PMID: 26569070 PMDBI10035 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. corresponding sulfide metabolites Reduction n.a. Decrease Efficacy n.a. n.a. Gastric ulcer n.a. Decreased activity PMID PMID: 26569070 PMDBI10036 Microbes metabolize substances PMDBM198 37734 Enterococcus casseliflavus PMDBD718 Quercetin-3-glucoside Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. Butyrate; acetate; 3,4-dihydroxyphenylacetic acid Deglycosylation n.a. n.a. n.a. n.a. Cardiovascular disease; tumors n.a. n.a. PMID PMID: 26569070 PMDBI10037 Microbes metabolize substances PMDBM223 39490 Eubacterium ramulus PMDBD718 Quercetin-3-glucoside Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. Butyrate; acetate; 3,4-dihydroxyphenylacetic acid Deglycosylation n.a. n.a. n.a. n.a. Cardiovascular disease; tumors n.a. n.a. PMID PMID: 26569070 PMDBI10038 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. acetaminophen sulfate; glucuronide O-Sulfation; C-S cleavage of acetaminophen-3-cysteine Increase Efficacy; Decrease Toxicity n.a. n.a. n.a. Microbial product(p-cresol) could alter the ratio of metabolites Altered activity or toxicity PMID PMID: 26569070 PMDBI10039 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrodigoxin; dihydrodigoxigenin Reduction n.a. Decrease Efficacy In vivo Human Heart disease n.a. Decreased cardiac activity PMID PMID: 26569070 PMDBI10040 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. m-tyrosine; m-tyramine; m-hydroxyphenylacetic acid Dehydroxylation n.a. Decrease Efficacy n.a. n.a. Parkinson’s disease (PD) n.a. Decreased activity PMID PMID: 26569070 PMDBI10041 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid; acetamide Reduction n.a. Increase Toxicity n.a. n.a. n.a. n.a. Probably increase its liver toxicity PMID PMID: 26569070 PMDBI10042 Microbes metabolize substances PMDBM42 n.a. Bacteroides fragilis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID PMID: 26569070; PMID: 27591027 PMDBI10043 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID PMID: 26569070; PMID: 27591027 PMDBI10044 Microbes metabolize substances PMDBM72 820 Bacteroides uniformis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID PMID: 26569070; PMID: 27591027 PMDBI10045 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID PMID: 26569070; PMID: 27591027 PMDBI10046 Microbes metabolize substances PMDBM39 28111 Bacteroides eggerthii PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID PMID: 26569070; PMID: 27591027 PMDBI10047 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. Microbial arylamine N-acetyltransferases Differences in gut microbial metabolism contribute to variations in drug efficacy PMID PMID: 11344150; PMID: 26972811 PMDBI10048 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD90 Azo dyes Environmental Substance Industrial Chemicals; Pollutants n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce azo bond n.a. PMID PMID: 26972811; PMID: 14489780 PMDBI10049 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD305 Enrofloxacin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Enrofloxacin-or vancomycin-treated Microbial fermentation of carbohydrates is disrupted Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels PMID PMID: 18698804; PMID: 26972811 PMDBI10050 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD888 Vancomycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Enrofloxacin-or vancomycin-treated Microbial fermentation of carbohydrates is disrupted Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels PMID PMID: 18698804; PMID: 26972811 PMDBI10053 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD650 Pentobarbital Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Animal model Germ-free,colonized n.a. Germ-free animals are more efficient at metabolizing drug PMID PMID: 19742318; PMID: 26972811 PMDBI10054 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. Treatment is positively associated with the production by the microbiota(lithocholic acid, taurolithocholic acid and glycolithocholic acid) PMID PMID: 22022402; PMID: 26972811 PMDBI10055 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD627 Oxaliplatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Production of reactive oxygen species Induces apoptosis PMID PMID: 24264989; PMID: 26972811 PMDBI10056 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Promote the translocation of bacteria into secondary lymphoid organs Limit tumour growth PMID PMID: 24264990; PMID: 26972811 PMDBI10057 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Cgr operon n.a. PMID PMID: 6836275; PMID: 26972811 PMDBI10058 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD422 Heterocyclic amines Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Β-glucuronidases Microbiota contribute to associations between the risk of CRC and the intake of heterocyclic amines PMID PMID: 8055651; PMID: 26972811 PMDBI10059 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial β-glucuronidase,liberate the sugar moiety from SN-38G Re-activate the drug causing increased toxicity(towards intestinal epithelial cells);exacerbate the diarrhoea PMID PMID: 8891470; PMID: 26972811 PMDBI10060 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD9 7-ethyl-10-hydroxycamptothecin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. SN-38G; ;cyanuric acid n.a. n.a. Increase Toxicity In vivo Animal model Germ-free,colonized n.a. Metabolites are harmful to the host PMID PMID: 26972811 PMDBI10061 Microbes metabolize substances PMDBM242 32066 Fusobacteria PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI PMID PMID: 26972811 PMDBI10062 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI PMID PMID: 26972811 PMDBI10063 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI PMID PMID: 26972811 PMDBI10064 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI PMID PMID: 26972811 PMDBI10065 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD50 Anti-PD-L1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase the efficacy of PD-1 PMID PMID: 26972811 PMDBI10066 Microbes metabolize substances PMDBM381 1279 Staphylococcus PMDBD51 Anti-TNF antibobies Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Therapy is accompanied by a substantial increase in the abundance of bacteria PMID PMID: 26972811 PMDBI10067 Microbes metabolize substances PMDBM22 162425 Aspergillus nidulans PMDBD119 Black tea Dietary Substance Drinks n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase the abundance of A. muciniphila PMID PMID: 26972811 PMDBI10069 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD190 Choline-containing compounds Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial glycyl radical enzymes Associate with the risk of cardiovascular disease PMID PMID: 26972811 PMDBI10070 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD190 Choline-containing compounds Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial glycyl radical enzymes Associate with the risk of cardiovascular disease PMID PMID: 26972811 PMDBI10071 Microbes metabolize substances PMDBM42 n.a. Bacteroides fragilis PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Blockade immunotherapy PMID PMID: 26972811 PMDBI10072 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Blockade immunotherapy PMID PMID: 26972811 PMDBI10073 Microbes metabolize substances PMDBM201 n.a. Enterococcus faecium PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10074 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10075 Microbes metabolize substances PMDBM276 97478 Lactobacillus mucosae PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10076 Microbes metabolize substances PMDBM188 1929886 Eggerthella sp. PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10077 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD272 Dietary phosphatidylcholine Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacteria provide a link for drugs PMID PMID: 26972811 PMDBI10078 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD299 Ellagic acid Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolize ellagitannins PMID PMID: 26972811 PMDBI10079 Microbes metabolize substances PMDBM22 162425 Aspergillus nidulans PMDBD411 Grape-derived polyphenols Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase the abundance of A. muciniphila PMID PMID: 26972811 PMDBI10080 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD421 Heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reactivate the compound PMID PMID: 26972811 PMDBI10081 Microbes metabolize substances PMDBM127 194 Campylobacter PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10082 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10083 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10084 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10085 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10086 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD460 Isoflavones Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10087 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD460 Isoflavones Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10088 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD460 Isoflavones Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10089 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD480 Lignans Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10090 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD480 Lignans Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10091 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD480 Lignans Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10093 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy In vivo Animal model Germ-free,colonized Conversion into a downstream metabolite with reduced bioactivity n.a. PMID PMID: 26972811 PMDBI10094 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD610 NSAIDs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. SN-38G; ;cyanuric acid n.a. n.a. Increase Toxicity In vivo Animal model Germ-free,colonized n.a. Metabolites are harmful to the host PMID PMID: 26972811 PMDBI10095 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38G; ;cyanuric acid n.a. n.a. Increase Toxicity In vivo Animal model Germ-free,colonized n.a. Metabolites are harmful to the host PMID PMID: 26972811 PMDBI10096 Microbes metabolize substances PMDBM261 577 Raoultella terrigena PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. n.a. In vivo Animal model n.a. n.a. Lead to increased kidney damage PMID PMID: 26972811 PMDBI10097 Microbes metabolize substances PMDBM261 577 Raoultella terrigena PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolism by the bacteria Lead to kidney stones PMID PMID: 26972811 PMDBI10098 Microbes metabolize substances PMDBM7 239935 Akkermansia muciniphila PMDBD684 Polyphenols Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Fed high-fat diets Couple with substantial sevenfold-to-tenfold blooms of drug Limit the risk of systemic inflammation PMID PMID: 26972811 PMDBI10099 Microbes metabolize substances PMDBM138 1898207 Clostridiales bacterium PMDBD761 Saccharin Therapeutic Substance; Dietary Substance; Herbal Substance Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10100 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol,enterolactone n.a. n.a. n.a. n.a. n.a. n.a. n.a. Product the cancer-protective compounds PMID PMID: 26972811 PMDBI10101 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Bioavailability n.a. n.a. n.a. Modulate the expression of host transporters,or directly compete with host transporters Contribute to the absorption of simvastatin PMID PMID: 26972811 PMDBI10102 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Animal model Germ-free,colonized Conversion to bioactive form Contribute to therapeutic concentrations PMID PMID: 26972811 PMDBI10103 Microbes metabolize substances PMDBM199 n.a. Enterococcus faecalis PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Antibiotic-treated or germ-free;convention n.a. Result in drug cleavage PMID PMID: 26972811 PMDBI10104 Microbes metabolize substances PMDBM283 1591 Lactobacillus sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Antibiotic-treated or germ-free;convention n.a. Result in drug cleavage PMID PMID: 26972811 PMDBI10105 Microbes metabolize substances PMDBM60 29523 Bacteroides sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Antibiotic-treated or germ-free;convention n.a. Result in drug cleavage PMID PMID: 26972811 PMDBI10106 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Animal model Germ-free,colonized Conversion to bioactive form Contribute to therapeutic concentrations PMID PMID: 26972811 PMDBI10107 Microbes metabolize substances PMDBM233 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Kidney transplant recipient n.a. The abundance of the gut bacterium has a positive correlation with an increase in tacrolimus dosing PMID PMID: 26972811 PMDBI10108 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD852 TMAO Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacteria provide a link for drugs PMID PMID: 26972811 PMDBI10109 Microbes metabolize substances PMDBM138 1898207 Clostridiales bacterium PMDBD906 Xylitol Therapeutic Substance; Herbal Substance; Dietary Substance Approved Drug; Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10110 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD147 Carboxymethylcellulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10111 Microbes metabolize substances PMDBM363 33038 [Ruminococcus] gnavus PMDBD147 Carboxymethylcellulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10112 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD690 Polysorbate 80 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10113 Microbes metabolize substances PMDBM363 33038 [Ruminococcus] gnavus PMDBD691 Polysorbate 81 Environmental Substance Industrial Chemicals; Pollutants n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10114 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD402 Glucuronidated compound Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Convention, germ-free Β-glucuronidases Reactivate the toxic compound and augment genotoxicity PMID PMID: 26972811 PMDBI10115 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. triamino benzene,sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduce azo bond Activate drug PMID PMID: 26972811 PMDBI10122 Microbes metabolize substances PMDBM199 n.a. Enterococcus faecalis PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10123 Microbes metabolize substances PMDBM221 1736 Eubacterium limosum PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10124 Microbes metabolize substances PMDBM157 29347 [Clostridium] scindens PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10125 Microbes metabolize substances PMDBM117 n.a. Blautia producta PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10126 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10127 Microbes metabolize substances PMDBM287 341220 Lactonifactor longoviformis PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10128 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial β-glucuronidase Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation PMID PMID: 26972811 PMDBI10129 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial β-glucuronidase Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation PMID PMID: 26972811 PMDBI10130 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD468 Ketoprofen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial β-glucuronidase Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation PMID PMID: 26972811 PMDBI10131 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD761 Saccharin Therapeutic Substance; Dietary Substance; Herbal Substance Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10132 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD830 Tempol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Increase the abundance of Bacteroidetes;decrease the abundance of Firmicutes PMID PMID: 26972811 PMDBI10133 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD830 Tempol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce members of the genus Lactobacillus PMID PMID: 26972811 PMDBI10134 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD906 Xylitol Therapeutic Substance; Herbal Substance; Dietary Substance Approved Drug; Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10135 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease expression of genes involved in antimicrobial defence Nearly eradicated the lactobacilli PMID PMID: 26972811 PMDBI10136 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Piglet n.a. n.a. Promote colonization by opportunistic pathogens PMID PMID: 26972811 PMDBI10137 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Piglet n.a. n.a. Promote colonization by opportunistic pathogens PMID PMID: 26972811 PMDBI10138 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD52 Antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Cause antibiotic-associated diarrhoea(AAD);pseudomembranous colitis(can cause death) PMID PMID: 26972811 PMDBI10139 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Total number of bacteria is reduced;overgrowth of C.albicans Allergic-airways diease develops after challenge with mould spores PMID PMID: 26972811 PMDBI10140 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD173 Cephalosporins Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans Increase susceptibility to asthma PMID PMID: 26972811 PMDBI10141 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD173 Cephalosporins Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans Increase susceptibility to asthma PMID PMID: 26972811 PMDBI10142 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD173 Cephalosporins Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans Increase susceptibility to asthma PMID PMID: 26972811 PMDBI10143 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD466 Kanamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Total number of anaerobes is reduced Clinical scores for atopic dermatitis are higher PMID PMID: 26972811 PMDBI10144 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. More bifidobacterium spp. PMID PMID: 26972811 PMDBI10145 Microbes metabolize substances PMDBM252 n.a. Gram-negative bacterium B1G-1A PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce expression of the gene encoding REG3γ n.a. PMID PMID: 26972811 PMDBI10146 Microbes metabolize substances PMDBM252 n.a. Gram-negative bacterium B1G-1A PMDBD579 Neomycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce expression of the gene encoding REG3γ n.a. PMID PMID: 26972811 PMDBI10147 Microbes metabolize substances PMDBM371 n.a. Salmonella enterica subsp. enterica serovar Typhimurium PMDBD804 Streptomycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Streptomycin treated Butyrate contribute to the increased infiltration of neutrophils Result in an increased inflammatory state PMID PMID: 26972811 PMDBI10148 Microbes metabolize substances PMDBM404 n.a. Unidentified vaginal microbes PMDBD884 Unspecified antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Loss of vaginal lactobacilli;and overgrowth of C.albicans n.a. PMID PMID: 26972811 PMDBI10149 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD884 Unspecified antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Loss of vaginal lactobacilli;and overgrowth of C.albicans n.a. PMID PMID: 26972811 PMDBI10150 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD888 Vancomycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Gram-negatinve populations are depleted(not being restricted by vancomycin) PMID PMID: 26972811 PMDBI10151 Microbes metabolize substances PMDBM252 n.a. Gram-negative bacterium B1G-1A PMDBD888 Vancomycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce expression of the gene encoding REG3γ n.a. PMID PMID: 26972811 PMDBI10152 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. hydroxyiminonizatidine n.a. n.a. n.a. In vitro Human n.a. Cleavage on an N-oxide bond n.a. PMID PMID: 27485182; PMID: 11955801 PMDBI10155 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD565 Nabumetone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 4-(6-methoxy-2-naphthyl)-butan-2-ol (reduced nabumetone) n.a. n.a. Decrease Efficacy In vivo (Rat); In vitro (Human) Rat; Human n.a. n.a. Cause lower absorbtion of nabumetone and lower its bioavailability;[drug interaction:erythromycin and tetracycline suppresses the reduction of digoxin] PMID PMID: 23584048; PMID: 27485182 PMDBI10156 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. a phosphorylated derivative and active 2-hydroxy lovastatic acid n.a. n.a. n.a. In vivo Rat n.a. Hydrolyzed [drug interaction]:antibiotics decreases the bioavailability of the active metabolite PMID PMID: 27485182; PMID: 24947972 PMDBI10157 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD497 Lovastatin related compounds Therapeutic Substance n.a. n.a. n.a. n.a. n.a. a phosphorylated derivative and active 2-hydroxy lovastatic acid n.a. n.a. n.a. In vivo Rat n.a. Hydrolyzed [drug interaction]:antibiotics decreases the bioavailability of the active metabolite PMID PMID: 27485182; PMID: 24947972 PMDBI10158 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo; In vitro Human; Rabbit Ileostomy patients Microbiota seems to be only site of sulfinpyrazone reduction(in man) n.a. PMID PMID: 3630204; PMID: 27485182 PMDBI10159 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulindac sulfide n.a. n.a. n.a. In vivo; In vitro Human; Rabbit n.a. n.a. n.a. PMID PMID: 3630204; PMID: 27485182 PMDBI10160 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid (mesalazine)and sulfapyridine n.a. n.a. Decrease Toxicity In vivo Human Ulcerative colitis Bacterial azoreductases Lead to side effect PMID PMID: 27485182; PMID: 4147555 PMDBI10161 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. p-aminophenyl-2-amin-1,3-propanediol n.a. n.a. Increase Toxicity In vitro human n.a. n.a. Produce toxic metabolite related to risk of marrow aplasia PMID PMID: 27485182; PMID: 4165044 PMDBI10162 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. n.a. In vivo Rat Conventional(CV), germ-free(GF) Reductive modification,disrupt the imidazole ring n.a. PMID PMID: 27485182; PMID: 430360 PMDBI10163 Microbes metabolize substances PMDBM153 n.a. Clostridium perfringens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. n.a. In vivo Rat Conventional(CV), germ-free(GF) Reductive modification,disrupt the imidazole ring n.a. PMID PMID: 27485182; PMID: 430360 PMDBI10164 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. m-tyramine and m-hydroxyphenylacetic acid n.a. n.a. n.a. In vivo Rat Conventional, in pathogen free Dehydroxylation of the catechol ring Form the metabolites PMID PMID: 4723308; PMID: 27485182 PMDBI10165 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD553 Misonidazole Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. amino derivative n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 6260109; PMID: 27485182 PMDBI10166 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. n.a. In vivo Mouse; Rat; Ferret n.a. n.a. n.a. PMID PMID: 27485182; PMID: 6345112 PMDBI10167 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Germ-free and ex-germ-free Nitro reduction n.a. PMID PMID: 27485182; PMID: 6506755 PMDBI10168 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. dihydroxy-risperidone and hydroxyl-ke-to-risperidone n.a. n.a. n.a. In vivo Rat n.a. n.a. [drug interaction]:(in the liver)antibiotics decrease the bioavailability of risperidone. PMID PMID: 27485182; PMID: 7512019 PMDBI10169 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfide metabolites n.a. n.a. n.a. In vivo Rat n.a. Reductive metabolism n.a. PMID PMID: 27485182; PMID: 7629748 PMDBI10170 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulfamoylacetylphenol n.a. n.a. n.a. In vivo Mouse; Rat; Hamster; Rabbit; Guinea pig n.a. Reductive metabolism [drug interaction]:antibiotics inhibit the urinary and faecal excretion of metabolites PMID PMID: 9231340; PMID: 27485182 PMDBI10171 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin and dihydrodigoxigenin n.a. n.a. Decrease Efficacy In vivo human Health Formation of inactive metabolites Have lower cardiac activity PMID PMID: 27485182; PMID: 7266632 PMDBI10172 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid n.a. n.a. n.a. n.a. Human; Rat; Guinea pig; Dog n.a. Acetylated by the gut microbiota n.a. PMID PMID: 27485182 PMDBI10173 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD811 Sulfapyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid n.a. n.a. n.a. n.a. Human; Rat; Guinea pig; Dog n.a. Acetylated by the gut microbiota n.a. PMID PMID: 27485182 PMDBI10174 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. p-cresol sulfate and phenylacetylglutamine n.a. n.a. Increase Toxicity n.a. n.a. n.a. O-sulfation; C-S cleavage of acetaminophen-3-cysteine Increased toxicity PMID PMID: 27485182 PMDBI10175 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose and galactose n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis of enzymes of the intestinal bacteria Lead to laxative effect of lactulose PMID PMID: 27485182 PMDBI10176 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose and galactose n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis of enzymes of the intestinal bacteria Lead to laxative effect of lactulose PMID PMID: 27485182 PMDBI10177 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose and galactose n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis of enzymes of the intestinal bacteria Lead to laxative effect of lactulose PMID PMID: 27485182 PMDBI10178 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I,levametabol-II,and levametabol-III n.a. n.a. Increase Efficacy n.a. human n.a. Open thiazole ring Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole PMID PMID: 27485182 PMDBI10179 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I,levametabol-II,and levametabol-III n.a. n.a. Increase Efficacy n.a. human n.a. Open thiazole ring Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole PMID PMID: 27485182 PMDBI10180 Microbes metabolize substances PMDBM210 1322345 Escherichia coli ATCC 25922 PMDBD565 Nabumetone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. a reduced pharmacologically inactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Cause lower absorbtion and lower bioavailability of the drug PMID PMID: 27485182 PMDBI10181 Microbes metabolize substances PMDBM152 1535 [Clostridium] leptum PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminonitrazepam n.a. n.a. n.a. In vivo Mouse; Rat n.a. Nitro reduction Produce products with teratogenic effects PMID PMID: 27485182 PMDBI10182 Microbes metabolize substances PMDBM60 29523 Bacteroides sp. PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil n.a. n.a. n.a. n.a. n.a. n.a. n.a. [drug interaction]:metabolites cause toxic level of anticancer drug 5-fluorouracil PMID PMID: 27485182 PMDBI10183 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction of the azo bond by azoreductases of the large intestinal microbiota Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil PMID PMID: 27485182 PMDBI10184 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction of the azo bond by azoreductases of the large intestinal microbiota Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil PMID PMID: 27485182 PMDBI10185 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity In vivo Mouse n.a. Β-glucuronidases Cause diarrhoea;[drug interaction]:(rat)ciprofloxacin and amoxapine can suppress diarrhoea PMID PMID: 21051639; PMID: 28270698 PMDBI10186 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Bacteria regulate the immune response to chemotherapy(primes tumour-associated innate myeloid cells for inflammatory cytokine production) [drug interaction]:antibiotic or germ-free (sterile) status attenuates this response PMID PMID: 24264989; PMID: 28270698 PMDBI10187 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide PMID PMID: 24264990; PMID: 28270698 PMDBI10188 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide PMID PMID: 24264990; PMID: 28270698 PMDBI10189 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity In vivo C57BL/6J mouse TLR2 knockout vs wildtype mice TLR2 signalling and drug transporter p-gp Bacteria regulate against chemotherapy-induced small bowel injury PMID PMID: 25589072; PMID: 28270698 PMDBI10190 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolized via microbiota from compound K79 Metabolites have anti-proliferative effects in human colon cancer cells;[drug interaction]:co-treatment with 5-FU and its pro-drug intermediate 5’-deoxy-5-fluorouridine,potentiate the anticancer effects PMID PMID: 25625815; PMID: 28270698 PMDBI10191 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Specific pathogen-free,germ-free(GF) n.a. MCA205 sarcoma progression is not controlled(in germ-free mice;or those treated with broad-spectrum antibiotics) PMID PMID: 26541610; PMID: 28270698 PMDBI10192 Microbes metabolize substances PMDBM300 2100 Mycoplasma hyorhinis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterium encode a thymidine phosphorylase Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds PMID PMID: 28270698 PMDBI10193 Microbes metabolize substances PMDBM300 2100 Mycoplasma hyorhinis PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterium encode a thymidine phosphorylase Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds PMID PMID: 28270698 PMDBI10194 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD50 Anti-PD-L1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Exhibit the association with antitumour T-cell responses(through dendritic cell activation) Combination of microbiota and anti-PD-L1 improve tumour control,inducte tumour-specific T cells,increase T cells in the tumour microenvironment PMID PMID: 28270698 PMDBI10195 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reducte bacteria that limit inflammation,increase bacteria associated with colitis PMID PMID: 28270698 PMDBI10196 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reducte bacteria that limit inflammation,increase bacteria associated with colitis PMID PMID: 28270698 PMDBI10197 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reducte bacteria that limit inflammation,increase bacteria associated with colitis PMID PMID: 28270698 PMDBI10198 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28270698 PMDBI10199 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28270698 PMDBI10200 Microbes metabolize substances PMDBM120 80840 Burkholderiales PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated mice PMID PMID: 28270698 PMDBI10201 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated mice PMID PMID: 28270698 PMDBI10202 Microbes metabolize substances PMDBM376 n.a. Segmented filamentous bacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Gram-positive commensals mediate accumulation of TH17 and TH1-cell response PMID PMID: 28270698 PMDBI10203 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Gram-positive commensals mediate accumulation of TH17 and TH1-cell response PMID PMID: 28270698 PMDBI10204 Microbes metabolize substances PMDBM347 287 Pseudomonas aeruginosa PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Fed a diet(high in protein, l-leucine, fish oil and specific oligosaccharides) n.a. Reduce incidence and severity of Pseudomonas aeruginosa translocation PMID PMID: 28270698 PMDBI10205 Microbes metabolize substances PMDBM202 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Inoculated with MCA205 tumours;microbiota-depleted As an orchestrator of cyclophosphamide effects n.a. PMID PMID: 28270698 PMDBI10206 Microbes metabolize substances PMDBM83 487174 Barnesiella intestinihominis PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Inoculated with MCA205 tumours;microbiota-depleted As an orchestrator of cyclophosphamide effects n.a. PMID PMID: 28270698 PMDBI10207 Microbes metabolize substances PMDBM202 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10208 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10209 Microbes metabolize substances PMDBM274 33959 Lactobacillus johnsonii PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10212 Microbes metabolize substances PMDBM202 1354 Enterococcus hirae PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10213 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10214 Microbes metabolize substances PMDBM274 33959 Lactobacillus johnsonii PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10216 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD299 Ellagic acid Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. urolithins n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28270698 PMDBI10218 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Pyrimidine nucleoside phosphorylase and cytidine deaminase enzyme Have deleterious effects on its therapeutic efficacy PMID PMID: 28270698 PMDBI10219 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD452 Ipilimumab Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterially mediated B vitamin production and polyamine transport deficiencies Bacteria is associated with increased risk of CTLA‑4 blockade‑induced colitis PMID PMID: 28270698 PMDBI10220 Microbes metabolize substances PMDBM194 543 Enterobacteriaceae PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Increase abundance of bacteria Cause diarrhoea; PMID PMID: 28270698 PMDBI10221 Microbes metabolize substances PMDBM392 1308 Streptococcus thermophilus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10222 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Increase abundance of bacteria Cause diarrhoea; PMID PMID: 28270698 PMDBI10223 Microbes metabolize substances PMDBM269 1579 Lactobacillus acidophilus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10224 Microbes metabolize substances PMDBM279 1590 Lactobacillus plantarum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10225 Microbes metabolize substances PMDBM278 1597 Lactobacillus paracasei PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10226 Microbes metabolize substances PMDBM94 1685 Bifidobacterium breve PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10227 Microbes metabolize substances PMDBM100 216816 Bifidobacterium longum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10228 Microbes metabolize substances PMDBM271 1585 Lactobacillus delbrueckii subsp. bulgaricus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10229 Microbes metabolize substances PMDBM103 1682 Bifidobacterium longum subsp. infantis PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10231 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea PMID PMID: 28270698 PMDBI10232 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea PMID PMID: 28270698 PMDBI10233 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea PMID PMID: 28270698 PMDBI10234 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea PMID PMID: 28270698 PMDBI10235 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea PMID PMID: 28270698 PMDBI10236 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea PMID PMID: 28270698 PMDBI10237 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD689 Polysaccharides (after cyclophosphamide administration) Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy PMID PMID: 28270698 PMDBI10238 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD689 Polysaccharides (after cyclophosphamide administration) Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy PMID PMID: 28270698 PMDBI10239 Microbes metabolize substances PMDBM42 n.a. Bacteroides fragilis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10240 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10241 Microbes metabolize substances PMDBM72 820 Bacteroides uniformis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10242 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10243 Microbes metabolize substances PMDBM39 28111 Bacteroides eggerthii PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10245 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbiota-driven drug metabolism Affect drug disposition and toxicity PMID PMID: 28270698 PMDBI10246 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbiota-driven drug metabolism Affect drug disposition and toxicity PMID PMID: 28270698 PMDBI10247 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity In vivo Mouse Conventional(CV),germ-free(GF) Microbial enzymes Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure PMID PMID: 30733391 PMDBI10248 Microbes metabolize substances PMDBM57 n.a. Bacteroides ovatus PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure PMID PMID: 30733391 PMDBI10249 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. aminoclonazepam (NH2-CLZ),aminohydroxyclonazepam (NH2OH-CLZ) n.a. n.a. Increase Toxicity In vivo Mouse Conventional(CV),germ-free(GF) Contribute to the reductive metabolism of CLZ Lead to toxicity PMID PMID: 30733391 PMDBI10250 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity In vivo Mouse Conventional(CV), germ-free(GF) Microbial enzymes Metabolized by members of this genus PMID PMID: 30733391 PMDBI10251 Microbes metabolize substances PMDBM57 n.a. Bacteroides ovatus PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Metabolized by members of this genus PMID PMID: 30733391 PMDBI10252 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 2-hydroxy lovastatic acid,2-hydroxy simvastatin acid n.a. n.a. Increase Efficacy In vivo Rat n.a. n.a. Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects PMID PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290 PMDBI10253 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 2-hydroxy lovastatic acid,2-hydroxy simvastatin acid n.a. n.a. Increase Efficacy In vivo Rat n.a. n.a. Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects PMID PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290 PMDBI10254 Microbes metabolize substances PMDBM153 n.a. Clostridium perfringens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. n.a. In vivo Rat n.a. Reduced metabolites n.a. PMID PMID: 231450; PMID: 430360; PMID: 25926432 PMDBI10255 Microbes metabolize substances PMDBM389 1314 Streptococcus pyogenes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy In vivo Mouse Streptococcus pyogenes systemic infection The gut microbiota transformed drug by azoreductases Exhibit potent antibacterial activity;drug interaction:antibiotics suppresses the conversion PMID PMID: 4405598; Peppercorn and Goldman,1976; PMID: 25926432 PMDBI10256 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. calycosin n.a. n.a. n.a. n.a. n.a. n.a. Aromatic hydroxylase and O-methyltransferase Drug interaction:antibiotics suppresses the transformation PMID PMID: 9657051; PMID: 25926432; PMID: 9781846 PMDBI10257 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity In vivo Human Cancer The b-glucuronidases of the gut microbiota Causes diarrhea;drug interaction:coadministration of the poorly absorbed aminoglycoside antibiotic neomycin could be advantageous for diarrhea PMID PMID: 25926432; PMID: 11350876 PMDBI10258 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD817 Sulindac sulfide Therapeutic Substance; Environmental Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Human or rabbit faeces n.a. Drug interaction:metronidazole decreases the formation of sulfides of sulindac ex vivo PMID PMID: 3630204; PMID: 25926432 PMDBI10259 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy In vivo Rat n.a. n.a. Product the pharmacologically active metabolite;drug interaction:antibiotics reduced the amount of sulfanilamide excreted in the urine after oral administration PMID PMID: 5173017; PMID: 25926432 PMDBI10260 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD553 Misonidazole Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. 1-(2-aminoimidazol-1-yl)-3-methoxypropan-2-ol n.a. n.a. Increase Toxicity In vivo Rat Convention,germ-free n.a. Drug interaction:antibiotic inhibits misonidazole transformation and toxicity PMID PMID: 6260109; PMID: 25926432 PMDBI10261 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam n.a. n.a. n.a. In vivo Rat Germ-free and ex–germ-free The reductive metabolism Drug interaction:antibiotic suppresses the reduction PMID PMID: 6506755; PMID: 25926432 PMDBI10262 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. loperamide n.a. n.a. n.a. In vivo Rat; Dog n.a. Microbiota is involved in reduction Drug interaction:absorption of orally delivered loperamide oxide is lower when administered with cotrimoxazole PMID PMID: 25926432; PMID: 8838438 PMDBI10263 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. daidzein,calycosin n.a. n.a. Increase Efficacy n.a. n.a. n.a. C-glucosidases and O-glucosidases Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides PMID PMID: 9657051; PMID: 25926432 PMDBI10264 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD714 Puerarin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. daidzein,calycosin n.a. n.a. Increase Efficacy n.a. n.a. n.a. C-glucosidases and O-glucosidases Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides PMID PMID: 9657051; PMID: 25926432 PMDBI10265 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD339 Fenfluramine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. Human; Mouse n.a. Deglycosylating enzymes of bacteria Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats PMID PMID: 25926432; PMID: 9875509 PMDBI10266 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD420 Hesperidin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. Human; Mouse n.a. Deglycosylating enzymes of bacteria Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats PMID PMID: 25926432; PMID: 9875509 PMDBI10267 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD574 Naringenin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. Human; Mouse n.a. Deglycosylating enzymes of bacteria Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats PMID PMID: 25926432; PMID: 9875509 PMDBI10268 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. Human; Mouse n.a. Deglycosylating enzymes of bacteria Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats PMID PMID: 25926432; PMID: 9875509 PMDBI10269 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. Human; Mouse n.a. Deglycosylating enzymes of bacteria Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats PMID PMID: 25926432; PMID: 9875509 PMDBI10270 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD904 Wognoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. Human; Mouse n.a. Deglycosylating enzymes of bacteria Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats PMID PMID: 25926432; PMID: 9875509 PMDBI10271 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin,dihydrodigoxigenin n.a. n.a. Decrease Efficacy In vivo Human Health n.a. Convert to the inactive metabolites;attenuates the drug’s effects;drug interaction:antibiotics（erythromycin and tetracycline）blocks the reduction of digoxin PMID PMID: 25926432; PMID:7266632 PMDBI10272 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulindac sulfide n.a. n.a. n.a. In vivo Rabbit n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10273 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioinactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10274 Microbes metabolize substances PMDBM286 1363 Lactococcus garvieae PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10275 Microbes metabolize substances PMDBM4 446660 Adlercreutzia equolifaciens PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10276 Microbes metabolize substances PMDBM379 n.a. Slackia equolifaciens PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10277 Microbes metabolize substances PMDBM380 n.a. Slackia isoflavoniconvertens PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10278 Microbes metabolize substances PMDBM286 1363 Lactococcus garvieae PMDBD386 Genistein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10279 Microbes metabolize substances PMDBM4 446660 Adlercreutzia equolifaciens PMDBD386 Genistein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10280 Microbes metabolize substances PMDBM379 n.a. Slackia equolifaciens PMDBD386 Genistein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10281 Microbes metabolize substances PMDBM380 n.a. Slackia isoflavoniconvertens PMDBD386 Genistein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. Human; Animal models n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10282 Microbes metabolize substances PMDBM367 41978 Ruminococcus sp. PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10283 Microbes metabolize substances PMDBM306 1945593 Oscillibacter sp. PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10284 Microbes metabolize substances PMDBM398 1981025 Sutterella sp. PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10285 Microbes metabolize substances PMDBM254 2049029 Holdemania sp. PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10286 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10287 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose,galactose n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs PMID PMID: 25926432 PMDBI10288 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose,galactose n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs PMID PMID: 25926432 PMDBI10289 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose,galactose n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs PMID PMID: 25926432 PMDBI10290 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I, levametabol-II, and levametabol-III n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect PMID PMID: 25926432 PMDBI10291 Microbes metabolize substances PMDBM63 n.a. Bacteroides spp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I, levametabol-II, and levametabol-III n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect PMID PMID: 25926432 PMDBI10292 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10293 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioinactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10294 Microbes metabolize substances PMDBM224 39491 [Eubacterium] rectale PMDBD668 Picosulfuric acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol] n.a. n.a. Increase Efficacy n.a. n.a. n.a. Arylsulfate sulfotransferase of bacteria Have a laxative effect;drug interaction:antibiotics inhibits the transformation PMID PMID: 25926432 PMDBI10295 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioinactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10296 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Azoreductases produced by metabolize Induces anti-inflammatory effects PMID PMID: 25926432 PMDBI10297 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD308 Epicatechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10298 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD48 Anthocyanidins Herbal Substance Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10299 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. n.a. In vivo Human n.a. Drug interaction:antibiotic suppresses the metabolism,limit its effectiveness PMID PMID: 25926432 PMDBI10300 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD191 Cianidanol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10301 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouracil n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antimicrobial agents may reduce the antifungal effect of flucytosine PMID PMID: 25926432 PMDBI10302 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD407 Glycyrrhizic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 18b-glycyrrhetic acid n.a. n.a. n.a. In vivo Rat Germ-free n.a. Drug interaction:antibiotics(amoxicillin and metronidazole)suppresses the conversion PMID PMID: 25926432 PMDBI10303 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD420 Hesperidin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. hesperetin n.a. n.a. n.a. In vivo Rat n.a. n.a. Suppress gut bacterial glycosidase activities;drug interaction:Antibiotic inhibits the metabolism PMID PMID: 25926432 PMDBI10304 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. tyramine,m-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics(vancomycin)inhibits the dehydroxylation of bile acid by the gut microbiota PMID PMID: 25926432 PMDBI10305 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-amino-nitrazepam n.a. n.a. Increase Toxicity In vivo Rat n.a. Transform drugs and phytochemicals into toxic metabolites Affect the pharmacokinetics,product an active teratogenic substance;drug interaction: antibiotic reduced nitrazepam-induced teratogenicity PMID PMID: 25926432 PMDBI10306 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. hydroxyiminonizatidine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10307 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. hydroxyiminoranitidine n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics(rifampicin)decreases the absorption of ranitidine PMID PMID: 25926432 PMDBI10308 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. dihydroxy-risperidone,hydroxy-keto-risperidone n.a. n.a. n.a. In vivo Rat n.a. Scission of isoxazole Drug interaction:Antibiotics(rifampin)inhibit the bioavailability of risperidone in the liver PMID PMID: 25926432 PMDBI10309 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. oroxylin A n.a. n.a. n.a. n.a. n.a. n.a. Aromatic hydroxylase and O-methyltransferase n.a. PMID PMID: 25926432 PMDBI10310 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD776 Sennosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. rheinanthrone n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reductase(s) and 3- b-D-glucosidase(s) Product a purgative compound;drug interaction:antibiotics（chloramphenicol, streptomycin, and rifampicin）inhibits the biotransformation PMID PMID: 25926432 PMDBI10311 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfinpyrazone sulfide n.a. n.a. n.a. In vivo Rabbit n.a. n.a. Drug interaction:Metronidazole decreases the extent of sulfinpyrazone reduction in rabbits in vivo PMID PMID: 25926432 PMDBI10312 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulfamoyacetylphenol n.a. n.a. n.a. n.a. n.a. n.a. Through the reduction n.a. PMID PMID: 25926432 PMDBI10314 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD432 Hydrazine Environmental Substance Industrial Chemicals; Medicinal chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity In vivo Rat n.a. DszA/NtaA-like oxygenase n.a. PMID PMID: 19396371; PMID: 26261284 PMDBI10315 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD372 Fostamatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Health O-demethylation and dihydroxylation by bacteria n.a. PMID PMID: 26261284; PMID: 20371637 PMDBI10316 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity In vivo Mouse n.a. Reactivated by bacterially expressed b-glucuronidase Result in diarrhea PMID PMID: 26261284; PMID: 21051639 PMDBI10317 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD114 BILR355 Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterially mediated N-oxide reduction Drug interaction:(with ritonavir)bacterial mediated reactions predominate PMID PMID: 26261284; PMID: 22393121 PMDBI10318 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD5 2-chloro-5-nitro-N-phenylbenzamide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial nitroreductases Alter its mutagenicity PMID PMID: 26261284; PMID: 22450444 PMDBI10319 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD56 Antiobiotics Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID PMID: 26261284; PMID: 23332745 PMDBI10320 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID PMID: 26261284; PMID: 23332745 PMDBI10321 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD657 Phenacetin Therapeutic Substance Approved Drug (Withdrawn) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID PMID: 26261284; PMID: 23332745 PMDBI10322 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID PMID: 26261284; PMID: 23332745 PMDBI10323 Microbes metabolize substances PMDBM396 n.a. Sulfite-reducing bacterium LF11mE1 PMDBD768 Saturated fats Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Excess consumption of fat leads to an increase in the growth of bacteria Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate) PMID PMID: 26261284; PMID: 24355793 PMDBI10324 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD768 Saturated fats Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Excess consumption of fat leads to an increase in the growth of bacteria Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate) PMID PMID: 26261284; PMID: 24355793 PMDBI10325 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Alter the gut microbiota PMID PMID: 26261284; PMID: 24413286 PMDBI10327 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial formation of its metabolite Lead to toxicity PMID PMID: 26261284; PMID: 25105361 PMDBI10328 Microbes metabolize substances PMDBM233 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the pharmacokinetics of tacrolimus PMID PMID: 26261284; PMID: 25815766 PMDBI10329 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD77 Astragali radix Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium) PMID PMID: 26261284; PMID: 26101224 PMDBI10330 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD138 Calycosin-7-O-b-D-glucoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium) PMID PMID: 26261284; PMID: 26101224 PMDBI10331 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD309 Epimedium grandiflorum top (flavonoids) Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolized by the colonic microflora to circulate in the plasma [disease]osteoporosis may modulate the metabolism of Epimedii and may affect its bioavailability and efficacy PMID PMID: 26135008; PMID: 26261284 PMDBI10332 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial (p-cresol) may compete for a host enzyme (SULT1A1) PMID PMID: 26261284 PMDBI10333 Microbes metabolize substances PMDBM180 876 Desulfovibrio desulfuricans PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Sulfate-reducing bacteria Product a more toxic form of arsenic PMID PMID: 26261284 PMDBI10335 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD135 Butyric Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Produce relatively high levels of butyrate in the gastrointestinal tract Limit the growth of pathogenic microorganisms PMID PMID: 26261284 PMDBI10336 Microbes metabolize substances PMDBM233 853 Faecalibacterium prausnitzii PMDBD135 Butyric Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Produce relatively high levels of butyrate in the gastrointestinal tract Limit the growth of pathogenic microorganisms PMID PMID: 26261284 PMDBI10337 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. tetrahydrocurcumin n.a. n.a. Increase Efficacy n.a. n.a. n.a. Enzyme(identified as CurA) n.a. PMID PMID: 26261284 PMDBI10338 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Cardiac glycoside expressed by bacteria Drug is inactivated PMID PMID: 26261284 PMDBI10339 Microbes metabolize substances PMDBM253 210 Helicobacter pylori PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Sequestration of bacteria Reactivated by microbially expressed enzymes PMID PMID: 26261284 PMDBI10340 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD597 Nitrobenzodiazepine Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Bacterial nitroreductase(NfsB) n.a. PMID PMID: 26261284 PMDBI10341 Microbes metabolize substances PMDBM292 1270 Micrococcus luteus PMDBD683 Polyaromatic compounds Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. hydroxyl metabolites n.a. n.a. n.a. n.a. n.a. n.a. n.a. Exhibit estrogenic activities PMID PMID: 26261284 PMDBI10342 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD697 PPIs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug is associated with Clostridium difficule infections PMID PMID: 26261284 PMDBI10344 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Enzyme(identified as CurA) n.a. PMID PMID: 26261284 PMDBI10345 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10346 Microbes metabolize substances PMDBM381 1279 Staphylococcus PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10347 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10348 Microbes metabolize substances PMDBM298 1763 Mycobacterium PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10349 Microbes metabolize substances PMDBM26 55087 Bacillus PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10350 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Be extensively metabolized by microbiota(demethylation, carbon-carbon bond cleavage, a or b oxidation,dihydroxylation, and cyclization of simvastatin) n.a. PMID PMID: 26261284 PMDBI10351 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD808 Sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-amino 5-salicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Convert drug to its pharmacologically active form by microbial enzymes n.a. PMID PMID: 26261284 PMDBI10352 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity In vivo Mouse n.a. Convertion to SN-38 Lead to the severe intestinal side effect of diarrhea;[drug interaction:Antibiotic/a potent inhibitor of β-glucuronidase can reduce intestinal side effect] PMID PMID: 26569070; PMID: 18927500 PMDBI10353 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. High level of a microbial metabolite(p-cresol) Show low postdose acetaminophen sulfate to acetaminophen glucuronide;alter the bioavailability;lead to hepatotoxicity;[drug interaction]:(rat)antibiotic lead to higher level of acetaminophen glutathione conjugates PMID PMID: 26569070; PMID: 19667173 PMDBI10354 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Several gut microbial-derived secondary bile acids Secondary bile acids can predict effect of simvastatin PMID PMID: 26569070; PMID: 24947972 PMDBI10355 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the composition of gut microbiota;induce the translocation(Gram positive bacteria)into secondary lymphoid organs PMID PMID: 26569070 PMDBI10356 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfide metabolites n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduction Decreased activity PMID PMID: 26569070 PMDBI10357 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Acetaminophen sulfate and glucuronide n.a. n.a. Decrease Efficacy; Increase Toxicity n.a. n.a. n.a. O-Sulfation; C-S cleavage of acetaminophen-3-cysteine Decrease activity,or increase cellular toxicity PMID PMID: 26569070 PMDBI10358 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD230 CpG-oligonucleotide immunotherapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Germ free,orantibiotic-treated Disruption of gut microbiota Microbiota impairs the therapeutic responses of tumors PMID PMID: 26569070 PMDBI10359 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA) n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction, phenolic ring opening Increased activity PMID PMID: 26569070 PMDBI10361 Microbes metabolize substances PMDBM160 n.a. Clostridium sp. HGH 136 PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA) n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction, phenolic ring opening Increased activity PMID PMID: 26569070 PMDBI10362 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Key enzyme: A cytochrome-encoding operon (termed the cardiac glycoside reductase) Produce inactive metabolite PMID PMID: 26569070 PMDBI10363 Microbes metabolize substances PMDBM72 820 Bacteroides uniformis PMDBD386 Genistein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 5-hydroxyequol n.a. n.a. n.a. n.a. n.a. n.a. Hydrogenation n.a. PMID PMID: 26569070 PMDBI10364 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Compound K n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis Increased activity PMID PMID: 26569070 PMDBI10365 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Compound K n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis Increased activity PMID PMID: 26569070 PMDBI10366 Microbes metabolize substances PMDBM227 n.a. Eubacterium sp. GLH PMDBD407 Glycyrrhizic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 18-β-glycyrrhetinic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis Increased activity PMID PMID: 26569070 PMDBI10367 Microbes metabolize substances PMDBM258 573 Klebsiella pneumoniae PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10368 Microbes metabolize substances PMDBM199 n.a. Enterococcus faecalis PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10369 Microbes metabolize substances PMDBM176 28141 Cronobacter sakazakii PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10370 Microbes metabolize substances PMDBM198 37734 Enterococcus casseliflavus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10371 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I, II and III n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increased activity PMID PMID: 26569070 PMDBI10372 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I, II and III n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increased activity PMID PMID: 26569070 PMDBI10373 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine, norephedrine and an unknown metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Demethylation Decreased activity PMID PMID: 26569070 PMDBI10374 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine, norephedrine and an unknown metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Demethylation Decreased activity PMID PMID: 26569070 PMDBI10375 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine, norephedrine and an unknown metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Demethylation Decreased activity PMID PMID: 26569070 PMDBI10376 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD682 Platinum chemotherapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Germ free,orantibiotic-treated Disruption of gut microbiota Microbiota impairs the therapeutic responses of tumors PMID PMID: 26569070 PMDBI10377 Microbes metabolize substances PMDBM198 37734 Enterococcus casseliflavus PMDBD718 Quercetin-3-glucoside Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. Deglycosylation n.a. PMID PMID: 26569070 PMDBI10378 Microbes metabolize substances PMDBM223 39490 Eubacterium ramulus PMDBD718 Quercetin-3-glucoside Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. Deglycosylation n.a. PMID PMID: 26569070 PMDBI10381 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Diclofenac glucuronide Hydrolysis to diclofenac n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 24780296; PMID: 22328575 PMDBI10382 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouracil Deamination n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 12714804; PMID: 3729334 PMDBI10387 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492 PMDBI10388 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492 PMDBI10389 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492 PMDBI10390 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492 PMDBI10392 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10393 Microbes metabolize substances PMDBM347 287 Pseudomonas aeruginosa PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10394 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10395 Microbes metabolize substances PMDBM256 571 Klebsiella oxytoca PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10396 Microbes metabolize substances PMDBM257 574 Klebsiella pneumoniae subsp. ozaenae PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10397 Microbes metabolize substances PMDBM295 582 Morganella morganii PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10398 Microbes metabolize substances PMDBM377 615 Serratia marcescens PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10399 Microbes metabolize substances PMDBM378 623 Shigella flexneri PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10400 Microbes metabolize substances PMDBM408 666 Vibrio cholerae PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10401 Microbes metabolize substances PMDBM324 703 Plesiomonas shigelloides PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10402 Microbes metabolize substances PMDBM132 35703 Citrobacter amalonaticus PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10403 Microbes metabolize substances PMDBM259 39831 Klebsiella pneumoniae subsp. rhinoscleromatis PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10404 Microbes metabolize substances PMDBM133 67824 Citrobacter farmeri PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356 PMDBI10405 Microbes metabolize substances PMDBM162 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Benzisoxazole ring reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 9231340; PMID: 1615700 PMDBI10408 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. N-oxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 11564550 PMDBI10409 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-oxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 11955801 PMDBI10412 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Thiazole ring opening n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 1949905 PMDBI10413 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Thiazole ring opening n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 1949905 PMDBI10414 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD372 Fostamatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. metabolite R529 O-Demethylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 20371637 PMDBI10420 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD811 Sulfapyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl sulfapyridine Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 2890356 PMDBI10422 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Sulfoxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 3630204 PMDBI10423 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Sulfoxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 27591027; PMID: 3630204 PMDBI10439 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027 PMDBI10440 Microbes metabolize substances PMDBM42 n.a. Bacteroides fragilis PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027 PMDBI10441 Microbes metabolize substances PMDBM386 1311 Streptococcus agalactiae PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027 PMDBI10442 Microbes metabolize substances PMDBM153 n.a. Clostridium perfringens PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027 PMDBI10443 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD7 3,4-Dihydro-5-Methyl-Isoquinolinone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Convention and germ-free n.a. DHQ production was dependent on bacteria PMID PMID: 27782392; PMID: 19234110 PMDBI10444 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug modulate or interact with the microbiota PMID PMID: 21060933; PMID: 27782392 PMDBI10445 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD430 Hippuric acid Environmental Substance Industrial Chemicals; Pollutants; Toxic Agents n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Mouse Germ-free,or with antibiotics n.a. Drug concentration in urine is reduced in either germ-free mice or in mice treated with antibiotics PMID PMID: 27782392; PMID: 23342949 PMDBI10446 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Increase hat fatty acid metabolism Contribute to metformin therapy PMID PMID: 25038099; PMID: 27782392 PMDBI10447 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug modulate or interact with the microbiota PMID PMID: 25038099; PMID: 27782392 PMDBI10448 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD475 Levocarnitine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. TMA, TMAO n.a. n.a. n.a. n.a. n.a. n.a. L-carnitine is metabolized to TMA by microbiota Decrease AGE levels PMID PMID: 25636076; PMID: 27782392 PMDBI10449 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Β-glucuronidase enzyme of bacteria Cause gut inflammation and irritation;drug interaction:irinotecan with a β-glucuronidase inhibitor decreases harmful metabolites and alleviates the gastrointestinal inflammation PMID PMID: 27782392; PMID: 26364932 PMDBI10452 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. m-tyramine n.a. n.a. n.a. In vivo Mouse Germ-free n.a. (GF mice)reduce metabolism of L-DOPA,prolong L-DOPA half-life and hence activity PMID PMID: 4974346; PMID: 27782392 PMDBI10453 Microbes metabolize substances PMDBM215 n.a. Escherichia sp. PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Cause an increase of Escherichia spp Result in an increase of gas metabolism pathways(side effect of metformin) PMID PMID: 27782392 PMDBI10454 Microbes metabolize substances PMDBM347 287 Pseudomonas aeruginosa PMDBD3 2,8-DHQ (including 2,4-DHQ) Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Drug is involved in the pathogenicity of bacteria PMID PMID: 27782392 PMDBI10455 Microbes metabolize substances PMDBM194 543 Enterobacteriaceae PMDBD75 Aspartame Therapeutic Substance; Dietary Substance; Herbal Substance Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. SCFA(propionate) n.a. n.a. n.a. In vivo Rat n.a. n.a. Aspartame increased total bacteria PMID PMID: 27782392 PMDBI10456 Microbes metabolize substances PMDBM152 1535 [Clostridium] leptum PMDBD75 Aspartame Therapeutic Substance; Dietary Substance; Herbal Substance Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. SCFA(propionate) n.a. n.a. n.a. In vivo Rat n.a. n.a. Aspartame increased total bacteria PMID PMID: 27782392 PMDBI10457 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD92 B-GOSr (prebiotic oligosaccharide) Therapeutic Substance n.a. n.a. n.a. n.a. n.a. SCFA(acetate) n.a. n.a. n.a. n.a. Human n.a. n.a. Bacteria populations increases acetate PMID PMID: 27782392 PMDBI10458 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD189 Choline Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. trimethylamine (TMA) n.a. n.a. n.a. n.a. n.a. n.a. n.a. Have a direct relationship to cardiovascular disease and atherosclerosis PMID PMID: 27782392 PMDBI10459 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. The cgr operon within strains of E. lenta reduce fumarate in E. lenta to reduce digoxin Lack cardiac activity PMID PMID: 27782392 PMDBI10460 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic acid,acetic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Produce its therapeutic metabolites PMID PMID: 27782392 PMDBI10461 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic acid,acetic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Produce its therapeutic metabolites PMID PMID: 27782392 PMDBI10462 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD787 Sodium cyclamate Dietary Substance Dietary Compounds; Artificial Sweeteners n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. n.a. Human; Mouse n.a. n.a. Drug interaction:antibiotic treatment reduce cyclohexylamine production PMID PMID: 27782392 PMDBI10463 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD787 Sodium cyclamate Dietary Substance Dietary Compounds; Artificial Sweeteners n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. n.a. Human; Mouse n.a. n.a. Drug interaction:antibiotic treatment reduce cyclohexylamine production PMID PMID: 27782392 PMDBI10464 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD6 3,3-dimethyl-1-butanol Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. TMA, TMAO n.a. n.a. n.a. In vivo Mouse n.a. n.a. Drug interaction:inhibition of TMA lyase inhibits microbial production of TMA, reducing TMAO levels PMID PMID: 27782392 PMDBI10465 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD68 Arabinoxylan-oligosaccharides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. SCFA; phenol, pcresol n.a. n.a. n.a. n.a. Human n.a. n.a. AXOS supplementation has a long-term effect on colonic microbe community PMID PMID: 27782392 PMDBI10466 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD73 Aryl hydrocarbon receptor activator Environmental Substance Industrial Chemicals; Pollutants; Toxic Agents n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10467 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD299 Ellagic acid Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10468 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10469 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD610 NSAIDs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Cleave the glucuronide by bacteria Yield harmful metabolites,cause the formation of ulcers in the gut; PMID PMID: 27782392 PMDBI10470 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD656 Persistent organic pollutant Environmental Substance Industrial Chemicals; Pollutants n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10471 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Hippuric acid n.a. n.a. n.a. In vivo Mouse n.a. n.a. Drug interaction:antibiotic(rifaximin)decreases microbial metabolites(hippuric acid) PMID PMID: 27782392 PMDBI10472 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD830 Tempol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. TβMCA n.a. n.a. n.a. In vivo Mouse n.a. n.a. Tempol reduces BSH activity of bacteria and produces antiobesity effects PMID PMID: 27782392 PMDBI10473 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD627 Oxaliplatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Mediated by TLR4 and reactive oxygen species production by myeloid cells PMID PMID: 18555978; PMID: 28270698 PMDBI10475 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases Decrease Efficacy n.a. n.a. n.a. Enzymatic degradation Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity PMID PMID: 28270698 PMDBI10476 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases Decrease Efficacy n.a. n.a. n.a. Enzymatic degradation Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity PMID PMID: 28270698 PMDBI10477 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD50 Anti-PD-L1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Tumour‑specific T‑cell induction;increase T cells in tumour microenvironment PMID PMID: 28270698 PMDBI10478 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduced diversity; ecological network function Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis PMID PMID: 28270698 PMDBI10479 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduced diversity; ecological network function Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis PMID PMID: 28270698 PMDBI10480 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduced diversity; ecological network function Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis PMID PMID: 28270698 PMDBI10481 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Priming of tumour‑associated myeloid inflammatory responses PMID PMID: 28270698 PMDBI10482 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Priming of tumour‑associated myeloid inflammatory responses PMID PMID: 28270698 PMDBI10483 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Decreased activation of splenic effector CD4 + T cells and tumour‑infiltrating lymphocytes PMID PMID: 28270698 PMDBI10484 Microbes metabolize substances PMDBM376 n.a. Segmented filamentous bacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response PMID PMID: 28270698 PMDBI10485 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response PMID PMID: 28270698 PMDBI10486 Microbes metabolize substances PMDBM202 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10487 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10488 Microbes metabolize substances PMDBM274 33959 Lactobacillus johnsonii PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10489 Microbes metabolize substances PMDBM202 1354 Enterococcus hirae PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10490 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10491 Microbes metabolize substances PMDBM274 33959 Lactobacillus johnsonii PMDBD290 Doxorubicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10492 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases Decrease Efficacy n.a. n.a. n.a. Enzymatic degradation Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity PMID PMID: 28270698 PMDBI10493 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD452 Ipilimumab Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Bacterially mediated B vitamin production and polyamine transport deficiencies associated with increased risk of CTLA‑4 blockade‑induced colitis PMID PMID: 28270698 PMDBI10494 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Bacterial β‑glucuronidase Increase Efficacy; Increase Toxicity n.a. n.a. n.a. Enzymatic degradation Bacterial β‑glucuronidase cleaves glucuronide from inactive metabolite, releasing active metabolite (SN‑38) in the gut PMID PMID: 28270698 PMDBI10497 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduced diversity; ecological network function Reduced diversity and shifts in relative abundance associated with chemotherapy‑induced diarrhoea PMID PMID: 28270698 PMDBI10498 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduced diversity; ecological network function Reduced diversity and shifts in relative abundance associated with chemotherapy‑induced diarrhoea PMID PMID: 28270698 PMDBI10499 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. N-acetylation by microbial N-acetyltransferases Yield a inactive metabolite PMID PMID: 11344150; PMID: 28642381 PMDBI10500 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfapyridine;5-ASA;N-acetyl 5-ASA n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduce Lack anti-inflammatory PMID PMID: 1425876; PMID: 28642381 PMDBI10501 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inhibit cytochrome P-450s;affect host xenobiotic metabolism PMID PMID: 16547074; PMID: 28642381 PMDBI10502 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD880 Tryptophan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. antioxidant indole-3-propionic acid;the neurotransmitter tryptamine;indole n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Generate the uremic toxin indoxyl sulfate PMID PMID: 17146590; PMID: 28642381 PMDBI10503 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD241 Cysteine-S-conjugates of xenobiotics Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. thiol metabolites n.a. n.a. n.a. n.a. n.a. n.a. Cleave cysteine-S-conjugates of polychlorinated biphenyls by C-S β-lyases Serve as a sole nitrogen,a potential role in nutrient acquisition PMID PMID: 20306345; PMID: 28642381 PMDBI10504 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Β-glucuronidase enzymes hydrolyze SN-38G;regenerate active agent Cause intestinal damage and severe diarrhea;drug interaction:inhibitors PMID PMID: 21051639; PMID: 28642381 PMDBI10505 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. Allow intestinal absorption PMID PMID: 26174047; PMID: 28642381 PMDBI10506 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD815 Sulfoxide Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce the sulfoxide n.a. PMID PMID: 3630204; PMID: 28642381 PMDBI10507 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD90 Azo dyes Environmental Substance Industrial Chemicals; Pollutants n.a. n.a. n.a. n.a. mutagenic bis-aniline benzidine n.a. n.a. Increase Toxicity In vivo Mouse n.a. n.a. Increase carcinogen exposure PMID PMID: 3726894; PMID: 28642381 PMDBI10508 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD540 Methylmercury Environmental Substance Industrial Chemicals; Pollutants; Toxic Agents n.a. n.a. n.a. n.a. inorganic mercury n.a. n.a. Decrease Toxicity In vivo Rat n.a. n.a. Lead to less toxicity,facilitate mercury excretion PMID PMID: 626001; PMID: 28642381 PMDBI10509 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD44 Amygdalin Herbal Substance; Dietary Substance Medicinal Herbal Compounds; Dietary Compounds n.a. n.a. n.a. n.a. mandelonitrile n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolyze the glycosidic linkage Produce benzaldehydy and toxic cyanide PMID PMID: 7362642; PMID: 28642381 PMDBI10510 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce the N-oxide n.a. PMID PMID: 7628301; PMID: 28642381 PMDBI10511 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. n.a. n.a. Human; GF mice n.a. Flavin-dependent reductase(Cgr2) n.a. PMID PMID: 28642381 PMDBI10512 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD54 Anticancer drugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase or decrease the efficacy of drug PMID PMID: 28642381 PMDBI10513 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD54 Anticancer drugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase or decrease the efficacy of drug PMID PMID: 28642381 PMDBI10514 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD152 CB954 Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct chemical modification n.a. PMID PMID: 28642381 PMDBI10515 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD359 Fludarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct chemical modification n.a. PMID PMID: 28642381 PMDBI10516 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct chemical modification n.a. PMID PMID: 28642381 PMDBI10517 Microbes metabolize substances PMDBM270 1580 Lactobacillus brevis PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. mtyramine n.a. n.a. n.a. n.a. n.a. n.a. Microbial decarboxylation and p-dehydroxylation(a tyrosine decarboxylase accepts L-dopa in vitro) Contribute to the substantial variation PMID PMID: 28642381 PMDBI10518 Microbes metabolize substances PMDBM255 570 Klebsiella PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. Increase Toxicity In vivo Mouse n.a. Deaminate Lead to renal toxicity PMID PMID: 28642381 PMDBI10519 Microbes metabolize substances PMDBM347 287 Pseudomonas aeruginosa PMDBD404 Gluten Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Elicit an enhanced gluten-specific immune response(compare with peptieds produced by Lactobacillus spp.from healthy individuals) PMID PMID: 28642381 PMDBI10520 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD839 Thiazolidinediones Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Diet-induced obesity n.a. Indirectlyaffect gut bacteria(HFD leads to an increase in the relative abundance of Proteobacteria) PMID PMID: 27751827; PMID: 28973971 PMDBI10521 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia or T2D Prevent starch processing and absorption; Enhance starch-fermenting and butyrate-producing bacteria;inhibit starch use by propionate-producing bacteria;increase Lactobacillus,Bifidobacterium and other SCFA-producing bacteria;associated with a diminution of Enterobacteriaceae,Bacteroidaceae and lecithinase positive Clostridum in human feces PMID PMID: 28973971 PMDBI10522 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Affect nutrient sources of bacteria Block the growth of E.coli PMID PMID: 28973971 PMDBI10523 Microbes metabolize substances PMDBM375 n.a. SCFA-producing bacteria PMDBD55 Antidiabetic drugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positively influence the bacteria PMID PMID: 28973971 PMDBI10524 Microbes metabolize substances PMDBM375 n.a. SCFA-producing bacteria PMDBD428 High-fiber diets Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positively influence the bacteria PMID PMID: 28973971 PMDBI10525 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD442 Incretin Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Primary murine colonic culture n.a. Microbiota fermentation products Influence incretin secretion PMID PMID: 28973971 PMDBI10526 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD487 Liraglutide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet(HFD),HF-fed,diabetes-induced n.a. Enrich Firmicutes;deplete Bacteroidetes,Proteobacteria and Actinobacteria phyla;enrich 13 phylotypes(Allobaculum,Turicibacter,Anaerostipes,Blautia,Lactobacillus,Butyricimonas,Desulfovibrio);decrease 20 phylotypes in the orders Clostridiales and Bacteroidales PMID PMID: 28973971 PMDBI10527 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. Inhibit the dihydrofolate reductase activity of bacteria Influence the side-effects of drug PMID PMID: 28973971 PMDBI10528 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10529 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positive effects PMID PMID: 28973971 PMDBI10530 Microbes metabolize substances PMDBM322 33024 Phascolarctobacterium PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10531 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10532 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10533 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. Decrease bacterial diversity PMID PMID: 28973971 PMDBI10534 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positive effects PMID PMID: 28973971 PMDBI10535 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. Decrease bacterial diversity PMID PMID: 28973971 PMDBI10536 Microbes metabolize substances PMDBM407 74201 Verrucomicrobia PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) Genus Akkermansia Increase the relative abundance of bacteria PMID PMID: 28973971 PMDBI10537 Microbes metabolize substances PMDBM88 1680 Bifidobacterium adolescentis PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Promote bacteria growth Contribute to the glucose-lowering effect PMID PMID: 28973971 PMDBI10538 Microbes metabolize substances PMDBM12 174708 Allobaculum PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positive effects PMID PMID: 28973971 PMDBI10539 Microbes metabolize substances PMDBM173 84107 Coriobacteriaceae PMDBD550 Miglitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse A high fat and high glucose diet Suppression of intestinal inflammation Reverse the increase of bacteria PMID PMID: 28973971 PMDBI10540 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD550 Miglitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse A high fat and high glucose diet Suppression of intestinal inflammation Reverse the increase of bacteria PMID PMID: 28973971 PMDBI10541 Microbes metabolize substances PMDBM375 n.a. SCFA-producing bacteria PMDBD667 Physical activity Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positively influence the bacteria PMID PMID: 28973971 PMDBI10542 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat High-fat diet (HFD) Correlate with the decrease of plasma endotoxin, TNF-α , IL-6 and MCP-1 levels Reduce the abundance of bacteria PMID PMID: 28973971 PMDBI10543 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD769 Saxagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse HF-fed,diabetic-induced n.a. Enrich Firmicutes,mainly the genera Lactobacillus,Allobaculum and Turicibacter;contain less Bacteroides and Prevotella;decrease the phylum Bacteroidetes PMID PMID: 28973971 PMDBI10544 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD785 Sitagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Diabetes n.a. Increase in the relative abundance of Bacteroidetes and Proteobacteria;decrease Firmicute;influence SCFA-producing bacteria;Lactobacillus and Bifidobacterium are depleted in feces PMID PMID: 28973971 PMDBI10545 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD898 Voglibose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease the Firmicutes to Bacteroidetes ratio and higher the abundance in Verrucomicrobia PMID PMID: 28973971 PMDBI10546 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetylated 5-aminosalicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. N-acetyltransferases from bacteria Exert physiopathological effects,increase activity PMID PMID: 11344150; PMID: 30227749 PMDBI10547 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Lead to poor bioavailability of ranitidine PMID PMID: 11564550; PMID: 30227749 PMDBI10548 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD560 Morphine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of glucuronide Increase drug toxicity PMID PMID: 1185599; PMID: 30227749 PMDBI10549 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. N-oxide bond cleavage Decrease activity PMID PMID: 30227749; PMID: 11955801 PMDBI10550 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. M1 (demethylbutyryl metabolite), M4 (hydroxylated metabolite), M8 (the active hydroxy acid metabolite), and M9 (hydroxylated M8) n.a. n.a. n.a. In vitro Human; Rat n.a. n.a. Produce four metabolites PMID PMID: 30227749; PMID: 24947972 PMDBI10551 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD253 Deleobuvir Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. CD 6168 n.a. n.a. n.a. n.a. n.a. n.a. An alkene reduction by the gut microbiota n.a. PMID PMID: 30227749; PMID: 26068924 PMDBI10552 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Increase activity PMID PMID: 30227749; PMID: 26630218 PMDBI10553 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD307 Epacadostat Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. Amidine metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decrease activity PMID PMID: 30227749; PMID: 27457784 PMDBI10554 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Amine formation n.a. PMID PMID: 30227749; PMID: 4165044 PMDBI10555 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Azoreductase enzymes,Activation of azo-bond containing prodrug to sulfanilamid Increase toxicity PMID PMID: 5173017; PMID: 30227749 PMDBI10556 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD814 Sulfonamide antibiotics Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial transformation n.a. PMID PMID: 5173017; PMID: 30227749 PMDBI10557 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam n.a. n.a. Increase Toxicity n.a. n.a. n.a. Nitro reduction n.a. PMID PMID: 6506755; PMID: 30227749 PMDBI10558 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Isoxazole scission or hydroxylation Decrease activity PMID PMID: 7512019; PMID: 30227749 PMDBI10559 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. active drug loperamide n.a. n.a. Increase Efficacy n.a. Human; Dog; Rat n.a. n.a. Make the metabolism and increase activity of loperamide oxide PMID PMID: 7628301; PMID: 30227749 PMDBI10560 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. No alteration of pharmacokinetics PMID PMID: 7629748; PMID: 30227749 PMDBI10561 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD137 Calcitonin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Susceptible to proteolysis,Protease Increase large-intestinal absorption,decrease activity PMID PMID: 30227749; PMID: 9055189 PMDBI10562 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD447 Insulin human Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Susceptible to proteolysis,Protease Increase large-intestinal absorption,decrease activity PMID PMID: 30227749; PMID: 9055189 PMDBI10563 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Influence drug delivery and absorption PMID PMID: 30227749 PMDBI10564 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD332 Famotidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Influence drug delivery and absorption PMID PMID: 30227749 PMDBI10565 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Influence drug delivery and absorption PMID PMID: 30227749 PMDBI10566 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl)uracil n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10567 Microbes metabolize substances PMDBM140 n.a. Clostridioides difficile PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy; Increase Toxicity n.a. n.a. n.a. P-cresol(microbial metabolite) reduces metabolic clearance Reduce activity;delay the metabolism of drug in the human body and increase risk of hepatotoxicity PMID PMID: 30227749 PMDBI10568 Microbes metabolize substances PMDBM195 n.a. Enterobacteriales PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency PMID PMID: 30227749 PMDBI10569 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency PMID PMID: 30227749 PMDBI10570 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency PMID PMID: 30227749 PMDBI10571 Microbes metabolize substances PMDBM214 316435 Escherichia coli Nissle 1917 PMDBD36 Amiodarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. DEA n.a. n.a. Increase Efficacy; Increase Bioavailability In vivo Animal model n.a. n.a. Increase bioavailability of AMI,increase plasma levels of desethylamiodarone(DEA),promote the absorption of AMI and increase the activity of CYP2C PMID PMID: 30227749 PMDBI10572 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid;Azoreductases Increase toxicity PMID PMID: 30227749 PMDBI10573 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. digoxigenin,or dihydrodigoxin n.a. n.a. Decrease Efficacy In vitro human n.a. Reduction Produce inactive metabolites;[interaction]:(gnotobiotic mice)dietary protein reduces microbial metabolism of digoxin(vivo) and changes drug concentration(in the serum and urine);[drug interaction]:antibiotics(tetracycline or erythromycin) increase plasma concentration of digoxin PMID PMID: 30227749 PMDBI10574 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD403 Glucuronides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon Increase toxicity PMID PMID: 30227749 PMDBI10575 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD403 Glucuronides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon Increase toxicity PMID PMID: 30227749 PMDBI10576 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD403 Glucuronides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon Increase toxicity PMID PMID: 30227749 PMDBI10577 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon,bacterial b-glucuronidases Increase toxicity PMID PMID: 30227749 PMDBI10578 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon,bacterial b-glucuronidases Increase toxicity PMID PMID: 30227749 PMDBI10579 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon,bacterial b-glucuronidases Increase toxicity PMID PMID: 30227749 PMDBI10580 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic and acetic acidsactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10581 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic and acetic acidsactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10582 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic and acetic acidsactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10583 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increase activity PMID PMID: 30227749 PMDBI10584 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increase activity PMID PMID: 30227749 PMDBI10585 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Catalyze p-dehydroxylation of L-dopa to mhydroxyphenylacetic acid n.a. PMID PMID: 30227749 PMDBI10586 Microbes metabolize substances PMDBM253 210 Helicobacter pylori PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Bioavailability In vivo Human Parkinson’s disease (PD) Dehydroxylation Reduce acute L-dopa absorption;reduce L-dopa onset time, ON duration, motor severity, and quality of life parameters PMID PMID: 30227749 PMDBI10587 Microbes metabolize substances PMDBM153 n.a. Clostridium perfringens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduction Reduce activity PMID PMID: 30227749 PMDBI10588 Microbes metabolize substances PMDBM152 1535 [Clostridium] leptum PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-acetylaminonitrazepam n.a. n.a. Decrease Toxicity n.a. n.a. n.a. Nitroreductase Produce teratogenic activity metabolites,Induce teratogenicity PMID PMID: 30227749 PMDBI10589 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid;Azoreductases Increase toxicity PMID PMID: 30227749 PMDBI10590 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Affect the pharmacokinetics and pharmacodynamics;increase the risk of myopathy PMID PMID: 30227749 PMDBI10591 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid;Azoreductases Increase toxicity PMID PMID: 30227749 PMDBI10592 Microbes metabolize substances PMDBM162 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulphamoylacetylphenol n.a. n.a. Increase Efficacy n.a. n.a. n.a. Zonisamide reductase Increase activity PMID PMID: 30227749 PMDBI10593 Microbes metabolize substances PMDBM348 294 Pseudomonas fluorescens PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10594 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10595 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10596 Microbes metabolize substances PMDBM199 n.a. Enterococcus faecalis PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10597 Microbes metabolize substances PMDBM162 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10598 Microbes metabolize substances PMDBM93 1681 Bifidobacterium bifidum PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10599 Microbes metabolize substances PMDBM282 47715 Lactobacillus rhamnosus PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10600 Microbes metabolize substances PMDBM371 n.a. Salmonella enterica subsp. enterica serovar Typhimurium PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10601 Microbes metabolize substances PMDBM226 n.a. Eubacterium sp. PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid;Azoreductases Increase toxicity PMID PMID: 30227749 PMDBI10602 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial b-glucuronidases Reduce intestinal tract toxicity PMID PMID: 30227749 PMDBI10603 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial b-glucuronidases Reduce intestinal tract toxicity PMID PMID: 30227749 PMDBI10604 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD468 Ketoprofen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial b-glucuronidases Reduce intestinal tract toxicity PMID PMID: 30227749 PMDBI10605 Microbes metabolize substances PMDBM226 n.a. Eubacterium sp. PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid;Azoreductases Increase toxicity PMID PMID: 30227749 PMDBI10606 Microbes metabolize substances PMDBM226 n.a. Eubacterium sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid;Azoreductases Increase toxicity PMID PMID: 30227749 PMDBI10607 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase Acetylating to acid PMID PMID: 11344150; PMID: 30338735 PMDBI10608 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolized by bacteria n.a. PMID PMID: 30338735; PMID: 11955801 PMDBI10609 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD814 Sulfonamide antibiotics Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Azoreductase enzymes Activation of prodrug to 5-aminosalicylic acid PMID PMID: 30338735; PMID: 1711964 PMDBI10610 Microbes metabolize substances PMDBM153 n.a. Clostridium perfringens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduction to acetamide PMID PMID: 30338735; PMID: 231450 PMDBI10611 Microbes metabolize substances PMDBM27 n.a. Bacterium DZY-HS11 PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce the abundance of bacteria n.a. PMID PMID: 30338735; PMID: 24413286 PMDBI10612 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Β-D-glucosidase, α-L-rhamnosidase,α-D-glucosidase enzyme Drug interaction:antibiotics can reduce the biotransformation PMID PMID: 30338735; PMID: 24947972 PMDBI10613 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Β-glucuronidase Hydrolysis of glucuronide PMID PMID: 28922; PMID: 30338735 PMDBI10614 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD588 Nifedipine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 30338735; PMID: 29790376 PMDBI10615 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD588 Nifedipine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hypoxic conditions at high altitudes Changes of intestinal microflora caused by high plateau hypoxia Increase the bioavailability of drug PMID PMID: 30338735; PMID: 29790376 PMDBI10616 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Result in increased toxicity PMID PMID: 30338735; PMID: 430360 PMDBI10617 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfapyridine and 5-ASA n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Lose activity PMID PMID: 30338735; PMID: 4402374 PMDBI10618 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Active 5-aminosalicyclic acid by intestinal azoreductase enzymes Increase the drug PMID PMID: 30338735; PMID: 4402374 PMDBI10619 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD279 Dihydroxyphenylalanine (DOPA) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct dopa to alternative metabolic pathways PMID PMID: 4723308; PMID: 30338735 PMDBI10620 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD72 Artificial sweetener cyclamate Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis n.a. PMID PMID: 7362642; PMID: 30338735 PMDBI10621 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD680 Plant-derived glycosides(amygdalin) Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis n.a. PMID PMID: 7362642; PMID: 30338735 PMDBI10622 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. loperamide n.a. n.a. n.a. n.a. Human; Dog; Rat n.a. Bacteria affect activation of prodrugs and drug inactivation n.a. PMID PMID: 30338735; PMID: 7628301 PMDBI10623 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-acetylaminonitrazepam n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase n.a. PMID PMID: 30338735; PMID: 9310649 PMDBI10624 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. p-cresol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10625 Microbes metabolize substances PMDBM195 n.a. Enterobacteriales PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics can potentiate the therapeutic potency PMID PMID: 30338735 PMDBI10626 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics can potentiate the therapeutic potency PMID PMID: 30338735 PMDBI10627 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics can potentiate the therapeutic potency PMID PMID: 30338735 PMDBI10628 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. calycosin n.a. n.a. n.a. n.a. n.a. n.a. Bacteria produces O-methyltransferase and aromatic hydroxylase n.a. PMID PMID: 30338735 PMDBI10629 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxigenin,dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduction to inactive metabolites n.a. PMID PMID: 30338735 PMDBI10630 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD284 Diosmin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10631 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD284 Diosmin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10632 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD284 Diosmin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10633 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD284 Diosmin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10634 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD284 Diosmin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10635 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis and release of SN-38 Leads to GI toxicity PMID PMID: 30338735 PMDBI10636 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis and release of SN-38 Leads to GI toxicity PMID PMID: 30338735 PMDBI10637 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Β-glucuronidases Enhance the irinotecan toxicity PMID PMID: 30338735 PMDBI10638 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Β-glucuronidases Enhance the irinotecan toxicity PMID PMID: 30338735 PMDBI10639 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Β-glucuronidases Enhance the irinotecan toxicity PMID PMID: 30338735 PMDBI10640 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis and release of SN-38 Leads to GI toxicity PMID PMID: 30338735 PMDBI10641 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic lactic,acids active n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10642 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic lactic,acids active n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10643 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic lactic,acids active n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10644 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I,levametabol-III n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Generate active metabolites PMID PMID: 30338735 PMDBI10645 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. levametabol-I,levametabol-III n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Generate active metabolites PMID PMID: 30338735 PMDBI10647 Microbes metabolize substances PMDBM224 39491 [Eubacterium] rectale PMDBD714 Puerarin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. daidzein n.a. n.a. n.a. n.a. n.a. n.a. Convert by bacteria n.a. PMID PMID: 30338735 PMDBI10648 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10649 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10650 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10651 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10652 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10653 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10654 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10655 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10656 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10657 Microbes metabolize substances PMDBM108 41200 Bifidobacterium sp. PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10658 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Increase the risk of myopathy PMID PMID: 30338735 PMDBI10659 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10660 Microbes metabolize substances PMDBM247 2701 Gardnerella PMDBD832 Tenofovir Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Catabolized tenofovir into an inactive compound n.a. PMID PMID: 30338735 PMDBI10661 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulphamoylacetylphenol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10662 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD244 Daidzein Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Calycosin n.a. n.a. n.a. n.a. n.a. n.a. Aromatic hydroxylase,O-methyltransferase n.a. PMID PMID: 30338735 PMDBI10663 Microbes metabolize substances PMDBM233 853 Faecalibacterium prausnitzii PMDBD57 Anti‑PD‑1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Metastatic melanoma n.a. Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum PMID PMID: 30530851 PMDBI10664 Microbes metabolize substances PMDBM100 216816 Bifidobacterium longum PMDBD57 Anti‑PD‑1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Metastatic melanoma n.a. Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum PMID PMID: 30530851 PMDBI10665 Microbes metabolize substances PMDBM7 239935 Akkermansia muciniphila PMDBD57 Anti‑PD‑1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Non-small cell lung cancer n.a. Increased relative abundance of bacteria in PD-1 R PMID PMID: 30530851 PMDBI10666 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. SLCO1B1 Increase Efficacy In vivo Human n.a. n.a. 221% increase in simvastatin AUC for homozygotes PMID PMID: 19833260; PMID: 18650507; PMID: 24918167; PMID: 22380001; PMID: 31171383 PMDBI10668 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Lactone ring reduction ABCB1 Increase Toxicity In vivo Human n.a. n.a. Decreased AUC; narrow therapeutic window PMID PMID: 24637603; PMID: 18334914; PMID: 31171383 PMDBI10669 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD900 Warfarin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. CYP2C9 n.a. n.a. Human n.a. Vitamin K production Altered activity of drug PMID PMID: 22380001; PMID: 17042764; PMID: 26962786; PMID: 31171383 PMDBI10670 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Amino-metabolite generation, Inactivation PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10671 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10672 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Amino-metabolite generation, Inactivation PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10673 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10674 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10675 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10676 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10677 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD468 Ketoprofen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10678 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Amino-metabolite generation, Inactivation PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10679 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID PMID: 27591027; PMID: 30227749; PMID: 31171383 PMDBI10680 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38G metabolite Deglucuronidation UGT1A1*28‘Gilbert's syndrome’ Increase Toxicity In vitro Human Health n.a. Defect in glucuronidation; increased toxicity PMID PMID: 29104759; PMID: 18349289; PMID: 31171383 PMDBI10681 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Sulfonation UGT1A; SULT1A3 Decrease Toxicity In vitro Human n.a. n.a. Increased rate of glucuronidation; decreased risk of liver failure PMID PMID: 23408116; PMID: 19667173; PMID: 29705271; PMID: 31171383 PMDBI10682 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. additional bromovinyluracil n.a. DYPD Increase Toxicity In vitro Human n.a. n.a. Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU PMID PMID: 9690942; PMID: 30733391; PMID: 31171383 PMDBI10683 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. additional bromovinyluracil n.a. DYPD Increase Toxicity n.a. Human n.a. n.a. Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU PMID PMID: 9690942; PMID: 30733391; PMID: 31171383 PMDBI10684 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy In vivo Human Ulcerative colitis n.a. Prodrug activation: local 5-ASA release PMID PMID: 27591027; PMID: 31171383 PMDBI10685 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD137 Calcitonin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Proteolysis n.a. Decrease Efficacy In vitro Human n.a. n.a. Breakdown of therapeutic protein PMID PMID: 27591027; PMID: 31171383 PMDBI10686 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. p-aminophenyl-2-amino-1,3-propanediol Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Bone marrow toxicity PMID PMID: 27591027; PMID: 31171383 PMDBI10687 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD447 Insulin human Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Proteolysis n.a. Decrease Efficacy In vitro Human n.a. n.a. Breakdown of therapeutic protein PMID PMID: 27591027; PMID: 31171383 PMDBI10688 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD453 Ipsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy In vivo Human Ulcerative colitis n.a. Prodrug activation: local 5-ASA release PMID PMID: 27591027; PMID: 31171383 PMDBI10689 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Azoreduction n.a. Increase Efficacy In vitro Rat n.a. n.a. Antibiotic activation PMID PMID: 27591027; PMID: 31171383 PMDBI10690 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy In vivo Human Ulcerative colitis n.a. Prodrug activation: local 5-ASA release PMID PMID: 27591027; PMID: 31171383 PMDBI10691 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD668 Picosulfuric acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Desulfation n.a. Increase Efficacy n.a. Human n.a. n.a. Solubility increase PMID PMID: 27591027; PMID: 31171383 PMDBI10692 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD711 Prontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Azoreduction n.a. Increase Efficacy In vivo Mouse (I.C.I. Albino strain); Rat (Wistar albino); Hamster n.a. n.a. Antibiotic activation PMID PMID: 27591027; PMID: 31171383 PMDBI10693 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD808 Sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy n.a. Human n.a. n.a. Prodrug activation: local 5-ASA release PMID PMID: 27591027; PMID: 31171383 PMDBI10694 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-Acetylation n.a. Decrease Efficacy n.a. Human n.a. n.a. Less efficacy; possible pancreatic toxicity PMID PMID: 30227749; PMID: 31171383 PMDBI10695 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD36 Amiodarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-dealkylation n.a. Increase Efficacy In vivo Rat EcN-treated rats n.a. Increased bioavailability of active metabolite PMID PMID: 30227749; PMID: 31171383 PMDBI10696 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD221 Codeine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Efficacy n.a. Human n.a. n.a. Reformation of active metabolite PMID PMID: 30227749; PMID: 31171383 PMDBI10697 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Lactone ring reduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID PMID: 30227749; PMID: 31171383 PMDBI10698 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-Demethylation n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID PMID: 30227749; PMID: 31171383 PMDBI10699 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD560 Morphine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Efficacy n.a. Human n.a. n.a. Reformation of active metabolite PMID PMID: 30227749; PMID: 31171383 PMDBI10700 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-Dealkylation n.a. Increase Toxicity In vitro Human n.a. n.a. Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation PMID PMID: 30733391; PMID: 31171383 PMDBI10701 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. N-Dealkylation n.a. Increase Toxicity n.a. Human n.a. n.a. Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation PMID PMID: 30733391; PMID: 31171383 PMDBI10702 Microbes metabolize substances PMDBM253 210 Helicobacter pylori PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. P-Dehydroxylation n.a. Decrease Efficacy n.a. Human n.a. n.a. Decrease in L-dopa absorption PMID PMID: 31171383 PMDBI10703 Microbes metabolize substances PMDBM347 287 Pseudomonas aeruginosa PMDBD560 Morphine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. morphine-glucuronide metabolite Deglucuronidation SLC22A1; OCT1 n.a. n.a. Human n.a. n.a. Decreased clearance of morphine; Induces virulence in some strains of Pseudomonas aeruginosa PMID PMID: 31171383 PMDBI10704 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD315 Estradiol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Bioavailability In vitro human n.a. Β-glucuronidase mediate deconjugation and enterohepatic circulation of estrogen Greater absroption of estrogens;develop estrogen-driven cancer PMID PMID: 27107051; PMID: 31184303; PMID: 24187630 PMDBI10705 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity In vivo BALB/c mouse Health Microbial β-glucuronidases mediate the reactivation of metabolite（deconjugation and reactivation of SN-38） Cause toxicity(epithelial damage;severe diarrhea);analog:plant-based compound scutellarin(inadvertently modulating the effect of cancer therapy) PMID PMID: 29104759; PMID: 21051639; PMID: 31184303 PMDBI10706 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD825 Taurine conjugated bile acid Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Meidate de-conjugation of taurineconjugates;generate hydrogen sulfid Contribute to the etiology of cancer PMID PMID: 27003186; PMID: 31184303 PMDBI10707 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. human n.a. Be linked to cgr operon expression levels;human microbiome reductase inactivates the drug Lead to inactivation and decreased bioavailability;drug substructure similarity:cardenolides(great),progesterone、cortisone(bad); PMID PMID: 31184303 PMDBI10708 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD30 Altretamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. Human n.a. Alter the drug structure Cause diarrhea and kidney damage;interaction:tamoxifen、diphenhydramine、theobromine PMID PMID: 31184303 PMDBI10709 Microbes metabolize substances PMDBM349 303 Pseudomonas putida PMDBD30 Altretamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial N-demethylase enzymes Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence) PMID PMID: 31184303 PMDBI10710 Microbes metabolize substances PMDBM393 211046 Styrax aureus PMDBD434 Hypochlorite Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human cutaneous T cell lymphoma n.a. Reduce the amount of bacteria PMID PMID: 18835065; PMID: 31186074 PMDBI10711 Microbes metabolize substances PMDBM403 n.a. Unidentified probiotic PMDBD226 Common azole treatment Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce the amount of azoleresistant fungal strains PMID PMID: 25362524; PMID: 31186074 PMDBI10712 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reactivate drug by the β-glucuronidase enzyme Result in side effects( stage 4 diarrhea and gastrointestinal damage) PMID PMID: 31186074; PMID: 26364932 PMDBI10713 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. m-tyramine, m-hydroxyphenylacetic acid (m-HPAA) n.a. n.a. Decrease Efficacy In vivo Rat n.a. n.a. Decrease L-DOPA half-life and efficacy PMID PMID: 4723308; PMID: 31186074 PMDBI10714 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic,lactic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Product therapeutic metabolites PMID PMID: 6804597; PMID: 31186074 PMDBI10715 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD53 Antibiotic (extensive treatment) Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Eliminate the majority of the intestinal microbiome and improve harmful bacteria(Clostridium difficile) Lead to intestinal complications(antibiotic-associated diarrhea and colitis);drug interaction: C. difficile can be treated with vancomycin and metronidazole PMID PMID: 31186074 PMDBI10716 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine n.a. n.a. n.a. n.a. n.a. n.a. Gut microbial nitroreductase activity n.a. PMID PMID: 2893665; PMID: 6506755 PMDBI10717 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine n.a. n.a. n.a. n.a. n.a. n.a. Gut microbial nitroreductase activity n.a. PMID PMID: 2893665; PMID: 6506755 PMDBI10718 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD695 Potassium oxonate Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 10997934 PMDBI10719 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl sulfapyridine,N-acetyl-5-aminosalicylic acid n.a. n.a. n.a. In vitro Human; Rat; Guinea pig; Dog n.a. Bacterial N-acetylation n.a. PMID PMID: 1425876 PMDBI10720 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD668 Picosulfuric acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 4,40-dihydroxydiphenyl-(2 pyridyl)-methane n.a. n.a. n.a. n.a. n.a. n.a. Conversion by gut bacteria n.a. PMID PMID: 1507649 PMDBI10721 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD666 Phosphate or sulfate ester prodrugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. The drug act on hydrolytic enzymes of bacteria n.a. PMID PMID: 1507649 PMDBI10722 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-amino 5-salicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Microbial azoreductases Convert to its pharmacologically active form;enhance drug distribution：olsalazine、balsalazide（inflammatory bowel disease）——introduction of azo bonds PMID PMID: 18305431 PMDBI10723 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD52 Antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Eliminate vitamin K-producing bacteria Lead to alteration in coagulation status PMID PMID: 18841274 PMDBI10724 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminonitrazepam,7-acetylaminonitrazepam n.a. n.a. Increase Toxicity In vivo Rat Pregnant Gut microbial nitroreductase activity Lead to nitrazepam-related teratogenicity;drug interaction:antibiotic reduced metabolites PMID PMID: 1925980 PMDBI10725 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. N-acetyl p-benzoquuinone imine n.a. n.a. Increase Toxicity In vivo Human Health A microbial-derived metabolite p-cresol compete with acetaminophen Impede the ability for the liver to detoxify PMID PMID: 19667173; PMID: 31462078 PMDBI10726 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD372 Fostamatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial O-dealkylation n.a. PMID PMID: 20371637 PMDBI10727 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Compete with TMA for metabolism by FMO3 Cause side effect on fish odor syndrom PMID PMID: 21422137 PMDBI10728 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Alterations in bacteria(expansion of proinflammatory bacteria) PMID PMID: 22328575 PMDBI10729 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 1-(2-aminoimidazol-1-yl)-3 methoxypropanol-2-ol and acetamide n.a. n.a. n.a. In vivo Rat n.a. Gut microbiome–derived nitroreduction Lead to rat carcinogen PMID PMID: 231450 PMDBI10730 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Microbial inactivation PMID PMID: 23869020 PMDBI10731 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD230 CpG-oligonucleotide immunotherapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Prime murine immune cells to secrete tumor necrosis factor(TNF) Stimulate the immune system to attack cancer cells PMID PMID: 24264989 PMDBI10733 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:long-term antibiotic treatment might lead to a failure to control serum cholesterol levels PMID PMID: 24947972 PMDBI10734 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Lead to activation of drug PMID PMID: 25091594 PMDBI10735 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD300 Eltrombopag Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human; Dog n.a. Reductive cleavag n.a. PMID PMID: 25581726 PMDBI10736 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD478 Levosimendan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human; Dog n.a. Reductive cleavag n.a. PMID PMID: 25581726 PMDBI10737 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD445 Indole Therapeutic Substance; Herbal Substance Investigational Drug n.a. n.a. n.a. n.a. indole-3-propionic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. Provide ligands for the aryl hydrocarbon receptor PMID PMID: 26041783 PMDBI10738 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD880 Tryptophan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. indole-3-propionic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. Provide ligands for the aryl hydrocarbon receptor PMID PMID: 26041783 PMDBI10739 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. B-glucuronidase activity Lead to severe diarrhea;drug interaction:antibiotic mixtures(streptomycin,penicillin or neomycin and bacitracin)eliminated fecal b-glucuronidase activity; TJ-14 administration moderate weight loss and delay the drug-associated diarrhea; the P-glycoprotein and (cMOA T/MRP2) inhibitor of cyclosporin A or (UDP)-glucuronosyltransferase inhibitor valproic acid increased intestinal toxicity PMID PMID: 26518357 PMDBI10740 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Mouse n.a. Β-glucuronidases Enhance pharmacological effect PMID PMID: 26701907 PMDBI10741 Microbes metabolize substances PMDBM402 n.a. Unidentified oral microbes PMDBD697 PPIs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Associated with changes toward a less healthy gut microbiome and in line with changes predisposing users to infection with C. difficile Species of bacteria were seen to be over-represented in the fecal microbiome PMID PMID: 26719299 PMDBI10742 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD697 PPIs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Changes in bacterial populations(decrease Bacteroidetes and increase Firmicutes) Predispose PPI-treated subjects to C. difficile infection;[drug interaction]:frequent use of PPIs can exacerbate NSAID-induced small intestinal injury;[probiotics]prevent NSAID-induced damage in patients receiving PPI and NSAIDs PMID PMID: 26923470 PMDBI10743 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse With rosuvastatin Reduce hepatic expression of the CYP27a1,alter the concentrations of bile acids Contribute to the composition of gut microbiota PMID PMID: 28209601 PMDBI10744 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity n.a. n.a. n.a. n.a. Causes toxic side effects PMID PMID: 29104759 PMDBI10745 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dopamine n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase n.a. PMID PMID: 30659181 PMDBI10746 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-FU n.a. n.a. n.a. n.a. n.a. n.a. Deamination by bacteria n.a. PMID PMID: 3729334 PMDBI10747 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD4 2-amino-3,6-dihydro-3H-imidazo[4,5-f]quinoline Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. 7-hydroxy metabolite n.a. n.a. n.a. n.a. n.a. n.a. Gut microbiotal oxidation/dehydrogenation n.a. PMID PMID: 3821779 PMDBI10748 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug is deacetylated n.a. PMID PMID: 4418213 PMDBI10749 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD657 Phenacetin Therapeutic Substance Approved Drug (Withdrawn) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug is deacetylated n.a. PMID PMID: 4418213 PMDBI10750 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. m-hydroxyphenylacetic acid n.a. n.a. n.a. In vivo Rat n.a. Some microbial dehydroxylation Reduce the exposure of the drug in the brain PMID PMID: 5343357 PMDBI10751 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Normal n.a. n.a. PMID PMID: 5345205 PMDBI10752 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD727 Radiation sensitizer misonidazole Therapeutic Substance n.a. n.a. n.a. n.a. n.a. l-(2-l-(2-aminoimidazol-l-yl)-3-methoxypropan-2-ol n.a. n.a. n.a. In vivo Rat Normal,germ-free(GF) Nitroreduction Drug interaction:penicillin increased drug exposure and decreased neurotoxicity PMID PMID: 6260109 PMDBI10753 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat; Dog n.a. Reductive metabolism n.a. PMID PMID: 7512019 PMDBI10754 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD137 Calcitonin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Drug is rapidly degraded;more prone to proteolysis;drug interaction:protease inhibitors(camostat/aprotinin) improve the stability and bioavailability of these peptides PMID PMID: 7550138 PMDBI10755 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. loperamide,the ranitidine,nitazidine n.a. n.a. n.a. In vivo Dog n.a. n.a. n.a. PMID PMID: 7628301 PMDBI10756 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfide metabolite n.a. n.a. n.a. n.a. n.a. n.a. Reduction n.a. PMID PMID: 7629748 PMDBI10757 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD87 Azetirelin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Drug interaction:concentrations of the drug were maintained after the administration of antibiotic PMID PMID: 9279880 PMDBI10758 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2 1-b-D-arabinofuranosyl-5-(E)-(2-bromovinyl)uracil Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. BVU n.a. n.a. n.a. In vivo Rat n.a. The result of hydrolysis by anaerobic bacteria Drug interaction: the drug with the anticancer drug 5-FU or prodrugs tegafur,5-FU accumulate(increase toxicity, including death) PMID PMID: 9808711 PMDBI10759 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. molecule sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Generate the active form of the drug PMID PMID: 31235939 PMDBI10760 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Germ-free(GF) Bt4096 encodes an enzyme that metabolizes diltiazem n.a. PMID PMID: 31235939 PMDBI10761 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD57 Anti‑PD‑1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human melanoma n.a. Prolong progession-free survival PMID PMID: 31462078 PMDBI10762 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD176 Checkpoint inhibitor therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity n.a. n.a. n.a. Overabundance of the bacteroidetes phylum Decrease occrrence of side effect PMID PMID: 31462078 PMDBI10763 Microbes metabolize substances PMDBM186 n.a. Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Bioavailability n.a. Human n.a. A cytochrome-encoding operon (termed the cardiac glycoside reductase) Convert to the inactive microbial metabolite;limit absorbtion;drug interaction:antibiotics,arginine-rich diet(impair this reaction) PMID PMID: 31462078 PMDBI10764 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia Activity of bacteria containing bile salt hydrolases Phyla Firmicutes、Fusobacteria（negatively associated with LDL-C levels）;Cyanobacteria、Lentisphaerae(positively) PMID PMID: 31462078 PMDBI10765 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia Bile salt hydrolase activity Reduce LDL-C levels PMID PMID: 31462078 PMDBI10766 Microbes metabolize substances PMDBM280 1598 Lactobacillus reuteri PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia Bile salt hydrolase activity Reduce LDL-C levels PMID PMID: 31462078 PMDBI10767 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Β-glucuronidases remove the glucuronide group;reactive the drug Sever diarrhea;drug interaction(mice:oral administration of a specific inhibitor of the β-glucuronidase enzyme,reduce irinotecan-induced toxicity) PMID PMID: 31462078 PMDBI10768 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD270 Dietary choline Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. trimethylamine-N-oxide(TMAO) n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbiome-derived metabolites Interfer with drug pharmacokinetics and pharmacodynamics PMID PMID: 31462078 PMDBI10769 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD475 Levocarnitine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. trimethylamine-N-oxide(TMAO) n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbiome-derived metabolites Interfer with drug pharmacokinetics and pharmacodynamics PMID PMID: 31462078 PMDBI10770 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Damage the mucosa of the upper GI tract;be able to distinguish aspirin users:(Prevotella species, Bacteroides species, a member of the Ruminococaceae family, and Barnesiella species PMID PMID: 31462078 PMDBI10771 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human; Rat n.a. Presystemic metabolism by dehydrogenation Decreased amount of active drug reaching target tissues;its major metabolite increased;drug interaction:rat(pretreated with ampicillin),enhance amlodipine's absorption; PMID PMID: 31462078 PMDBI10772 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD78 Atorvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human; Rat High-fat diet (Rat); Hypercholesterolemia (Human) Decreased amount of secondary bile acids Increase abundance of putative anti-inflammatory species PMID PMID: 31462078 PMDBI10773 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD143 Captopril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Hypertensive Decreased intestinal permeability and fibrosis; and improved villi length Reverse the dysbiotic state PMID PMID: 31462078 PMDBI10774 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazapam n.a. n.a. n.a. n.a. n.a. n.a. Reduction reactions Drug interaction:antibiotics(inhibit) PMID PMID: 31462078 PMDBI10777 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Microbial-derived bile acids competing for host uptake transporters Decreased amount of drug reaching target tissues PMID PMID: 31462078 PMDBI10778 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. Bacterial-derived bile acids(lithocholic acid,taurolithocholic acid,glycolithocholic acid) Predict the magnitude of LDL-C lowering PMID PMID: 31462078 PMDBI10780 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-amino-nitrazepam n.a. n.a. Increase Toxicity n.a. n.a. n.a. Nitro reduction by microbiota Produce a teratogenic metabolite;drug interaction:antibiotics(inhibit) PMID PMID: 31462078 PMDBI10842 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD26 Alfuzosin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10843 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD29 Alprenolol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI10844 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.828 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10845 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD140 Camylofine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI10846 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.688 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10847 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD204 Clemizole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10848 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD285 Diphenylpyraline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10849 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD323 Ethoxzolamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10850 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD456 Irsogladine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10851 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD488 Lofexidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10852 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD543 Metitepine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10853 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD625 Orphenadrine citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI10854 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD629 Oxcarbazepine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI10855 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD640 Papaverine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI10856 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD642 Paroxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10857 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD752 Rizatriptan benzoate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10858 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD819 Sulpiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI10859 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD876 Trimetazidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10860 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD893 Verapamil Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10861 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10862 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD13 Acecainide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10863 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD13 Acecainide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10864 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD46 Anastrozole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10865 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD46 Anastrozole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10866 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD103 Benzthiazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI10867 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD103 Benzthiazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI10868 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD112 Bicalutamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.612 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10869 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD112 Bicalutamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI10870 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD130 Bupropion Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI10871 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD130 Bupropion Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10872 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD170 Celecoxib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10873 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD170 Celecoxib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10874 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD234 Cyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10875 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD234 Cyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10876 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10877 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI10878 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD521 Memantine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10879 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD521 Memantine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI10880 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD538 Methsuximide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10881 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD538 Methsuximide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10882 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD542 Methysergide maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10883 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD542 Methysergide maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10884 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD545 Metoprolol tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI10885 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD545 Metoprolol tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.328 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI10886 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD569 Naftopidil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10887 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD569 Naftopidil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.006 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI10888 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10889 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI10890 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD845 Thiothixene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI10891 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD845 Thiothixene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10892 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD864 Tranilast Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI10893 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD864 Tranilast Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI10894 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD897 Vinpocetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI10895 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD897 Vinpocetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI10896 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10897 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI10898 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.805 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI10899 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI10900 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10901 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI10902 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD302 Enalapril maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10903 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD302 Enalapril maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10904 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD302 Enalapril maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10905 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD370 Fluvoxamine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI10906 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD370 Fluvoxamine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10907 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD370 Fluvoxamine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI10908 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD781 Sildenafil citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10909 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD781 Sildenafil citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10910 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD781 Sildenafil citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.424 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10911 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10912 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10913 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10914 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD900 Warfarin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10915 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD900 Warfarin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI10916 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD900 Warfarin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10917 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD913 Ziprasidone mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI10918 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD913 Ziprasidone mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10919 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD913 Ziprasidone mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10920 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10921 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10922 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10923 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10924 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10925 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10926 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI10927 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI10928 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.956 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI10929 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10930 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.23 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI10931 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.969 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10932 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10933 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10934 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10935 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.995 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10936 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI10937 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10938 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10939 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10940 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10941 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.725 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10942 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10943 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI10944 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI10945 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI10946 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10947 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10948 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI10949 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10950 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10951 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.583 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI10952 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10953 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10954 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI10955 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10956 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10957 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI10958 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10959 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10960 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10961 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10962 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI10963 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10964 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI10965 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10966 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10967 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10968 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10969 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI10970 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10971 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10972 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI10973 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10974 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10975 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10976 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI10977 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10978 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10979 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.327 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI10980 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.961 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI10981 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI10982 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI10983 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10984 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10985 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10986 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10987 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI10988 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10989 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10990 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI10991 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.057 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI10992 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI10993 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10994 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10995 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10996 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10997 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10998 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10999 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11000 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11001 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.346 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11002 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11003 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11004 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11005 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11006 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11007 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11008 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11009 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11010 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11011 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11012 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11013 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11014 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11015 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11016 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11017 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11018 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11019 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11020 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11021 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11022 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11023 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11024 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11025 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11026 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11027 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11028 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11029 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11030 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11031 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11032 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.516 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11033 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.559 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11034 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11035 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.308 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11036 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.855 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11037 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.527 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11038 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11039 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11040 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.067 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11041 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11042 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.136 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11043 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.204 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11044 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11045 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11046 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11047 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11048 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.698 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11049 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.744 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11050 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11051 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.41 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11052 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11053 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11054 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11055 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11056 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11057 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.692 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11058 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11059 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11060 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11061 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11062 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11063 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11064 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11065 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11066 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.162 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11067 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.328 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11068 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11069 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11070 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI11071 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.47 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11072 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.287 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11073 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11074 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11075 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11076 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11077 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11078 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11079 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11080 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD731 Ranitidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11081 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11082 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11083 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11084 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11085 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11086 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11087 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11088 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.843 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11089 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11090 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.605 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11091 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11092 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11093 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11094 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.363 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11095 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11096 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11097 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11098 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11099 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11100 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11101 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11102 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11103 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11104 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11105 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11106 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11107 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11108 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11109 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11110 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11111 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11112 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11113 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11114 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11115 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11116 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.937 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11117 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.453 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11118 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11119 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11120 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11121 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11122 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11123 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11124 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11125 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11126 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11127 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11128 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11129 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11130 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11131 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.673 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11132 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11133 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11134 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11135 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11136 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11137 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11138 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11139 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11140 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11141 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.868 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11142 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11143 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11144 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11145 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11146 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11147 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11148 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11149 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11150 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11151 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11152 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11153 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11154 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11155 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11156 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.188 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11157 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11158 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.751 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11159 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.029 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11160 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11161 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11162 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11163 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11164 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11165 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11166 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11167 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11168 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11169 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11170 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11171 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11172 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11173 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11174 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11175 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11176 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11177 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11178 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11179 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11180 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11181 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11182 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11183 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11184 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11185 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11186 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.572 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11187 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11188 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.509 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11189 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11190 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11191 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.36 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11192 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11193 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11194 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11195 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11196 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11197 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11198 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11199 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11200 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11201 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11202 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11203 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11204 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11205 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11206 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11207 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11208 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11209 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11210 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11211 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11212 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11213 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11214 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11215 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11216 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11217 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11218 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11219 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11220 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11221 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11222 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11223 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11224 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11225 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11226 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11227 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11228 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11229 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11230 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11231 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11232 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11233 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11234 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11235 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11236 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11237 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11238 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11239 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11240 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11241 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11242 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11243 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11244 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11245 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11246 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.852 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11247 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11248 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11249 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.069 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11250 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11251 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11252 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11253 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11254 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11255 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11256 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11257 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11258 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11259 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11260 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11261 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11262 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11263 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.912 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11264 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11265 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11266 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11267 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11268 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11269 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11270 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11271 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11272 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11273 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11274 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11275 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11276 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11277 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11278 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11279 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11280 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11281 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.735 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11282 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11283 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11284 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11285 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11286 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.039 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11287 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11288 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11289 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11290 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11291 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11292 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11293 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11294 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11295 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11296 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11297 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11298 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11299 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11300 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11301 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.67 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11302 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11303 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD377 Galantamine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11304 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11305 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11306 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11307 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.721 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11308 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11309 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11310 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11311 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11312 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11313 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11314 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11315 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD415 Griseofulvin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11316 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11317 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11318 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11319 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11320 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11321 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11322 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11323 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11324 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11325 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11326 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11327 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11328 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11329 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11330 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.722 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11331 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.98 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11332 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11333 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11334 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11335 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11336 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11337 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11338 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.708 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11339 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD572 Naloxone Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11340 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11341 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11342 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11343 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11344 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11345 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11346 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11347 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11348 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11349 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11350 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11351 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11352 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11353 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11354 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11355 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11356 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11357 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11358 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11359 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11360 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11361 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11362 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11363 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11364 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.999 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11365 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11366 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11367 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11368 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.886 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11369 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11370 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.005 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11371 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11372 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11373 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11374 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11375 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.615 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11376 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11377 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11378 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11379 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11380 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11381 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11382 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11383 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11384 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11385 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11386 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11387 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11388 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD223 Colchicine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11389 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11390 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11391 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11392 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11393 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11394 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.781 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11395 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11396 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.207 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11397 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11398 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.677 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11399 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.654 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11400 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.964 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11401 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11402 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11403 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11404 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11405 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11406 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11407 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11408 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11409 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11410 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11411 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.601 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11412 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11413 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11414 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.655 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11415 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11416 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11417 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11418 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11419 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11420 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11421 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11422 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11423 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11424 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11425 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.63 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11426 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11427 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11428 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11429 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11430 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11431 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11432 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11433 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11434 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11435 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11436 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11437 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11438 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11439 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11440 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.727 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11441 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11442 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11443 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11444 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11445 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11446 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11447 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11448 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11449 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11450 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11451 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11452 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11453 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11454 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11455 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11456 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11457 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11458 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11459 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.427 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11460 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11461 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11462 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11463 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11464 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11465 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11466 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11467 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11468 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11469 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11470 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11471 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11472 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11473 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11474 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11475 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11476 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11477 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.484 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11478 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11479 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11480 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11481 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11482 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11483 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11484 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11485 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11486 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11487 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11488 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11489 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11490 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11491 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11492 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11493 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11494 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11495 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.78 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11496 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11497 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11498 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11499 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11500 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11501 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11502 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11503 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11504 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11505 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11506 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11507 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11508 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11509 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11510 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11511 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11512 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11513 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11514 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11515 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11516 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11517 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.334 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11518 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11519 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11520 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.997 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11521 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11522 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11523 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11524 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11525 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11526 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.922 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11527 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.225 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11528 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.632 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11529 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.426 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11530 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.691 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11531 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.975 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11532 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.243 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11533 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.653 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11534 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.566 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11535 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.604 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI11536 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11537 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.092 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11538 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.46 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11539 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.656 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11540 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.322 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11541 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11542 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11543 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11544 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.428 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11545 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11546 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11547 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11548 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11549 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11550 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11551 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11552 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11553 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11554 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11555 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11556 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11557 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.6 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11558 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11559 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.215 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11560 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11561 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.342 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11562 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.623 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11563 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.764 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11564 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.722 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11565 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.787 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11566 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.253 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11567 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.544 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11568 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.018 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11569 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.902 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11570 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.569 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11571 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11572 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11573 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11574 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11575 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11576 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11577 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11578 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.768 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11579 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.603 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11580 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11581 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11582 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11583 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11584 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11585 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11586 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.013 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11587 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.989 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11588 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.126 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11589 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11590 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11591 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11592 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11593 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11594 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.052 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11595 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11596 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11597 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.833 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11598 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11599 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11600 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11601 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11602 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11603 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11604 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.747 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11605 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11606 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11607 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.816 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11608 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11609 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11610 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11611 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11612 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11613 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11614 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11615 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.922 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11616 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11617 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11618 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11619 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11620 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11621 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11622 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11623 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11624 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.542 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11625 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11626 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11627 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11628 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11629 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11630 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.829 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11631 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11632 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.969 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11633 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11634 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.908 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11635 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11636 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.867 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11637 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.66 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11638 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11639 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11640 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11641 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11642 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11643 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11644 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11645 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11646 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.637 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11647 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11648 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.825 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11649 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11650 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11651 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11652 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11653 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11654 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11655 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11656 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11657 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11658 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11659 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11660 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11661 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11662 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11663 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11664 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11665 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11666 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11667 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11668 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11669 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11670 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11671 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11672 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.83 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11673 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11674 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11675 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11676 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11677 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11678 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11679 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11680 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11681 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11682 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11683 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11684 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11685 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11686 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11687 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11688 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11689 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11690 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11691 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11692 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11693 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11694 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11695 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11696 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11697 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11698 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11699 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11700 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.146 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11701 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11702 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11703 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.011 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11704 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11705 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11706 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11707 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11708 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11709 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11710 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11711 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11712 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11713 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11714 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11715 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD537 Methoxsalen Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.93 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11716 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11717 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11718 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11719 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11720 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11721 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11722 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11723 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11724 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11725 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11726 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11727 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11728 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11729 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11730 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11731 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11732 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11733 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11734 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11735 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11736 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11737 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11738 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11739 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11740 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11741 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.703 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11742 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11743 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11744 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11745 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11746 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11747 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11748 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11749 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11750 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11751 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.481 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11752 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11753 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.604 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11754 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11755 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11756 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11757 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11758 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11759 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11760 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11761 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11762 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11763 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11764 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11765 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11766 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11767 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11768 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11769 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11770 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11771 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11772 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11773 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11774 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11775 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11776 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11777 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11778 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11779 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.864 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11780 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11781 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11782 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11783 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11784 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11785 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.752 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11786 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.802 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11787 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11788 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11789 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11790 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11791 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.104 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11792 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11793 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11794 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11795 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.963 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11796 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11797 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.777 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11798 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.94 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11799 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11800 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11801 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.231 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11802 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.171 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11803 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.133 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11804 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.821 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11805 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11806 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11807 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.3 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11808 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.178 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11809 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11810 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11811 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11812 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11813 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11814 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11815 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.591 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11816 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11817 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.84 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11818 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11819 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11820 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.965 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11821 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11822 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11823 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11824 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.01 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11825 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.072 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11826 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11827 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11828 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11829 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11830 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.771 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11831 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11832 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11833 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11834 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11835 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11836 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11837 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11838 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11839 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11840 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11841 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11842 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11843 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11844 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11845 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11846 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11847 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11848 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11849 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11850 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11851 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11852 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11853 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11854 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11855 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11856 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11857 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11858 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11859 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11860 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11861 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11862 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11863 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11864 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11865 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11866 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11867 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.86 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11868 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11869 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11870 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11871 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11872 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11873 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11874 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.468 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11875 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.607 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11876 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11877 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11878 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11879 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11880 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11881 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11882 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.393 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11883 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11884 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11885 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.631 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11886 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11887 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11888 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11889 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11890 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11891 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11892 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11893 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11894 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11895 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11896 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11897 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11898 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11899 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11900 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11901 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11902 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11903 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11904 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11905 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11906 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11907 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.562 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11908 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.725 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11909 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11910 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11911 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11912 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.96 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11913 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11914 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11915 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11916 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.876 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11917 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11918 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11919 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.089 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11920 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11921 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11922 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11923 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11924 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11925 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11926 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11927 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11928 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11929 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.988 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11930 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11931 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.179 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11932 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11933 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11934 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.096 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11935 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.183 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11936 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11937 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11938 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.351 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11939 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11940 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11941 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11942 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11943 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11944 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11945 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11946 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11947 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11948 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11949 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11950 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11951 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD474 Levamisole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.697 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11952 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11953 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11954 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11955 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11956 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11957 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11958 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11959 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11960 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11961 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.777 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11962 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11963 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11964 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11965 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11966 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11967 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11968 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11969 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11970 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11971 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11972 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD490 Loperamide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11973 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11974 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11975 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11976 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11977 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11978 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.024 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11979 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11980 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11981 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11982 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11983 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11984 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11985 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11986 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11987 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11988 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11989 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11990 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11991 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11992 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11993 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11994 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11995 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11996 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.579 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11997 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.565 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11998 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.571 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11999 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.148 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12000 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12001 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12002 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12003 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12004 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12005 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12006 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12007 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.605 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12008 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12009 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12010 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12011 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12012 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12013 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.846 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12014 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12015 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12016 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12017 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12018 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12019 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12020 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.323 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12021 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12022 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12023 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12024 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12025 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.794 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12026 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12027 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12028 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.6 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12029 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.395 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12030 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI12031 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12032 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12033 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12034 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12035 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12036 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12037 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12038 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12039 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12040 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12041 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12042 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12043 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12044 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12045 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12046 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12047 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.575 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12048 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12049 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12050 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12051 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12052 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12053 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12054 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12055 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12056 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12057 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI12058 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12059 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12060 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12061 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.55 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12062 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12063 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.44 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12064 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12065 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12066 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.987 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12067 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12068 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12069 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12070 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.86 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12071 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12072 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.05 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12073 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12074 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12075 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.045 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12076 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12077 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.149 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12078 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12079 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.351 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12080 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12081 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12082 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12083 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12084 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.421 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12085 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12086 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12087 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12088 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12089 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12090 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12091 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12092 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12093 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12094 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12095 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12096 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12097 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12098 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12099 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12100 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12101 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12102 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12103 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12104 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12105 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12106 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD275 Digitoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12107 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12108 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12109 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12110 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12111 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12112 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12113 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12114 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12115 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12116 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12117 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12118 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12119 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12120 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12121 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12122 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12123 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12124 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12125 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12126 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12127 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12128 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.979 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI12129 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12130 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12131 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12132 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12133 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12134 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12135 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12136 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12137 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.368 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12138 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12139 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12140 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12141 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12142 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12143 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12144 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12145 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12146 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12147 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.416 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12148 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12149 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12150 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12151 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12152 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12153 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.972 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12154 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12155 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.822 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12156 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12157 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12158 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.801 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12159 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12160 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12161 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12162 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.463 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12163 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12164 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.672 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12165 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.051 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12166 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12167 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12168 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12169 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12170 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.451 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12171 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12172 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.964 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI12173 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12174 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12175 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12176 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.019 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12177 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD821 Tacrolimus Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12178 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.11 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12179 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12180 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.076 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12181 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.041 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12182 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12183 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.931 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12184 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12185 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12186 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12187 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12188 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12189 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.884 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12190 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.5 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12191 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.94 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12192 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12193 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI12194 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI12195 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12196 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12197 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12198 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12199 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12200 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12201 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12202 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12203 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD496 Lovastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12204 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12205 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12206 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12207 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12208 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12209 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12210 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12211 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12212 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12213 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12214 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12215 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12216 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12217 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12218 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12219 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12220 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12221 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI12222 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12223 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12224 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12225 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12226 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12227 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12228 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12229 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI12230 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12231 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12232 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12233 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12234 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12235 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12236 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12237 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12238 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12239 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12240 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12241 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12242 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12243 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12244 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12245 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12246 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12247 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12248 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12249 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12250 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12251 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12252 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12253 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12254 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12255 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12256 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12257 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12258 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.766 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12259 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12260 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12261 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12262 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.957 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12263 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12264 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12265 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12266 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12267 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.811 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12268 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12269 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12270 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12271 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12272 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12273 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12274 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12275 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12276 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12277 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12278 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12279 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12280 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12281 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12282 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12283 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12284 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.687 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12285 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12286 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12287 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12288 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12289 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.737 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12290 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.699 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12291 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.23 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12292 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.9 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12293 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12294 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.675 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12295 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.287 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12296 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.602 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12297 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12298 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.304 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12299 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.4 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12300 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.075 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12301 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.163 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12302 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.091 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12303 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.049 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12304 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.485 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12305 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.018 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12306 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.449 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12307 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.025 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12308 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12309 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.714 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12310 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12311 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.525 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12312 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.985 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12313 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12314 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12315 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.198 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12316 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.726 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12317 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.194 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12318 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12319 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.667 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12320 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12321 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12322 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.773 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12323 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.084 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12324 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.485 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12325 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.916 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12326 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12327 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12328 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.073 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12329 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.272 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12330 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.27 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12331 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12332 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12333 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.231 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12334 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12335 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.913 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12336 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.389 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12337 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12338 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.315 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12339 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.262 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12340 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12341 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12342 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.852 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12343 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.786 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12344 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12345 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.797 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12346 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12347 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.926 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12348 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.603 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12349 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.022 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12350 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.84 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12351 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12352 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.199 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12353 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.744 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12354 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.635 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12355 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.919 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12356 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.957 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12357 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.857 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI12358 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.998 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12359 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.783 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12360 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.331 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12361 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.225 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12362 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12363 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.791 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12364 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12365 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.383 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12366 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12367 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.95 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12368 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.474 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12369 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.096 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12370 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.639 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12371 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.397 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12372 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.783 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12373 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.554 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12374 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.872 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12375 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.353 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12376 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.818 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12377 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.942 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12378 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.097 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12379 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI12380 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12381 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12382 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12383 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.061 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12384 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.639 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12385 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12386 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12387 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12388 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12389 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12390 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12391 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12392 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12393 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.062 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12394 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.698 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12395 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12396 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12397 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12398 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12399 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12400 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12401 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12402 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12403 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12404 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.746 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12405 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12406 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12407 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12408 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12409 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.948 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12410 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12411 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12412 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12413 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12414 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12415 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12416 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12417 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12418 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12419 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12420 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12421 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12422 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.002 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12423 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12424 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12425 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12426 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12427 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12428 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12429 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI12430 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI12431 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12432 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12433 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.418 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12434 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12435 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12436 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12437 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.849 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12438 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12439 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12440 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12441 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.03 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12442 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.342 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12443 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.806 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12444 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12445 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12446 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.949 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12447 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.962 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12448 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.505 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12449 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12450 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.892 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12451 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12452 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12453 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.178 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12454 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.073 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12455 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.515 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12456 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.735 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12457 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12458 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12459 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.054 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12460 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.949 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12461 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12462 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.898 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12463 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.549 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12464 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.476 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12465 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.901 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12466 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12467 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.134 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12468 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12469 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12470 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12471 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.091 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12472 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.015 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12473 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12474 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.202 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12475 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12476 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.39 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12477 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12478 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12479 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.132 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12480 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12481 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.233 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12482 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12483 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.672 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12484 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.38 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12485 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.826 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12486 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.316 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12487 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12488 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12489 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.305 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12490 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.537 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12491 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.273 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12492 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.14 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12493 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12494 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.875 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12495 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.369 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12496 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.404 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12497 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.04 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12498 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.159 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12499 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12500 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.859 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12501 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.981 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12502 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.76 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12503 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.89 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12504 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.799 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12505 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.489 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12506 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12507 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.91 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12508 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.97 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12509 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.794 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12510 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12511 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.298 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12512 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.488 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12513 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.93 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12514 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.33 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12515 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.418 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12516 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.144 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12517 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.766 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12518 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.133 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12519 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.491 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12520 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12521 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.607 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12522 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12523 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12524 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.133 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12525 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.876 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12526 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12527 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.379 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12528 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.033 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12529 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.37 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12530 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.251 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12531 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.435 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12532 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.493 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12533 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI12534 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12535 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12536 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.811 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12537 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.766 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12538 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.382 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12539 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.362 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12540 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.313 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12541 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.428 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12542 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.922 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12543 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.831 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12544 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.629 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12545 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.419 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12546 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.071 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12547 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.164 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12548 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.959 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12549 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12550 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.801 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12551 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.567 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12552 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12553 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.715 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12554 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.804 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12555 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12556 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12557 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.556 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12558 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.672 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12559 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.664 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12560 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.684 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12561 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12562 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.066 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12563 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.333 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12564 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.515 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12565 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12566 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.664 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12567 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.527 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12568 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12569 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.612 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12570 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12571 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12572 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI12573 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.566 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12574 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.885 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12575 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12576 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.039 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12577 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.853 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12578 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12579 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.728 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12580 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.386 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12581 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.23 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12582 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.706 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12583 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.426 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12584 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.312 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12585 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.694 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12586 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.254 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12587 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12588 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.057 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12589 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.932 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12590 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.366 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12591 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12592 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12593 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.939 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12594 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.431 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12595 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.026 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12596 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12597 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.139 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12598 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.106 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12599 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12600 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.671 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12601 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI12602 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI12603 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12604 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12605 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12606 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12607 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.818 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12608 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.556 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12609 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.06 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12610 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.205 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12611 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.869 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12612 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12613 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12614 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12615 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.613 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12616 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.21 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12617 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12618 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.262 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12619 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.105 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12620 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12621 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12622 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12623 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12624 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12625 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.253 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12626 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.293 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12627 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.344 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12628 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.166 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12629 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.92 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12630 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12631 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.756 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12632 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12633 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12634 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.731 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12635 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.875 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12636 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12637 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12638 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12639 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12640 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12641 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12642 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12643 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12644 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12645 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12646 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.567 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12647 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12648 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12649 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12650 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12651 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12652 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12653 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12654 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12655 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12656 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12657 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12658 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12659 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12660 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12661 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12662 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.984 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12663 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12664 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12665 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.155 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12666 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12667 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12668 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12669 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12670 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI12671 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12672 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12673 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12674 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.718 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12675 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.824 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12676 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12677 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12678 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12679 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12680 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.123 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12681 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12682 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.017 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12683 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12684 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.606 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12685 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.215 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12686 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12687 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12688 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.38 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12689 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD366 Fluoxetine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.666 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12690 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.764 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12691 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.178 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12692 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.136 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12693 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.872 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12694 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12695 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.961 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12696 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.886 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12697 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.983 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12698 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.213 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12699 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12700 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12701 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.715 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12702 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.719 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12703 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12704 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.471 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12705 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.21 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12706 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.719 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12707 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.711 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12708 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12709 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.977 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12710 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.813 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12711 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.98 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12712 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.047 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12713 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.105 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12714 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12715 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.52 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12716 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.531 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12717 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.243 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12718 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12719 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.536 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12720 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.164 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12721 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.581 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12722 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12723 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.825 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12724 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.806 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12725 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.878 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12726 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.017 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12727 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12728 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12729 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.086 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12730 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12731 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.613 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12732 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.071 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12733 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.578 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12734 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.856 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12735 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.69 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12736 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.729 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12737 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12738 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.792 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12739 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.153 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12740 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12741 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.225 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12742 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.878 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12743 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.966 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12744 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.11 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12745 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.19 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12746 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.103 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12747 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.037 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12748 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.173 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12749 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.479 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12750 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.222 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12751 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.514 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12752 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.516 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12753 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.868 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12754 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.937 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12755 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.569 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12756 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.556 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12757 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12758 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.631 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12759 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12760 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.073 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12761 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12762 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.095 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12763 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.385 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12764 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.858 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12765 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.938 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12766 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.443 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12767 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.168 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12768 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.237 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12769 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.484 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12770 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.786 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12771 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.982 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12772 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.999 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12773 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.666 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12774 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.08 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12775 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12776 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.384 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12777 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.432 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12778 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.272 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12779 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.037 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12780 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.551 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12781 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.975 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12782 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.045 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12783 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.736 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12784 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.463 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12785 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.258 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12786 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.846 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12787 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.876 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12788 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.669 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12789 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.286 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12790 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.928 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12791 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.836 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12792 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.663 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12793 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.509 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12794 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.279 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12795 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.725 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12796 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12797 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.322 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12798 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.234 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12799 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.631 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12800 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.224 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12801 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.648 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12802 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.056 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12803 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.351 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12804 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.911 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12805 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.167 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12806 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.405 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12807 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.389 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12808 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.722 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12809 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.247 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12810 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12811 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.046 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12812 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12813 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.59 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12814 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.234 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12815 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.08 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12816 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.639 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12817 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.631 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12818 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.502 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12819 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.242 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12820 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.629 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12821 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.679 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12822 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.826 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12823 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.064 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12824 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.088 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12825 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.113 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12826 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.256 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12827 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI12828 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.337 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12829 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.522 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12830 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12831 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.071 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12832 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.478 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12833 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.296 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12834 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.007 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12835 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.693 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12836 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.184 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12837 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12838 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.182 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12839 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.031 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12840 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.585 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12841 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.384 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12842 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.184 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12843 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.663 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12844 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.888 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12845 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.605 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12846 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12847 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.916 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12848 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12849 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12850 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.892 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12851 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12852 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12853 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.002 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12854 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.854 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12855 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.072 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12856 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.61 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12857 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.01 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12858 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.927 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12859 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.039 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12860 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12861 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.303 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12862 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12863 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12864 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12865 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.844 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12866 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.252 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12867 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.327 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12868 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.522 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12869 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.398 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12870 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.576 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12871 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.641 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12872 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.756 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12873 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.211 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12874 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.21 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12875 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.326 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12876 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.625 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12877 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.355 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12878 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.221 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12879 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.879 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12880 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12881 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12882 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.51 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12883 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.402 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12884 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.773 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12885 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.078 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12886 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12887 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.163 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12888 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.325 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12889 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.75 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12890 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.885 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12891 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.333 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12892 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12893 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.896 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12894 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.977 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12895 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.401 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12896 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.688 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12897 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.251 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12898 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.946 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12899 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.152 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12900 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.03 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12901 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.863 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12902 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.098 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12903 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.082 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12904 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.527 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12905 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.682 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12906 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.753 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12907 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.781 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12908 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.021 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12909 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.284 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12910 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.676 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12911 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.668 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12912 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.134 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12913 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.536 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12914 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.592 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12915 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.624 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12916 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.053 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12917 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.387 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12918 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.609 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12919 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12920 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.603 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12921 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.448 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12922 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.943 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12923 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.845 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12924 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.338 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12925 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12926 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12927 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12928 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.31 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12929 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.418 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12930 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.685 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12931 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.839 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12932 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.07 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12933 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.71 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12934 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.543 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12935 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.994 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12936 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12937 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.098 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12938 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12939 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12940 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.89 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12941 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12942 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12943 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12944 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12945 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12946 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12947 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12948 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.657 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12949 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI12950 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12951 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12952 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12953 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12954 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12955 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12956 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12957 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.462 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12958 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.353 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12959 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.799 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12960 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.044 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12961 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.3 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12962 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12963 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12964 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12965 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12966 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12967 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12968 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12969 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.877 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12970 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12971 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.781 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12972 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12973 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12974 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12975 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12976 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.223 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12977 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12978 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12979 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12980 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12981 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12982 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.079 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12983 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12984 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.675 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12985 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12986 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12987 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12988 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12989 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.175 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12990 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12991 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.665 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12992 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12993 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12994 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12995 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12996 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12997 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12998 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12999 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13000 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13001 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13002 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.242 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13003 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.889 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13004 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13005 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.164 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13006 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.789 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13007 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.977 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13008 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI13009 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.348 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13010 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.02 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13011 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13012 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI13013 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13014 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13015 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.327 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13016 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13017 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13018 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.993 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13019 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13020 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13021 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.64 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13022 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13023 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI13024 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13025 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI13026 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13027 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13028 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13029 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13030 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.364 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13031 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.13 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13032 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.272 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI13033 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI13034 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.023 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13035 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13036 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13037 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.911 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13038 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.097 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13039 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.343 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13040 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.933 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13041 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.361 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13042 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13043 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.127 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13044 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13045 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13046 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13047 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI13048 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.976 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13049 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13050 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13051 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.921 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13052 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.925 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI13053 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.718 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13054 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.102 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13055 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.548 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13056 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.563 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13057 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI13058 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13059 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13060 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13061 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13062 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.157 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13063 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.198 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13064 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13065 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.066 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13066 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.099 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13067 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13068 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.539 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13069 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.594 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13070 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.053 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13071 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.579 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI13072 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.15 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13073 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.246 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13074 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.121 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13075 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.363 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13076 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.878 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13077 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.194 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13078 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.106 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13079 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.731 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13080 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.636 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13081 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI13082 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.532 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13083 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.365 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13084 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13085 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.004 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13086 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.445 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13087 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.862 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13088 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.171 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13089 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.7 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13090 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI13091 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13092 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.008 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13093 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13094 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.342 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13095 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.631 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13096 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.282 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13097 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.099 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13098 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.865 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13099 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13100 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.119 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13101 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.964 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13102 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.665 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13103 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13104 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.393 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13105 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.315 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13106 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.548 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13107 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.281 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13108 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13109 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.034 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13110 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.254 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13111 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.375 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13112 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.213 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13113 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.255 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13114 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.258 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13115 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13116 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.842 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13117 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.076 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13118 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13119 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13120 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13121 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.063 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13122 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.104 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13123 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.135 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13124 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13125 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.42 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13126 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13127 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.58 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13128 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.77 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13129 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.83 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13130 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.775 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13131 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.56 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13132 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.334 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13133 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.788 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13134 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.839 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13135 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.877 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13136 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13137 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13138 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.29 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13139 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13140 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.012 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13141 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.172 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13142 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.539 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI13143 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.805 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13144 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.544 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13145 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.099 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13146 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.901 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13147 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.527 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13148 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.834 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13149 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.318 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13150 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13151 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.254 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13152 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.623 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13153 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.624 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13154 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.772 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI13155 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.139 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13156 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.848 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13157 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.913 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13158 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.237 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13159 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.912 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13160 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.35 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13161 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.388 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13162 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.995 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13163 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.165 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13164 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13165 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.826 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13166 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.035 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13167 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.009 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13168 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.493 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13169 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.68 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI13170 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.212 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13171 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.48 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13172 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.371 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13173 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.315 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13174 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.112 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13175 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.335 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13176 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13177 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.617 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13178 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13179 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13180 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.285 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13181 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.181 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13182 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.454 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13183 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13184 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.594 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13185 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.994 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI13186 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.247 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13187 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13188 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.43 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13189 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.818 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13190 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.465 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13191 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.732 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13192 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13193 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.789 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13194 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13195 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.135 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13196 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13197 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.187 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13198 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.772 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13199 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.917 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13200 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.995 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13201 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.67 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13202 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.352 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13203 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13204 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.655 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13205 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.937 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13206 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13207 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.763 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13208 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13209 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13210 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.675 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI13211 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.823 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI13212 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.724 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI13213 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.867 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI13214 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.32 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13215 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.068 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13216 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.1 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13217 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.523 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13218 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.841 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13219 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.955 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13220 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.708 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13221 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.407 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13222 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13223 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.848 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13224 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.248 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13225 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.84 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13226 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13227 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.048 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13228 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.744 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13229 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.042 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13230 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.687 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13231 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.783 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13232 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.833 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13233 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.968 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13234 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.611 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI13235 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.32 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13236 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.227 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13237 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.44 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13238 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13239 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.804 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13240 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.024 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13241 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.912 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI13242 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.086 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13243 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.877 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI13244 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.491 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13245 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.817 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13246 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.831 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13247 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.717 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13248 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.158 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13249 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.367 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13250 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13251 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.638 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13252 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.433 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13253 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.12 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13254 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.345 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13255 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.595 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13256 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.46 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13257 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13258 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.291 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13259 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.178 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13260 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.41 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13261 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13262 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.138 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13263 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13264 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.67 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13265 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.406 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13266 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.404 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13267 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.57 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13268 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.716 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13269 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.131 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13270 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.916 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13271 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.244 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13272 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.117 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI13273 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.334 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13274 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.709 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13275 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.928 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13276 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13277 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.109 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13278 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.531 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13279 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.103 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13280 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.76 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13281 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.572 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13282 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.686 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13283 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.301 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13284 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.649 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13285 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.671 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13286 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13287 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.733 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13288 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.947 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13289 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.983 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13290 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.5 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13291 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.028 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13292 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.156 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13293 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.414 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13294 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.609 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13295 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.062 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13296 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.408 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13297 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13298 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.373 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13299 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.668 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13300 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.97 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13301 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.147 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13302 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.801 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13303 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13304 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.671 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13305 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.378 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13306 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.635 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13307 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13308 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.38 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13309 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.096 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13310 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.521 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13311 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.22 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13312 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.556 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13313 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13314 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.423 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13315 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.089 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13316 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13317 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.92 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13318 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.898 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13319 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.645 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13320 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI13321 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.183 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13322 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13323 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.166 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13324 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.863 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13325 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.529 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13326 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.676 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13327 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.927 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13328 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13329 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.216 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13330 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.259 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13331 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.117 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13332 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.366 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13333 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.709 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13334 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13335 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.065 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13336 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.642 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13337 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.583 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13338 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.576 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13339 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13340 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13341 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13342 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.595 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13343 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.215 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13344 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.392 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13345 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.268 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13346 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.246 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13347 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.28 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13348 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.156 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI13349 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.966 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13350 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.873 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13351 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.453 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13352 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.013 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13353 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.812 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13354 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.563 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13355 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.397 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13356 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.517 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13357 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.289 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13358 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.345 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13359 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13360 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.183 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13361 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.458 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13362 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.355 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13363 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.371 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13364 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.558 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13365 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.065 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13366 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.334 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13367 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.464 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13368 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.374 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13369 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.584 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13370 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13371 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.412 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13372 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.3 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13373 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13374 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13375 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.385 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13376 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.391 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13377 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13378 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13379 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.844 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13380 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.526 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13381 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13382 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.901 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13383 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.173 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13384 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.316 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13385 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.874 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13386 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.784 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13387 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.195 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13388 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.467 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13389 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.27 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13390 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.311 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13391 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.146 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13392 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.006 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13393 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.571 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13394 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.505 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13395 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.849 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13396 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13397 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.645 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13398 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.733 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13399 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.445 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI13400 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.543 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13401 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13402 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13403 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.581 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13404 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.699 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13405 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.776 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13406 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.296 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13407 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.344 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13408 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.443 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13409 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13410 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13411 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.615 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13412 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.786 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13413 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.363 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13414 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.249 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13415 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.861 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13416 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.686 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13417 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13418 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13419 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.601 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13420 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.731 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13421 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.281 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13422 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.742 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13423 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.148 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13424 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.706 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13425 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.802 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13426 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.855 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13427 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.448 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13428 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.162 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13429 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.005 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13430 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.718 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13431 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.153 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13432 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.851 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13433 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.201 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13434 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.659 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13435 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.61 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13436 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.892 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13437 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.492 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13438 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.986 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13439 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.578 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13440 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.773 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13441 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.513 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13442 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.681 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13443 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13444 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.467 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13445 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.362 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13446 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.316 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13447 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.65 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13448 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.463 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13449 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.2 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13450 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13451 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.436 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13452 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.415 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13453 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13454 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.097 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI13455 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.775 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI13456 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.071 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI13457 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.503 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13458 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.67 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13459 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.396 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13460 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13461 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.628 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI13462 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.499 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13463 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.014 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13464 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.563 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13465 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.246 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13466 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.067 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13467 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13468 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.804 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13469 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.496 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13470 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.786 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13471 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.449 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13472 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.045 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13473 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.212 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13474 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.419 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13475 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13476 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.679 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13477 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.287 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI13478 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.319 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13479 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.391 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13480 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.987 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13481 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.875 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13482 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.814 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13483 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13484 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.944 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13485 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.527 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13486 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.421 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13487 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.418 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13488 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.794 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13489 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.716 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13490 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.222 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13491 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.207 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13492 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.66 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13493 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.531 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13494 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13495 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.654 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13496 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.87 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13497 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.612 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13498 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.102 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13499 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.027 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13500 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.233 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13501 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.813 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13502 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.878 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13503 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.22 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13504 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.378 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13505 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.752 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13506 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.091 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13507 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.989 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13508 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-12.105 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13509 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.313 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13510 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.466 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13511 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.173 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13512 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13513 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.431 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13514 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.122 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13515 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.718 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13516 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.5 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13517 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.186 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13518 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.204 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13519 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.255 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13520 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.885 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13521 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13522 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.422 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13523 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.311 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13524 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.728 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13525 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.452 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13526 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.686 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13527 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.712 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13528 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.324 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI13529 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.654 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13530 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.456 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13531 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.716 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13532 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.49 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13533 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.584 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13534 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.081 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13535 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.328 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13536 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.122 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13537 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.549 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13538 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.863 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13539 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.547 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13540 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.23 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13541 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.41 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13542 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.369 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13543 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.192 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13544 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.472 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13545 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.201 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13546 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.266 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13547 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.587 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13548 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13549 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.678 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13550 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.639 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13551 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.854 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13552 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.863 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13553 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.33 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13554 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.0 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13555 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.708 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13556 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.324 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13557 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.482 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13558 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.339 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13559 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.438 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13560 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.176 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13561 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.146 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13562 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.462 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13563 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.412 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13564 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.394 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13565 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.531 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13566 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.5 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13567 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.735 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13568 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.213 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13569 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.349 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13570 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.329 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13571 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.467 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13572 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.69 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13573 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.127 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13574 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.295 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13575 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.788 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13576 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.796 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13577 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.658 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13578 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.571 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13579 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.068 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13580 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.955 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13581 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.441 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13582 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.52 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13583 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.869 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13584 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.412 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13585 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.969 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13586 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.142 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13587 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.785 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13588 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.529 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13589 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13590 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.657 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13591 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.488 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13592 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.949 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13593 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.2 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13594 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.127 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13595 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.673 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13596 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.432 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13597 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.41 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13598 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.326 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13599 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.147 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13600 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.965 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13601 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.968 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13602 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.823 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13603 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.304 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13604 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.47 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13605 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13606 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.297 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13607 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.973 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13608 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.704 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13609 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.711 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13610 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.726 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13611 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.622 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13612 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.618 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13613 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.254 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13614 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.301 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13615 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.758 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13616 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.454 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13617 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.289 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13618 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.754 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13619 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.645 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13620 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.417 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13621 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13622 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13623 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13624 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.905 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13625 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.588 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13626 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.235 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13627 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13628 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.954 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13629 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.768 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13630 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.734 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13631 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.71 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13632 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.074 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13633 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.528 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13634 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.385 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13635 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.445 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13636 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.393 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13637 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.216 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13638 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.383 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13639 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.233 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13640 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.234 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13641 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.345 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13642 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13643 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.014 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13644 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.95 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13645 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.492 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13646 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.196 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13647 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.862 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13648 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.808 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13649 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.753 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13650 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.773 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13651 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.945 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13652 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.55 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13653 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.373 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13654 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.959 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13655 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.119 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13656 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.079 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13657 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.484 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13658 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.711 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13659 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.503 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13660 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.705 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13661 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.12 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13662 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.579 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13663 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.747 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13664 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.42 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13665 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.17 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13666 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.643 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13667 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.399 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13668 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.707 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13669 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.462 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13670 Microbes metabolize substances PMDBM18 n.a. Anaerostipes sp. PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.543 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13671 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13672 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.181 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13673 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.443 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13674 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.542 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13675 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13676 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13677 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.09 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13678 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.853 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13679 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.116 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13680 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.99 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13681 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.76 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI13682 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.312 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13683 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.948 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13684 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.484 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13685 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.892 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13686 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13687 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.468 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13688 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13689 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.307 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13690 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.779 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13691 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.879 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13692 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.232 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13693 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13694 Microbes metabolize substances PMDBM107 n.a. Bifidobacterium ruminatum PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.706 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13695 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13696 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.112 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI13697 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.788 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13698 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.406 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13699 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.642 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13700 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.147 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13701 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.449 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13702 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.952 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13703 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.709 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13704 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13705 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13706 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.421 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13707 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.337 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13708 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13709 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.065 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13710 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13711 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.689 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13712 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.387 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13713 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.87 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13714 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.729 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13715 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.835 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13716 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.624 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13717 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.695 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13718 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.086 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13719 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.188 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13720 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI13721 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.069 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13722 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13723 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.267 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13724 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.621 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13725 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD639 Pantoprazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.158 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13726 Microbes metabolize substances PMDBM251 n.a. Gordonibacter urolithinfaciens sp. nov PMDBD645 Pedunculagin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Ellagic acid; urolithin A, B, C and D n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.foodres.2011.04.027; PMID: 24744017 PMDBI13727 Microbes metabolize substances PMDBM130 n.a. Chaetomium spp. PMDBD95 Baicalin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 4’,5,6,7-tetrahydroxyflavone; 5,7-dihydroxy-6-methoxxyflavone n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI ; DOI: 10.1016/j.molcatb.2007.08.009 PMDBI13729 Microbes metabolize substances PMDBM51 n.a. Bacteroides fragilis subspp. Thetaotus PMDBD780 Shikonin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Anhydroalkannin; deoxyshikonin; cycloshikonin; metaboshikonin I; metaboshikonin II; shikometabolins A; B, C, D and E n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI ; DOI: 10.1016/S0040-4020(01)81108-X PMDBI13735 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD644 Pectin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Nogalacturonic acid; SCFAs n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 10742206 PMDBI13736 Microbes metabolize substances PMDBM229 n.a. Eubacterium spp. SDG-2 PMDBD773 Secoisolariciresinol diglucoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. (-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11086885 PMDBI13737 Microbes metabolize substances PMDBM320 n.a. Peptostreptococcus spp. SDG-1 PMDBD773 Secoisolariciresinol diglucoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. (-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11086885 PMDBI13738 Microbes metabolize substances PMDBM229 n.a. Eubacterium spp. SDG-2 PMDBD136 Caffeic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrocaffeic acid; m-hydroxyphenylpropionic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11767089 PMDBI13739 Microbes metabolize substances PMDBM63 n.a. Bacteroides spp. PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11824558 PMDBI13740 Microbes metabolize substances PMDBM109 n.a. Bifidobacterium spp. PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11824558 PMDBI13741 Microbes metabolize substances PMDBM228 n.a. Eubacterium spp. PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11824558 PMDBI13742 Microbes metabolize substances PMDBM145 1492 Clostridium butyricum PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13743 Microbes metabolize substances PMDBM88 1680 Bifidobacterium adolescentis PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13744 Microbes metabolize substances PMDBM51 n.a. Bacteroides fragilis subspp. Thetaotus PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13745 Microbes metabolize substances PMDBM151 n.a. Clostridium innocuum ES 24-06 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13746 Microbes metabolize substances PMDBM244 n.a. Fusobacterium nucleatum G-470 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13747 Microbes metabolize substances PMDBM318 n.a. Peptostreptococcus anaerobius 0240 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13748 Microbes metabolize substances PMDBM319 n.a. Peptostreptococcus intermedius EBF 77/25 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13749 Microbes metabolize substances PMDBM338 n.a. Proteus mirabillis S2 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13750 Microbes metabolize substances PMDBM368 n.a. Ruminococcus spp. P01-3 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Isophorbol; deoxyphorbol; 4β,9α,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4β,9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4β,9a,20-trihydroxy-14(13→12)-abeo12aH-1,6-tigliadiene-3,13-dione n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13751 Microbes metabolize substances PMDBM124 831 Butyrivibrio fibrisolvens PMDBD485 Linoleic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17644775 PMDBI13752 Microbes metabolize substances PMDBM125 43305 Butyrivibrio proteoclasticus PMDBD485 Linoleic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17644775 PMDBI13755 Microbes metabolize substances PMDBM53 n.a. Bacteroides intestinalis AM-1 PMDBD177 Chenodeoxycholic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 7-oxo-lithocholic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 19243441 PMDBI13756 Microbes metabolize substances PMDBM53 n.a. Bacteroides intestinalis AM-1 PMDBD188 Cholic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 7-oxo-deoxycholic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 19243441 PMDBI13757 Microbes metabolize substances PMDBM189 n.a. Eggerthella sp. Julong732 PMDBD277 Dihydrodaidzein Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. (3S)-equol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 19304836 PMDBI13759 Microbes metabolize substances PMDBM42 n.a. Bacteroides fragilis PMDBD385 Geniposide Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Genipin n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. n.a. PMID PMID: 22553067 PMDBI13760 Microbes metabolize substances PMDBM102 n.a. Bifidobacterium longum HY8001 PMDBD385 Geniposide Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Genipin n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. n.a. PMID PMID: 22553067 PMDBI13761 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13762 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13763 Microbes metabolize substances PMDBM382 1280 Staphylococcus aureus PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13764 Microbes metabolize substances PMDBM199 n.a. Enterococcus faecalis PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13765 Microbes metabolize substances PMDBM201 n.a. Enterococcus faecium PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13766 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13767 Microbes metabolize substances PMDBM101 n.a. Bifidobacterium longum H-1 PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13768 Microbes metabolize substances PMDBM97 n.a. Bifidobacterium breve K-110 PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13769 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13770 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13771 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13772 Microbes metabolize substances PMDBM331 28135 Prevotella oris PMDBD389 Ginsenoside Rb1 Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13773 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13774 Microbes metabolize substances PMDBM101 n.a. Bifidobacterium longum H-1 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13775 Microbes metabolize substances PMDBM97 n.a. Bifidobacterium breve K-110 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13776 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13777 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13778 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13779 Microbes metabolize substances PMDBM331 28135 Prevotella oris PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13780 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13781 Microbes metabolize substances PMDBM101 n.a. Bifidobacterium longum H-1 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13782 Microbes metabolize substances PMDBM97 n.a. Bifidobacterium breve K-110 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13783 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13784 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13785 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13786 Microbes metabolize substances PMDBM331 28135 Prevotella oris PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13787 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13788 Microbes metabolize substances PMDBM67 n.a. Bacteroides stercoris HJ-15 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13789 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13790 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13791 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13792 Microbes metabolize substances PMDBM67 n.a. Bacteroides stercoris HJ-15 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13793 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13794 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13795 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13796 Microbes metabolize substances PMDBM67 n.a. Bacteroides stercoris HJ-15 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13797 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13798 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. protopanaxatriol; ginsenoside F1; ginsenoside Rh1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13799 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13800 Microbes metabolize substances PMDBM101 n.a. Bifidobacterium longum H-1 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13801 Microbes metabolize substances PMDBM97 n.a. Bifidobacterium breve K-110 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13802 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13803 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13804 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13805 Microbes metabolize substances PMDBM331 28135 Prevotella oris PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13806 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13807 Microbes metabolize substances PMDBM101 n.a. Bifidobacterium longum H-1 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13808 Microbes metabolize substances PMDBM97 n.a. Bifidobacterium breve K-110 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13809 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13810 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13811 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13812 Microbes metabolize substances PMDBM331 28135 Prevotella oris PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13813 Microbes metabolize substances PMDBM63 n.a. Bacteroides spp. PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13814 Microbes metabolize substances PMDBM284 n.a. Lactobacillus spp. PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13819 Microbes metabolize substances PMDBM266 29370 Lacrimispora sphenoides PMDBD775 Sennoside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 8-glucosylrheinanthrone; rheinanthrone; sennidin n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 3368516 PMDBI13820 Microbes metabolize substances PMDBM224 39491 [Eubacterium] rectale PMDBD775 Sennoside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 8-glucosylrheinanthrone; rheinanthrone; sennidin n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 3368516 PMDBI13821 Microbes metabolize substances PMDBM228 n.a. Eubacterium spp. PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydrodigoxin n.a. n.a. Decrease Toxicity n.a. n.a. n.a. n.a. n.a. PMID PMID: 7266632 PMDBI13822 Microbes metabolize substances PMDBM390 n.a. Streptococcus S-2 PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13823 Microbes metabolize substances PMDBM55 n.a. Bacteroides J-37 PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13824 Microbes metabolize substances PMDBM217 n.a. Eubacterium A-44 PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13825 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD245 Daidzin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13826 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13827 Microbes metabolize substances PMDBM231 n.a. Eubacterium YK-4 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13828 Microbes metabolize substances PMDBM235 n.a. Feptostreptoccous YK-10 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13829 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13830 Microbes metabolize substances PMDBM275 n.a. Lactobacillus L-2 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13831 Microbes metabolize substances PMDBM390 n.a. Streptococcus S-2 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13832 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13833 Microbes metabolize substances PMDBM92 n.a. Bifidobacterium B-9 PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13834 Microbes metabolize substances PMDBM231 n.a. Eubacterium YK-4 PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13835 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13836 Microbes metabolize substances PMDBM275 n.a. Lactobacillus L-2 PMDBD760 Rutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI20001 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD11 Acacia catechu Herbal Substance Medicinal Herb epicatechin- and catechins-rich extract n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28422543 PMDBI20002 Substances alter microbe abundance PMDBM372 n.a. Salmonella spp. PMDBD11 Acacia catechu Herbal Substance Medicinal Herb epicatechin- and catechins-rich extract n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28422543 PMDBI20003 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD27 Aloe vera Herbal Substance Medicinal Herb Aloe vera mucilage n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25504136 PMDBI20004 Substances alter microbe abundance PMDBM24 n.a. Atopobium spp. PMDBD27 Aloe vera Herbal Substance Medicinal Herb Aloe vera mucilage n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25504136 PMDBI20005 Substances alter microbe abundance PMDBM118 n.a. Blautia spp. PMDBD994 AMC formula Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro Human Type 2 diabetes with hyperlipidemia n.a. n.a. PMID PMID: 29789365 PMDBI20006 Substances alter microbe abundance PMDBM234 n.a. Faecalibacterium spp. PMDBD994 AMC formula Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro Human Type 2 diabetes with hyperlipidemia n.a. n.a. PMID PMID: 29789365 PMDBI20007 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD58 Antrodia cinnamomea Herbal Substance Medicinal Herb water extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Obesity n.a. n.a. PMID PMID: 28630461 PMDBI20009 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD97 Bawei Xileisan Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20010 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD97 Bawei Xileisan Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20011 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20012 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20013 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20014 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20015 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20016 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20017 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20018 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20019 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20020 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20021 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20022 Substances alter microbe abundance PMDBM30 n.a. Bacteroidales unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20023 Substances alter microbe abundance PMDBM139 n.a. Clostridiales unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20024 Substances alter microbe abundance PMDBM265 n.a. Lachnospiraceae unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20025 Substances alter microbe abundance PMDBM358 n.a. Ruminococcaceae unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20026 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20033 Substances alter microbe abundance PMDBM11 28117 Alistipes putredinis PMDBD232 Curcuma longa Herbal Substance Medicinal Herb Roots n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20034 Substances alter microbe abundance PMDBM190 1432052 Eisenbergiella tayi PMDBD232 Curcuma longa Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20036 Substances alter microbe abundance PMDBM20 169435 Anaerotruncus colihominis PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20037 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20038 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20039 Substances alter microbe abundance PMDBM311 328812 Parabacteroides goldsteinii PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20040 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20041 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20044 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20045 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20046 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20047 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20048 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20049 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20050 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20051 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20052 Substances alter microbe abundance PMDBM233 853 Faecalibacterium prausnitzii PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20053 Substances alter microbe abundance PMDBM248 204475 Gemmiger PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20054 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20055 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20056 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20057 Substances alter microbe abundance PMDBM343 46205 Pseudobutyrivibrio PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20058 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20059 Substances alter microbe abundance PMDBM264 n.a. Lachnospiraceae incertae sedis PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20060 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20061 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20062 Substances alter microbe abundance PMDBM135 508459 Cloacibacillus PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20063 Substances alter microbe abundance PMDBM179 872 Desulfovibrio PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20064 Substances alter microbe abundance PMDBM199 n.a. Enterococcus faecalis PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20065 Substances alter microbe abundance PMDBM248 204475 Gemmiger PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20066 Substances alter microbe abundance PMDBM258 573 Klebsiella pneumoniae PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20067 Substances alter microbe abundance PMDBM315 577310 Parasutterella PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20068 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20069 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase > 150 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20070 Substances alter microbe abundance PMDBM228 n.a. Eubacterium spp. PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20071 Substances alter microbe abundance PMDBM321 n.a. Phascolarctobacter PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase > 150 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20072 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD406 Glycyrrhiza uralensis Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20073 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD406 Glycyrrhiza uralensis Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20075 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20076 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20077 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20078 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20079 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20080 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20081 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20082 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20083 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20084 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20085 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20086 Substances alter microbe abundance PMDBM365 46228 [Ruminococcus] lactaris PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20087 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20088 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20089 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20092 Substances alter microbe abundance PMDBM262 n.a. Lachnospiracae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20093 Substances alter microbe abundance PMDBM352 n.a. Rosburia ssp, S24-7 PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20098 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20099 Substances alter microbe abundance PMDBM32 85831 Bacteroides acidifaciens PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20100 Substances alter microbe abundance PMDBM42 n.a. Bacteroides fragilis PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20101 Substances alter microbe abundance PMDBM117 n.a. Blautia producta PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20102 Substances alter microbe abundance PMDBM122 501571 Butyricicoccus pullicaecorum PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20103 Substances alter microbe abundance PMDBM146 358743 Enterocloster citroniae PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20104 Substances alter microbe abundance PMDBM233 853 Faecalibacterium prausnitzii PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20105 Substances alter microbe abundance PMDBM280 1598 Lactobacillus reuteri PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20106 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20107 Substances alter microbe abundance PMDBM362 1265 Ruminococcus flavefaciens PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20108 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD612 Oil tea Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 30122197 PMDBI20109 Substances alter microbe abundance PMDBM60 29523 Bacteroides sp. PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20110 Substances alter microbe abundance PMDBM93 1681 Bifidobacterium bifidum PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20111 Substances alter microbe abundance PMDBM126 28121 Butyrivibrio sp. PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20112 Substances alter microbe abundance PMDBM226 n.a. Eubacterium sp. PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20113 Substances alter microbe abundance PMDBM272 1613 Lactobacillus fermentum PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20114 Substances alter microbe abundance PMDBM272 1613 Lactobacillus fermentum PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.foodhyd.2017.12.026 PMDBI20115 Substances alter microbe abundance PMDBM280 1598 Lactobacillus reuteri PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20116 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.foodhyd.2017.12.026 PMDBI20117 Substances alter microbe abundance PMDBM332 n.a. Prevotella pneumophila PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.foodhyd.2017.12.026 PMDBI20118 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD693 Pomegranate extract Herbal Substance; Dietary Substance Herbal Substance; Dietary Substance n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20119 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD693 Pomegranate extract Herbal Substance; Dietary Substance Herbal Substance; Dietary Substance n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20120 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD696 Potentilla discolor Bunge Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 30897784 PMDBI20122 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD722 Qushi Huayu Fang Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Chronic liver disease n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20123 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD722 Qushi Huayu Fang Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 23453736 PMDBI20129 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD733 Red Ginseng Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20130 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD733 Red Ginseng Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20131 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20132 Substances alter microbe abundance PMDBM152 1535 [Clostridium] leptum PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20133 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20134 Substances alter microbe abundance PMDBM288 1243 Leuconostoc PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20135 Substances alter microbe abundance PMDBM316 1253 Pediococcus PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20137 Substances alter microbe abundance PMDBM113 1532 Blautia coccoides PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20138 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD763 Salvia officinalis Herbal Substance Medicinal Herb Leaves n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20139 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD763 Salvia officinalis Herbal Substance Medicinal Herb Leaves n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20140 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD774 Semen Coicis Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20141 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD774 Semen Coicis Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20142 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD782 Silybum marianum Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20143 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD782 Silybum marianum Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20144 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD782 Silybum marianum Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20145 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD835 Terminalia arjuna Herbal Substance Medicinal Herb hydro-ethanolic extract n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30367989 PMDBI20149 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD885 Urolithin-A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20150 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD885 Urolithin-A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20151 Substances alter microbe abundance PMDBM23 5062 Aspergillus oryzae PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20152 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20153 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20154 Substances alter microbe abundance PMDBM290 2172 Methanobrevibacter PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20155 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20156 Substances alter microbe abundance PMDBM411 1583 Weissella confusa PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20158 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD905 Xiao-Qing-Long Tang Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 31396536 PMDBI20159 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD905 Xiao-Qing-Long Tang Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 31396536 PMDBI20160 Substances alter microbe abundance PMDBM3 n.a. Actinobacteria PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20161 Substances alter microbe abundance PMDBM3 n.a. Actinobacteria PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20162 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20163 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20164 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20165 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20166 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20167 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20168 Substances alter microbe abundance PMDBM206 526525 Erysipelotrichales PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20169 Substances alter microbe abundance PMDBM207 526524 Erysipelotrichia PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20170 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20171 Substances alter microbe abundance PMDBM205 n.a. Erysipelotrichacesae PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20172 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20173 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD378 Gallic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20174 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20175 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD195 Cinnamon essential oil Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17551716 PMDBI20176 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20177 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20179 Substances alter microbe abundance PMDBM330 840 Prevotella loescheii PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20180 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20181 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20182 Substances alter microbe abundance PMDBM246 1236 Gammaproteobacteria PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20183 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20184 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20185 Substances alter microbe abundance PMDBM382 1280 Staphylococcus aureus PMDBD195 Cinnamon essential oil Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17551716 PMDBI20188 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD378 Gallic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20189 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20190 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD786 Sodium butyrate Environmental Substance Microbiota metabolite n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 28104981 PMDBI20191 Substances alter microbe abundance PMDBM272 1613 Lactobacillus fermentum PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20195 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20196 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20199 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD802 Stachyose Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20201 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD28 Aloin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat n.a. n.a. PMID PMID: 28525602 PMDBI20202 Substances alter microbe abundance PMDBM174 84999 Coriobacteriales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20203 Substances alter microbe abundance PMDBM174 84999 Coriobacteriales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Wild type n.a. n.a. PMID PMID: 26218141 PMDBI20204 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20205 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Wild type n.a. n.a. PMID PMID: 26218141 PMDBI20207 Substances alter microbe abundance PMDBM14 135622 Alteromonadales PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20209 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20210 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20211 Substances alter microbe abundance PMDBM267 186826 Lactobacillales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20212 Substances alter microbe abundance PMDBM267 186826 Lactobacillales PMDBD233 Curcumin Therapeutic Substance; Herbal Substance Investigational Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Wild type n.a. n.a. PMID PMID: 26218141 PMDBI20216 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20217 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20218 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD28 Aloin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat n.a. n.a. PMID PMID: 28525602 PMDBI20219 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20220 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD136 Caffeic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20221 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20222 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20223 Substances alter microbe abundance PMDBM394 292632 Subdoligranulum PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20224 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20225 Substances alter microbe abundance PMDBM296 437755 Moryella PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20227 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD786 Sodium butyrate Environmental Substance Microbiota metabolite n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 28104981 PMDBI20229 Substances alter microbe abundance PMDBM121 580596 Butyricicoccus PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20230 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD786 Sodium butyrate Environmental Substance Microbiota metabolite n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 28104981 PMDBI20234 Substances alter microbe abundance PMDBM118 n.a. Blautia spp. PMDBD530 Metformin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes with hyperlipidemia n.a. n.a. PMID PMID: 29789365 PMDBI20240 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD136 Caffeic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20241 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20243 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20244 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20245 Substances alter microbe abundance PMDBM335 n.a. Prevotellaceae_NK3B31_group PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI30001 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30002 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30003 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30004 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30005 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30006 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30007 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 μg/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30008 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD21 Agaricus bisporus Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Normal n.a. n.a. PMID PMID: 30424006 PMDBI30010 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD60 Apple juice Dietary Substance Drinks free access, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30011 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD60 Apple juice Dietary Substance Drinks free access, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30012 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD61 Apple juice colloid Dietary Substance Drinks free access, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30013 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30014 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30015 Substances alter microbe abundance PMDBM526 n.a. Enterobacteria PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30016 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30017 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30018 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD65 Aqueous soy extract (fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30019 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD65 Aqueous soy extract (fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30020 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD65 Aqueous soy extract (fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30021 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD66 Aqueous soy extract (hypecholesterolemic plus unfermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30022 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD67 Aqueous soy extract (hypercholesterolemic plus isoflavone-supplemented fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw−2.1 mg of total isoflavone/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30023 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD67 Aqueous soy extract (hypercholesterolemic plus isoflavone-supplemented fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw−2.1 mg of total isoflavone/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30024 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD67 Aqueous soy extract (hypercholesterolemic plus isoflavone-supplemented fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw−2.1 mg of total isoflavone/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30028 Substances alter microbe abundance PMDBM260 576 Klebsiella sp. PMDBD120 Black tea extract Dietary Substance Dietary Compounds 1000 mg/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30028 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD120 Black tea extract Dietary Substance Dietary Compounds 1000 mg/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30033 Substances alter microbe abundance PMDBM253 210 Helicobacter pylori PMDBD142 Capsaicin Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28405001 PMDBI30034 Substances alter microbe abundance PMDBM326 837 Porphyromonas gingivalis PMDBD142 Capsaicin Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28405001 PMDBI30035 Substances alter microbe abundance PMDBM382 1280 Staphylococcus aureus PMDBD142 Capsaicin Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28405001 PMDBI30036 Substances alter microbe abundance PMDBM522 n.a. Bifidobacterium breve NZRM3932 PMDBD171 Centurion cultivar blueberry extract Dietary Substance Dietary Compounds 10−25% v/v Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30037 Substances alter microbe abundance PMDBM511 n.a. Lactobacillus rhamnosus NZRM 299 PMDBD171 Centurion cultivar blueberry extract Dietary Substance Dietary Compounds 10−25% v/v Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30038 Substances alter microbe abundance PMDBM524 n.a. Clostridium histolyticum group PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30039 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30040 Substances alter microbe abundance PMDBM505 n.a. Eubacterium rectale−C. coccoides group PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30041 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30042 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30043 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30044 Substances alter microbe abundance PMDBM505 n.a. Eubacterium rectale−C. coccoides group PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30045 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30046 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD228 Conventional soy milk (26.5% β-conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30047 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD228 Conventional soy milk (26.5% β-conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30048 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD228 Conventional soy milk (26.5% β-conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30049 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD228 Conventional soy milk (26.5% β-conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30050 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD228 Conventional soy milk (26.5% β-conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30051 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD227 Conventional soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30052 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD227 Conventional soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30053 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30054 Substances alter microbe abundance PMDBM523 n.a. Blautia coccoides−Eubacterium rectale PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30055 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30056 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30057 Substances alter microbe abundance PMDBM242 32066 Fusobacteria PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30058 Substances alter microbe abundance PMDBM25 91061 Bacilli PMDBD258 Deshipu stachyose granules Dietary Substance Dietary Compounds 0.42, 0.83, 2.49 g/kg BW/day, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30061 Substances alter microbe abundance PMDBM516 n.a. Bacteroidaceae/Bifidobacteriaceae ratio PMDBD269 Diet rich in fiber Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30062 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD269 Diet rich in fiber Dietary Substance Foods n.a. Gut Decrease Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30063 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30064 Substances alter microbe abundance PMDBM17 2086 Anaeroplasma PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30065 Substances alter microbe abundance PMDBM19 244127 Anaerotruncus PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30066 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30067 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30068 Substances alter microbe abundance PMDBM301 182709 Oceanobacillus PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30069 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30070 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD301 Emulsifiers (P80 and CMC) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30071 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD301 Emulsifiers (P80 and CMC) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30072 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD343 Fermentable fibre (inulin) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30073 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD343 Fermentable fibre (inulin) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30074 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30075 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30076 Substances alter microbe abundance PMDBM526 n.a. Enterobacteria PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30077 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30078 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30079 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD345 Fermented soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30080 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD345 Fermented soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30081 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD345 Fermented soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30082 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30083 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30084 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30085 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30086 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30087 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30088 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30089 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30090 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30091 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD348 Fermented soy product Dietary Substance Drinks 3 mL/kg bw/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30093 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD348 Fermented soy product Dietary Substance Drinks 3 mL/kg bw/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30095 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD349 Fermented soybean milk Dietary Substance Drinks 100 g/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30097 Substances alter microbe abundance PMDBM3 n.a. Actinobacteria PMDBD351 Fibre Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30098 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD351 Fibre Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30099 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30101 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30102 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30103 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30104 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30105 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30106 Substances alter microbe abundance PMDBM528 n.a. Pseudof lavonifractor PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30107 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30108 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD409 Grape antioxidant dietary fiber Dietary Substance Dietary Compounds 50 g/kg diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30109 Substances alter microbe abundance PMDBM506 n.a. Lactobacillus acidophilus ATCC 4356 PMDBD409 Grape antioxidant dietary fiber Dietary Substance Dietary Compounds nonextractable polyphenols 2.4 mg/mL Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30110 Substances alter microbe abundance PMDBM510 n.a. Lactobacillus reuteri ATCC 23272 PMDBD409 Grape antioxidant dietary fiber Dietary Substance Dietary Compounds nonextractable polyphenols 2.4 mg/mL Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30111 Substances alter microbe abundance PMDBM513 n.a. Paenibacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 60 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30111 Substances alter microbe abundance PMDBM515 n.a. Bacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 60 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30112 Substances alter microbe abundance PMDBM178 49338 Desulfitobacterium hafniense PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 60 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30113 Substances alter microbe abundance PMDBM513 n.a. Paenibacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30113 Substances alter microbe abundance PMDBM515 n.a. Bacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30114 Substances alter microbe abundance PMDBM178 49338 Desulfitobacterium hafniense PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30115 Substances alter microbe abundance PMDBM512 n.a. Nocardioides spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30116 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30116 Substances alter microbe abundance PMDBM514 n.a. Acinobacter spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30117 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD412 Green tea Dietary Substance Drinks 1000 mL/day, 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30118 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD413 Green tea extracts Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30119 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD413 Green tea extracts Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30120 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD414 Green tea leaves powder Dietary Substance Dietary Compounds 4% w/w of GTf + Lactobacillus plantarum DSM 15313 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30121 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD426 High-fat (saturated and unsaturated) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30122 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD426 High-fat (saturated and unsaturated) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30123 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD426 High-fat (saturated and unsaturated) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30124 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30125 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30126 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30127 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30128 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD429 High-flavanol cocoa powder extract Dietary Substance Dietary Compounds 1 mg/mL; 0.4 mg/mL flavanols Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30129 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD448 Intact soy protein isolate Dietary Substance Dietary Compounds 24% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30130 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD501 Low-fibre diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30131 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD501 Low-fibre diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30132 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD499 Low glycinin soy milk (49.5% β-conglycinin/6% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30133 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD499 Low glycinin soy milk (49.5% β-conglycinin/6% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30134 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD499 Low glycinin soy milk (49.5% β-conglycinin/6% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30135 Substances alter microbe abundance PMDBM518 n.a. Bacteroides−Prevotella PMDBD498 Low glycinin soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30136 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD498 Low glycinin soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30137 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD498 Low glycinin soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30138 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD500 Low-fiber diet Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30139 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD500 Low-fiber diet Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30140 Substances alter microbe abundance PMDBM129 2747 Carnobacterium PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30141 Substances alter microbe abundance PMDBM525 n.a. Cytophaga-Flexibacter PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30142 Substances alter microbe abundance PMDBM291 1269 Micrococcus PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30143 Substances alter microbe abundance PMDBM294 46225 Moraxella PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30144 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30145 Substances alter microbe abundance PMDBM522 n.a. Bifidobacterium breve NZRM3932 PMDBD510 Maru cultivar blueberry extract Dietary Substance Dietary Compounds 10−25% v/v Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30146 Substances alter microbe abundance PMDBM520 n.a. Bifidobacterium bifidum HDD541 PMDBD557 Monomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 414 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30147 Substances alter microbe abundance PMDBM95 1036735 Bifidobacterium breve CECT 7263 PMDBD557 Monomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 414 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30148 Substances alter microbe abundance PMDBM509 n.a. Lactobacillus plantarum IFPL93 PMDBD557 Monomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 414 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30149 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD15 Acesulfame-potassium Dietary Substance Dietary Compounds; Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30150 Substances alter microbe abundance PMDBM152 1535 [Clostridium] leptum PMDBD75 Aspartame Therapeutic Substance; Dietary Substance; Herbal Substance Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30151 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD761 Saccharin Therapeutic Substance; Dietary Substance; Herbal Substance Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30152 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD761 Saccharin Therapeutic Substance; Dietary Substance; Herbal Substance Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30153 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD761 Saccharin Therapeutic Substance; Dietary Substance; Herbal Substance Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30155 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD604 Nonfermented soybean milk Dietary Substance Drinks 100 g/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30157 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD613 Okara (soy pulp/soy fiber) Dietary Substance Dietary Compounds 0.3 g/kg BW/day, 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30158 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD613 Okara (soy pulp/soy fiber) Dietary Substance Dietary Compounds 0.3 g/kg BW/day, 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30160 Substances alter microbe abundance PMDBM507 n.a. Lactobacillus bulgaricus LBY-27 PMDBD616 Oligomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 279 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30161 Substances alter microbe abundance PMDBM508 n.a. Lactobacillus casei IFPL7190 PMDBD616 Oligomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 279 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30162 Substances alter microbe abundance PMDBM177 191394 Deferribacteraceae PMDBD643 Partially hydrolyzed soy protein isolate Dietary Substance Dietary Compounds 24% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30163 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD643 Partially hydrolyzed soy protein isolate Dietary Substance Dietary Compounds 24% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30164 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD685 Polyphenols (caffeic acid) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30165 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD686 Polyphenols (grape and/or cranberry extract) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30166 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD687 Polyphenols (resveratrol) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30167 Substances alter microbe abundance PMDBM521 n.a. Bifidobacterium breve NRRL B-41408 PMDBD692 Pomegranate byproduct Dietary Substance Dietary Compounds 0.01% (v/v) of PPE Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30168 Substances alter microbe abundance PMDBM502 n.a. Bifidobacterium infantis NRRL B-41661 PMDBD692 Pomegranate byproduct Dietary Substance Dietary Compounds 0.01% (v/v) of PPE Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30170 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD693 Pomegranate extract Herbal Substance; Dietary Substance Herbal Substance; Dietary Substance 250 mg/kg, 25 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30172 Substances alter microbe abundance PMDBM519 n.a. Bacteroides−Prevotella spp. PMDBD694 Pomegranate peel extract Dietary Substance Dietary Compounds 0.2% (6 mg/day), 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30173 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD694 Pomegranate peel extract Dietary Substance Dietary Compounds 0.2% (6 mg/day), 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30174 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD706 Proanthocyanidin-rich grape seed extract Dietary Substance Dietary Compounds 0.5 g/day/subject extract (0.19 g/day/subject as proanthocyanidins), 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30175 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30176 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30177 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30178 Substances alter microbe abundance PMDBM530 n.a. Sulfate-reducing bacteria PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30179 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30180 Substances alter microbe abundance PMDBM517 n.a. Bacteroides uniformis sp. PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30181 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30182 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30183 Substances alter microbe abundance PMDBM523 n.a. Blautia coccoides−Eubacterium rectale PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30184 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30185 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30186 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30187 Substances alter microbe abundance PMDBM242 32066 Fusobacteria PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30188 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30189 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30190 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30191 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30192 Substances alter microbe abundance PMDBM135 508459 Cloacibacillus PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30193 Substances alter microbe abundance PMDBM260 576 Klebsiella sp. PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30194 Substances alter microbe abundance PMDBM409 172900 Victivallis PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30195 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD737 Regular soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30196 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD737 Regular soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30197 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD737 Regular soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30198 Substances alter microbe abundance PMDBM81 n.a. Bacteroidetes/Firmicutes ratio PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30199 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30200 Substances alter microbe abundance PMDBM199 n.a. Enterococcus faecalis PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30201 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD740 Resveratrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30202 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30203 Substances alter microbe abundance PMDBM110 35832 Bilophila PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30204 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30205 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30206 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30207 Substances alter microbe abundance PMDBM529 n.a. S24-7 (Bacteroidetes) PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30208 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30209 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD767 Saturated fat (palmitate) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30210 Substances alter microbe abundance PMDBM529 n.a. S24-7 (Bacteroidetes) PMDBD767 Saturated fat (palmitate) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30211 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30212 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30213 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30214 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30216 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30217 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30218 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30219 Substances alter microbe abundance PMDBM237 204430 Fibrobacteria PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30220 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30221 Substances alter microbe abundance PMDBM267 186826 Lactobacillales PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30222 Substances alter microbe abundance PMDBM323 203683 Planctomycetia PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30223 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30224 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh × Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30225 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30226 Substances alter microbe abundance PMDBM94 1685 Bifidobacterium breve PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30227 Substances alter microbe abundance PMDBM103 1682 Bifidobacterium longum subsp. infantis PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30228 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30229 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30230 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30231 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30232 Substances alter microbe abundance PMDBM526 n.a. Enterobacteria PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30233 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30234 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30235 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30236 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30237 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30238 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30239 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30240 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30241 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30242 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30243 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30244 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30245 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD794 Soy protein Dietary Substance Dietary Compounds 20% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30247 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD794 Soy protein Dietary Substance Dietary Compounds 20% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30248 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD795 Soy protein concentrate (SPC) Dietary Substance Dietary Compounds 27% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30249 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD795 Soy protein concentrate (SPC) Dietary Substance Dietary Compounds 27% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30250 Substances alter microbe abundance PMDBM503 n.a. Clostridiales spp. PMDBD795 Soy protein concentrate (SPC) Dietary Substance Dietary Compounds 27% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30251 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD796 Soybean oil Dietary Substance Foods 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30252 Substances alter microbe abundance PMDBM5 644 Aeromonas hydrophila PMDBD796 Soybean oil Dietary Substance Foods 18% Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30253 Substances alter microbe abundance PMDBM236 833 Fibrobacter succinogenes PMDBD796 Soybean oil Dietary Substance Foods 4% w/w, 21 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Holstein cows Primiparous n.a. n.a. PMID PMID: 27798832 PMDBI30254 Substances alter microbe abundance PMDBM360 1264 Ruminococcus albus PMDBD796 Soybean oil Dietary Substance Foods 4% w/w, 21 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Holstein cows Primiparous n.a. n.a. PMID PMID: 27798832 PMDBI30255 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD797 Soygerm powder Dietary Substance Dietary Compounds 2.5 g/day, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30257 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD827 Tea polyphenols Dietary Substance Dietary Compounds Suphenon, 0.4 g/3 times per day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30258 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD854 Tofu diet Dietary Substance Foods 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30259 Substances alter microbe abundance PMDBM527 n.a. Lactic acid producing bacteria PMDBD854 Tofu diet Dietary Substance Foods 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30260 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD882 Unfermented soy product Dietary Substance Foods 3 mL/kg bw/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30261 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD883 Unsaturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30262 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD883 Unsaturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30263 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD883 Unsaturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30264 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD901 Western high-fat diets Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 18407065 PMDBI30265 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD902 Wild blueberry Dietary Substance Foods 25 g/day, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30266 Substances alter microbe abundance PMDBM269 1579 Lactobacillus acidophilus PMDBD902 Wild blueberry Dietary Substance Foods 25 g/day, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30267 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD903 Wine polyphenols Dietary Substance Dietary Compounds 50 mg/kg bw, 15 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30268 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD903 Wine polyphenols Dietary Substance Dietary Compounds 50 mg/kg bw, 15 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30269 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD903 Wine polyphenols Dietary Substance Dietary Compounds 50 mg/kg bw, 15 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI40001 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 μg/kg per day in the diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209 PMDBI40001 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.58E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40002 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 μg/kg per day in the diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209 PMDBI40002 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40003 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.32E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40003 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 μg/kg per day in the diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209 PMDBI40004 Substances alter microbe abundance PMDBM666 830 Butyrivibrio PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 μg/kg per day in the diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209 PMDBI40004 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40005 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000682966] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40005 Substances alter microbe abundance PMDBM777 117743 Flavobacteria PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 μg/kg per day in the diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209 PMDBI40006 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40006 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40007 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40007 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40008 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40008 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40009 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40009 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40010 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40010 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.84E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40011 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40011 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40012 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40012 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40013 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40013 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40014 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 μg/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631 PMDBI40014 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40015 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1011 Acesulfame potassium Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28594855 PMDBI40015 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.04E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40016 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD1011 Acesulfame potassium Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28594855 PMDBI40016 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40017 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1011 Acesulfame potassium Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28594855 PMDBI40017 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.32E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40018 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40018 Substances alter microbe abundance PMDBM815 n.a. lactic acid bacteria PMDBD1019 Aflatoxin B1 Environmental Substance Biological Contaminants n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26612839 PMDBI40019 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1416 Silver nanoparticles Environmental Substance Nanoparticles (NPs) 9, 18, and 36 mg/kg body weight for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24877679 PMDBI40019 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40020 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40020 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40021 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40021 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40022 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40022 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.62E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40023 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40023 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40024 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40024 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40025 Substances alter microbe abundance PMDBM637 1385 Bacillales PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40025 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40026 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30406643 PMDBI40026 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40027 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27268458 PMDBI40027 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000289729] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40028 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 100 ppb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28973555 PMDBI40028 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40029 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0 or 10 ppm for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24413286 PMDBI40029 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40030 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0 or 10 ppm for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24413286 PMDBI40030 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40031 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0 or 10 ppm in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24490651 PMDBI40031 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40032 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 100 ppb for 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28973555 PMDBI40032 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00597968] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40033 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27268458 PMDBI40033 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40034 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40034 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0 or 10 ppm in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24490651 PMDBI40035 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40035 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0.05 mg/kg bw Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30108172 PMDBI40036 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40036 Substances alter microbe abundance PMDBM727 1117 Cyanobacteria PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0 or 10 ppm for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24413286 PMDBI40037 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40037 Substances alter microbe abundance PMDBM773 97253 Eubacterium plexicaudatum PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30108172 PMDBI40038 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40038 Substances alter microbe abundance PMDBM731 200930 Deferribacteres PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30108172 PMDBI40039 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40039 Substances alter microbe abundance PMDBM845 248039 Mucispirillum schaedleri PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30108172 PMDBI40040 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002343758] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40040 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0 or 10 ppm for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24413286 PMDBI40041 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000176808] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40041 Substances alter microbe abundance PMDBM809 1506553 Lachnoclostridium PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30108172 PMDBI40042 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40042 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1041 Arsenic and zinc Environmental Substance Heavy Metals; Toxic Agents Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30518676 PMDBI40043 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40043 Substances alter microbe abundance PMDBM934 22 Shewanella PMDBD1041 Arsenic and zinc Environmental Substance Heavy Metals; Toxic Agents Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30518676 PMDBI40044 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40044 Substances alter microbe abundance PMDBM907 67575 Rheinheimera PMDBD1041 Arsenic and zinc Environmental Substance Heavy Metals; Toxic Agents Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30518676 PMDBI40045 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40045 Substances alter microbe abundance PMDBM795 189772 Herpetosiphonales PMDBD1041 Arsenic and zinc Environmental Substance Heavy Metals; Toxic Agents Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30518676 PMDBI40046 Substances alter microbe abundance PMDBM152 1535 Clostridium leptum PMDBD75 Aspartame Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25313461 PMDBI40046 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40047 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD75 Aspartame Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25313461 PMDBI40047 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002712] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40048 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD75 Aspartame Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25313461 PMDBI40048 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40049 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD1047 Atrazine Environmental Substance Pesticides 1.0 μg/l atrazine dose (0.42 μg/l measured) in water environment starting at 4.5 months of age for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40049 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40050 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1047 Atrazine Environmental Substance Pesticides 1.0 μg/l atrazine dose (0.42 μg/l measured) in water environment starting at 4.5 months of age for 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40050 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000313055] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40051 Substances alter microbe abundance PMDBM673 1016 Capnocytophaga PMDBD1047 Atrazine Environmental Substance Pesticides 1.0 μg/l atrazine dose (0.42 μg/l measured) in water environment starting at 4.5 months of age for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40051 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000651143] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40052 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD1048 Atrazine; estradiol; PCB126; PCB153 Environmental Substance Persistent Organic Pollutants DMSO or 1.0 μg/l of environmental pollutant mixture Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40052 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000569297] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40053 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1050 Azoxystrobin Environmental Substance Pesticides 5 mg/kg azoxystrobin in dry soil environment for 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31284112 PMDBI40053 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001780397] n.a. n.a. n.a. n.a. In vivo Enchytraeus crypticus Health n.a. n.a. PMID PMID: 29555994 PMDBI40054 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1050 Azoxystrobin Environmental Substance Pesticides 0.1 mg/kg azoxystrobin in dry soil environment for 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31284112 PMDBI40054 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-05] n.a. n.a. n.a. n.a. In vivo Enchytraeus crypticus Health n.a. n.a. PMID PMID: 29555994 PMDBI40055 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40055 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507548] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40056 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40056 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.59E-06] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40057 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40057 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002065724] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40058 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40058 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40059 Substances alter microbe abundance PMDBM315 577310 Parasutterella PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40059 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006585507] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40060 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40060 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00010915] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40061 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40061 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40062 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.08E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40062 Substances alter microbe abundance PMDBM784 1378 Gemella PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40063 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40063 Substances alter microbe abundance PMDBM784 1378 Gemella PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40064 Substances alter microbe abundance PMDBM636 292480 Atopostipes PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40064 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.76E-06] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40065 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000121136] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40065 Substances alter microbe abundance PMDBM863 1100891 Paenalcaligenes PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week. compared with normal diet+vehicle group Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40066 Substances alter microbe abundance PMDBM672 1331051 Candidatus Saccharimonas PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40066 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.70E-05] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40067 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40067 Substances alter microbe abundance PMDBM997 n.a. α-Diversity PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29523931 PMDBI40068 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40068 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40069 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40069 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.36E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40070 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40070 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.60E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40071 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40071 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000864218] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40072 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40072 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00358652] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40073 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40073 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40074 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40074 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000539056] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40075 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40075 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40076 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40076 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0056596] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40077 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40077 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000933639] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40078 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000323877] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40078 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40079 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40079 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003400942] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40080 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40080 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40081 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002509681] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40081 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40082 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001347342] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40082 Substances alter microbe abundance PMDBM870 577309 Paraprevotella PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40083 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD74 Asenapine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003502773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40083 Substances alter microbe abundance PMDBM871 n.a. Paraprevotellaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127 PMDBI40084 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD418 Haloperidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006623603] n.a. n.a. n.a. n.a. n.a. Rodent Health n.a. n.a. PMID PMID: 29555994 PMDBI40084 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD1054 Berry fruits(cranberries; raspberries) Environmental Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25080446 PMDBI40085 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1061 bisphenol A; ethinyl estradiol Environmental Substance Industrial Compounds; Bisphenols incorporation into the diet from periconception through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 27624382 PMDBI40085 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD513 Mebhydroline 1,5-naphtalenedisulfonate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40086 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1061 bisphenol A; ethinyl estradiol Environmental Substance Industrial Compounds; Bisphenols incorporation into the diet from periconception through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 27624382 PMDBI40086 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD871 Triflupromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000685478] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40087 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1061 bisphenol A; ethinyl estradiol Environmental Substance Industrial Compounds; Bisphenols incorporation into the diet from periconception through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 27624382 PMDBI40087 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD184 Chlorpheniramine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003216147] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40088 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40088 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008307524] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40089 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40089 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD865 Trazodone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000277264] n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID PMID: 29555994 PMDBI40090 Substances alter microbe abundance PMDBM290 2172 Methanobrevibacter PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40090 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD104 Benzydamine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000584515] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40091 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40091 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD99 Benfluorex hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007068035] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40092 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 2 μg/L BPA + 100μg/l nano-TiO2 in water environment for 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40092 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD126 Bromperidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009428028] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40093 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 200 μg/kg bw dams dosed orally from GD 15 to PND 7 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29034330 PMDBI40093 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD179 Chlorcyclizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000594816] n.a. n.a. n.a. n.a. In vivo Rabbit Health n.a. n.a. PMID PMID: 29555994 PMDBI40094 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40094 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40095 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40095 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 200 μg/kg bw dams dosed orally from GD 15 to PND 7 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rabbit Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29034330 PMDBI40096 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40096 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 30 μg/kg BW gavaged from PND 28 to 56 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Nonobese diabetic n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30600366 PMDBI40097 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40097 Substances alter microbe abundance PMDBM57 28116 Bacteroides ovatus PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40098 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40098 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40099 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40099 Substances alter microbe abundance PMDBM63 29523 Bacteroides spp. PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40100 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40100 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 μg/kg bw dams dosed orally from GD 15 to weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29101397 PMDBI40101 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40101 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 200 μg/kg bw dams dosed orally from GD 15 to PND 7 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rabbit Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29034330 PMDBI40102 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40102 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40103 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40103 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 μg/kg bw dams dosed orally from GD 15 to weaning Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29101397 PMDBI40104 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40104 Substances alter microbe abundance PMDBM799 81 Hyphomicrobium PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 0, 2, and 20 μg/L and 2 or 20 μg/L BPA + 100μg/l nano-TiO2 in water environment for 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40105 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40105 Substances alter microbe abundance PMDBM850 481 Neisseriaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 0, 0.2, 0.6, 1.7, 2.9, 5.7, 11.5, 23.0, or 45.0 μM in water environment Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30321396 PMDBI40106 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro n.a. Health n.a. n.a. PMID PMID: 29555994 PMDBI40106 Substances alter microbe abundance PMDBM619 507 Alcaligenes PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 25, 250, and 2500 μg/L in nutritional medium for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29778027 PMDBI40107 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40107 Substances alter microbe abundance PMDBM682 1046 Chromatiaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 0, 0.2, 0.6, 1.7, 2.9, 5.7, 11.5, 23.0, or 45.0 mM in water environment Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30321396 PMDBI40108 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro n.a. Health n.a. n.a. PMID PMID: 29555994 PMDBI40108 Substances alter microbe abundance PMDBM839 33882 Microbacterium PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 25, 250, and 2500 μg/L in nutritional medium for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29778027 PMDBI40109 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40109 Substances alter microbe abundance PMDBM680 188913 Cetobacterium somerae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40110 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40110 Substances alter microbe abundance PMDBM851 203693 Nitrospira PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 30 μg/kg BW gavaged from PND 28 to 56 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Nonobese diabetic n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30600366 PMDBI40111 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40111 Substances alter microbe abundance PMDBM786 219685 Gemmatimonadetes PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 30 μg/kg BW gavaged from PND 28 to 56 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Nonobese diabetic n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30600366 PMDBI40112 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40112 Substances alter microbe abundance PMDBM832 1091138 Lawsonia PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 0, 2, and 20 μg/L and 2 or 20 μg/L BPA + 100μg/l nano-TiO2 in water environment for 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29356515 PMDBI40113 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40113 Substances alter microbe abundance PMDBM778 n.a. Flexispira spp PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40114 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40114 Substances alter microbe abundance PMDBM843 n.a. Mogibacteriaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40115 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40115 Substances alter microbe abundance PMDBM843 n.a. Mogibacteriaceae PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40116 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40116 Substances alter microbe abundance PMDBM888 n.a. Prevotella spp. PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40117 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40117 Substances alter microbe abundance PMDBM920 n.a. Ruminococcus spp. PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 12–18 μg/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27932218 PMDBI40118 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40118 Substances alter microbe abundance PMDBM962 n.a. Sutterella spp. PMDBD1060 Bisphenol A Environmental Substance Industrial Compounds; Bisphenols 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27624382 PMDBI40119 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 5, 100, and 200 μg/ l from Gosner stage 26 to 38 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31121551 PMDBI40119 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.79E-05] n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID PMID: 29555994 PMDBI40120 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 10 ppm in drinking water for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26352046 PMDBI40120 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.23E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40121 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 50, and 500 μg Cd/l in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30597321 PMDBI40121 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID PMID: 29555994 PMDBI40122 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 26352046 PMDBI40122 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40123 Substances alter microbe abundance PMDBM242 203490 Fusobacteria PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 50, and 500 μg Cd/l in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30597321 PMDBI40123 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID PMID: 29555994 PMDBI40124 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40124 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 5, 100, and 200 μg/ l from Gosner stage 26 to 38 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31121551 PMDBI40125 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40125 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 50, and 500 μg Cd/l in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30597321 PMDBI40126 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40126 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 5, 100, and 200 μg/ l from Gosner stage 26 to 38 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31121551 PMDBI40127 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40127 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 0, 50, and 500 μg Cd/l in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30597321 PMDBI40128 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40128 Substances alter microbe abundance PMDBM998 n.a. γ-Proteobacteria PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 26352046 PMDBI40129 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000119893] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40129 Substances alter microbe abundance PMDBM998 n.a. γ-Proteobacteria PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 10 ppm in drinking water for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26352046 PMDBI40130 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1074 Carbamate aldicarb Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 30406643 PMDBI40130 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40131 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40131 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1074 Carbamate aldicarb Environmental Substance Pesticides n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 30406643 PMDBI40132 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454 PMDBI40132 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40133 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454 PMDBI40133 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40134 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40134 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454 PMDBI40135 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40135 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454 PMDBI40136 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2–5 mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30496565 PMDBI40136 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40137 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40137 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2–5 mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30496565 PMDBI40138 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40138 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2–5 mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30496565 PMDBI40139 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40139 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2–5 mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30496565 PMDBI40140 Substances alter microbe abundance PMDBM29 171549 Bacteroidales PMDBD1079 carboxymethylcellulose or polysorbate-80 Environmental Substance Food Additives Feeding mice for 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25731162 PMDBI40140 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40141 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000275861] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40141 Substances alter microbe abundance PMDBM363 33038 Ruminococcus gnavus PMDBD1079 carboxymethylcellulose or polysorbate-80 Environmental Substance Food Additives Feeding mice for 12 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25731162 PMDBI40142 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40142 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40143 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40143 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40144 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40144 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40145 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282 PMDBI40145 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40146 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40146 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.51E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40147 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282 PMDBI40147 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40148 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40148 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40149 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40149 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40150 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40150 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40151 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40151 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40152 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40152 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 100nM Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282 PMDBI40153 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40153 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40154 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172932] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40154 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282 PMDBI40155 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40155 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40156 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.52E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40156 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40157 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40157 Substances alter microbe abundance PMDBM603 12916 Acidovorax PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40158 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40158 Substances alter microbe abundance PMDBM944 13687 Sphingomonas PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 100nM Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282 PMDBI40159 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40159 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40160 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40160 Substances alter microbe abundance PMDBM896 43263 Pseudomonas alcaligenes PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40161 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40161 Substances alter microbe abundance PMDBM671 84646 Candidatus Odyssella PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40162 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40162 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40163 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40163 Substances alter microbe abundance PMDBM623 n.a. Alpha and beta diversity PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282 PMDBI40164 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40164 Substances alter microbe abundance PMDBM853 n.a. norank_c_Cyanobacteria PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40165 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40165 Substances alter microbe abundance PMDBM854 n.a. norank_f_Erysipelotrichaceae PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40166 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40166 Substances alter microbe abundance PMDBM981 n.a. Unclassified_f_Comamonadaceae PMDBD1068 Cadmium Environmental Substance Heavy Metals; Toxic Agents 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321 PMDBI40167 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40167 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1107 Chlorothalonil Environmental Substance Pesticides Chlorothalonil : 10 μg/l in 30% sucrose solution for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27579024 PMDBI40168 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Chronic exposure to low doses Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 23135753 PMDBI40168 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro; In vivo(Rat) Human; Rats n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40169 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Chronic exposure to low doses Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 23135753 PMDBI40169 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro; In vivo(Rat) Human; Rats n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40170 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40170 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg body weight per day by oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27018521 PMDBI40171 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003263891] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40171 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27018521 PMDBI40172 Substances alter microbe abundance PMDBM113 1532 Clostridium coccoides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 3.5 mg/kg gavage to dams from GD 1 until PND 21, gavage to pups from PND 21 to 60; inulin cotreatment Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27827942 PMDBI40172 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40173 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40173 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40174 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27827942 PMDBI40174 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40175 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 5 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21–60 (pups) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25643018 PMDBI40175 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009959859] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40176 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40176 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40177 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27827942 PMDBI40177 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40178 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40178 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003138697] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40179 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27018521 PMDBI40179 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001045178] n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40180 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 3.5 mg/kg gavage to dams from GD 1 until PND 21, gavage to pups from PND 21 to 60; inulin cotreatment Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27827942 PMDBI40180 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.19E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40181 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21–60 (pups) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40181 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-06] n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40182 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40182 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40183 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 3.5 mg/day injection in media into SHIME reactor for 30 days; cells treated with SHIME supernatant for 6 or 24 h; inulin cotreatment Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model; Caco-2/TC7 human intestinal cells Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29808406 PMDBI40183 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40184 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 5 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21–60 (pups) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25643018 PMDBI40184 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.25E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40185 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27018521 PMDBI40185 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001902308] n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40186 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21–60 (pups) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40186 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001339048] n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40187 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40187 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001689365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40188 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27827942 PMDBI40188 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40189 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002157434] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40189 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 5 mg/kg by gavage daily at 4 weeks of age for 12 weeks with normal-or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse; CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30744700 PMDBI40190 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40190 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 30–100 μg/l in water environment for 21 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31400786 PMDBI40191 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40191 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 5 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21–60 (pups) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25643018 PMDBI40192 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40192 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 5 mg/kg by gavage daily at 4 weeks of age for 12 weeks with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse; CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30744700 PMDBI40193 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000559075] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40193 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27018521 PMDBI40194 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40194 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21–60 (pups) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40195 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.26E-05] n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID PMID: 29555994 PMDBI40195 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23135753 PMDBI40196 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001078837] n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model; Caco-2/TC7 human intestinal cells Health n.a. n.a. PMID PMID: 29555994 PMDBI40196 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 3.5 mg/day injection in media into SHIME reactor for 30 days; cells treated with SHIME supernatant for 6 or 24 h; inulin cotreatment Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29808406 PMDBI40197 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244787] n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID PMID: 29555994 PMDBI40197 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27827942 PMDBI40198 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40198 Substances alter microbe abundance PMDBM612 1375 Aerococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40199 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40199 Substances alter microbe abundance PMDBM625 29331 Amphibacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40200 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40200 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27018521 PMDBI40201 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40201 Substances alter microbe abundance PMDBM663 41275 Brevundimonas PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40202 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000756371] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40202 Substances alter microbe abundance PMDBM973 82802 Trichococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with norma diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40203 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129582] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40203 Substances alter microbe abundance PMDBM859 133925 Olsenella PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40204 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001220011] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40204 Substances alter microbe abundance PMDBM760 580024 Enterorhabdus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29109040 PMDBI40205 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27579024 PMDBI40205 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112711] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40206 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 650 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40206 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000301738] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40207 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003741022] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40207 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27579024 PMDBI40208 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000249869] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40208 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 650 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40209 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1115 Chromium (VI) Environmental Substance Heavy Metals; Toxic Agents 2 mM for 7 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 29118411 PMDBI40209 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005590073] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40210 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1115 Chromium (VI) Environmental Substance Heavy Metals; Toxic Agents 2 mM for 7 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 29118411 PMDBI40210 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40211 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000223955] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40211 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1115 Chromium (VI) Environmental Substance Heavy Metals; Toxic Agents 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 29118411 PMDBI40212 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00431781] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40212 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1115 Chromium (VI) Environmental Substance Heavy Metals; Toxic Agents 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 29118411 PMDBI40213 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000488322] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40213 Substances alter microbe abundance PMDBM871 n.a. Paraprevotellaceae PMDBD1115 Chromium (VI) Environmental Substance Heavy Metals; Toxic Agents 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 29118411 PMDBI40214 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40214 Substances alter microbe abundance PMDBM921 n.a. S24-7 PMDBD1115 Chromium (VI) Environmental Substance Heavy Metals; Toxic Agents 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 29118411 PMDBI40215 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003977197] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40215 Substances alter microbe abundance PMDBM943 204457 Sphingomonadales PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40216 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005043812] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40216 Substances alter microbe abundance PMDBM927 1936988 Saprospirales PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40217 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005682417] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40217 Substances alter microbe abundance PMDBM846 n.a. Mycobacterium spp. PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40218 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005259467] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40218 Substances alter microbe abundance PMDBM852 n.a. Nocardia spp. PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40219 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1133 Cyclamate Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 4655823 PMDBI40219 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004412596] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40220 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates Newborns who did not receive intravenous infusion (control) vs newborns with respiratory distress who were given intravenous infusions Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human Health Newborn infants n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31356917 PMDBI40220 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD433 Hydrocortisone base Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008623045] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40221 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 μM DEHP in cecal contents(in vitro) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40221 Substances alter microbe abundance PMDBM33 47678 Bacteroides caccae PMDBD296 Eburnamonine (-) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002903472] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40222 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 μM DEHP in cecal contents(in vitro) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40222 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.05E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40223 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40223 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 μM DEHP in cecal contents(in vitro) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40224 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40224 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 μM DEHP in cecal contents(in vitro) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40225 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40225 Substances alter microbe abundance PMDBM865 44249 Paenibacillus PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 μM DEHP in cecal contents(in vitro) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40226 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40226 Substances alter microbe abundance PMDBM809 1506553 Lachnoclostridium PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 10, or 100 μM DEHP in cecal contents (in vitro) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40227 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40227 Substances alter microbe abundance PMDBM809 1506553 Lachnoclostridium PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31822602 PMDBI40228 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. n.a. Human Health Newborn infants n.a. n.a. PMID PMID: 29555994 PMDBI40228 Substances alter microbe abundance PMDBM915 n.a. Rothia spp. PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates Newborns who did not receive intravenous infusion (control) vs newborns with respiratory distress who were given intravenous infusions Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31356917 PMDBI40229 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD1146 Deoxynivalenol Environmental Substance Biological Contaminants 100 μg/kg DON Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24260424 PMDBI40229 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40230 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40230 Substances alter microbe abundance PMDBM890 n.a. Prevotella/Bacteroides PMDBD1146 Deoxynivalenol Environmental Substance Biological Contaminants 100 μg/kg DON Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24260424 PMDBI40231 Substances alter microbe abundance PMDBM25 91061 Bacilli PMDBD1147 DEP; methylparaben; triclosan Environmental Substance Phthalates 0.1735, 0.105, and 0.05 mg/kg/day Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27301250 PMDBI40231 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000104068] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40232 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1147 DEP; methylparaben; triclosan Environmental Substance Phthalates 0.1735, 0.105, and 0.05 mg/kg/day Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27301250 PMDBI40232 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.45E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40233 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003986644] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40233 Substances alter microbe abundance PMDBM749 641853 Elusimicrobia PMDBD1147 DEP; methylparaben; triclosan Environmental Substance Phthalates 0.1735, 0.105, and 0.05 mg/kg/day Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27301250 PMDBI40234 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40234 Substances alter microbe abundance PMDBM805 43994 Johnsonella PMDBD1155 Diazinon Environmental Substance Pesticides 13 weeks of diazinon exposure (4 ppm) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Specific pathogen-free n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 27203275 PMDBI40235 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40235 Substances alter microbe abundance PMDBM805 43994 Johnsonella PMDBD1155 Diazinon Environmental Substance Pesticides 13 weeks of diazinon exposure (4 ppm) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 27203275 PMDBI40236 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40236 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.23E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40237 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40237 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40238 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40238 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40239 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40239 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.12E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40240 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40240 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40241 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40241 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40242 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40242 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27203275 PMDBI40243 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238 PMDBI40243 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.39E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40244 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238 PMDBI40244 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40245 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238 PMDBI40245 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40246 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238 PMDBI40246 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40247 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40247 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238 PMDBI40248 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31137755 PMDBI40248 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000489548] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40249 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31137755 PMDBI40249 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.10E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40250 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40250 Substances alter microbe abundance PMDBM792 209 Helicobacter PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31137755 PMDBI40251 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40251 Substances alter microbe abundance PMDBM870 577309 Paraprevotella PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31137755 PMDBI40252 Substances alter microbe abundance PMDBM349 303 Pseudomonas putida PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31467957 PMDBI40252 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis Health n.a. n.a. PMID PMID: 29555994 PMDBI40253 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40253 Substances alter microbe abundance PMDBM642 1423 Bacillus subtilis PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31467957 PMDBI40254 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40254 Substances alter microbe abundance PMDBM897 256466 Pseudomonas japonica PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31467957 PMDBI40255 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40255 Substances alter microbe abundance PMDBM601 1287736 Achromobacter aegrifaciens PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31467957 PMDBI40256 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1173 Emulsifiers (P80 and CMC) Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25731162 PMDBI40256 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40257 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40257 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1173 Emulsifiers (P80 and CMC) Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25731162 PMDBI40258 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299 PMDBI40258 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40259 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299 PMDBI40259 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-06] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40260 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299 PMDBI40260 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000427754] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40261 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299 PMDBI40261 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40262 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40262 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299 PMDBI40263 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40263 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299 PMDBI40264 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 or 100 mg/kg via diet for 90 days starting at 9 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25766299 PMDBI40264 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40265 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 or 100 mg/kg via diet for 90 days starting at 9 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25766299 PMDBI40265 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109768] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40266 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281647] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40266 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 or 100 mg/kg via diet for 90 days starting at 9 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25766299 PMDBI40267 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40267 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002053979] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40268 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40268 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40269 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.09E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40269 Substances alter microbe abundance PMDBM942 1196083 Snodgrassella alvi PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40270 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40270 Substances alter microbe abundance PMDBM787 1196095 Gilliamella apicola PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40271 Substances alter microbe abundance PMDBM157 29347 Clostridium scindens PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569 PMDBI40271 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40272 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569 PMDBI40272 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40273 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569 PMDBI40273 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000288831] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40274 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001529607] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40274 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569 PMDBI40275 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40275 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569 PMDBI40276 Substances alter microbe abundance PMDBM199 1351 Enterococcus faecalis PMDBD1218 Glyphosate Environmental Substance Pesticides n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 23396248 PMDBI40276 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000124525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40277 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581 PMDBI40277 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40278 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40278 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581 PMDBI40279 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40279 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581 PMDBI40280 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40280 Substances alter microbe abundance PMDBM921 n.a. S24-7 PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581 PMDBI40281 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1218 Glyphosate Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40281 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40282 Substances alter microbe abundance PMDBM121 580596 Butyricicoccus PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31066122 PMDBI40282 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40283 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40283 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40284 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40284 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40285 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40285 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40286 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31066122 PMDBI40286 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00209371] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40287 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40287 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000812744] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40288 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1218 Glyphosate Environmental Substance Pesticides 1.5 or 7.5 mM in sugar syrup for 15 days; infection with parasite Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30990837 PMDBI40288 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.24E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40289 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/l for 5 days of adult workers Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30249635 PMDBI40289 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40290 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1218 Glyphosate Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40290 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.45E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40291 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD1218 Glyphosate Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40291 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40292 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1218 Glyphosate Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40292 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40293 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40293 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40294 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40294 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40295 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1218 Glyphosate Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40295 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105033] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40296 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002594892] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40296 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31066122 PMDBI40297 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40297 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1218 Glyphosate Environmental Substance Pesticides 5 or 10 mg/l for 5 days of adult workers; 1 mM for 2 days or 0.1 mM for 5 days of newly hatched workers Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30249635 PMDBI40298 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.18E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40298 Substances alter microbe abundance PMDBM615 416916 Aggregatibacter PMDBD1218 Glyphosate Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40299 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000269368] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40299 Substances alter microbe abundance PMDBM942 1196083 Snodgrassella alvi PMDBD1218 Glyphosate Environmental Substance Pesticides 5 or 10 mg/l for 5 days of adult workers; 1 mM for 2 days or 0.1 mM for 5 days of newly hatched workers Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30249635 PMDBI40300 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40300 Substances alter microbe abundance PMDBM942 1196083 Snodgrassella alvi PMDBD1218 Glyphosate Environmental Substance Pesticides 1.5 or 7.5 mM in sugar syrup for 15 days; infection with parasite Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30990837 PMDBI40301 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40301 Substances alter microbe abundance PMDBM787 1196095 Gilliamella apicola PMDBD1218 Glyphosate Environmental Substance Pesticides 1.5 or 7.5 mM in sugar syrup for 15 days; infection with parasite Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30990837 PMDBI40302 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40302 Substances alter microbe abundance PMDBM787 1196095 Gilliamella apicola PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/l for 5 days of adult workers Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30249635 PMDBI40303 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40303 Substances alter microbe abundance PMDBM729 n.a. Dasytricha spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 μg/ml in rumen fluid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen fluid n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25407376 PMDBI40304 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209667] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40304 Substances alter microbe abundance PMDBM745 n.a. Diplodinium spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 μg/ml in rumen fluid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen fluid n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25407376 PMDBI40305 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005817323] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40305 Substances alter microbe abundance PMDBM761 n.a. Entodinium spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 μg/ml in rumen fluid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen fluid n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25407376 PMDBI40306 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40306 Substances alter microbe abundance PMDBM762 n.a. Epidinium spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 μg/ml in rumen fluid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen fluid n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25407376 PMDBI40307 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40307 Substances alter microbe abundance PMDBM861 n.a. Ophryoscolex spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 μg/ml in rumen fluid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen fluid n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25407376 PMDBI40308 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40308 Substances alter microbe abundance PMDBM998 n.a. γ-Proteobacteria PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29992812 PMDBI40309 Substances alter microbe abundance PMDBM127 194 Campylobacter PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075–5 mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23224412 PMDBI40309 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00055263] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40310 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides Bacterial strains from rat feces were treated with 0.1 ppb, 400 ppm, or 5000 ppm in media for 24 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29854581 PMDBI40310 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000699998] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40311 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29635013 PMDBI40311 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160752] n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40312 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075–5 mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23224412 PMDBI40312 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001030079] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40313 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides Bacterial strains from rat feces were treated with 400 ppm or 5000 ppm in media for 24 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29854581 PMDBI40313 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001585698] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40314 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31066122 PMDBI40314 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006143524] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40315 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29635013 PMDBI40315 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824] n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40316 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075–5 mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23224412 PMDBI40316 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000518619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40317 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075–5 mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23224412 PMDBI40317 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40318 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40318 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00065096] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40319 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29635013 PMDBI40319 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000617244] n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40320 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40320 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.89E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40321 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40321 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159762] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40322 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40322 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40323 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29475651 PMDBI40323 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000560041] n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID PMID: 29555994 PMDBI40324 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40324 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31066122 PMDBI40325 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40325 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.1 ppb, 400 ppm, or 5000 ppm in tap water for 673 days (50 ng/l, 0.1 g/l, and 2.25 g/l of glyphosate, respectively) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29854581 PMDBI40326 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324943] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40326 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29635013 PMDBI40327 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00165225] n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40327 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075–5 mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23224412 PMDBI40328 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002103888] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40328 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides Bacterial strains from rat feces were treated with 0.1 ppb, 400 ppm, or 5000 ppm in media for 24 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29854581 PMDBI40329 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000539738] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40329 Substances alter microbe abundance PMDBM938 620 Shigella PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29475651 PMDBI40330 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40330 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40331 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40331 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.1 ppb, 400 ppm, or 5000 ppm in tap water for 673 days (50 ng/l, 0.1 g/l, and 2.25 g/l of glyphosate, respectively) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29854581 PMDBI40332 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000278128] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40332 Substances alter microbe abundance PMDBM866 53335 Pantoea PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29475651 PMDBI40333 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005331174] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40333 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29475651 PMDBI40334 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00888111] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40334 Substances alter microbe abundance PMDBM615 416916 Aggregatibacter PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29843725 PMDBI40335 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160215] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI40335 Substances alter microbe abundance PMDBM840 n.a. microbial diversity PMDBD1223 Hexachlorocyclohexane Environmental Substance Persistent Organic Pollutants n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31394347 PMDBI40336 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1223 Hexachlorocyclohexane Environmental Substance Pesticides Colostrum samples collected from eastern China Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31394347 PMDBI40336 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006648497] n.a. n.a. n.a. n.a. In vitro Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40337 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1223 Hexachlorocyclohexane Environmental Substance Pesticides Colostrum samples collected from eastern China Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31394347 PMDBI40337 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000208434] n.a. n.a. n.a. n.a. In vitro Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40338 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40338 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1223 Hexachlorocyclohexane Environmental Substance Pesticides Colostrum samples collected from eastern China Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro Human n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31394347 PMDBI40339 Substances alter microbe abundance PMDBM110 35832 Bilophila PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40339 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003048825] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40340 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40340 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241869] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40341 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40341 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000680623] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40342 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40342 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000250272] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40343 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40343 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00665058] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40344 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40344 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00893217] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40345 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001700046] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40345 Substances alter microbe abundance PMDBM946 1569 Sporosarcina PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40346 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40346 Substances alter microbe abundance PMDBM733 51514 Dehalobacterium PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40347 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD319 Ethacrynic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000869818] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40347 Substances alter microbe abundance PMDBM804 227979 Jeotgalicoccus PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40348 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009316771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40348 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40349 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009528998] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40349 Substances alter microbe abundance PMDBM628 n.a. anaerobic bacteria PMDBD1279 Mercury Environmental Substance Heavy Metals; Toxic Agents Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432 PMDBI40350 Substances alter microbe abundance PMDBM179 872 Desulfovibrio PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40350 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000537636] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40351 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40351 Substances alter microbe abundance PMDBM46 n.a. Bacteroides fragilis enterotoxigenic PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001316391] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40352 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40352 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40353 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40353 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40354 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40354 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40355 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40355 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40356 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40356 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40357 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40357 Substances alter microbe abundance PMDBM734 28221 Deltaproteobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971 PMDBI40358 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD303 Enilconazole Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 27393971 PMDBI40358 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40359 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD303 Enilconazole Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 27393971 PMDBI40359 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40360 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50, or 100 mg/kg bw/day orally via diet for 4 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27393971 PMDBI40360 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40361 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 μg/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28888875 PMDBI40361 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40362 Substances alter microbe abundance PMDBM242 203490 Fusobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 μg/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28888875 PMDBI40362 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.15E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40363 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50, or 100 mg/kg bw/day orally via diet for 4 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27393971 PMDBI40363 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40364 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 μg/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28888875 PMDBI40364 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40365 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40365 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 μg/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28888875 PMDBI40366 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40366 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 0.1, 0.5, or 2.5 mg/kg bw/day orally via diet for 2, 5, or 15 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30496565 PMDBI40367 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40367 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50, or 100 mg/kg bw/day orally via diet for 4 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27393971 PMDBI40368 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40368 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 μg/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28888875 PMDBI40369 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40369 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 μg/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28888875 PMDBI40370 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1234 Imidacloprid Environmental Substance Pesticides 10–100 μM in food (length of treatment not given) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28578396 PMDBI40370 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-06] n.a. n.a. n.a. n.a. In vivo Drosophila melanogaster Health n.a. n.a. PMID PMID: 29555994 PMDBI40371 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1234 Imidacloprid Environmental Substance Pesticides 3.5 μg/kg in sugar syrup for 24–34 h to interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40371 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000267555] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40372 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40372 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1234 Imidacloprid Environmental Substance Pesticides 3.5 μg/kg in sugar syrup for 24–34 h to interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40373 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40373 Substances alter microbe abundance PMDBM600 434 Acetobacter PMDBD1234 Imidacloprid Environmental Substance Pesticides 10–100 μM in food (length of treatment not given) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Drosophila melanogaster Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28578396 PMDBI40374 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40374 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40375 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm for 13 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28234468 PMDBI40375 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40376 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40376 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40377 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40377 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.95E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40378 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm for 13 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28234468 PMDBI40378 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40379 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28234468 PMDBI40379 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40380 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm for 13 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28234468 PMDBI40380 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40381 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28234468 PMDBI40381 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40382 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40382 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40383 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40383 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40384 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40384 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40385 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40385 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 24325943 PMDBI40386 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40386 Substances alter microbe abundance PMDBM843 n.a. Mogibacteriaceae PMDBD1264 Malathion Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 29097220 PMDBI40387 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40387 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40388 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40388 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.90E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40389 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40389 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40390 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40390 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.82E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40391 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40391 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40392 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40392 Substances alter microbe abundance PMDBM884 186818 Planococcaceae PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40393 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40393 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29097220 PMDBI40394 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1265 Manganese Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28610994 PMDBI40394 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40395 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1265 Manganese Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28610994 PMDBI40395 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001677974] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40396 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40396 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD1265 Manganese Environmental Substance Heavy Metals; Toxic Agents n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28610994 PMDBI40397 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40397 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40398 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40398 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.67E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40399 Substances alter microbe abundance PMDBM315 577310 Parasutterella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40399 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40400 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40400 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40401 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40401 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40402 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.09E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40402 Substances alter microbe abundance PMDBM964 195950 Tannerella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40403 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000906821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40403 Substances alter microbe abundance PMDBM715 1348911 Coprobacter PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40404 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002477444] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40404 Substances alter microbe abundance PMDBM803 1392389 Intestinimonas PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40405 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001321505] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40405 Substances alter microbe abundance PMDBM797 1573535 Holdemanella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30384071 PMDBI40406 Substances alter microbe abundance PMDBM110 35832 Bilophila PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40406 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40407 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40407 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00457977] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40408 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40408 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.95E-06] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40409 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40409 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001126779] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40410 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40410 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40411 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40411 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40412 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40412 Substances alter microbe abundance PMDBM946 1569 Sporosarcina PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40413 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40413 Substances alter microbe abundance PMDBM733 51514 Dehalobacterium PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40414 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001022261] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40414 Substances alter microbe abundance PMDBM804 227979 Jeotgalicoccus PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30105432 PMDBI40415 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 150 ppm in drinking water for 30 day Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31733937 PMDBI40415 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID PMID: 29555994 PMDBI40416 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008610966] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40416 Substances alter microbe abundance PMDBM945 203692 Spirochaetes PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 150 ppm in drinking water for 90 day Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31733937 PMDBI40417 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40417 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 150 ppm in drinking water for 30 day Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31733937 PMDBI40418 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40418 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1278 Mercuric chloride Environmental Substance Heavy Metals; Toxic Agents 0 or 150 ppm in drinking water for 60 day Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31733937 PMDBI40419 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40419 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD530 Metformin Environmental Substance Approved Drug n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 27999002; PMID: 28530702 PMDBI40420 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents Fathead minnow (FHM): control (0.02 μg/g), 0.72 μg/g, 5.50 μg/g Hg dry weight for twice a day for 30 days Mice: control (0.02 μg/g), 0.43 μg/g, 4.39 μg/g Hg dry weight in diet for twice a day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29943971 PMDBI40420 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646302] n.a. n.a. n.a. n.a. In vivo FHM; CD-1 mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40421 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. Some of the MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite. MeHg + sodium selenite compared with MeHg group Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31585392 PMDBI40421 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.57E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40422 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. Some of the MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite. MeHg treatment groups compared with control Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31585392 PMDBI40422 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000125508] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40423 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40423 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. MeHg treatment groups compared with control Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31585392 PMDBI40424 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40424 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite. MeHg+sodium selenite compared with MeHg Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31585392 PMDBI40425 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40425 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents Fathead minnow (FHM): control (0.02 μg/g), 0.72 μg/g, 5.50 μg/g Hg dry weight for twice a day for 30 days Mice: control (0.02 μg/g), 0.43 μg/g, 4.39 μg/g Hg dry weight in diet for twice a day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo FHM; CD-1 mice Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29943971 PMDBI40426 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40426 Substances alter microbe abundance PMDBM727 1117 Cyanobacteria PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. Some of the MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31585392 PMDBI40427 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40427 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents Fathead minnow (FHM): control (0.02 μg/g), 0.72 μg/g, 5.50 μg/g Hg dry weight for twice a day for 30 days Mice: control (0.02 μg/g), 0.43 μg/g, 4.39 μg/g Hg dry weight in diet for twice a day for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo FHM; CD-1 mice Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29943971 PMDBI40428 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40428 Substances alter microbe abundance PMDBM626 n.a. an unclassified member of the Neisseriaceae family PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents Fathead minnow (FHM): control (0.02 μg/g), 0.72 μg/g, 5.50 μg/g Hg dry weight for twice a day for 30 days Mice: control (0.02 μg/g), 0.43 μg/g, 4.39 μg/g Hg dry weight in diet for twice a day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo FHM; CD-1 mice Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29943971 PMDBI40429 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40429 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40430 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40430 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187809] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40431 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40431 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00759669] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40432 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40432 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.27E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40433 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000857592] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40433 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40434 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003534694] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40434 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40435 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001829832] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40435 Substances alter microbe abundance PMDBM909 41295 Rhodospirillaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40436 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000416203] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40436 Substances alter microbe abundance PMDBM794 72293 Helicobacteraceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40437 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001836614] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40437 Substances alter microbe abundance PMDBM876 186807 Peptococcaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40438 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40438 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40439 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003903545] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40439 Substances alter microbe abundance PMDBM963 995019 Sutterellaceae PMDBD540 Methylmercury Environmental Substance Heavy Metals; Toxic Agents 0 or 10 μg/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31918252 PMDBI40440 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD546 Metronidazole Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 21321077 PMDBI40440 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003217095] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40441 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40441 Substances alter microbe abundance PMDBM629 n.a. anaerobic Bacteroidales PMDBD546 Metronidazole Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 21321077 PMDBI40442 Substances alter microbe abundance PMDBM157 29347 Clostridium scindens PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics clindamycin; ampicillin Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25337874 PMDBI40442 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40443 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1301 Mixture Environmental Substance Approved Drug; Antibiotics metronidazole; metronidazole; gentamicin Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29524228 PMDBI40443 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vivo Piglet Health n.a. n.a. PMID PMID: 29555994 PMDBI40444 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics metronidazole; metronidazole; gentamicin Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29524228 PMDBI40444 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vivo Piglet Health n.a. n.a. PMID PMID: 29555994 PMDBI40445 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000385531] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40445 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics ampicillin; streptomycin; clindamycin Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26963277 PMDBI40446 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187916] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40446 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics metronidazole; metronidazole; gentamicin Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Piglet Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29524228 PMDBI40447 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40447 Substances alter microbe abundance PMDBM992 338 Xanthomonas PMDBD1301 Mixture Environmental Substance Approved Drug; Antibiotics ampicillin; streptomycin; clindamycin Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26963277 PMDBI40448 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004975989] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40448 Substances alter microbe abundance PMDBM952 40323 Stenotrophomonas PMDBD1301 Mixture Environmental Substance Approved Drug; Antibiotics ampicillin; streptomycin; clindamycin Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26963277 PMDBI40449 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40449 Substances alter microbe abundance PMDBM628 n.a. anaerobic bacteria PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics norfloxacin and ampicillin (1g/Leach) for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 18326786 PMDBI40450 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00262628] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40450 Substances alter microbe abundance PMDBM933 n.a. Shannon index PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics Neomycin sulfate (1g/L), vancomycin (500mg/L) and ampicillin (1g/L), and metronidazole (1g/L) each day by gavage for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 31434991 PMDBI40451 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000504227] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40451 Substances alter microbe abundance PMDBM678 n.a. Cecal aerobic bacteria PMDBD1301 Mixture Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics norfloxacin and ampicillin (1g/Leach) for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 18326786 PMDBI40452 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1317 Neotame Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 29425148 PMDBI40452 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40453 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD1319 Nickel Environmental Substance Heavy Metals; Toxic Agents 0–900 mg/kg NiCl2 for 42 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205 PMDBI40453 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003029048] n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID PMID: 29555994 PMDBI40454 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1319 Nickel Environmental Substance Heavy Metals; Toxic Agents 0–900 mg/kg NiCl2 for 42 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205 PMDBI40454 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704304] n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID PMID: 29555994 PMDBI40455 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002511467] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40455 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD1319 Nickel Environmental Substance Heavy Metals; Toxic Agents 0–900 mg/kg NiCl2 for 42 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205 PMDBI40456 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40456 Substances alter microbe abundance PMDBM967 n.a. The bacterial diversity PMDBD1319 Nickel Environmental Substance Heavy Metals; Toxic Agents 0–900 mg/kg NiCl2 for 42 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205 PMDBI40457 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40457 Substances alter microbe abundance PMDBM661 n.a. Bifidobacterium spp. PMDBD1319 Nickel Environmental Substance Heavy Metals; Toxic Agents 0–900 mg/kg NiCl2 for 42 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205 PMDBI40458 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40458 Substances alter microbe abundance PMDBM775 n.a. F16 PMDBD1320 Nicotine Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 29035044 PMDBI40459 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40459 Substances alter microbe abundance PMDBM775 n.a. F16 PMDBD1320 Nicotine Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 29035044 PMDBI40460 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1326 Ochratoxin A Environmental Substance Biological Contaminants 0, 70, and 210 μg/kg body weight via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24973096 PMDBI40460 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017055] n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40461 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1330 Omega-3 PUFA supplementation Environmental Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 28951525 PMDBI40461 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135733] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40462 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1330 Omega-3 PUFA supplementation Environmental Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 28951525 PMDBI40462 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005294977] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40463 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.82E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40463 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1330 Omega-3 PUFA supplementation Environmental Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 28951525 PMDBI40464 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40464 Substances alter microbe abundance PMDBM850 481 Neisseriaceae PMDBD1335 Other bisphenols Environmental Substance Industrial Compounds; Bisphenols BPF (0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 μM) in water environment for 10 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30321396 PMDBI40465 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40465 Substances alter microbe abundance PMDBM850 481 Neisseriaceae PMDBD1335 Other bisphenols Environmental Substance Industrial Compounds; Bisphenols BPS (0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 μM) in water environment for 10 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30321396 PMDBI40466 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40466 Substances alter microbe abundance PMDBM682 1046 Chromatiaceae PMDBD1335 Other bisphenols Environmental Substance Industrial Compounds; Bisphenols BPF(0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 μM) in water environment for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30321396 PMDBI40467 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000612559] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40467 Substances alter microbe abundance PMDBM726 246874 Cryomorphaceae PMDBD1335 Other bisphenols Environmental Substance Industrial Compounds; Bisphenols BPS(0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 μM) in water environment for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30321396 PMDBI40468 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40468 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40469 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40469 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0018713] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40470 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40470 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40471 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31195221 PMDBI40471 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000859086] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40472 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40472 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000671946] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40473 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40473 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40474 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008623045] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40474 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31195221 PMDBI40475 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00406747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40475 Substances alter microbe abundance PMDBM727 1117 Cyanobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31195221 PMDBI40476 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001913202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40476 Substances alter microbe abundance PMDBM731 200930 Deferribacteres PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31195221 PMDBI40477 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1370 Polycyclic aromatic hydrocarbon Environmental Substance Persistent Organic Pollutants No exposure to oil (northern Norway area)or 0.01 ppm exposure to oil (southern Norway area) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336609 PMDBI40477 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000343393] n.a. n.a. n.a. n.a. In vivo Gadus Morhua Health n.a. n.a. PMID PMID: 29555994 PMDBI40478 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40478 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001921381] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40479 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40479 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002112696] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40480 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40480 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.97E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40481 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40481 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003286927] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40482 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40482 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000437689] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40483 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40483 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40484 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40484 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40485 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000276431] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40485 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40486 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003731208] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40486 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943 PMDBI40487 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40487 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00203836] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40488 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40488 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40489 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003573495] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40489 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40490 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000762503] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40490 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40491 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00184996] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40491 Substances alter microbe abundance PMDBM677 204458 Caulobacterales PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40492 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003451354] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40492 Substances alter microbe abundance PMDBM760 580024 Enterorhabdus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40493 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD319 Ethacrynic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000683269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40493 Substances alter microbe abundance PMDBM711 n.a. Clostridium XIVb PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.3390/nu11010022; PMID: 26962054 PMDBI40494 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1345 PCB congeners Environmental Substance Persistent Organic Pollutants 5 mg/kg (P77 and P153) and 50 mg/kg (P126) per week via oral gavage then with HF diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29674211 PMDBI40494 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003050721] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40495 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00641235] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40495 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1345 PCB congeners Environmental Substance Persistent Organic Pollutants 5 mg/kg (P77 and P153) and 50 mg/kg (P126) per week via oral gavage then with HF diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29674211 PMDBI40496 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40496 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007141128] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40497 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008962491] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40497 Substances alter microbe abundance PMDBM949 1282 Staphylococcus epidermidis PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40498 Substances alter microbe abundance PMDBM50 n.a. Bacteroides fragilis nontoxigenic PMDBD675 Pipemidic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001002675] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40498 Substances alter microbe abundance PMDBM719 1653 Corynebacteriaceae PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40499 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40499 Substances alter microbe abundance PMDBM974 2039 Tropheryma whipplei PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase Fold change = 1.5 n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40500 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40500 Substances alter microbe abundance PMDBM956 68892 Streptococcus infantis PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40501 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40501 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40502 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40502 Substances alter microbe abundance PMDBM670 526863 Candidatus Aquirestis calciphila PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40503 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40503 Substances alter microbe abundance PMDBM898 n.a. Pseudomonas plecoglossicida strain CGMCC 2093 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40504 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40504 Substances alter microbe abundance PMDBM899 n.a. Pseudomonas plecoglossicida strain R18 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40505 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40505 Substances alter microbe abundance PMDBM900 n.a. Pseudomonas putida strain SRI156 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40506 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40506 Substances alter microbe abundance PMDBM649 n.a. Bacteroides thetaiotaomicron strain 8669 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 23632211 PMDBI40507 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40507 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID PMID: 29555994 PMDBI40508 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40508 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID PMID: 29555994 PMDBI40509 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40509 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40510 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40510 Substances alter microbe abundance PMDBM654 28216 Betaproteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40511 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40511 Substances alter microbe abundance PMDBM734 28221 Deltaproteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40512 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40512 Substances alter microbe abundance PMDBM731 200930 Deferribacteres PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants DM mice compared with WT mice following exposure to 1 mg/kg/day PCB dose Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Mouse with FMR1 and RyR double mutations n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40513 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40513 Substances alter microbe abundance PMDBM644 n.a. Bacteroidales family S7-25 PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31336350 PMDBI40514 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1348 PCB-126 Environmental Substance Persistent Organic Pollutants 0 or1 μmol/kg/day at weeks 2 and 4 Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30373033 PMDBI40514 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Ldlr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40515 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40515 Substances alter microbe abundance PMDBM997 n.a. α-Diversity PMDBD1348 PCB-126 Environmental Substance Persistent Organic Pollutants 0 or1 μmol/kg/day at weeks 2 and 4 Cecum Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Ldlr-/- mice n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30373033 PMDBI40516 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD1351 Penicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics low doses to mice early in life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25126780 PMDBI40516 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40517 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1351 Penicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics low doses to mice early in life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25126780 PMDBI40517 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40518 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40518 Substances alter microbe abundance PMDBM634 49082 Arthromitus PMDBD1351 Penicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics low doses to mice early in life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25126780 PMDBI40519 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40519 Substances alter microbe abundance PMDBM81 n.a. Bacteroidetes/Firmicutes ratio PMDBD1352 Penicillin G; erythromycin, or both Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 60/10 mg/mL in drinking water for 6/14 weeks, total concentration Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 27503388 PMDBI40520 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0–100 μg/L in water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342 PMDBI40520 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID PMID: 29555994 PMDBI40521 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40521 Substances alter microbe abundance PMDBM833 445 Legionella PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0–100 μg/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342 PMDBI40522 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40522 Substances alter microbe abundance PMDBM633 1663 Arthrobacter PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0–100 μg/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342 PMDBI40523 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40523 Substances alter microbe abundance PMDBM839 33882 Microbacterium PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0–100 μg/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342 PMDBI40524 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40524 Substances alter microbe abundance PMDBM683 59732 Chryseobacterium PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0–100 μg/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342 PMDBI40525 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 1, 50, or 100 μg/l in water environment for 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26378342 PMDBI40525 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID PMID: 29555994 PMDBI40526 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40526 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 1, 50, or 100 μg/l in water environment for 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26378342 PMDBI40527 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931 PMDBI40527 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40528 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931 PMDBI40528 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40529 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931 PMDBI40529 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40530 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931 PMDBI40530 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40531 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40531 Substances alter microbe abundance PMDBM886 836 Porphyromonas PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931 PMDBI40532 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21,4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26898931 PMDBI40532 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40533 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21,4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26898931 PMDBI40533 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40534 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21,4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26898931 PMDBI40534 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40535 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40535 Substances alter microbe abundance PMDBM886 836 Porphyromonas PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21, 4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 26898931 PMDBI40536 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 μg/l for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31319243 PMDBI40536 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000923016] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40537 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 μg/l for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31319243 PMDBI40537 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40538 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 μg/l for 10 weeks, after subchronic exposure Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31319243 PMDBI40538 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40539 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40539 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 μg/l for 10 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31319243 PMDBI40540 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Marine medaka Health n.a. n.a. PMID PMID: 29555994 PMDBI40540 Substances alter microbe abundance PMDBM883 118 Planctomyces PMDBD1356 Perfluorobutanesulfonic acid Environmental Substance Persistent Organic Pollutants 0, 1.0, 2.9, 9.5 μg/l for the entire lifecycle Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065 PMDBI40541 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Marine medaka Health n.a. n.a. PMID PMID: 29555994 PMDBI40541 Substances alter microbe abundance PMDBM989 662 Vibrio PMDBD1356 Perfluorobutanesulfonic acid Environmental Substance Persistent Organic Pollutants 0, 1.0, 2.9, 9.5 μg/l for the entire lifecycle, in F1 females after exposure of F0 parents to 9.5 μg/ l PDBS Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065 PMDBI40542 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Marine medaka Health n.a. n.a. PMID PMID: 29555994 PMDBI40542 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD1356 Perfluorobutanesulfonic acid Environmental Substance Persistent Organic Pollutants 2.9 μg/l for the entire lifecycle Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065 PMDBI40543 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40543 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40544 Substances alter microbe abundance PMDBM179 872 Desulfovibrio PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40544 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40545 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40545 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40546 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40546 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40547 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40547 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40548 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40548 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40549 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40549 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40550 Substances alter microbe abundance PMDBM323 203683 Planctomycetes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40550 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001659558] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40551 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40551 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004276717] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40552 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40552 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001403982] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40553 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00013257] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40553 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40554 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00921525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40554 Substances alter microbe abundance PMDBM733 51514 Dehalobacterium PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40555 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40555 Substances alter microbe abundance PMDBM681 200795 Chloroflexi PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40556 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40556 Substances alter microbe abundance PMDBM602 204432 Acidobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40557 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40557 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40558 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40558 Substances alter microbe abundance PMDBM971 n.a. TM7 PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725 PMDBI40559 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 1–10 mg/l in drinking water for 10 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29906725 PMDBI40559 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40560 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40560 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615579] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40561 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 1000 μg/l in water environment for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30544157 PMDBI40561 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40562 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40562 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40563 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40563 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40564 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40564 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40565 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 100 and 1000 μg/l in water environment for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30544157 PMDBI40565 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40566 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40566 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 1–10 mg/l in drinking water for 10 weeks beginning at 6 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29906725 PMDBI40567 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40567 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40568 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40568 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 100 and 1000 μg/l in water environment for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 30544157 PMDBI40569 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.89E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40569 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40570 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40570 Substances alter microbe abundance PMDBM971 n.a. TM7 PMDBD1387 Propamocarb Environmental Substance Pesticides 3–300 mg/l in drinking water (0.5–50 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 29137890 PMDBI40571 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human Cirrhosis n.a. n.a. PMID PMID: 29555994 PMDBI40571 Substances alter microbe abundance PMDBM987 31977 Veillonellaceae PMDBD747 Rifaximin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24374295 PMDBI40572 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro Human Cirrhosis n.a. n.a. PMID PMID: 29555994 PMDBI40572 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD747 Rifaximin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24374295 PMDBI40573 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25231862 PMDBI40573 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40574 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28472674 PMDBI40574 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002632027] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40575 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 25231862 PMDBI40575 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40576 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28472674 PMDBI40576 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001943] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40577 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28472674 PMDBI40577 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40578 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28472674 PMDBI40578 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004295111] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40579 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1411 saccharin; sucralose; aspartame Environmental Substance Noncaloric Artificial Sweeteners (NAS) n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25231862 PMDBI40579 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000650497] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40580 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1411 saccharin; sucralose; aspartame Environmental Substance Noncaloric Artificial Sweeteners (NAS) n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25231862 PMDBI40580 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003295689] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40581 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291 PMDBI40581 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000945301] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40582 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291 PMDBI40582 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40583 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291 PMDBI40583 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40584 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40584 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291 PMDBI40585 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006747737] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40585 Substances alter microbe abundance PMDBM627 n.a. anaerobes PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291 PMDBI40586 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40586 Substances alter microbe abundance PMDBM972 n.a. total aerobic bacteria PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291 PMDBI40587 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD804 Streptomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 200 mg/L in drinking water for 9 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 26754178 PMDBI40587 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007729025] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40588 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD804 Streptomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507 PMDBI40588 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40589 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD804 Streptomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507 PMDBI40589 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003459073] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40590 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD804 Streptomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507 PMDBI40590 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40591 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD804 Streptomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507 PMDBI40591 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001233291] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40592 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1426 Sucralose Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28790923 PMDBI40592 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001691631] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40593 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1426 Sucralose Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28790923 PMDBI40593 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40594 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002099054] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40594 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1426 Sucralose Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28790923 PMDBI40595 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1435 Tau-fluvalinate Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27579024 PMDBI40595 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.23E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40596 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40596 Substances alter microbe abundance PMDBM676 76892 Caulobacteraceae PMDBD1435 Tau-fluvalinate Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27579024 PMDBI40597 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0–30 μg/kg/day for 28 and 92 days with the latter having a 30-day recovery period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28475713 PMDBI40597 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40598 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 μg/kg biweekly for 26 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27221631 PMDBI40598 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007347466] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID PMID: 29555994 PMDBI40599 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 μg/kg biweekly for 26 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27221631 PMDBI40599 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID PMID: 29555994 PMDBI40600 Substances alter microbe abundance PMDBM42 817 Bacteroides fragilis PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or30 μg/kg/day every 4 days for 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28936204 PMDBI40600 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001083172] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40601 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40601 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 μg/kg biweekly for 26 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27221631 PMDBI40602 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40602 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 μg/kg biweekly for 26 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27221631 PMDBI40603 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40603 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 μg/kg biweekly for 26 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27221631 PMDBI40604 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000991397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40604 Substances alter microbe abundance PMDBM928 n.a. Segmented filamentous bacteria (SFB) PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or30 μg/kg/day every 4 days for 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28936204 PMDBI40605 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40605 Substances alter microbe abundance PMDBM606 n.a. Actinobacteria cluster ACK M1 PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 μg/kg biweekly for 26 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27221631 PMDBI40606 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 μg/kg/day for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25768209 PMDBI40606 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40607 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 μg/kg/day for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25768209 PMDBI40607 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40608 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 μg/kg per day in the diet for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25768209 PMDBI40608 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507497] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40609 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40609 Substances alter microbe abundance PMDBM777 117743 Flavobacteria PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 μg/kg/day for 5 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25768209 PMDBI40610 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324146] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40610 Substances alter microbe abundance PMDBM928 n.a. Segmented filamentous bacteria (SFB) PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 μg/kg/day for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25768209 PMDBI40611 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002723341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40611 Substances alter microbe abundance PMDBM667 n.a. Butyrivibrio spp. PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 μg/kg/day for 5 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 25768209 PMDBI40612 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40612 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.49E-05] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40613 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40613 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40614 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40614 Substances alter microbe abundance PMDBM624 28211 Alphaproteobacteria PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40615 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40615 Substances alter microbe abundance PMDBM787 1196095 Gilliamella apicola PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 μg/kg in sugar syrup for 24–34 h of interior worker bees Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 31378758 PMDBI40616 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1468 Traffic-related air Environmental Substance Environmental Chemicals n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 29220800 PMDBI40616 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40617 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD1468 Traffic-related air Environmental Substance Environmental Chemicals n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1124/pr.118.015768; PMID: 29220800 PMDBI40617 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40618 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1476 Trichlorfon Environmental Substance Pesticides 12 μg/g bw single dose by oral gavage at 8 weeks of age, collected 24 h after dosing Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27168998 PMDBI40618 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002320022] n.a. n.a. n.a. n.a. In vivo Japanese quail Health n.a. n.a. PMID PMID: 29555994 PMDBI40619 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1476 Trichlorfon Environmental Substance Pesticides 12 μg/g bw single dose by oral gavage at 8 weeks of age, collected 24 h after dosing Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 27168998 PMDBI40619 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109489] n.a. n.a. n.a. n.a. In vivo Japanese quail Health n.a. n.a. PMID PMID: 29555994 PMDBI40620 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28606169 PMDBI40620 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009510718] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40621 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28606169 PMDBI40621 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001963588] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40622 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000469925] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40622 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28606169 PMDBI40623 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40623 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28606169 PMDBI40624 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157443] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40624 Substances alter microbe abundance PMDBM975 n.a. Turicibacteraceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.3390/toxics8010019; PMID: 28606169 PMDBI40625 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD888 Vancomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40625 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003354848] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40626 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40626 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006642697] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40627 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD888 Vancomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517 PMDBI40627 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000352557] n.a. n.a. n.a. n.a. In vivo Human Obese n.a. n.a. PMID PMID: 29555994 PMDBI40628 Substances alter microbe abundance PMDBM239 1239 Gram-positive bacteria PMDBD888 Vancomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517 PMDBI40628 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006173365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40629 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD888 Vancomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40629 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000601342] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40630 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40630 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001080494] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40631 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD888 Vancomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40631 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000755608] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40632 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517 PMDBI40632 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD325 Etofenamate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000304871] n.a. n.a. n.a. n.a. In vivo Human Obese n.a. n.a. PMID PMID: 29555994 PMDBI40633 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD888 Vancomycin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40633 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD363 Flunixin meglumine Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001747188] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40634 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503 PMDBI40634 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD337 Fenbufen Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006136783] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40635 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD739 Reserpine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001439963] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40635 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 22422004 PMDBI40636 Substances alter microbe abundance PMDBM57 n.a. Bacteroides ovatus PMDBD809 Sulfamonomethoxine Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129611] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40636 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 22422004 PMDBI40637 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.34E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40637 Substances alter microbe abundance PMDBM788 n.a. Gram-negative bacteria PMDBD888 Vancomycin Environmental Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517 PMDBI40638 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1496 β-Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40638 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40639 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1496 β-Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40639 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40640 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1496 β-Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40640 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40641 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1496 β-Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40641 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.66E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40642 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40642 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1496 β-Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065; PMID: 28392238 PMDBI40643 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40643 Substances alter microbe abundance PMDBM968 n.a. The diversity of microbiota in colon PMDBD1301 Mixture Environmental Substance Approved Drug; Antibiotics Bacitracin (108.0mg), ampicillin (43.2mg), neomycin (108mg), vancomycin and meropenem (21.6 mg)(6.48mg) dissolved in 4.5 mL for 11 days by oral gavage (10mL/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Acetate(Decrease); n-butyrate (Decrease); propionate (Decrease); PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26923630 PMDBI40644 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1301 Mixture Environmental Substance Approved Drug; Antibiotics penicillin VK, vancomycin for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Acetate(Increase); propionate(Increase); butyrate(Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 22914093 PMDBI40644 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40645 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40645 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.51E-06] n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID PMID: 29555994 PMDBI40646 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40646 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06] n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID PMID: 29555994 PMDBI40647 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.51E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40647 Substances alter microbe abundance PMDBM922 95818 Saccharibacteria PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40648 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40648 Substances alter microbe abundance PMDBM855 n.a. Norank_f_Hados. Sed. Eubac.3 PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40649 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40649 Substances alter microbe abundance PMDBM856 n.a. Norank_f_Peptostreptococcaceae PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40650 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40650 Substances alter microbe abundance PMDBM966 n.a. The bacterial community diversity PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40651 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40651 Substances alter microbe abundance PMDBM970 n.a. TM6_Dependentiae PMDBD1114 Chromium Environmental Substance Heavy Metals; Toxic Agents 416 μg Cr6+ L-1 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300 PMDBI40652 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40652 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.57E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40653 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40653 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40654 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40654 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.68E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40655 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40655 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40656 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40656 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40657 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40657 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40658 Substances alter microbe abundance PMDBM602 204432 Acidobacteria PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40658 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40659 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40659 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40660 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40660 Substances alter microbe abundance PMDBM728 n.a. Cyanobacteria/Chloroplast PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40661 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40661 Substances alter microbe abundance PMDBM971 n.a. TM7 PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881 PMDBI40662 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1497 β-lactam Environmental Substance Approved Drug; Antibiotics Intravenous cefazolin alone for 14 days. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Five putative glycerophospholipids and fatty acid carnitines (Increase); GTPases(Decrease); aerobic CobN cobaltochelatases (Decrease); antimicrobial peptide transporters (Increase);multidrug efflux pumps (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 23236009 PMDBI40662 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40663 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1497 β-lactam Environmental Substance Approved Drug; Antibiotics Intravenous cefazolin alone for 14 days. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Five putative glycerophospholipids and fatty acid carnitines (Increase); GTPases(Decrease); aerobic CobN cobaltochelatases (Decrease); antimicrobial peptide transporters (Increase);multidrug efflux pumps (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 23236009 PMDBI40663 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40664 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40664 Substances alter microbe abundance PMDBM969 n.a. The diversity of total bacteria PMDBD1497 β-lactam Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics Intravenous cefazolin alone for 14 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Five putative glycerophospholipids and fatty acid carnitines (Increase); GTPases(Decrease); aerobic CobN cobaltochelatases (Decrease); antimicrobial peptide transporters (Increase);multidrug efflux pumps (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 23236009 PMDBI40665 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40665 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40666 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD881 Tylosin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40666 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40667 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40667 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40668 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD881 Tylosin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40668 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40669 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD881 Tylosin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40669 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.80E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40670 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40670 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40671 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD881 Tylosin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40671 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40672 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40672 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40673 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.48E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40673 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40674 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40674 Substances alter microbe abundance PMDBM841 n.a. microbiota PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut delay microbiota maturation n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40675 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.38E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40675 Substances alter microbe abundance PMDBM976 n.a. unclassified Clostridiales PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40676 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.66E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40676 Substances alter microbe abundance PMDBM911 n.a. Richness and Shannon evenness PMDBD881 Tylosin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40677 Substances alter microbe abundance PMDBM645 n.a. Bacteroidales other PMDBD881 Tylosin Environmental Substance Approved Drug; Antibiotics 0.333 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entner– Doudoroff pathway (Increase); the classic Embden–Meyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40677 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40678 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD42 Amoxicillin Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40678 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40679 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD42 Amoxicillin Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40679 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40680 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD42 Amoxicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40680 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40681 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD42 Amoxicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40681 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40682 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD42 Amoxicillin Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40682 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40683 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD42 Amoxicillin Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40683 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000393088] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40684 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40684 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD42 Amoxicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40685 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750494] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40685 Substances alter microbe abundance PMDBM841 n.a. microbiota PMDBD42 Amoxicillin Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut delay microbiota maturation n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40686 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40686 Substances alter microbe abundance PMDBM932 n.a. Shannon evenness PMDBD42 Amoxicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40687 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002379728] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40687 Substances alter microbe abundance PMDBM976 n.a. unclassified Clostridiales PMDBD42 Amoxicillin Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40688 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40688 Substances alter microbe abundance PMDBM910 n.a. Richness PMDBD42 Amoxicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40689 Substances alter microbe abundance PMDBM645 n.a. Bacteroidales other PMDBD42 Amoxicillin Therapeutic Substance; Environmental Substance Approved Drug; Antibiotics 0.167 mg mL-1 at days 10–15, 28–31 and 37–40 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase) PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276 PMDBI40689 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40690 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40690 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40691 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40691 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40692 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40692 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40693 Substances alter microbe abundance PMDBM675 424536 Catabacteriaceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40693 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000174956] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40694 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40694 Substances alter microbe abundance PMDBM690 538999 Clostridiales incertae sedis PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40695 Substances alter microbe abundance PMDBM638 n.a. Bacillales_Other PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40695 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40696 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40696 Substances alter microbe abundance PMDBM691 n.a. Clostridiales_unassigned PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. Indolelacticacid Decrease PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286 PMDBI40697 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000390662] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40697 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD530 Metformin Therapeutic Substance Approved Drug 6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. metformin promotes in vivo the growth of the bacterial species PMID PMID: 25038099 PMDBI40698 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40698 Substances alter microbe abundance PMDBM703 69824 Clostridium cocleatum PMDBD530 Metformin Therapeutic Substance Approved Drug 6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. metformin promotes in vivo the growth of the bacterial species PMID PMID: 25038099 PMDBI40699 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40699 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40700 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40700 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40701 Substances alter microbe abundance PMDBM201 1352 Enterococcus faecium PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40701 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40702 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40702 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40703 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001858081] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40703 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40704 Substances alter microbe abundance PMDBM157 29347 Clostridium scindens PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40704 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001596639] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40705 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40705 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00323688] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40706 Substances alter microbe abundance PMDBM345 135621 Pseudomonadaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40706 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.06E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40707 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40707 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.96E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40708 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000478376] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40708 Substances alter microbe abundance PMDBM912 301302 Roseburia faecis PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40709 Substances alter microbe abundance PMDBM345 135621 Pseudomonadaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40709 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40710 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001275288] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40710 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40711 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000758779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40711 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40712 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug Rats were injected once intravenously in the tail vein with Methotrexate (90 mg/kg). n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Methotrexate results in reduced microbiota diversity and compositional shifts in the abundance of Bacteroides associated with the induction of diarrhea in rats. PMID PMID: 25376667 PMDBI40712 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40713 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40713 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002546255] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40714 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40714 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000322832] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40715 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40715 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40716 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40716 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000958761] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40717 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40717 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001797486] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40718 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40718 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40719 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00040782] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40719 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance Heavy Metals; Toxic Agents 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668 PMDBI40720 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468 PMDBI40720 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40721 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468 PMDBI40721 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40722 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468 PMDBI40722 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006561372] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40723 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468 PMDBI40723 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40724 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40724 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm Pb for 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468 PMDBI40725 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40725 Substances alter microbe abundance PMDBM916 n.a. Ruminococcaceae_other PMDBD1251 Lead Environmental Substance Heavy Metals; Toxic Agents 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468 PMDBI40726 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40726 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40727 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40727 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244742] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40728 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40728 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002834728] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40729 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40729 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008429051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40730 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40730 Substances alter microbe abundance PMDBM938 620 Shigella PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40731 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Increase P < 0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40731 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40732 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Decrease P < 0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40732 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007469016] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40733 Substances alter microbe abundance PMDBM63 29523 Bacteroides spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Decrease P < 0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40733 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007503786] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40734 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40734 Substances alter microbe abundance PMDBM951 n.a. Staphylococcus spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Increase P < 0.05 n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40735 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000321751] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40735 Substances alter microbe abundance PMDBM709 n.a. Clostridium spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Increase P < 0.05 n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40736 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1009 ACE inhibitors Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40736 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40737 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008333416] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40737 Substances alter microbe abundance PMDBM746 88431 Dorea longicatena PMDBD1009 ACE inhibitors Therapeutic Substance Drug Class n.a. Gut Decrease Bacterial taxa negatively associated with drug use. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40738 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI40738 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40739 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40739 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000835296] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40740 Substances alter microbe abundance PMDBM233 853 Faecalibacterium prausnitzii PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40740 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40741 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40741 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003263891] n.a. n.a. n.a. n.a. In vivo Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40742 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-05] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40742 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40743 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000462902] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40743 Substances alter microbe abundance PMDBM810 28050 Lachnospira PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40744 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001072952] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40744 Substances alter microbe abundance PMDBM748 84111 Eggerthella PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40745 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019571] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40745 Substances alter microbe abundance PMDBM912 301302 Roseburia faecis PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40746 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40746 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000612907] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40747 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324701] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40747 Substances alter microbe abundance PMDBM987 31977 Veillonellaceae PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40748 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005767488] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40748 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40749 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009785517] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40749 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40750 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40750 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD526 Mesoridazine besylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001895632] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40751 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40751 Substances alter microbe abundance PMDBM68 818 Bacteroides thetaiotaomicron PMDBD606 Norcyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007567399] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40752 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 8243490; PMID: 7961199 PMDBI40752 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40753 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490 PMDBI40753 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40754 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16272491; PMID: 9023640 PMDBI40754 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40755 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634; Infection 1991:208–15; PMID: 7961199 PMDBI40755 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40756 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40756 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40757 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40757 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40758 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634 PMDBI40758 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40759 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40759 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40760 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 1906634 PMDBI40760 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40761 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; Infection 1991:208–15 PMDBI40761 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40762 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 1906634; Infection 1991:208–15 PMDBI40762 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40763 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 8243490; PMID: 7961199 PMDBI40763 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40764 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25006989 PMDBI40764 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40765 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8036475; PMID: 8243490; PMID: 1906634 PMDBI40765 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40766 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634 PMDBI40766 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40767 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; Infection 1991:208–15 PMDBI40767 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40768 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25006989 PMDBI40768 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40769 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8036475; PMID: 8243490; PMID: 1906634; PMID: 7961199 PMDBI40769 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.83E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40770 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634 PMDBI40770 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40771 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40771 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40772 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 1906634 PMDBI40772 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40773 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40773 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40774 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25006989; Infection 1991:208–15 PMDBI40774 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40775 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 7961199 PMDBI40775 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40776 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40776 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40777 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25006989 PMDBI40777 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40778 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16272491 PMDBI40778 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40779 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490 PMDBI40779 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40780 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634; Infection 1991:208–15 PMDBI40780 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40781 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634 PMDBI40781 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40782 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40782 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40783 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 1906634 PMDBI40783 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40784 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40784 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40785 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40785 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 7961199 PMDBI40786 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40786 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634; Infection 1991:208–15 PMDBI40787 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40787 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40788 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640 PMDBI40788 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40789 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40789 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 9023640 PMDBI40790 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40790 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25006989 PMDBI40791 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40791 Substances alter microbe abundance PMDBM844 90690 Morganella PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640 PMDBI40792 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40792 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD42 Amoxicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI40793 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40793 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40794 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40794 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40795 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40795 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40796 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40796 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40797 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40797 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.76E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40798 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40798 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40799 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40799 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40800 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40800 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.98E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40801 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40801 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40802 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40802 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40803 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40803 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40804 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40804 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI40805 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15004076; PMID: 11868762 PMDBI40805 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40806 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27973989 PMDBI40806 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40807 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020; PMID: 23209691; PMID: 15004076 PMDBI40807 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005211253] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40808 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI40808 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40809 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020; PMID: 27973989; PMID: 23209691; PMID: 11868762 PMDBI40809 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008278923] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40810 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI40810 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40811 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI40811 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40812 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI40812 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40813 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27973989 PMDBI40813 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40814 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15004076 PMDBI40814 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40815 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI40815 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.94E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40816 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27973989 PMDBI40816 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40817 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23209691 PMDBI40817 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40818 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.82E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40818 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23209691; PMID: 15004076; PMID: 11868762 PMDBI40819 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI40819 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.23E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40820 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40820 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40821 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40821 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.14E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40822 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40822 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40823 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40823 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40824 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40824 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40825 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40825 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40826 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40826 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40827 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40827 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40828 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000191748] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40828 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ampicillin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI40829 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40829 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40830 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40830 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000507497] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40831 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40831 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40832 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40832 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40833 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1031 Ampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40833 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003325765] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40834 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40834 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40835 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40835 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40836 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40836 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.60E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40837 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40837 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180117] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40838 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007728184] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40838 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40839 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40839 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40840 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40840 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40841 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40841 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004873795] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40842 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40842 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40843 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001295533] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40843 Substances alter microbe abundance PMDBM758 81852 Enterococcaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40844 Substances alter microbe abundance PMDBM631 186333 Anaeroplasmataceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40844 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000358235] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40845 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40845 Substances alter microbe abundance PMDBM876 186807 Peptococcaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40846 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40846 Substances alter microbe abundance PMDBM978 186928 unclassified Lachnospiraceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40847 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40847 Substances alter microbe abundance PMDBM980 552397 unclassified Ruminococcaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40848 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000108547] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40848 Substances alter microbe abundance PMDBM858 1853231 Odoribacteraceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40849 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40849 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1034 Antihistamines (H1 inhibitor) Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40850 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1035 Antihistamines (H2 inhibitor) Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40850 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40851 Substances alter microbe abundance PMDBM143 208479 Clostridium bolteae PMDBD1036 Antihistamines (H3 inhibitor) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40851 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001729015] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40852 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1040 aracytine Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI40852 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103719] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40853 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1040 aracytine Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI40853 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40854 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1040 aracytine Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI40854 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000146112] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40855 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40855 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40856 Substances alter microbe abundance PMDBM143 208479 Clostridium bolteae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40856 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005367666] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40857 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40857 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007823119] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40858 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40858 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004605859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40859 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40859 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002015009] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40860 Substances alter microbe abundance PMDBM57 28116 Bacteroides ovatus PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40860 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005268297] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40861 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40861 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40862 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.94E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40862 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40863 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000806109] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40863 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40864 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40864 Substances alter microbe abundance PMDBM959 1305 Streptococcus sanguinis PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40865 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007399353] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40865 Substances alter microbe abundance PMDBM957 1309 Streptococcus mutans PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40866 Substances alter microbe abundance PMDBM657 1689 Bifidobacterium dentium PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40866 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003190057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40867 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40867 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40868 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40868 Substances alter microbe abundance PMDBM812 n.a. Lachnospiraceae bacterium 3 1 57FAA CT1 PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40869 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004551067] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40869 Substances alter microbe abundance PMDBM813 n.a. Lachnospiraceae bacterium 7 1 58FAA PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40870 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD88 Azithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597 PMDBI40870 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40871 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD88 Azithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597 PMDBI40871 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001757589] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40872 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD88 Azithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597 PMDBI40872 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40873 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40873 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00032003] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40874 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40874 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000532567] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40875 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40875 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001694919] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40876 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40876 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002181305] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40877 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40877 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000201749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40878 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40878 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0035891] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40879 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40879 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40880 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40880 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40881 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1049 Azlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564 PMDBI40881 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008277451] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40882 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40882 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003377072] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40883 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40883 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131961] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40884 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40884 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001986996] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40885 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40885 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007710688] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40886 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40886 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40887 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40887 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40888 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40888 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004546858] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40889 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40889 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40890 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.92E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40890 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40891 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40891 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40892 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005217961] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40892 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1051 Bacampicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356 PMDBI40893 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1055 Beta blockers Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40893 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002422736] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40894 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1055 Beta blockers Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40894 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001765715] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40895 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40895 Substances alter microbe abundance PMDBM957 1309 Streptococcus mutans PMDBD1055 Beta blockers Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40896 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004974898] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40896 Substances alter microbe abundance PMDBM785 n.a. Gemellaceae PMDBD1071 Calcium Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40897 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1080 carmustine Therapeutic Substance Approved Drug n.a. n.a. Decrease P = 0.0002 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI40897 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002066042] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40898 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1080 carmustine Therapeutic Substance Approved Drug n.a. n.a. Decrease P = 0.0002 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI40898 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40899 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1080 carmustine Therapeutic Substance Approved Drug n.a. n.a. Increase P = 0.0002 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI40899 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40900 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40900 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.59E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40901 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40901 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100831] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40902 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40902 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.92E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40903 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40903 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40904 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40904 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002355867] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40905 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40905 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000653747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40906 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40906 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001158548] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40907 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40907 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD319 Ethacrynic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40908 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40908 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40909 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40909 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00869897] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40910 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40910 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157656] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40911 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40911 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40912 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40912 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40913 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40913 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004347253] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40914 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40914 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008016364] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40915 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40915 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD40 Amodiaquin dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003290192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40916 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40916 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002824993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40917 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD526 Mesoridazine besylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000861551] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40917 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40918 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD491 Loperamide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007377276] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40918 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750 PMDBI40919 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1083 Cefaclor Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262 PMDBI40919 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD17 Acetopromazine maleate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003467683] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40920 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40920 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD702 Pridinol methanesulfonate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40921 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40921 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD71 Artemisinin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000890931] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40922 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40922 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD239 Cyproheptadine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001175749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40923 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40923 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD728 Raloxifene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003432585] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40924 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40924 Substances alter microbe abundance PMDBM72 820 Bacteroides uniformis PMDBD679 Pizotifen malate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000111644] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40925 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40925 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40926 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD154 Cefadroxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI40926 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.98E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40927 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40927 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40928 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40928 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40929 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40929 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40930 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40930 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.63E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40931 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40931 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40932 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40932 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40933 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40933 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000104443] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40934 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40934 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40935 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40935 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40936 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40936 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00052783] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40937 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40937 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40938 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40938 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40939 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40939 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40940 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.86E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40940 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1085 Cefepime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502 PMDBI40941 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1086 Cefetamet-pivoxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40941 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.12E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40942 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110 PMDBI40942 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40943 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110 PMDBI40943 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40944 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262; PMID: 8618110 PMDBI40944 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40945 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110 PMDBI40945 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40946 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262; PMID: 3222669 PMDBI40946 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40947 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40947 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40948 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669 PMDBI40948 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40949 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40949 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40950 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40950 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40951 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40951 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40952 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669 PMDBI40952 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40953 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40953 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40954 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40954 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110 PMDBI40955 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.30E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40955 Substances alter microbe abundance PMDBM923 590 Salmonella PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40956 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40956 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD158 Cefixime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI40957 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40957 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40958 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40958 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40959 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284 PMDBI40959 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40960 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40960 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40961 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40961 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40962 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284 PMDBI40962 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40963 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284 PMDBI40963 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40964 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40964 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40965 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40965 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40966 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40966 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40967 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40967 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40968 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40968 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40969 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40969 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.68E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40970 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40970 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40971 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40971 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.30E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40972 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40972 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40973 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284 PMDBI40973 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40974 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40974 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40975 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40975 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40976 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284 PMDBI40976 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40977 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40977 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40978 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40978 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40979 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40979 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40980 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40980 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40981 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40981 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI40982 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141464] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40982 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054 PMDBI40983 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40983 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40984 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40984 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40985 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40985 Substances alter microbe abundance PMDBM864 186822 Paenibacillaceae PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40986 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40986 Substances alter microbe abundance PMDBM975 n.a. Turicibacteraceae PMDBD160 Cefoperazone Therapeutic Substance Approved Drug; Antibiotics C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40987 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1087 Cefotaxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40987 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.21E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40988 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1087 Cefotaxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40988 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40989 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1087 Cefotaxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40989 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40990 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1087 Cefotaxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40990 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40991 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1087 Cefotaxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40991 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40992 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1087 Cefotaxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40992 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40993 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD164 Cefotetan Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40993 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40994 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD164 Cefotetan Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40994 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40995 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD164 Cefotetan Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40995 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40996 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD164 Cefotetan Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40996 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40997 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD164 Cefotetan Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40997 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40998 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD164 Cefotetan Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40998 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40999 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI40999 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41000 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41000 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41001 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41001 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41002 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41002 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41003 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41003 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41004 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41004 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.21E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41005 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41005 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41006 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41006 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000321397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41007 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41007 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000288543] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41008 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41008 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41009 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41009 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.80E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41010 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848; PMID: 6508264 PMDBI41010 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41011 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41011 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41012 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41012 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41013 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41013 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41014 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848; PMID: 6508264 PMDBI41014 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41015 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41015 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41016 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41016 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41017 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41017 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003081374] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41018 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.03E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41018 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848; PMID: 6508264 PMDBI41019 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41019 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41020 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41020 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848 PMDBI41021 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41021 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41022 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001280508] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41022 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1088 Cefoxitin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264 PMDBI41023 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1089 Cefpirome Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1601763 PMDBI41023 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000585698] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41024 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41024 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41025 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41025 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41026 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41026 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41027 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110; PMID: 7961199 PMDBI41027 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41028 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41028 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000134609] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41029 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41029 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41030 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41030 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41031 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490 PMDBI41031 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000197672] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41032 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490 PMDBI41032 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41033 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41033 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00226359] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41034 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41034 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000266312] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41035 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41035 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006634684] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41036 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 8618110 PMDBI41036 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41037 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41037 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41038 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41038 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000182756] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41039 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490 PMDBI41039 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41040 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41040 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41041 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41041 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199 PMDBI41042 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.86E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41042 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490 PMDBI41043 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1091 Cefprozil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680 PMDBI41043 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.38E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41044 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1091 Cefprozil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680 PMDBI41044 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41045 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1091 Cefprozil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680 PMDBI41045 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017654] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41046 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1091 Cefprozil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680 PMDBI41046 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009344181] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41047 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41047 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117632] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41048 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41048 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41049 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41049 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000280716] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41050 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41050 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001127486] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41051 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41051 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001563951] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41052 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41052 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002638689] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41053 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41053 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000514387] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41054 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000178054] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41054 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41055 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1092 Ceftaroline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399 PMDBI41055 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41056 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41056 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41057 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41057 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41058 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41058 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004419106] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41059 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41059 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00029395] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41060 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41060 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002426018] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41061 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41061 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000325495] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41062 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41062 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41063 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41063 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005806766] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41064 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000761829] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41064 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1093 Ceftaroline/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638 PMDBI41065 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41065 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41066 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41066 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41067 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41067 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000394597] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41068 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41068 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41069 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41069 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005675801] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41070 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41070 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41071 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41071 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41072 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41072 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1094 Ceftazidime/avibactam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639 PMDBI41073 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199 PMDBI41073 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001913202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41074 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41074 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009732678] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41075 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366 PMDBI41075 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006752846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41076 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41076 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41077 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199 PMDBI41077 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.57E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41078 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199 PMDBI41078 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00289599] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41079 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366 PMDBI41079 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41080 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41080 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003326216] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41081 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41081 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41082 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366 PMDBI41082 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41083 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000380382] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41083 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1095 Ceftibuten Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41084 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41084 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001419173] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41085 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41085 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41086 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41086 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41087 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41087 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41088 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41088 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41089 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41089 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704304] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41090 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41090 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1096 Ceftobiprole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263 PMDBI41091 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 1800369; PMID: 3992209; PMID: 11020259 PMDBI41091 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428916] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41092 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11531985; PMID: 15388432 PMDBI41092 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000656515] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41093 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 11020259 PMDBI41093 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD319 Ethacrynic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372795] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41094 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209; PMID: 11020259 PMDBI41094 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41095 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 1767260; PMID: 3138129; PMID: 3992209; PMID: 11531985; PMID: 11020259; PMID: 15388432 PMDBI41095 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007973156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41096 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 3138129; PMID: 11531985; PMID: 11020259; PMID: 15388432 PMDBI41096 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41097 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209 PMDBI41097 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41098 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3138129 PMDBI41098 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000287651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41099 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11531985 PMDBI41099 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41100 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41100 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00597968] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41101 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3138129 PMDBI41101 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003489677] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41102 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11531985; PMID: 11020259; PMID: 15388432 PMDBI41102 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD196 Cinnarizine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004182486] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41103 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 11531985; PMID: 11020259 PMDBI41103 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD526 Mesoridazine besylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000191026] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41104 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1800369; PMID: 2396083; PMID: 3138129; PMID: 3992209; PMID: 15388432 PMDBI41104 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD41 Amoxapine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41105 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3138129 PMDBI41105 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD17 Acetopromazine maleate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003784869] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41106 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209; PMID: 11020259 PMDBI41106 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD702 Pridinol methanesulfonate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41107 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209; PMID: 11020259 PMDBI41107 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD441 Imiquimod Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005790619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41108 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD719 Quetiapine hemifumarate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000472811] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41108 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1800369; PMID: 2396083; PMID: 3138129; PMID: 3992209; PMID: 11531985; PMID: 11020259; PMID: 15388432 PMDBI41109 Substances alter microbe abundance PMDBM75 821 Bacteroides vulgatus PMDBD536 Methotrimeprazine maleat salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006991298] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41109 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1097 Ceftriaxone Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209 PMDBI41110 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1098 Cefuroxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41110 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41111 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1098 Cefuroxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41111 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41112 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1098 Cefuroxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41112 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41113 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1098 Cefuroxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41113 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41114 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1098 Cefuroxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41114 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41115 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1098 Cefuroxime Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41115 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41116 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 8618110; PMID: 7961199 PMDBI41116 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41117 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 9314469; PMID: 7961199 PMDBI41117 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41118 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41118 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41119 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9 PMDBI41119 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002247276] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41120 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41120 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41121 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 8618110; PMID: 7961199 PMDBI41121 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41122 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41122 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41123 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41123 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41124 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9 PMDBI41124 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41125 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41125 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41126 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9 PMDBI41126 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41127 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41127 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41128 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110; PMID: 7961199 PMDBI41128 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41129 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9 PMDBI41129 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41130 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199 PMDBI41130 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41131 Substances alter microbe abundance PMDBM316 1253 Pedicoccus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41131 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41132 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9 PMDBI41132 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41133 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41133 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41134 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41134 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41135 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9 PMDBI41135 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41136 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000349651] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41136 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110; PMID: 7961199 PMDBI41137 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41137 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 9314469 PMDBI41138 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41138 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41139 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41139 Substances alter microbe abundance PMDBM923 590 Salmonella PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41140 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41140 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1099 Cefuroxime axetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110 PMDBI41141 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41141 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41142 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41142 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41143 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41143 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41144 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41144 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41145 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41145 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41146 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41146 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41147 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41147 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001081854] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41148 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.22E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41148 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41149 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41149 Substances alter microbe abundance PMDBM875 n.a. Pedicoccus PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469 PMDBI41150 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1102 Cephaloridine Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41150 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41151 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1102 Cephaloridine Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41151 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41152 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1103 Cephazolin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41152 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41153 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1103 Cephazolin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41153 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41154 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1103 Cephazolin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41154 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000495356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41155 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1103 Cephazolin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41155 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41156 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41156 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41157 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41157 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41158 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41158 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008452406] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41159 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41159 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41160 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41160 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41161 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41161 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41162 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41162 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000146181] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41163 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41163 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41164 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41164 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41165 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41165 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41166 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41166 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41167 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41167 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41168 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41168 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41169 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41169 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41170 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-06] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41170 Substances alter microbe abundance PMDBM836 906 Megasphaera PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41171 Substances alter microbe abundance PMDBM635 1380 Atopobium PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41171 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41172 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133401] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41172 Substances alter microbe abundance PMDBM810 28050 Lachnospira PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41173 Substances alter microbe abundance PMDBM630 165779 Anaerococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41173 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41174 Substances alter microbe abundance PMDBM611 447020 Adlercreutzia PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41174 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41175 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI41175 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41176 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2941281; PMID: 2940965; PMID: 2934338 PMDBI41176 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009577361] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41177 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522; PMID: 9646219 PMDBI41177 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41178 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2941281; PMID: 2940965 PMDBI41178 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41179 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41179 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41180 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41180 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000677598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41181 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41181 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000376726] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41182 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219 PMDBI41182 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009237436] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41183 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6517559 PMDBI41183 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135542] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41184 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072; PMID: 3438150; PMID: 9257749; PMID: 2356443; PMID: 3182454; PMID: 3428128; PMID: 2941281 PMDBI41184 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003770771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41185 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9255893 PMDBI41185 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41186 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 28333351; PMID: 2356443; PMID: 3182454; PMID: 2940965 PMDBI41186 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41187 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405; PMID: 2938072; PMID: 9257749; PMID: 9646219 PMDBI41187 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41188 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405; PMID: 9257749; PMID: 9646219; PMID: 3182454; PMID: 2934338 PMDBI41188 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41189 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI41189 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41190 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2940965 PMDBI41190 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001467225] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41191 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI41191 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41192 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41192 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41193 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219 PMDBI41193 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41194 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9257749; PMID: 9646219 PMDBI41194 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41195 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2940965 PMDBI41195 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000878667] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41196 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25658522 PMDBI41196 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000631183] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41197 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219; PMID: 2934338 PMDBI41197 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41198 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2941281; PMID: 2940965 PMDBI41198 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001974927] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41199 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics Ciprofloxacin (10 mg/kg of body weight) was administered via oral gavage for one time. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI41199 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001467284] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41200 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41200 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41201 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41201 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41202 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219 PMDBI41202 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41203 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2941281 PMDBI41203 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41204 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41204 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000524332] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41205 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI41205 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404149] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41206 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41206 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002768125] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41207 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25658522 PMDBI41207 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003090159] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41208 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9257749 PMDBI41208 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007617779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41209 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9257749; PMID: 9646219; PMID: 2356443; PMID: 2941281; PMID: 2940965; PMID: 6517559 PMDBI41209 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007046361] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41210 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2940965; PMID: 6517559 PMDBI41210 Substances alter microbe abundance PMDBM78 371601 Bacteroides xylanisolvens PMDBD236 Cyclopenthiazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41211 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20847294 PMDBI41211 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41212 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41212 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41213 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41213 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41214 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522; PMID: 2356443; PMID: 2940965; PMID: 2934338 PMDBI41214 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41215 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41215 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405; PMID: 25658522; PMID: 20847294 PMDBI41216 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41216 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics Ciprofloxacin (10 mg/kg of body weight) was administered via oral gavage for one time. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI41217 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219; PMID: 2934338; PMID: 6517559 PMDBI41217 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41218 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41218 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41219 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2940965 PMDBI41219 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41220 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41220 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41221 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41221 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443 PMDBI41222 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI41222 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41223 Substances alter microbe abundance PMDBM798 61170 Holdemania PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41223 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41224 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41224 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41225 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1119 Ciprofloxacin plus clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9255893 PMDBI41225 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41226 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1119 Ciprofloxacin plus clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9255893 PMDBI41226 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41227 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 12111597; PMID: 10716083 PMDBI41227 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41228 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41228 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41229 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083 PMDBI41229 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41230 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41230 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41231 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 10716083 PMDBI41231 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41232 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI41232 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41233 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083 PMDBI41233 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41234 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 10716083 PMDBI41234 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41235 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41235 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41236 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.06E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41236 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI41237 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41237 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41238 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41238 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 10716083 PMDBI41239 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41239 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41240 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 10716083 PMDBI41240 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41241 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083 PMDBI41241 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41242 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41242 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41243 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 12111597 PMDBI41243 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41244 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41244 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41245 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 12111597; PMID: 10716083 PMDBI41245 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41246 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 10716083 PMDBI41246 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41247 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083 PMDBI41247 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41248 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41248 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41249 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI41249 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41250 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41250 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41251 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41251 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41252 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI41252 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41253 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41253 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41254 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41254 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41255 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 10716083 PMDBI41255 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41256 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI41256 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41257 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41257 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41258 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41258 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41259 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI41259 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41260 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11552917 PMDBI41260 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41261 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917 PMDBI41261 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41262 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20352091 PMDBI41262 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41263 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917 PMDBI41263 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41264 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 20352091; PMID: 11552917 PMDBI41264 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41265 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI41265 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41266 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11552917 PMDBI41266 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41267 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917 PMDBI41267 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41268 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917 PMDBI41268 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691798] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41269 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 20352091 PMDBI41269 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41270 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 20352091; PMID: 11552917 PMDBI41270 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41271 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41271 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI41272 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41272 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979 PMDBI41273 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41273 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41274 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41274 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41275 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41275 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41276 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41276 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41277 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41277 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41278 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41278 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41279 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41279 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41280 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41280 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41281 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41281 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41282 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41282 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41283 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41283 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41284 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41284 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000201053] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41285 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41285 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41286 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132 PMDBI41286 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41287 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41287 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41288 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41288 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41289 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405 PMDBI41289 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41290 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405 PMDBI41290 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41291 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41291 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41292 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812 PMDBI41292 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41293 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41293 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41294 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41294 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41295 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 19107676; PMID: 15640226 PMDBI41295 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41296 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812 PMDBI41296 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41297 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41297 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41298 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41298 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000458844] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41299 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 15640226 PMDBI41299 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41300 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41300 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41301 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41301 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41302 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI41302 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41303 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41303 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41304 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41304 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41305 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41305 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41306 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41306 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41307 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201; PMID: 17046967; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41307 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41308 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41308 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41309 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41309 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004146819] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41310 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41310 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41311 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405 PMDBI41311 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41312 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405 PMDBI41312 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41313 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41313 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41314 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI41314 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41315 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41315 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41316 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41316 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41317 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41317 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41318 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41318 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41319 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201;PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41319 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41320 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41320 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41321 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41321 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41322 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41322 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405 PMDBI41323 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006721124] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41323 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Clindamycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41324 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17–25 PMDBI41324 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000347105] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41325 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI41325 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001480541] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41326 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41326 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41327 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.23E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41327 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI41328 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005860626] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41328 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611 PMDBI41329 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41329 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001704978] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41330 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405 PMDBI41330 Substances alter microbe abundance PMDBM88 1680 Bifidobacterium adolescentis PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41331 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41331 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41332 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41332 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID PMID: 24264990; PMID: 29789015 PMDBI41333 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41333 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41334 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41334 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID PMID: 23791611; PMID: 29789015 PMDBI41335 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41335 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID PMID: 24264990; PMID: 29789015 PMDBI41336 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41336 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID PMID: 23791611; PMID: 29789015 PMDBI41337 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41337 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID PMID: 23791611; PMID: 29789015 PMDBI41338 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41338 Substances alter microbe abundance PMDBM25 91061 Bacilli PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41339 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41339 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID PMID: 24264990; PMID: 29789015 PMDBI41340 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41340 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41341 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41341 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID PMID: 24264990; PMID: 29789015 PMDBI41342 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41342 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41343 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41343 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41344 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41344 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41345 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41345 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID PMID: 23791611; PMID: 29789015 PMDBI41346 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41346 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID PMID: 24264990; PMID: 29789015 PMDBI41347 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41347 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41348 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41348 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41349 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41349 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41350 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41350 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41351 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41351 Substances alter microbe abundance PMDBM624 28211 Alphaproteobacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41352 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41352 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41353 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41353 Substances alter microbe abundance PMDBM909 41295 Rhodospirillaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41354 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41354 Substances alter microbe abundance PMDBM717 84998 Coriobacteriia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41355 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41355 Substances alter microbe abundance PMDBM947 90964 Staphylococcaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41356 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41356 Substances alter microbe abundance PMDBM651 200643 Bacteroidia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41357 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41357 Substances alter microbe abundance PMDBM921 n.a. S24-7 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 25553830; PMID: 29789015 PMDBI41358 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41358 Substances alter microbe abundance PMDBM702 n.a. Clostridium cluster XIVa PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID PMID: 24264990; PMID: 29789015 PMDBI41359 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41359 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1137 Dalbavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427 PMDBI41360 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.96E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41360 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1137 Dalbavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427 PMDBI41361 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41361 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1137 Dalbavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427 PMDBI41362 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41362 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1137 Dalbavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427 PMDBI41363 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000153485] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41363 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1137 Dalbavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427 PMDBI41364 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41364 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41365 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41365 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41366 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41366 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41367 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41367 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41368 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41368 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41369 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41369 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41370 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41370 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41371 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41371 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41372 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41372 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD287 Dirithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127 PMDBI41373 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41373 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619 PMDBI41374 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41374 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373 PMDBI41375 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41375 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41376 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41376 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619 PMDBI41377 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41377 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41378 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41378 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373 PMDBI41379 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41379 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619 PMDBI41380 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.40E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41380 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41381 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41381 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41382 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41382 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373 PMDBI41383 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41383 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373 PMDBI41384 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41384 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41385 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41385 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373 PMDBI41386 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41386 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41387 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41387 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41388 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41388 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373 PMDBI41389 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41389 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41390 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41390 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41391 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41391 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41392 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41392 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41393 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41393 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41394 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41394 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41395 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41395 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41396 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41396 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41397 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41397 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41398 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41398 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41399 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41399 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41400 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41400 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD304 Enoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305 PMDBI41401 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41401 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1179 Ertapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432 PMDBI41402 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.92E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41402 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1179 Ertapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432 PMDBI41403 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41403 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1179 Ertapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432 PMDBI41404 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41404 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1179 Ertapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432 PMDBI41405 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41405 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1179 Ertapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432 PMDBI41406 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41406 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1179 Ertapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432 PMDBI41407 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41407 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41408 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41408 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41409 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41409 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527 PMDBI41410 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41410 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41411 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41411 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527 PMDBI41412 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41412 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527 PMDBI41413 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41413 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41414 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41414 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527 PMDBI41415 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41415 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527 PMDBI41416 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0065524] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41416 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527 PMDBI41417 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001890094] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41417 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41418 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41418 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41419 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41419 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527 PMDBI41420 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41420 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527 PMDBI41421 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41421 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41422 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922229] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41422 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385 PMDBI41423 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41423 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD314 Erythromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527 PMDBI41424 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. n.a. PMID PMID: 29555994 PMDBI41424 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1184 Etanercept Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI41425 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. Rheumatoid arthritis n.a. n.a. PMID PMID: 29555994 PMDBI41425 Substances alter microbe abundance PMDBM857 1161 Nostocales PMDBD1184 Etanercept Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31675176 PMDBI41426 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000779058] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41426 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41427 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41427 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41428 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41428 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41429 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41429 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD353 Fleroxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539 PMDBI41430 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41430 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD353 Fleroxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539 PMDBI41431 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41431 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD353 Fleroxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539 PMDBI41432 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00109898] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41432 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD353 Fleroxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539 PMDBI41433 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007685758] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41433 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD353 Fleroxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539 PMDBI41434 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009131895] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41434 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1197 Flucloxacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI41435 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008270317] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41435 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1197 Flucloxacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI41436 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008178731] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41436 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1197 Flucloxacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI41437 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000977939] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41437 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1197 Flucloxacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI41438 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000413539] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41438 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1197 Flucloxacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020 PMDBI41439 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007674264] n.a. n.a. n.a. n.a. n.a. n.a. Acute lymphocytic leukemia (ALL) n.a. n.a. PMID PMID: 29555994 PMDBI41439 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41440 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003982696] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41440 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503 PMDBI41441 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41441 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503; PMID: 318971 PMDBI41442 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41442 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503 PMDBI41443 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003650878] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41443 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 318971 PMDBI41444 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD278 Dihydrostreptomycin sulfate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41444 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503; PMID: 318971 PMDBI41445 Substances alter microbe abundance PMDBM100 216816 Bifidobacterium longum PMDBD570 Naftopidil dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41445 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503 PMDBI41446 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503 PMDBI41447 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503 PMDBI41448 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 318971 PMDBI41449 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1206 Fosfomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503 PMDBI41450 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41451 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41452 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41453 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41454 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41455 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41456 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41457 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41458 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41459 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1211 Garenoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415 PMDBI41460 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41461 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41462 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41463 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41464 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41465 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41466 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41467 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781 PMDBI41468 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI41469 Substances alter microbe abundance PMDBM140 1496 Peptoclostridium difficile PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41470 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41471 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41472 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41473 Substances alter microbe abundance PMDBM29 171549 Bacteroidales PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41474 Substances alter microbe abundance PMDBM32 85831 Bacteroides acidifaciens PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41475 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41476 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41477 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41478 Substances alter microbe abundance PMDBM7 239935 Akkermansia muciniphila PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41479 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41480 Substances alter microbe abundance PMDBM819 1605 Lactobacillus animalis PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID PMID: 29473096; PMID: 29789015 PMDBI41481 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41482 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI41483 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800; PMID: 11158764 PMDBI41484 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800; PMID: 11158764 PMDBI41485 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41486 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41487 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI41488 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41489 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI41490 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800; PMID: 11158764 PMDBI41491 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41492 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41493 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800 PMDBI41494 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41495 Substances alter microbe abundance PMDBM19 244127 Anaerotruncus PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41496 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed a normal-chow diet for a period of 6 weeks. Gut Increase p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41497 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41498 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41499 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41500 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41501 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed a normal-chow diet for a period of 6 weeks. Gut Decrease p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41502 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41503 Substances alter microbe abundance PMDBM831 420345 Lactonifactor PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41504 Substances alter microbe abundance PMDBM832 1091138 Lawsonia PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41505 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI41506 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41507 Substances alter microbe abundance PMDBM233 853 Faecalibacterium prausnitzii PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41508 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41509 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41510 Substances alter microbe abundance PMDBM810 28050 Lachnospira PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41511 Substances alter microbe abundance PMDBM748 84111 Eggerthella PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41512 Substances alter microbe abundance PMDBM912 301302 Roseburia faecis PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41513 Substances alter microbe abundance PMDBM140 1496 Peptoclostridium difficile PMDBD455 Irinotecan Therapeutic Substance Approved Drug Irinotecan (125 mg/kg×3 days) n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Colon cancer n.a. n.a. PMID PMID: 22844397; PMID: 29789015 PMDBI41514 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD455 Irinotecan Therapeutic Substance Approved Drug Irinotecan (125 mg/kg×3 days) n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Colon cancer n.a. n.a. PMID PMID: 22844397; PMID: 29789015 PMDBI41515 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.50E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41515 Substances alter microbe abundance PMDBM317 186804 Clostridium cluster XI PMDBD455 Irinotecan Therapeutic Substance Approved Drug Irinotecan (125 mg/kg×3 days) n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Colon cancer n.a. n.a. PMID PMID: 22844397; PMID: 29789015 PMDBI41516 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41516 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1249 Latamoxef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41517 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41517 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1249 Latamoxef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41518 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41518 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1249 Latamoxef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41519 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41519 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1249 Latamoxef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41520 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41520 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1249 Latamoxef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41521 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41521 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1249 Latamoxef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41522 Substances alter microbe abundance PMDBM106 28026 Bifidobacterium pseudocatenulatum PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41522 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41523 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41523 Substances alter microbe abundance PMDBM116 40520 Ruminococcus obeum PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41524 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41524 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41525 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41525 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41526 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41526 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41527 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41527 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41528 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41528 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41529 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41529 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41530 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41530 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41531 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41531 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41532 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41532 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41533 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41533 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41534 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41534 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41535 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41535 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41536 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41536 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41537 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41537 Substances alter microbe abundance PMDBM979 41296 unclassified Rhodospirillaceae PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41538 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41538 Substances alter microbe abundance PMDBM648 46506 Bacteroides stercoris PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41539 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41539 Substances alter microbe abundance PMDBM716 116085 Coprococcus catus PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41540 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41540 Substances alter microbe abundance PMDBM643 1118061 Bacteroidales bacterium ph8 PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41541 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41541 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41542 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000310041] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41542 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41543 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41543 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064; PMID: 1885423 PMDBI41544 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.97E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41544 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41545 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41545 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41546 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41546 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41547 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41547 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41548 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41548 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41549 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41549 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41550 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41550 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1885423 PMDBI41551 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41551 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41552 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41552 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41553 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41553 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1252 Lemofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064 PMDBI41554 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41554 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41555 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41555 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41556 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41556 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41557 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41557 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41558 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41558 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41559 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41559 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41560 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41560 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41561 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41561 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41562 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.05E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41562 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41563 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41563 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41564 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41564 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41565 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41565 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1254 Lenapenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072 PMDBI41566 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41566 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920 PMDBI41567 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41567 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920 PMDBI41568 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41568 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920 PMDBI41569 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41569 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920 PMDBI41570 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41570 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254 PMDBI41571 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41571 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920 PMDBI41572 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41572 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920 PMDBI41573 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41573 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254 PMDBI41574 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41574 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920 PMDBI41575 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41575 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920 PMDBI41576 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41576 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920 PMDBI41577 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41577 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920 PMDBI41578 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41578 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920 PMDBI41579 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.13E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41579 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41580 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41580 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41581 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338291] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41581 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41582 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41582 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41583 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41583 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41584 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41584 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41585 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41585 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41586 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41586 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD484 Linezolid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762 PMDBI41587 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41587 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475 PMDBI41588 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41588 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41589 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41589 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41590 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41590 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41591 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41591 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41592 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41592 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 1853174 PMDBI41593 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41593 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41594 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.10E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41594 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475 PMDBI41595 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41595 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41596 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.59E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41596 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41597 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41597 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41598 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.12E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41598 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41599 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41599 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41600 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41600 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41601 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41601 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD493 Loracarbef Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174 PMDBI41602 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41602 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41603 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41603 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41604 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41604 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41605 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41605 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41606 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41606 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41607 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41607 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41608 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41608 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1268 MCB3837 Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053 PMDBI41609 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41609 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41610 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.62E-07] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41610 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41611 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41611 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26147207; PMID: 29789015 PMDBI41612 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41612 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41613 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41613 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41614 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41614 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41615 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41615 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41616 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.28E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41616 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41617 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.88E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41617 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41618 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41618 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41619 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41619 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41620 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41620 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41621 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.04E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41621 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41622 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007130854] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41622 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41623 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41623 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41624 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41624 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41625 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.62E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41625 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD524 Meropenem Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390 PMDBI41626 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 23804561 PMDBI41626 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41627 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41627 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41628 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41628 Substances alter microbe abundance PMDBM168 411903 Collinsella aerofaciens ATCC 25986 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41629 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41629 Substances alter microbe abundance PMDBM168 411903 Collinsella aerofaciens ATCC 25986 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41630 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181568] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41630 Substances alter microbe abundance PMDBM169 521003 Collinsella intestinalis DSM 13280 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41631 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41631 Substances alter microbe abundance PMDBM169 521003 Collinsella intestinalis DSM 13280 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41632 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.81E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41632 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41633 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41633 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41634 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.43E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41634 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41635 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41635 Substances alter microbe abundance PMDBM19 244127 Anaerotruncus PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41636 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000106944] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41636 Substances alter microbe abundance PMDBM192 500639 Enterobacter cancerogenus ATCC 35316 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=3.455607077, FDR-p value=8.24019E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41637 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.35E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41637 Substances alter microbe abundance PMDBM192 500639 Enterobacter cancerogenus ATCC 35316 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.530215106, FDR-p value=2.92612E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41638 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41638 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41639 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41639 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. Microbial shifts under metformin treatment contribute to improved glucose control and to adverse effects. PMID PMID: 26633628 PMDBI41640 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41640 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41641 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.23E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41641 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41642 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016296] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41642 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a normal-chow diet were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 23804561 PMDBI41643 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41643 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41644 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.02E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41644 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41645 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41645 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41646 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000470942] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41646 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41647 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41647 Substances alter microbe abundance PMDBM342 471874 Providencia stuartii ATCC 25827 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.37429031, FDR-p value=0.006587299 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41648 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41648 Substances alter microbe abundance PMDBM342 471874 Providencia stuartii ATCC 25827 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41649 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.81E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41649 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41650 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.84E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41650 Substances alter microbe abundance PMDBM38 547042 Bacteroides coprophilus DSM 18228 = JCM 13818 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41651 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.43E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41651 Substances alter microbe abundance PMDBM38 547042 Bacteroides coprophilus DSM 18228 = JCM 13818 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41652 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41652 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41653 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000345879] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41653 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41654 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003454674] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41654 Substances alter microbe abundance PMDBM395 411471 Subdoligranulum variabile DSM 15176 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-0.555370186, FDR-p value=0.003267857 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41655 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00063536] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41655 Substances alter microbe abundance PMDBM395 411471 Subdoligranulum variabile DSM 15176 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41656 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41656 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a normal-chow diet were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut No significant change p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 23804561 PMDBI41657 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41657 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice, fed a ahigh-fat diet (HFD), were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41658 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41658 Substances alter microbe abundance PMDBM42 817 Bacteroides fragilis PMDBD530 Metformin Therapeutic Substance Approved Drug newly diagnosed individuals with T2D who received oral metformin hydrochloride treatment (1000 mg b.i.d, Merck Serono) for 3 d. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. metformin acts in part through a B. fragilis-GUDCA-intestinal FXR axis to improve metabolic dysfunction, including hyperglycemia. PMID PMID: 30397356 PMDBI41659 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41659 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41660 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001204364] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41660 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a normal-chow diet were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 23804561 PMDBI41661 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41661 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41662 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001470956] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41662 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41663 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00025014] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41663 Substances alter microbe abundance PMDBM710 1511 Clostridium sticklandii PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.632748187, FDR-p value=1.04667E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41664 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41664 Substances alter microbe abundance PMDBM710 1511 Clostridium sticklandii PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.53115063, FDR-p value=6.68753E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41665 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41665 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41666 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.95E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41666 Substances alter microbe abundance PMDBM746 88431 Dorea longicatena PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41667 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41667 Substances alter microbe abundance PMDBM736 177439 Desulfotalea psychrophila LSv54 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41668 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008448038] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41668 Substances alter microbe abundance PMDBM736 177439 Desulfotalea psychrophila LSv54 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41669 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00037081] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41669 Substances alter microbe abundance PMDBM735 188626 Dermacoccus sp. Ellin185 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.408391853, FDR-p value=0.002834337 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41670 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41670 Substances alter microbe abundance PMDBM735 188626 Dermacoccus sp. Ellin185 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.505327642, FDR-p value=0.002245307 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41671 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41671 Substances alter microbe abundance PMDBM741 198628 Dickeya dadantii 3937 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.80251936, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41672 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41672 Substances alter microbe abundance PMDBM741 198628 Dickeya dadantii 3937 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.267692359, FDR-p value=0.005809229 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41673 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41673 Substances alter microbe abundance PMDBM737 207559 Desulfovibrio alaskensis G20 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.700365998, FDR-p value=0.023893497 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41674 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41674 Substances alter microbe abundance PMDBM737 207559 Desulfovibrio alaskensis G20 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41675 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41675 Substances alter microbe abundance PMDBM873 218491 Pectobacterium atrosepticum SCRI1043 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.305509866, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41676 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004929581] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41676 Substances alter microbe abundance PMDBM873 218491 Pectobacterium atrosepticum SCRI1043 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41677 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000452093] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41677 Substances alter microbe abundance PMDBM924 218493 Salmonella bongori NCTC 12419 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.265290612, FDR-p value=0.002107056 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41678 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004008817] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41678 Substances alter microbe abundance PMDBM924 218493 Salmonella bongori NCTC 12419 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.380107218, FDR-p value=0.000710559 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41679 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41679 Substances alter microbe abundance PMDBM664 243160 Burkholderia mallei ATCC 23344 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41680 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41680 Substances alter microbe abundance PMDBM664 243160 Burkholderia mallei ATCC 23344 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41681 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009471157] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41681 Substances alter microbe abundance PMDBM882 243265 Photorhabdus luminescens subsp. laumondii TTO1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.025852269, FDR-p value=0.013302006 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41682 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001064221] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41682 Substances alter microbe abundance PMDBM882 243265 Photorhabdus luminescens subsp. laumondii TTO1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41683 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000140478] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41683 Substances alter microbe abundance PMDBM825 257314 Lactobacillus johnsonii NCC 533 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.869448838, FDR-p value=0.011460102 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41684 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41684 Substances alter microbe abundance PMDBM825 257314 Lactobacillus johnsonii NCC 533 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41685 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD196 Cinnarizine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001296087] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41685 Substances alter microbe abundance PMDBM665 269482 Burkholderia vietnamiensis G4 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41686 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD310 Epirizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41686 Substances alter microbe abundance PMDBM665 269482 Burkholderia vietnamiensis G4 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41687 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000723187] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41687 Substances alter microbe abundance PMDBM685 290338 Citrobacter koseri ATCC BAA-895 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.322795865, FDR-p value=0.001184309 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41688 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD336 Fenbendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002022672] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41688 Substances alter microbe abundance PMDBM685 290338 Citrobacter koseri ATCC BAA-895 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.550284088, FDR-p value=0.000191515 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41689 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005811135] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41689 Substances alter microbe abundance PMDBM693 290402 Clostridium beijerinckii NCIMB 8052 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.935456291, FDR-p value=1.68244E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41690 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD14 Acenocoumarol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.21E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41690 Substances alter microbe abundance PMDBM693 290402 Clostridium beijerinckii NCIMB 8052 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.180967822, FDR-p value=1.63819E-06 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41691 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD122 Bosentan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41691 Substances alter microbe abundance PMDBM621 293826 Alkaliphilus metalliredigens QYMF PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.396739312, FDR-p value=0.008992925 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41692 Substances alter microbe abundance PMDBM116 40520 Blautia obeum PMDBD631 Oxibendazol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615387] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41692 Substances alter microbe abundance PMDBM621 293826 Alkaliphilus metalliredigens QYMF PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41693 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41693 Substances alter microbe abundance PMDBM827 314315 Lactobacillus sakei subsp. sakei 23K PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41694 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41694 Substances alter microbe abundance PMDBM827 314315 Lactobacillus sakei subsp. sakei 23K PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41695 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41695 Substances alter microbe abundance PMDBM993 316273 Xanthomonas campestris pv. vesicatoria str. 85-10 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.785442807, FDR-p value=0.001647526 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41696 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41696 Substances alter microbe abundance PMDBM993 316273 Xanthomonas campestris pv. vesicatoria str. 85-10 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41697 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41697 Substances alter microbe abundance PMDBM935 318167 Shewanella frigidimarina NCIMB 400 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41698 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41698 Substances alter microbe abundance PMDBM935 318167 Shewanella frigidimarina NCIMB 400 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41699 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41699 Substances alter microbe abundance PMDBM622 350688 Alkaliphilus oremlandii OhILAs PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.404113177, FDR-p value=0.012985681 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41700 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41700 Substances alter microbe abundance PMDBM622 350688 Alkaliphilus oremlandii OhILAs PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.268766679, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41701 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41701 Substances alter microbe abundance PMDBM647 357276 Bacteroides dorei PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41702 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41702 Substances alter microbe abundance PMDBM669 360107 Campylobacter hominis ATCC BAA-381 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41703 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41703 Substances alter microbe abundance PMDBM669 360107 Campylobacter hominis ATCC BAA-381 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41704 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41704 Substances alter microbe abundance PMDBM705 386415 Clostridium novyi NT PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.399368333, FDR-p value=0.022167527 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41705 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41705 Substances alter microbe abundance PMDBM705 386415 Clostridium novyi NT PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.284918994, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41706 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41706 Substances alter microbe abundance PMDBM996 393305 Yersinia enterocolitica subsp. enterocolitica 8081 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.120033541, FDR-p value=0.006748256 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41707 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41707 Substances alter microbe abundance PMDBM996 393305 Yersinia enterocolitica subsp. enterocolitica 8081 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.401555425, FDR-p value=0.001114606 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41708 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41708 Substances alter microbe abundance PMDBM782 393480 Fusobacterium nucleatum subsp. polymorphum ATCC 10953 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41709 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41709 Substances alter microbe abundance PMDBM782 393480 Fusobacterium nucleatum subsp. polymorphum ATCC 10953 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41710 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.19E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41710 Substances alter microbe abundance PMDBM656 398513 Bifidobacterium bifidum NCIMB 41171 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41711 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.54E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41711 Substances alter microbe abundance PMDBM656 398513 Bifidobacterium bifidum NCIMB 41171 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41712 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.56E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41712 Substances alter microbe abundance PMDBM930 399741 Serratia proteamaculans 568 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.055616701, FDR-p value=0.044674306 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41713 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41713 Substances alter microbe abundance PMDBM930 399741 Serratia proteamaculans 568 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41714 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41714 Substances alter microbe abundance PMDBM756 399742 Enterobacter sp. 638 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.73204629, FDR-p value=0.003071288 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41715 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41715 Substances alter microbe abundance PMDBM756 399742 Enterobacter sp. 638 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.869186914, FDR-p value=0.001278267 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41716 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41716 Substances alter microbe abundance PMDBM936 399804 Shewanella putrefaciens 200 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.430097656, FDR-p value=0.000474933 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41717 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41717 Substances alter microbe abundance PMDBM936 399804 Shewanella putrefaciens 200 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41718 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41718 Substances alter microbe abundance PMDBM995 406817 Xenorhabdus nematophila ATCC 19061 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.359407385, FDR-p value=0.013649734 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41719 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41719 Substances alter microbe abundance PMDBM995 406817 Xenorhabdus nematophila ATCC 19061 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41720 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41720 Substances alter microbe abundance PMDBM994 406818 Xenorhabdus bovienii SS-2004 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.228183644, FDR-p value=0.044674306 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41721 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41721 Substances alter microbe abundance PMDBM994 406818 Xenorhabdus bovienii SS-2004 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41722 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41722 Substances alter microbe abundance PMDBM893 411467 Pseudoflavonifractor capillosus ATCC 29799 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-0.438854387, FDR-p value=0.029026142 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41723 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41723 Substances alter microbe abundance PMDBM893 411467 Pseudoflavonifractor capillosus ATCC 29799 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41724 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.79E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41724 Substances alter microbe abundance PMDBM655 411481 Bifidobacterium adolescentis L2-32 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.742138652, FDR-p value=0.010221867 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41725 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41725 Substances alter microbe abundance PMDBM655 411481 Bifidobacterium adolescentis L2-32 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41726 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41726 Substances alter microbe abundance PMDBM831 420345 Lactonifactor PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41727 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41727 Substances alter microbe abundance PMDBM830 420890 Lactococcus garvieae Lg2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41728 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41728 Substances alter microbe abundance PMDBM830 420890 Lactococcus garvieae Lg2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41729 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41729 Substances alter microbe abundance PMDBM824 440497 Lactobacillus jensenii 1153 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.215894228, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41730 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41730 Substances alter microbe abundance PMDBM824 440497 Lactobacillus jensenii 1153 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41731 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41731 Substances alter microbe abundance PMDBM641 441769 Bacillus coahuilensis m4-4 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.031673872, FDR-p value=0.009194719 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41732 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41732 Substances alter microbe abundance PMDBM641 441769 Bacillus coahuilensis m4-4 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.078729007, FDR-p value=0.005809229 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41733 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41733 Substances alter microbe abundance PMDBM696 445337 Clostridium botulinum C str. Eklund PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.695314834, FDR-p value=0.000183528 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41734 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41734 Substances alter microbe abundance PMDBM696 445337 Clostridium botulinum C str. Eklund PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.299844607, FDR-p value=0.022714196 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41735 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00243064] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41735 Substances alter microbe abundance PMDBM692 445973 Clostridium bartlettii DSM 16795 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.643594699, FDR-p value=1.25224E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41736 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41736 Substances alter microbe abundance PMDBM692 445973 Clostridium bartlettii DSM 16795 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.230344191, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41737 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41737 Substances alter microbe abundance PMDBM712 445975 Collinsella stercoris DSM 13279 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41738 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41738 Substances alter microbe abundance PMDBM712 445975 Collinsella stercoris DSM 13279 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41739 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000524699] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41739 Substances alter microbe abundance PMDBM984 450749 Veillonella sp. 6_1_27 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41740 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41740 Substances alter microbe abundance PMDBM984 450749 Veillonella sp. 6_1_27 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41741 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004980222] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41741 Substances alter microbe abundance PMDBM707 451755 Clostridium perfringens E str. JGS1987 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.683428005, FDR-p value=0.000160155 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41742 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41742 Substances alter microbe abundance PMDBM707 451755 Clostridium perfringens E str. JGS1987 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.689121212, FDR-p value=0.029059088 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41743 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41743 Substances alter microbe abundance PMDBM706 451756 Clostridium perfringens CPE str. F4969 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.47198195, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41744 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001738587] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41744 Substances alter microbe abundance PMDBM706 451756 Clostridium perfringens CPE str. F4969 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.15525023, FDR-p value=0.003081898 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41745 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001096791] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41745 Substances alter microbe abundance PMDBM708 457396 Clostridium sp. 7_2_43FAA PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.595495199, FDR-p value=1.74946E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41746 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.54E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41746 Substances alter microbe abundance PMDBM708 457396 Clostridium sp. 7_2_43FAA PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.755719438, FDR-p value=0.000178937 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41747 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.23E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41747 Substances alter microbe abundance PMDBM918 457412 Ruminococcus sp. 5_1_39BFAA PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=0.601222601, FDR-p value=0.035744039 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41748 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41748 Substances alter microbe abundance PMDBM918 457412 Ruminococcus sp. 5_1_39BFAA PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=0.644897181, FDR-p value=0.019241663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41749 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41749 Substances alter microbe abundance PMDBM765 465817 Erwinia tasmaniensis Et1/99 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.599688661, FDR-p value=0.001225249 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41750 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41750 Substances alter microbe abundance PMDBM765 465817 Erwinia tasmaniensis Et1/99 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.449901175, FDR-p value=3.63324E-06 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41751 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00012308] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41751 Substances alter microbe abundance PMDBM687 469595 Citrobacter sp. 30_2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.656980457, FDR-p value=0.000288855 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41752 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41752 Substances alter microbe abundance PMDBM687 469595 Citrobacter sp. 30_2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.952388911, FDR-p value=2.92612E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41753 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41753 Substances alter microbe abundance PMDBM783 469606 Fusobacterium nucleatum subsp. vincentii 4_1_13 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41754 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41754 Substances alter microbe abundance PMDBM783 469606 Fusobacterium nucleatum subsp. vincentii 4_1_13 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41755 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41755 Substances alter microbe abundance PMDBM940 471855 Slackia heliotrinireducens DSM 20476 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41756 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000196949] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41756 Substances alter microbe abundance PMDBM940 471855 Slackia heliotrinireducens DSM 20476 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41757 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41757 Substances alter microbe abundance PMDBM694 498214 Clostridium botulinum A3 str. Loch Maree PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.075608857, FDR-p value=0.000211621 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41758 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41758 Substances alter microbe abundance PMDBM694 498214 Clostridium botulinum A3 str. Loch Maree PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.749316365, FDR-p value=0.002715502 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41759 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41759 Substances alter microbe abundance PMDBM704 500633 Clostridium hiranonis DSM 13275 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41760 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41760 Substances alter microbe abundance PMDBM704 500633 Clostridium hiranonis DSM 13275 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41761 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41761 Substances alter microbe abundance PMDBM688 500640 Citrobacter youngae ATCC 29220 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.852298241, FDR-p value=0.000320929 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41762 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41762 Substances alter microbe abundance PMDBM688 500640 Citrobacter youngae ATCC 29220 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.955117605, FDR-p value=0.00026017 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41763 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004717236] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41763 Substances alter microbe abundance PMDBM767 502347 Escherichia albertii TW07627 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.559216276, FDR-p value=0.000171663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41764 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.48E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41764 Substances alter microbe abundance PMDBM767 502347 Escherichia albertii TW07627 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.644468481, FDR-p value=0.000155853 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41765 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41765 Substances alter microbe abundance PMDBM908 506534 Rheinheimera sp. A13L PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.163610081, FDR-p value=0.010593629 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41766 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.60E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41766 Substances alter microbe abundance PMDBM908 506534 Rheinheimera sp. A13L PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.282398293, FDR-p value=0.005103239 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41767 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41767 Substances alter microbe abundance PMDBM808 507522 Klebsiella pneumoniae 342 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=3.02111568, FDR-p value=0.00034365 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41768 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41768 Substances alter microbe abundance PMDBM808 507522 Klebsiella pneumoniae 342 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=4.522142971, FDR-p value=5.02008E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41769 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41769 Substances alter microbe abundance PMDBM608 525245 Actinomyces coleocanis DSM 15436 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.462058179, FDR-p value=0.037370083 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41770 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41770 Substances alter microbe abundance PMDBM608 525245 Actinomyces coleocanis DSM 15436 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41771 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41771 Substances alter microbe abundance PMDBM720 525262 Corynebacterium jeikeium ATCC 43734 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41772 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00282779] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41772 Substances alter microbe abundance PMDBM720 525262 Corynebacterium jeikeium ATCC 43734 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41773 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.47E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41773 Substances alter microbe abundance PMDBM721 525263 Corynebacterium lipophiloflavum DSM 44291 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.887722054, FDR-p value=0.01941076 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41774 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.10E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41774 Substances alter microbe abundance PMDBM721 525263 Corynebacterium lipophiloflavum DSM 44291 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.213645212, FDR-p value=0.003944251 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41775 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41775 Substances alter microbe abundance PMDBM722 525264 Corynebacterium pseudogenitalium ATCC 33035 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41776 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41776 Substances alter microbe abundance PMDBM722 525264 Corynebacterium pseudogenitalium ATCC 33035 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41777 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41777 Substances alter microbe abundance PMDBM724 525268 Corynebacterium striatum ATCC 6940 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.937531565, FDR-p value=0.01941076 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41778 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001362] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41778 Substances alter microbe abundance PMDBM724 525268 Corynebacterium striatum ATCC 6940 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.332867835, FDR-p value=0.003071288 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41779 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41779 Substances alter microbe abundance PMDBM817 525306 Lactobacillus acidophilus ATCC 4796 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.692905134, FDR-p value=0.033240142 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41780 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001159592] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41780 Substances alter microbe abundance PMDBM817 525306 Lactobacillus acidophilus ATCC 4796 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.913457198, FDR-p value=0.013709185 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41781 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000661825] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41781 Substances alter microbe abundance PMDBM820 525310 Lactobacillus brevis subsp. gravesensis ATCC 27305 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.293771827, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41782 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41782 Substances alter microbe abundance PMDBM820 525310 Lactobacillus brevis subsp. gravesensis ATCC 27305 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41783 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001031773] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41783 Substances alter microbe abundance PMDBM823 525326 Lactobacillus gasseri JV-V03 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.189352734, FDR-p value=0.004093915 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41784 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00027409] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41784 Substances alter microbe abundance PMDBM823 525326 Lactobacillus gasseri JV-V03 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41785 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.75E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41785 Substances alter microbe abundance PMDBM828 525365 Lactobacillus ultunensis DSM 16047 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.772985275, FDR-p value=0.009779385 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41786 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.33E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41786 Substances alter microbe abundance PMDBM828 525365 Lactobacillus ultunensis DSM 16047 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41787 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41787 Substances alter microbe abundance PMDBM834 525367 Listeria grayi DSM 20601 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41788 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41788 Substances alter microbe abundance PMDBM834 525367 Listeria grayi DSM 20601 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41789 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41789 Substances alter microbe abundance PMDBM950 525376 Staphylococcus epidermidis W23144 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.374785171, FDR-p value=0.044870479 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41790 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003531295] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41790 Substances alter microbe abundance PMDBM950 525376 Staphylococcus epidermidis W23144 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41791 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000530647] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41791 Substances alter microbe abundance PMDBM906 533247 Raphidiopsis brookii D9 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.588467041, FDR-p value=0.010704071 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41792 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002100295] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41792 Substances alter microbe abundance PMDBM906 533247 Raphidiopsis brookii D9 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41793 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004374242] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41793 Substances alter microbe abundance PMDBM700 536227 Clostridium carboxidivorans P7 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.320074187, FDR-p value=0.00392092 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41794 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41794 Substances alter microbe abundance PMDBM700 536227 Clostridium carboxidivorans P7 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41795 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001863675] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41795 Substances alter microbe abundance PMDBM698 536233 Clostridium botulinum E1 str. 'BoNT E Beluga' PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.802220104, FDR-p value=5.02008E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41796 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009606166] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41796 Substances alter microbe abundance PMDBM698 536233 Clostridium botulinum E1 str. 'BoNT E Beluga' PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.356574993, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41797 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000926063] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41797 Substances alter microbe abundance PMDBM848 546263 Neisseria elongata subsp. glycolytica ATCC 29315 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.561060703, FDR-p value=0.00252331 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41798 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41798 Substances alter microbe abundance PMDBM848 546263 Neisseria elongata subsp. glycolytica ATCC 29315 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41799 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000327625] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41799 Substances alter microbe abundance PMDBM849 546266 Neisseria mucosa ATCC 25996 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.939340536, FDR-p value=0.001544492 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41800 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00575307] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41800 Substances alter microbe abundance PMDBM849 546266 Neisseria mucosa ATCC 25996 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.063888827, FDR-p value=0.000843551 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41801 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00132593] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41801 Substances alter microbe abundance PMDBM983 546273 Veillonella dispar ATCC 17748 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41802 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000516951] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41802 Substances alter microbe abundance PMDBM983 546273 Veillonella dispar ATCC 17748 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41803 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117098] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41803 Substances alter microbe abundance PMDBM659 547043 Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41804 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.99E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41804 Substances alter microbe abundance PMDBM659 547043 Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41805 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006857437] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41805 Substances alter microbe abundance PMDBM674 553178 Capnocytophaga gingivalis ATCC 33624 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.510785896, FDR-p value=0.032299347 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41806 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.10E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41806 Substances alter microbe abundance PMDBM674 553178 Capnocytophaga gingivalis ATCC 33624 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.521956757, FDR-p value=0.035377676 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41807 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000289776] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41807 Substances alter microbe abundance PMDBM668 553220 Campylobacter gracilis RM3268 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41808 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD319 Ethacrynic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005559527] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41808 Substances alter microbe abundance PMDBM668 553220 Campylobacter gracilis RM3268 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41809 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008674811] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41809 Substances alter microbe abundance PMDBM781 556263 Fusobacterium necrophorum D12 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.627931551, FDR-p value=0.019241663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41810 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005736582] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41810 Substances alter microbe abundance PMDBM781 556263 Fusobacterium necrophorum D12 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41811 Substances alter microbe abundance PMDBM143 208479 Enterocloster bolteae PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002537439] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41811 Substances alter microbe abundance PMDBM744 561229 Dickeya zeae Ech1591 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.910451267, FDR-p value=0.043895048 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41812 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41812 Substances alter microbe abundance PMDBM744 561229 Dickeya zeae Ech1591 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.971726928, FDR-p value=0.031075441 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41813 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41813 Substances alter microbe abundance PMDBM874 561231 Pectobacterium wasabiae WPP163 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.3812479, FDR-p value=0.01941076 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41814 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41814 Substances alter microbe abundance PMDBM874 561231 Pectobacterium wasabiae WPP163 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41815 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41815 Substances alter microbe abundance PMDBM889 563008 Prevotella oris C735 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41816 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.06E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41816 Substances alter microbe abundance PMDBM889 563008 Prevotella oris C735 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41817 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41817 Substances alter microbe abundance PMDBM759 565654 Enterococcus casseliflavus EC10 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.183354227, FDR-p value=0.043895048 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41818 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41818 Substances alter microbe abundance PMDBM759 565654 Enterococcus casseliflavus EC10 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41819 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41819 Substances alter microbe abundance PMDBM743 579405 Dickeya dadantii Ech703 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.114542755, FDR-p value=0.039417774 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41820 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41820 Substances alter microbe abundance PMDBM743 579405 Dickeya dadantii Ech703 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.501949726, FDR-p value=0.008015127 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41821 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.18E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41821 Substances alter microbe abundance PMDBM818 585524 Lactobacillus amylolyticus DSM 11664 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.773792802, FDR-p value=0.013709185 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41822 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41822 Substances alter microbe abundance PMDBM818 585524 Lactobacillus amylolyticus DSM 11664 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41823 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41823 Substances alter microbe abundance PMDBM742 590409 Dickeya dadantii Ech586 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.467930302, FDR-p value=0.025565282 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41824 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41824 Substances alter microbe abundance PMDBM742 590409 Dickeya dadantii Ech586 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41825 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000619008] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41825 Substances alter microbe abundance PMDBM697 592027 Clostridium botulinum D str. 1873 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.809632604, FDR-p value=2.33067E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41826 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41826 Substances alter microbe abundance PMDBM697 592027 Clostridium botulinum D str. 1873 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.863663383, FDR-p value=0.00138343 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41827 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001313179] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41827 Substances alter microbe abundance PMDBM868 592316 Pantoea sp. At-9b PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.765848702, FDR-p value=0.048292655 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41828 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41828 Substances alter microbe abundance PMDBM868 592316 Pantoea sp. At-9b PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.382110424, FDR-p value=0.002681787 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41829 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41829 Substances alter microbe abundance PMDBM881 596315 Peptostreptococcus stomatis DSM 17678 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-0.977184181, FDR-p value=0.027617344 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41830 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41830 Substances alter microbe abundance PMDBM881 596315 Peptostreptococcus stomatis DSM 17678 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41831 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00061907] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41831 Substances alter microbe abundance PMDBM887 596327 Porphyromonas uenonis 60-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41832 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41832 Substances alter microbe abundance PMDBM887 596327 Porphyromonas uenonis 60-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41833 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41833 Substances alter microbe abundance PMDBM789 626369 Granulicatella elegans ATCC 700633 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41834 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41834 Substances alter microbe abundance PMDBM789 626369 Granulicatella elegans ATCC 700633 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41835 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41835 Substances alter microbe abundance PMDBM902 629259 Pseudomonas syringae pv. morsprunorum str. M302280 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.934384014, FDR-p value=0.029620989 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41836 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41836 Substances alter microbe abundance PMDBM902 629259 Pseudomonas syringae pv. morsprunorum str. M302280 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41837 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41837 Substances alter microbe abundance PMDBM699 632245 Clostridium butyricum E4 str. BoNT E BL5262 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.617949905, FDR-p value=1.85148E-08 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41838 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41838 Substances alter microbe abundance PMDBM699 632245 Clostridium butyricum E4 str. BoNT E BL5262 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.356166923, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41839 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41839 Substances alter microbe abundance PMDBM860 633147 Olsenella uli DSM 7084 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41840 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001835278] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41840 Substances alter microbe abundance PMDBM860 633147 Olsenella uli DSM 7084 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41841 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004692789] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41841 Substances alter microbe abundance PMDBM764 634500 Erwinia billingiae Eb661 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.691049642, FDR-p value=0.00252331 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41842 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41842 Substances alter microbe abundance PMDBM764 634500 Erwinia billingiae Eb661 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.888477517, FDR-p value=0.000683858 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41843 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001117861] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41843 Substances alter microbe abundance PMDBM747 634503 Edwardsiella ictaluri 93-146 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.087120925, FDR-p value=0.021796713 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41844 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.32E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41844 Substances alter microbe abundance PMDBM747 634503 Edwardsiella ictaluri 93-146 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41845 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00079853] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41845 Substances alter microbe abundance PMDBM686 637910 Citrobacter rodentium ICC168 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.660488871, FDR-p value=4.16674E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41846 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.25E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41846 Substances alter microbe abundance PMDBM686 637910 Citrobacter rodentium ICC168 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.677704858, FDR-p value=2.02091E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41847 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.28E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41847 Substances alter microbe abundance PMDBM730 639282 Deferribacter desulfuricans SSM1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.315385139, FDR-p value=0.022255128 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41848 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41848 Substances alter microbe abundance PMDBM730 639282 Deferribacter desulfuricans SSM1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41849 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41849 Substances alter microbe abundance PMDBM751 640513 Enterobacter asburiae LF7a PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.32807204, FDR-p value=0.011456502 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41850 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000234995] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41850 Substances alter microbe abundance PMDBM751 640513 Enterobacter asburiae LF7a PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.797095531, FDR-p value=0.001075253 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41851 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.39E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41851 Substances alter microbe abundance PMDBM917 641112 Ruminococcus flavefaciens FD-1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-0.97431946, FDR-p value=0.009565832 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41852 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41852 Substances alter microbe abundance PMDBM917 641112 Ruminococcus flavefaciens FD-1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41853 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41853 Substances alter microbe abundance PMDBM939 649764 Slackia exigua ATCC 700122 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41854 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41854 Substances alter microbe abundance PMDBM939 649764 Slackia exigua ATCC 700122 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41855 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41855 Substances alter microbe abundance PMDBM739 653733 Desulfurispirillum indicum S5 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.115968801, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41856 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.64E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41856 Substances alter microbe abundance PMDBM739 653733 Desulfurispirillum indicum S5 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41857 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103471] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41857 Substances alter microbe abundance PMDBM769 656449 Escherichia coli TW10509 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.567658358, FDR-p value=0.000191515 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41858 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171892] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41858 Substances alter microbe abundance PMDBM769 656449 Escherichia coli TW10509 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.721061424, FDR-p value=0.000129651 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41859 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41859 Substances alter microbe abundance PMDBM919 657323 Ruminococcus sp. SR1/5 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41860 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41860 Substances alter microbe abundance PMDBM919 657323 Ruminococcus sp. SR1/5 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41861 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41861 Substances alter microbe abundance PMDBM723 662755 Corynebacterium resistens DSM 45100 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41862 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000638361] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41862 Substances alter microbe abundance PMDBM723 662755 Corynebacterium resistens DSM 45100 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41863 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41863 Substances alter microbe abundance PMDBM954 663952 Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41864 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100702] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41864 Substances alter microbe abundance PMDBM954 663952 Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41865 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41865 Substances alter microbe abundance PMDBM929 667129 Serratia odorifera DSM 4582 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.211691931, FDR-p value=0.017934627 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41866 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41866 Substances alter microbe abundance PMDBM929 667129 Serratia odorifera DSM 4582 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.329116737, FDR-p value=0.011449719 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41867 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41867 Substances alter microbe abundance PMDBM990 675811 Vibrio furnissii CIP 102972 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.248372349, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41868 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41868 Substances alter microbe abundance PMDBM990 675811 Vibrio furnissii CIP 102972 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41869 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41869 Substances alter microbe abundance PMDBM793 679897 Helicobacter mustelae 12198 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=4.130588109, FDR-p value=0.0007715 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41870 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.29E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41870 Substances alter microbe abundance PMDBM793 679897 Helicobacter mustelae 12198 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=4.569821736, FDR-p value=0.000106099 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41871 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185668] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41871 Substances alter microbe abundance PMDBM914 680646 Rothia mucilaginosa DY-18 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.199480889, FDR-p value=0.035377676 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41872 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41872 Substances alter microbe abundance PMDBM914 680646 Rothia mucilaginosa DY-18 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41873 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.37E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41873 Substances alter microbe abundance PMDBM725 693216 Cronobacter turicensis z3032 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.45720173, FDR-p value=0.00252331 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41874 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41874 Substances alter microbe abundance PMDBM725 693216 Cronobacter turicensis z3032 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.963526975, FDR-p value=0.000106099 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41875 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41875 Substances alter microbe abundance PMDBM640 699184 Bacillus cereus SJ1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.178117422, FDR-p value=0.004656101 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41876 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41876 Substances alter microbe abundance PMDBM640 699184 Bacillus cereus SJ1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.750279107, FDR-p value=0.000246599 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41877 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41877 Substances alter microbe abundance PMDBM718 700015 Coriobacterium glomerans PW2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41878 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001584198] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41878 Substances alter microbe abundance PMDBM718 700015 Coriobacterium glomerans PW2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41879 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000254074] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41879 Substances alter microbe abundance PMDBM755 701347 Enterobacter lignolyticus SCF1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.050390527, FDR-p value=0.00639885 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41880 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001440752] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41880 Substances alter microbe abundance PMDBM755 701347 Enterobacter lignolyticus SCF1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.443474267, FDR-p value=0.000474933 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41881 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000247101] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41881 Substances alter microbe abundance PMDBM835 702453 Listeria seeligeri FSL N1-067 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41882 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000562878] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41882 Substances alter microbe abundance PMDBM835 702453 Listeria seeligeri FSL N1-067 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41883 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003421461] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41883 Substances alter microbe abundance PMDBM605 707232 Acinetobacter haemolyticus ATCC 19194 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.320471234, FDR-p value=0.000595034 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41884 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004646157] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41884 Substances alter microbe abundance PMDBM605 707232 Acinetobacter haemolyticus ATCC 19194 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41885 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001423006] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41885 Substances alter microbe abundance PMDBM822 712938 Lactobacillus fermentum CECT 5716 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.348898935, FDR-p value=0.037504396 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41886 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003996211] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41886 Substances alter microbe abundance PMDBM822 712938 Lactobacillus fermentum CECT 5716 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41887 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.71E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41887 Substances alter microbe abundance PMDBM763 716540 Erwinia amylovora ATCC 49946 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.249706167, FDR-p value=0.037264707 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41888 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41888 Substances alter microbe abundance PMDBM763 716540 Erwinia amylovora ATCC 49946 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.872804342, FDR-p value=0.002834337 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41889 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000380382] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41889 Substances alter microbe abundance PMDBM753 716541 Enterobacter cloacae subsp. cloacae ATCC 13047 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.407318727, FDR-p value=0.000352065 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41890 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41890 Substances alter microbe abundance PMDBM753 716541 Enterobacter cloacae subsp. cloacae ATCC 13047 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.432745788, FDR-p value=0.000211621 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41891 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00469744] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41891 Substances alter microbe abundance PMDBM754 718254 Enterobacter cloacae subsp. cloacae NCTC 9394 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.659961714, FDR-p value=4.8626E-06 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41892 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000328272] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41892 Substances alter microbe abundance PMDBM754 718254 Enterobacter cloacae subsp. cloacae NCTC 9394 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=4.038769728, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41893 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002546255] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41893 Substances alter microbe abundance PMDBM701 720554 Clostridium clariflavum DSM 19732 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41894 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00739182] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41894 Substances alter microbe abundance PMDBM701 720554 Clostridium clariflavum DSM 19732 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41895 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001734051] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41895 Substances alter microbe abundance PMDBM904 741091 Rahnella sp. Y9602 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.724851882, FDR-p value=0.000257223 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41896 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41896 Substances alter microbe abundance PMDBM904 741091 Rahnella sp. Y9602 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41897 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202694] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41897 Substances alter microbe abundance PMDBM903 745277 Rahnella aquatilis CIP 78.65 = ATCC 33071 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.132822941, FDR-p value=0.012098214 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41898 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126633] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41898 Substances alter microbe abundance PMDBM903 745277 Rahnella aquatilis CIP 78.65 = ATCC 33071 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41899 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004646898] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41899 Substances alter microbe abundance PMDBM776 748224 Faecalibacterium cf. prausnitzii KLE1255 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-0.728616189, FDR-p value=0.023392474 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41900 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41900 Substances alter microbe abundance PMDBM776 748224 Faecalibacterium cf. prausnitzii KLE1255 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41901 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005306086] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41901 Substances alter microbe abundance PMDBM894 748280 Pseudogulbenkiania sp. NH8B PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.427383556, FDR-p value=0.044870479 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41902 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005212897] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41902 Substances alter microbe abundance PMDBM894 748280 Pseudogulbenkiania sp. NH8B PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41903 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009795205] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41903 Substances alter microbe abundance PMDBM948 754026 Staphylococcus aureus subsp. aureus MRSA177 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.325157575, FDR-p value=0.013709185 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41904 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009586015] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41904 Substances alter microbe abundance PMDBM948 754026 Staphylococcus aureus subsp. aureus MRSA177 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41905 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006726948] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41905 Substances alter microbe abundance PMDBM662 759914 Brachyspira pilosicoli 95/1000 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41906 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007631742] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41906 Substances alter microbe abundance PMDBM662 759914 Brachyspira pilosicoli 95/1000 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41907 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000869382] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41907 Substances alter microbe abundance PMDBM796 760142 Hippea maritima DSM 10411 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.415675601, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41908 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006460559] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41908 Substances alter microbe abundance PMDBM796 760142 Hippea maritima DSM 10411 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41909 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001293302] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41909 Substances alter microbe abundance PMDBM958 760570 Streptococcus parasanguinis ATCC 15912 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.134677832, FDR-p value=0.044674306 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41910 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41910 Substances alter microbe abundance PMDBM958 760570 Streptococcus parasanguinis ATCC 15912 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41911 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001391325] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41911 Substances alter microbe abundance PMDBM609 762963 Actinomyces sp. oral taxon 170 str. F0386 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41912 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001096233] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41912 Substances alter microbe abundance PMDBM609 762963 Actinomyces sp. oral taxon 170 str. F0386 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41913 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41913 Substances alter microbe abundance PMDBM646 762984 Bacteroides clarus YIT 12056 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.168360159, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41914 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD523 Mercaptopurine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41914 Substances alter microbe abundance PMDBM646 762984 Bacteroides clarus YIT 12056 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41915 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404149] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41915 Substances alter microbe abundance PMDBM931 768490 Serratia sp. AS12 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.970477841, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41916 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944477] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41916 Substances alter microbe abundance PMDBM931 768490 Serratia sp. AS12 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41917 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD145 Carbenoxolone disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002796885] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41917 Substances alter microbe abundance PMDBM658 871562 Bifidobacterium dentium ATCC 27679 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41918 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD867 Tribenoside Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004733857] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41918 Substances alter microbe abundance PMDBM658 871562 Bifidobacterium dentium ATCC 27679 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41919 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD342 Fentiazac Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000634437] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41919 Substances alter microbe abundance PMDBM614 878320 Aeromonas caviae Ae398 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.440430469, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41920 Substances alter microbe abundance PMDBM140 n.a. Clostridioides difficile PMDBD401 Gliquidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006069732] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41920 Substances alter microbe abundance PMDBM614 878320 Aeromonas caviae Ae398 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41921 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.96E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41921 Substances alter microbe abundance PMDBM877 879308 Peptoniphilus sp. oral taxon 375 str. F0436 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=0.421746652, FDR-p value=0.049124707 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41922 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41922 Substances alter microbe abundance PMDBM877 879308 Peptoniphilus sp. oral taxon 375 str. F0436 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41923 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41923 Substances alter microbe abundance PMDBM985 879309 Veillonella sp. oral taxon 158 str. F0412 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41924 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41924 Substances alter microbe abundance PMDBM985 879309 Veillonella sp. oral taxon 158 str. F0412 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41925 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41925 Substances alter microbe abundance PMDBM925 882884 Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.529077443, FDR-p value=0.00037212 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41926 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41926 Substances alter microbe abundance PMDBM925 882884 Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.626655863, FDR-p value=0.000171663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41927 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41927 Substances alter microbe abundance PMDBM821 888027 Lactobacillus delbrueckii subsp. lactis DSM 20072 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.868633697, FDR-p value=0.028170194 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41928 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41928 Substances alter microbe abundance PMDBM821 888027 Lactobacillus delbrueckii subsp. lactis DSM 20072 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41929 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41929 Substances alter microbe abundance PMDBM847 888742 Neisseria bacilliformis ATCC BAA-1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41930 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41930 Substances alter microbe abundance PMDBM847 888742 Neisseria bacilliformis ATCC BAA-1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41931 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41931 Substances alter microbe abundance PMDBM885 891974 Plautia stali symbiont PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=3.192733917, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41932 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41932 Substances alter microbe abundance PMDBM885 891974 Plautia stali symbiont PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41933 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41933 Substances alter microbe abundance PMDBM772 903814 Eubacterium limosum KIST612 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41934 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41934 Substances alter microbe abundance PMDBM772 903814 Eubacterium limosum KIST612 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41935 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41935 Substances alter microbe abundance PMDBM926 909945 Salmonella enterica subsp. enterica serovar Dublin str. SD3246 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.61522486, FDR-p value=0.00026017 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41936 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41936 Substances alter microbe abundance PMDBM926 909945 Salmonella enterica subsp. enterica serovar Dublin str. SD3246 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.788588462, FDR-p value=5.97097E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41937 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41937 Substances alter microbe abundance PMDBM991 911104 Weissella cibaria KACC 11862 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.964812413, FDR-p value=0.043895048 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41938 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41938 Substances alter microbe abundance PMDBM991 911104 Weissella cibaria KACC 11862 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41939 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41939 Substances alter microbe abundance PMDBM695 929506 Clostridium botulinum BKT015925 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.819744919, FDR-p value=5.29255E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41940 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41940 Substances alter microbe abundance PMDBM695 929506 Clostridium botulinum BKT015925 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.755940694, FDR-p value=0.003267857 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41941 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41941 Substances alter microbe abundance PMDBM604 980514 Acinetobacter baumannii TCDC-AB0715 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.547944979, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41942 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41942 Substances alter microbe abundance PMDBM604 980514 Acinetobacter baumannii TCDC-AB0715 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41943 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41943 Substances alter microbe abundance PMDBM901 996285 Pseudomonas stutzeri DSM 4166 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.546250033, FDR-p value=0.008015127 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41944 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41944 Substances alter microbe abundance PMDBM901 996285 Pseudomonas stutzeri DSM 4166 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41945 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41945 Substances alter microbe abundance PMDBM806 1006551 Klebsiella oxytoca KCTC 1686 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.795582236, FDR-p value=0.00026017 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41946 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41946 Substances alter microbe abundance PMDBM806 1006551 Klebsiella oxytoca KCTC 1686 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.672789777, FDR-p value=2.2381E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41947 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41947 Substances alter microbe abundance PMDBM750 1028307 Enterobacter aerogenes KCTC 2190 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.354538187, FDR-p value=0.003574388 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41948 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41948 Substances alter microbe abundance PMDBM750 1028307 Enterobacter aerogenes KCTC 2190 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.842625114, FDR-p value=0.000191515 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41949 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41949 Substances alter microbe abundance PMDBM826 1040964 Lactobacillus ruminis SPM0211 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41950 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41950 Substances alter microbe abundance PMDBM826 1040964 Lactobacillus ruminis SPM0211 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41951 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41951 Substances alter microbe abundance PMDBM752 1045856 Enterobacter cloacae EcWSU1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.12259286, FDR-p value=0.024051055 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41952 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41952 Substances alter microbe abundance PMDBM752 1045856 Enterobacter cloacae EcWSU1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.169148203, FDR-p value=0.018165801 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41953 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41953 Substances alter microbe abundance PMDBM616 1050720 Agrobacterium tumefaciens F2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41954 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41954 Substances alter microbe abundance PMDBM616 1050720 Agrobacterium tumefaciens F2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41955 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41955 Substances alter microbe abundance PMDBM891 1051006 Propionibacterium acnes SK182B-JCVI PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41956 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41956 Substances alter microbe abundance PMDBM891 1051006 Propionibacterium acnes SK182B-JCVI PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41957 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41957 Substances alter microbe abundance PMDBM960 1051074 Streptococcus thermophilus JIM 8232 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41958 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41958 Substances alter microbe abundance PMDBM960 1051074 Streptococcus thermophilus JIM 8232 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41959 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41959 Substances alter microbe abundance PMDBM837 1064535 Megasphaera elsdenii DSM 20460 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41960 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41960 Substances alter microbe abundance PMDBM837 1064535 Megasphaera elsdenii DSM 20460 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41961 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41961 Substances alter microbe abundance PMDBM955 1069533 Streptococcus infantarius subsp. infantarius CJ18 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41962 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41962 Substances alter microbe abundance PMDBM955 1069533 Streptococcus infantarius subsp. infantarius CJ18 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41963 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41963 Substances alter microbe abundance PMDBM895 1089456 Pseudomonas aeruginosa NCGM2.S1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.761073416, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41964 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41964 Substances alter microbe abundance PMDBM895 1089456 Pseudomonas aeruginosa NCGM2.S1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.594793617, FDR-p value=7.95032E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41965 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41965 Substances alter microbe abundance PMDBM832 1091138 Lawsonia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41966 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41966 Substances alter microbe abundance PMDBM867 1123863 Pantoea ananatis LMG 5342 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.708788524, FDR-p value=0.000596366 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41967 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41967 Substances alter microbe abundance PMDBM867 1123863 Pantoea ananatis LMG 5342 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.823475384, FDR-p value=0.00037212 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41968 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41968 Substances alter microbe abundance PMDBM829 1423814 Lactobacillus vaginalis ATCC 49540 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41969 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41969 Substances alter microbe abundance PMDBM829 1423814 Lactobacillus vaginalis ATCC 49540 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41970 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41970 Substances alter microbe abundance PMDBM802 1505657 Intestinibacter PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. Microbial shifts under metformin treatment contribute to improved glucose control and to adverse effects. PMID PMID: 26633628 PMDBI41971 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41971 Substances alter microbe abundance PMDBM937 n.a. Shewanella sp. Ana-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.121166792, FDR-p value=0.00416827 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin’s antidiabetic effects. PMID PMID: 28530702 PMDBI41972 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41972 Substances alter microbe abundance PMDBM937 n.a. Shewanella sp. Ana-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41973 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41973 Substances alter microbe abundance PMDBM617 n.a. Akkermansia spp. PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice, fed either a normal-chow diet or ahigh-fat diet (HFD), were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. The Akkermansia spp. Population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. The increase in the Akkermansia spp. population may contribute to the antidiabetic effects of metformin. PMID PMID: 23804561 PMDBI41974 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41974 Substances alter microbe abundance PMDBM652 n.a. Barnesiellaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41975 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41975 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Acute lymphocytic leukemia (ALL) n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41976 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41976 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41977 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41977 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41978 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41978 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41979 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41979 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41980 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41980 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41981 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41981 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41982 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41982 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41983 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41983 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41984 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41984 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41985 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41985 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41986 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41986 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41987 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41987 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD546 Metronidazole Therapeutic Substance Approved Drug; Antibiotics Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI41988 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1294 Mezlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41988 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41989 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.33E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41989 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1294 Mezlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41990 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41990 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1294 Mezlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41991 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41991 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1294 Mezlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41992 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41992 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1294 Mezlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI41993 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41993 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1294 Mezlocillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI41994 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41994 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41995 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41995 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41996 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41996 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41997 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41997 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41998 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41998 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI41999 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41999 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42000 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42000 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42001 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42001 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42002 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005474974] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42002 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42003 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42003 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42004 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42004 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42005 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42005 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275 PMDBI42006 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42006 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42007 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42007 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42008 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42008 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42009 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42009 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42010 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42010 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42011 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42011 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42012 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42012 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42013 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283455] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42013 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42014 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42014 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42015 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42015 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42016 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42016 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42017 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42017 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083 PMDBI42018 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42018 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1308 Nalidixic acid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072 PMDBI42019 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42019 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1308 Nalidixic acid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072 PMDBI42020 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.05E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42020 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1308 Nalidixic acid Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072 PMDBI42021 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42021 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42022 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42022 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42023 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42023 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42024 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42024 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003 PMDBI42025 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42025 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003 PMDBI42026 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42026 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42027 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42027 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42028 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.43E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42028 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42029 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100844] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42029 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42030 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42030 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42031 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42031 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42032 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42032 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25766736 PMDBI42033 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42033 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522 PMDBI42034 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42034 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42035 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42035 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42036 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.98E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42036 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42037 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42037 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 3438150; PMID: 3729360; PMID: 9210003 PMDBI42038 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42038 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202; PMID: 9210003 PMDBI42039 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001820012] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42039 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202 PMDBI42040 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42040 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42041 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42041 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42042 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42042 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202 PMDBI42043 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42043 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42044 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004419677] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42044 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202 PMDBI42045 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42045 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419 PMDBI42046 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42046 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202 PMDBI42047 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.43E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42047 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202 PMDBI42048 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42048 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD607 Norfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202 PMDBI42049 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.35E-05] n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. n.a. PMID PMID: 29555994 PMDBI42049 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1324 NSAIDs and sulfasalazine therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI42050 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201 PMDBI42050 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008990004] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42051 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200 PMDBI42051 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00294464] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42052 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254 PMDBI42052 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001729015] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42053 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42053 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 9360254 PMDBI42054 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42054 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 3471178; PMID: 3182454 PMDBI42055 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42055 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 3182454; PMID: 9360254 PMDBI42056 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42056 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3182454; PMID: 9360254 PMDBI42057 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.46E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42057 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200 PMDBI42058 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185636] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42058 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200 PMDBI42059 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42059 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201; PMID: 3134200 PMDBI42060 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000981233] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42060 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201 PMDBI42061 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000221323] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42061 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 9360254 PMDBI42062 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42062 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200 PMDBI42063 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006417648] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42063 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3471178 PMDBI42064 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42064 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3471178 PMDBI42065 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42065 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201; PMID: 3134200; PMID: 9360254 PMDBI42066 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004788164] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42066 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD611 Ofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200 PMDBI42067 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.87E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42067 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42068 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.83E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42068 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42069 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000451654] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42069 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42070 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000568494] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42070 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42071 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253827] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42071 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42072 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42072 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42073 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000468584] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42073 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42074 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000893552] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42074 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42075 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00147683] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42075 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42076 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42076 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42077 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004209638] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42077 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42078 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009617755] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42078 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42079 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005776539] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42079 Substances alter microbe abundance PMDBM657 1689 Bifidobacterium dentium PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42080 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.55E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42080 Substances alter microbe abundance PMDBM862 75682 Oxalobacteraceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42081 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.63E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42081 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42082 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007164988] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42082 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42083 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000436959] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42083 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1343 Paromomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862 PMDBI42084 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1343 Paromomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862 PMDBI42084 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00390871] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42085 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1343 Paromomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862 PMDBI42085 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD319 Ethacrynic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001641042] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42086 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000926722] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42086 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1343 Paromomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862 PMDBI42087 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007289477] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42087 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1343 Paromomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862 PMDBI42088 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.26E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42088 Substances alter microbe abundance PMDBM798 61170 Holdemania PMDBD1343 Paromomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862 PMDBI42089 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008240679] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42089 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1349 Pefloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072 PMDBI42090 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42090 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1349 Pefloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072 PMDBI42091 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42091 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1349 Pefloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 1597205 PMDBI42092 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 3846592 PMDBI42092 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007239027] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42093 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI42093 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004608193] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42094 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD842 Thioguanosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00037355] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42094 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI42095 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD444 Indatraline hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00684289] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42095 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42096 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.50E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42096 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382; PMID: 118526 PMDBI42097 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD145 Carbenoxolone disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42097 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI42098 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD328 Etretinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000341198] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42098 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42099 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD636 Paclitaxel Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42099 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI42100 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD661 Phenindione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00940513] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42100 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI42101 Substances alter microbe abundance PMDBM153 n.a. Clostridium perfringens PMDBD82 Azacytidine-5 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42101 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382 PMDBI42102 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42102 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 3846592 PMDBI42103 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42103 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382; PMID: 118526; PMID: 3846592 PMDBI42104 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42104 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382; PMID: 118526 PMDBI42105 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42105 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI42106 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42106 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI42107 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42107 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1351 Penicillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526 PMDBI42108 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42108 Substances alter microbe abundance PMDBM703 69824 Clostridium cocleatum PMDBD1360 Phenformin Therapeutic Substance Approved Drug 6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 25038099 PMDBI42109 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1365 Piperacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42109 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42110 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1365 Piperacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42110 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42111 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.61E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42111 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1365 Piperacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42112 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42112 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1365 Piperacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42113 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.42E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42113 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD1365 Piperacillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42114 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42114 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42115 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42115 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42116 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42116 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42117 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42117 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42118 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42118 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42119 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42119 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42120 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42120 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42121 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000176723] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42121 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42122 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42122 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42123 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42123 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1368 Pivmecillinam Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889 PMDBI42124 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1371 Polymyxin E Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3378584 PMDBI42124 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42125 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1371 Polymyxin E Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3378584 PMDBI42125 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42126 Substances alter microbe abundance PMDBM143 208479 Clostridium bolteae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42126 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42127 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42127 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42128 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42128 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42129 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42129 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42130 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42130 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42131 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42131 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42132 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42132 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42133 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42133 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42134 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42134 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42135 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42135 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42136 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42136 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42137 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42137 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42138 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42138 Substances alter microbe abundance PMDBM872 712 Pasteurellaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42139 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42139 Substances alter microbe abundance PMDBM790 724 Haemophilus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42140 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42140 Substances alter microbe abundance PMDBM791 729 Haemophilus parainfluenzae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42141 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42141 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42142 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42142 Substances alter microbe abundance PMDBM959 1305 Streptococcus sanguinis PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42143 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000158672] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42143 Substances alter microbe abundance PMDBM957 1309 Streptococcus mutans PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42144 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.90E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42144 Substances alter microbe abundance PMDBM953 1328 Streptococcus anginosus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42145 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42145 Substances alter microbe abundance PMDBM607 1654 Actinomyces PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42146 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.13E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42146 Substances alter microbe abundance PMDBM657 1689 Bifidobacterium dentium PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42147 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.91E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42147 Substances alter microbe abundance PMDBM610 2049 Actinomycetaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42148 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.91E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42148 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42149 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42149 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42150 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.36E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42150 Substances alter microbe abundance PMDBM771 39488 Eubacterium hallii PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42151 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.25E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42151 Substances alter microbe abundance PMDBM774 39496 Eubacterium ventriosum PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42152 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42152 Substances alter microbe abundance PMDBM758 81852 Enterococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42153 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42153 Substances alter microbe abundance PMDBM746 88431 Dorea longicatena PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42154 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42154 Substances alter microbe abundance PMDBM716 116085 Coprococcus catus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42155 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42155 Substances alter microbe abundance PMDBM876 186807 Peptococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42156 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000215531] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42156 Substances alter microbe abundance PMDBM779 203492 Fusobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42157 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42157 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42158 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42158 Substances alter microbe abundance PMDBM766 n.a. Erysipelotrichaceae noname PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42159 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42159 Substances alter microbe abundance PMDBM785 n.a. Gemellaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42160 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000217474] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42160 Substances alter microbe abundance PMDBM986 n.a. Veillonella unclassified PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42161 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777 PMDBI42161 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42162 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777 PMDBI42162 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42163 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777 PMDBI42163 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003441605] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42164 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42164 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777 PMDBI42165 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31906281 PMDBI42165 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI42166 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31906281 PMDBI42166 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002743209] n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI42167 Substances alter microbe abundance PMDBM199 1351 Enterococcus faecalis PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 24722352; PMID: 31906281 PMDBI42167 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000469876] n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI42168 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42168 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID PMID: 24722352; PMID: 31906281 PMDBI42169 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42169 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID PMID: 24722352; PMID: 31906281 PMDBI42170 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42170 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID PMID: 24722352; PMID: 31906281 PMDBI42171 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42171 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID PMID: 24722352; PMID: 31906281 PMDBI42172 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42172 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42173 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42173 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42174 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42174 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42175 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42175 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42176 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42176 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995; PMID: 23565181 PMDBI42177 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42177 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42178 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.83E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42178 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995; PMID: 23565181 PMDBI42179 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42179 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42180 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009455871] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42180 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995 PMDBI42181 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42181 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42182 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42182 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42183 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42183 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995 PMDBI42184 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42184 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42185 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42185 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995; PMID: 23565181 PMDBI42186 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001307245] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42186 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD747 Rifaximin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181 PMDBI42187 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1404 Ritipenem acoxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248 PMDBI42187 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005301499] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42188 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000964707] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42188 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1404 Ritipenem acoxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248 PMDBI42189 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42189 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1404 Ritipenem acoxil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248 PMDBI42190 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD758 Roxithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207 PMDBI42190 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42191 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207 PMDBI42191 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42192 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007815455] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42192 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD758 Roxithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207 PMDBI42193 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.98E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42193 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207 PMDBI42194 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1410 Rulfoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202; PMID: 8961053 PMDBI42194 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000491757] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42195 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1410 Rulfoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202; PMID: 8961053 PMDBI42195 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42196 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0078121] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42196 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1410 Rulfoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202 PMDBI42197 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002583972] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42197 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1410 Rulfoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202; PMID: 8961053 PMDBI42198 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42198 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1410 Rulfoxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202 PMDBI42199 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42199 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42200 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42200 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42201 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42201 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42202 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42202 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42203 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001779948] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42203 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42204 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42204 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42205 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42205 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42206 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42206 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42207 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42207 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42208 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42208 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1417 Sitafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450 PMDBI42209 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42209 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001023755] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42210 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42210 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000102773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42211 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.87E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42211 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42212 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.70E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42212 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42213 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.75E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42213 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42214 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42214 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42215 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42215 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000770567] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42216 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034551] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42216 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1419 Solithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483 PMDBI42217 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42217 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00080865] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42218 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42218 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000533178] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42219 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42219 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283823] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42220 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027896] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42220 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42221 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42221 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42222 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42222 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42223 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42223 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42224 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000661483] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42224 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42225 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD371 Folic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017316] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42225 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42226 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD288 Disulfiram Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001296427] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42226 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42227 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD243 Dacarbazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000695859] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42227 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42228 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42228 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837 PMDBI42229 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.76E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42229 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42230 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42230 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42231 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42231 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42232 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42232 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42233 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42233 Substances alter microbe abundance PMDBM871 n.a. Paraprevotellaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42234 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42234 Substances alter microbe abundance PMDBM975 n.a. Turicibacteraceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42235 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42235 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42236 Substances alter microbe abundance PMDBM143 208479 Clostridium bolteae PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42236 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42237 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42237 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42238 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42238 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42239 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00030367] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42239 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42240 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.33E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42240 Substances alter microbe abundance PMDBM233 853 Faecalibacterium prausnitzii PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42241 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42241 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42242 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42242 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42243 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42243 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42244 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42244 Substances alter microbe abundance PMDBM746 88431 Dorea longicatena PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42245 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42245 Substances alter microbe abundance PMDBM838 n.a. Methanobrevibacter unclassified PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42246 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42246 Substances alter microbe abundance PMDBM878 n.a. Peptostreptococcaceae noname PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42247 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42247 Substances alter microbe abundance PMDBM879 n.a. Peptostreptococcaceae noname unclassified PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42248 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42248 Substances alter microbe abundance PMDBM714 n.a. Coprobacillus unclassified PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42249 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42249 Substances alter microbe abundance PMDBM811 n.a. Lachnospiraceae bacterium 2 1 58FAA PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42250 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42250 Substances alter microbe abundance PMDBM812 n.a. Lachnospiraceae bacterium 3 1 57FAA CT1 PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42251 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42251 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD804 Streptomycin Therapeutic Substance Approved Drug; Antibiotics Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI42252 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42252 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD804 Streptomycin Therapeutic Substance Approved Drug; Antibiotics Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI42253 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42253 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD804 Streptomycin Therapeutic Substance Approved Drug; Antibiotics Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI42254 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42254 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD804 Streptomycin Therapeutic Substance Approved Drug; Antibiotics Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI42255 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42255 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD804 Streptomycin Therapeutic Substance Approved Drug; Antibiotics Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI42256 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42256 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD804 Streptomycin Therapeutic Substance Approved Drug; Antibiotics Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animals’ gut PMID PMID: 26173701 PMDBI42257 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. Microbiota and JIA susceptibility PMID PMID: 31675176 PMDBI42257 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42258 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42258 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1428 Sulphalene Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 333556 PMDBI42259 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.52E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42259 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1429 Sulphasomidine Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 333556 PMDBI42260 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1437 Teicoplanin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42260 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42261 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42261 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1437 Teicoplanin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42262 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42262 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1437 Teicoplanin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42263 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42263 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1437 Teicoplanin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42264 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42264 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42265 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42265 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42266 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42266 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42267 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42267 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42268 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42268 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42269 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.40E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42269 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42270 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42270 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42271 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005906099] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42271 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1438 Telavancin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049 PMDBI42272 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42272 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42273 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42273 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000601093] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42274 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42274 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42275 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00181158] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42275 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42276 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42276 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42277 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.17E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42277 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42278 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42278 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42279 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42279 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42280 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.14E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42280 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42281 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42281 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42282 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42282 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42283 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42283 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42284 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42284 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42285 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42285 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42286 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42286 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193 PMDBI42287 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42287 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1451 Thiopurines Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42288 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1454 Ticarcillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42288 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42289 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42289 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1454 Ticarcillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42290 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42290 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1454 Ticarcillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42291 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42291 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1454 Ticarcillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42292 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42292 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1454 Ticarcillin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592 PMDBI42293 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42293 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42294 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42294 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42295 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42295 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42296 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003205469] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42296 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42297 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42297 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42298 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42298 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42299 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42299 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42300 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42300 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42301 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42301 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42302 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.11E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42302 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42303 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42303 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42304 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42304 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42305 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42305 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816 PMDBI42306 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820 PMDBI42306 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42307 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42307 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42308 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42308 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42309 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.15E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42309 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316 PMDBI42310 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00013664] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42310 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820 PMDBI42311 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42311 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42312 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42312 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820 PMDBI42313 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42313 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42314 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42314 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42315 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42315 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42316 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42316 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42317 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002397008] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42317 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820 PMDBI42318 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42318 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1457 Tigecycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820 PMDBI42319 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42319 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42320 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296105] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42320 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42321 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000117411] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42321 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42322 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42322 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42323 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42323 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42324 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100937] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42324 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7247360 PMDBI42325 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42325 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD877 Trimethoprim Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7247360 PMDBI42326 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42326 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD877 Trimethoprim Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 7247360 PMDBI42327 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42327 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1480 Trimethoprim/sulfamethoxazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003 PMDBI42328 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42328 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1480 Trimethoprim/sulfamethoxazole Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003 PMDBI42329 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000263951] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42329 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1483 Trovafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI42330 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42330 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1483 Trovafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI42331 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007412673] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42331 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1483 Trovafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI42332 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.58E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42332 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1483 Trovafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI42333 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42333 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1483 Trovafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI42334 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42334 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1483 Trovafloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764 PMDBI42335 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42335 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42336 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42336 Substances alter microbe abundance PMDBM209 562 Escherichia coli PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42337 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42337 Substances alter microbe abundance PMDBM233 853 Faecalibacterium prausnitzii PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42338 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42338 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42339 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-06] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42339 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42340 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42340 Substances alter microbe abundance PMDBM938 620 Shigella PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42341 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002742893] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42341 Substances alter microbe abundance PMDBM912 301302 Roseburia faecis PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42342 Substances alter microbe abundance PMDBM140 1496 Clostridium difficile PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42342 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000130388] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42343 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003535641] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42343 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42344 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001497309] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42344 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42345 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000631234] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42345 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42346 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42346 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42347 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110855] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42347 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42348 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008553647] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42348 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42349 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000314737] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42349 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42350 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42350 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42351 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42351 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animals’ gut. PMID PMID: 26173701 PMDBI42352 Substances alter microbe abundance PMDBM156 84030 Lacrimispora saccharolytica PMDBD847 Thyroxine (L) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001274877] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42352 Substances alter microbe abundance PMDBM875 n.a. Pedicoccus PMDBD888 Vancomycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064 PMDBI42353 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1487 Vedolizumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42353 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42354 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.79E-07] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42354 Substances alter microbe abundance PMDBM913 360807 Roseburia inulinivorans PMDBD1487 Vedolizumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42355 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42355 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD1492 Vitamin D Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42356 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42356 Microbes metabolize substances PMDBM801 n.a. Intestinal microflora PMDBD490 Loperamide Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. loperamide n.a. n.a. Activation of prodrug In vivo rat; dog n.a. n.a. n.a. PMID PMID: 7628301 PMDBI42357 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42357 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD618 Olsalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. n.a. n.a. n.a. Activation of prodrug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007; PMID: 25091594; PMID: 32466672 PMDBI42358 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase and nitroreductase Activation of prodrug In vitro Human Health n.a. n.a. PMID PMID: 30158249; PMID: 8565901; PMID: 25091594 PMDBI42358 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42359 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug n.a. Human Inflammatory bowel disease (IBD) n.a. Sulfasalazine is prodrug converted to the active agent 2-ASA by gut microbes PMID PMID: 31675176 PMDBI42359 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42360 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42360 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42361 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42361 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 4-ASA by gut microbes PMID PMID: 31675176 PMDBI42362 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42362 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42363 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42363 Microbes metabolize substances PMDBM363 33038 Ruminococcus gnavus PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 3-ASA by gut microbes PMID PMID: 31675176 PMDBI42364 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42364 Microbes metabolize substances PMDBM371 90371 Salmonella typhimurium PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42365 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42365 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. sulfapyridine; 5-aminosalicylate Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42366 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42366 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD96 Balsalazide Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. n.a. n.a. n.a. Activation of prodrug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007; PMID: 25091594; PMID: 32466672 PMDBI42367 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42367 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD636 Paclitaxel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. developmental delay PMID PMID: 30890566; PMID: 28431244 PMDBI42368 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42368 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD636 Paclitaxel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. developmental delay PMID PMID: 30890566; PMID: 28431244 PMDBI42369 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42369 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouridine monophospate Phosphorylation Uracil phosphoribosyltransferase Increase activity In vivo Caenorhabditis elegans n.a. n.a. Lead to sterility PMID PMID: 30890566; PMID: 28431244 PMDBI42370 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42370 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouridine monophospate Phosphorylation Uracil phosphoribosyltransferase Increase activity In vivo Caenorhabditis elegans n.a. n.a. Lead to sterility PMID PMID: 30890566; PMID: 28431244 PMDBI42371 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42371 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1005 5-fluoro-2'-deoxyuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. completely sterile PMID PMID: 30890566; PMID: 28431244 PMDBI42372 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42372 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1072 Camptothecin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. production of few dead embryos PMID PMID: 30890566; PMID: 28431244 PMDBI42373 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42373 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1072 Camptothecin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. production of few dead embryos PMID PMID: 30890566; PMID: 28431244 PMDBI42374 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42374 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42375 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42375 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42376 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42376 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD200 Cladribine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42377 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42377 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD200 Cladribine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42378 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42378 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42379 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.85E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42379 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42380 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42380 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42381 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42381 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42382 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42382 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42383 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42383 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42384 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42384 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD455 Irinotecan Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42385 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42385 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42386 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42386 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42387 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42387 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1006 5-fluorocytosine Therapeutic Substance Approved Drug; Prodrug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase chemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42388 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42388 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1006 5-fluorocytosine Therapeutic Substance Approved Drug; Prodrug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42389 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42389 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1008 6-Mercaptopurine-2′-deoxyriboside Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42390 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42390 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1015 Actinomycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42391 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42391 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1038 AQ4N Therapeutic Substance Approved Drug; Prodrug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase cemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42392 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42392 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1039 Ara G hydrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42393 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42393 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1039 Ara G hydrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42394 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42394 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1082 CB1954 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42395 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42395 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1082 CB1954 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42396 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42396 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1124 Clofarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42397 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42397 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1124 Clofarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42398 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42398 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1136 Cytarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42399 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42399 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1136 Cytarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42400 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42400 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1142 Daunorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42401 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42401 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1142 Daunorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42402 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42402 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1182 Estramustine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42403 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42403 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1198 Fludarabine de phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42404 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42404 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1198 Fludarabine de phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42405 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42405 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1232 Idarubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42406 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42406 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1275 Menadione Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42407 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42407 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1299 Mitomycin C Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42408 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42408 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1300 Mitoxantrone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42409 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42409 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1314 Nelarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42410 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42410 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1314 Nelarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42411 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42411 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1354 Pentostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42412 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42412 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1354 Pentostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42413 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42413 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1425 Streptonegrin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42414 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.37E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42414 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1436 Tegafur Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42415 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42415 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1436 Tegafur Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42416 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.86E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42416 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1486 Valacyclovir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42417 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42417 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1489 Vidarabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42418 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.81E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42418 Microbes metabolize substances PMDBM289 1643 Listeria welshimeri PMDBD1489 Vidarabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42419 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00692846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42419 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1490 Vinblastine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID PMID: 26416623; PMID: 30890566 PMDBI42420 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42420 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1498 Β-Lapachone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID PMID: 26416623; PMID: 30890566 PMDBI42421 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42421 Microbes metabolize substances PMDBM186 84112 Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. dihydrodigoxin Reduction Cardiac glycoside reductase Reduce bioavailability; Decrease activity In vivo Mouse n.a. n.a. Digoxin is converted to the inactive metabolite dihydrodigoxin by Eggerthella lenta, limiting the amount of active drug that is absorbed into the systemic circulation. PMID PMID: 23869020 PMDBI42422 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42422 Microbes metabolize substances PMDBM258 573 Klebsiella pneumoniae PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vivo Mouse n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42423 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42423 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. Nitro reduction Nitroreductase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42424 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42424 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD136 Caffeic acid Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Reduction and dehydoxylation n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42425 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42425 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD189 Choline Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. Trimethylamine C-N bond cleavage elimination/oxidation Glycyl radical enzymes Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO PMID PMID: 30890566 PMDBI42426 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42426 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 7-aminoclonazapam Nitro reduction Nitroreductase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42427 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42427 Microbes metabolize substances PMDBM620 626932 Alistipes indistinctus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42428 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42428 Microbes metabolize substances PMDBM4 446660 Adlercreutzia equolifaciens PMDBD245 Daidzin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. daidzein; equol n.a. Bacterial β-glucosidases Metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 12468591 PMDBI42429 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42429 Microbes metabolize substances PMDBM941 n.a. Slackia spp. PMDBD245 Daidzin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. daidzein; equol n.a. Bacterial β-glucosidases Metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 12468591 PMDBI42430 Microbes metabolize substances PMDBM143 208479 Clostridium bolteae PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Microbiota species involved in ALL chemotherapeutics metabolism PMID PMID: 31675176 PMDBI42430 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42431 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42431 Microbes metabolize substances PMDBM42 817 Bacteroides fragilis PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42432 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164863] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42432 Microbes metabolize substances PMDBM660 78346 Bifidobacterium ruminantium PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42433 Microbes metabolize substances PMDBM157 29347 Clostridium scindens PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. Dexamethasone side chain cleavage n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Microbiota species involved in ALL chemotherapeutics metabolism PMID PMID: 31675176 PMDBI42433 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138066] n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42434 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42434 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Glucuronide hydrolysis Bacterial β-glucuronidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42435 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42435 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vivo Mouse n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42436 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42436 Microbes metabolize substances PMDBM211 679895 Escherichia coli BW25113 PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-deoxydoxorubicinol; 7-deoxydoxorubicinolone n.a. n.a. Reduced toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 29160065 PMDBI42437 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42437 Microbes metabolize substances PMDBM258 573 Klebsiella pneumoniae PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 29160065 PMDBI42438 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42438 Microbes metabolize substances PMDBM905 575 Raoultella planticola PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vivo Mouse n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42439 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42439 Microbes metabolize substances PMDBM905 575 Raoultella planticola PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-deoxydoxorubicinol; 7-deoxydoxorubicinolone reductive deglycosylation n.a. reduced toxicity In vitro High-throughput incubation assays n.a. n.a. For cancer patients, inactivation of doxorubicin by gut microbes could result in a decrease in active doxorubicin levels, potentially altering the efficacy of chemotherapeutic treatment and the severity of side effects. PMID PMID: 30890566; PMID: 29160065 PMDBI42440 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42440 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42441 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000977135] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42441 Microbes metabolize substances PMDBM39 28111 Bacteroides eggerthii PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42442 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42442 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42443 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42443 Microbes metabolize substances PMDBM648 46506 Bacteroides stercoris PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42444 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42444 Microbes metabolize substances PMDBM869 387661 Parabacteroides johnsonii PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI42445 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42445 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Glucuronide hydrolysis Bacterial β-glucuronidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42446 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42446 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD453 Ipsalazide Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32466672 PMDBI42447 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42447 Microbes metabolize substances PMDBM186 84112 Eggerthella lenta PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. m-tyramine n.a. molybdenum-dependent dehydroxylase Decreases bioavailability; Increase toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31196984; PMID: 32409589 PMDBI42448 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42448 Microbes metabolize substances PMDBM199 1351 Enterococcus faecalis PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dopamine decarboxylation Gut bacterial tyrosine decarboxylases Decreases bioavailability In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31196984; PMID: 30659181; PMID: 32409589 PMDBI42449 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42449 Microbes metabolize substances PMDBM201 1352 Enterococcus faecium PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dopamine decarboxylation Gut bacterial tyrosine decarboxylases Decreases bioavailability In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31196984; PMID: 30659181; PMID: 32409589 PMDBI42450 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426771] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42450 Microbes metabolize substances PMDBM284 n.a. Lactobacillus spp. PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dopamine decarboxylation Gut bacterial tyrosine decarboxylases Decreases bioavailability In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589; PMID: 30659181; PMID: 32409589 PMDBI42451 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42451 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD496 Lovastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Hydroxylation n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 24947972 PMDBI42452 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42452 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42453 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42453 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 7-amino-nitrazepam Nitro reduction Nitroreductase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Nitrazepam is metabolized into 7-aminonitrazepam, which undergoes host hepatic metabolism into a teratogen PMID PMID: 30890566 PMDBI42454 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42454 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD602 Nizatidine Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. nitroso-deoxygenated metabolite n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42455 Microbes metabolize substances PMDBM103 1682 Bifidobacterium longum subsp. Infantis PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. piceid n.a. n.a. Does not change activity n.a. n.a. n.a. n.a. n.a. PMID PMID: 9784180; PMID: 27497981; PMID: 31906281 PMDBI42455 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42456 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001689] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42456 Microbes metabolize substances PMDBM269 1579 Lactobacillus acidophilus PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. piceid n.a. n.a. Does not change activity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 9784180; PMID: 27497981; PMID: 31906281 PMDBI42457 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42457 Microbes metabolize substances PMDBM639 1396 Bacillus cereus PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. piceid n.a. n.a. Does not change activity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 9784180; PMID: 27497981; PMID: 31906281 PMDBI42458 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42458 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD750 Risperidone Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. ketone n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42459 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004132065] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42459 Microbes metabolize substances PMDBM757 543 Enterobacteriaceae PMDBD788 Sorivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. (e)-5-(2-bromovinyl) uracil n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31885474 PMDBI42460 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42460 Microbes metabolize substances PMDBM650 n.a. Bacteroidetes sp. PMDBD788 Sorivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. (e)-5-(2-bromovinyl) uracil n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31885474 PMDBI42461 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42461 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD788 Sorivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Hydrolysis Phosphorylysases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Reduction and dehydoxylation Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) PMID PMID: 30890566 PMDBI42462 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42462 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. sulfoxide reduction n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42463 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42463 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD816 Sulindac Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. deoxysulindac sulfoxide reduction n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42464 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42464 Microbes metabolize substances PMDBM233 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. M1 n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Faecalibacterium prausnitzii metabolizes tacrolimus into less potent metabolites M1, which is 15-fold less potent than tacrolimus as an immunosuppressant. PMID PMID: 30598508 PMDBI42465 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.14E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42465 Microbes metabolize substances PMDBM800 n.a. Indole-producing bacteria PMDBD880 Tryptophan Dietary Substance Dietary Compounds n.a. Gut n.a. n.a. indole Deamination Tryptophanase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule PMID PMID: 30890566; PMID: 26439294 PMDBI42466 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42466 Microbes metabolize substances PMDBM801 n.a. Intestinal microflora PMDBD1006 5-fluorocytosine Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. 5-fluorouracil deamination n.a. Increase toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 3729334 PMDBI42467 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42467 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD1007 5-fluorodeoxyuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42468 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42468 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1026 Amino acids Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Peptide bond formation Peptide synthetase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Dipeiptide aldehyde produced can inhibit human cathepsins L PMID PMID: 30890566; PMID: 28111075 PMDBI42469 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42469 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1058 Bile acids Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Deconjugation Bile salt hydrolyase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 25483337 PMDBI42470 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42470 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1081 Carnitine Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. Trimethylamine Oxidation/Reduction Carnitine oxygenase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO PMID PMID: 30890566 PMDBI42471 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42471 Microbes metabolize substances PMDBM647 357276 Bacteroides dorei PMDBD1129 Corticosteroids Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42472 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42472 Microbes metabolize substances PMDBM4 446660 Adlercreutzia equolifaciens PMDBD1214 Genistin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. genistein n.a. Bacterial β-glucosidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 12468591 PMDBI42473 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42473 Microbes metabolize substances PMDBM941 n.a. Slackia spp. PMDBD1214 Genistin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. genistein n.a. Bacterial β-glucosidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 12468591 PMDBI42474 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.27E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42474 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1216 Glucocorticoids Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42475 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42475 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1237 Indigestible polysaccharides Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Fermentation Saccharolytic pathways; butyryl-CoA:acetate CoA transferase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42476 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001404915] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42476 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1263 L-tyrosine Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Removal of carboxyl group Decarboxylase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Bacterial production of p-cresol, which is sulfated by the host. P-cresol competes with acetaminophen for sulfation. PMID PMID: 30890566 PMDBI42477 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42477 Microbes metabolize substances PMDBM258 573 Klebsiella pneumonia PMDBD1273 Melamine Dietary Substance Dietary Compounds; Industrial Compounds Melamine was administered orally to rats at a daily dose of 600 mg/kg for 15 days. n.a. n.a. n.a. cyanuric acid Hydrolysis n.a. Increase toxicity In vivo Rat Health n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. PMID PMID: 30890566; PMID: 23408055 PMDBI42478 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42478 Microbes metabolize substances PMDBM261 577 Klebsiella terrigena PMDBD1273 Melamine Dietary Substance Dietary Compounds; Industrial Compounds Melamine was administered orally to rats at a daily dose of 600 mg/kg for 15 days. n.a. n.a. n.a. cyanuric acid Hydrolysis n.a. Increase toxicity In vivo Rat Health n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. PMID PMID: 30890566; PMID: 23408055 PMDBI42479 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42479 Microbes metabolize substances PMDBM807 575 Klebsiella planticola PMDBD1273 Melamine Dietary Substance Dietary Compounds; Industrial Compounds Melamine was administered orally to rats at a daily dose of 600 mg/kg for 15 days. n.a. n.a. n.a. cyanuric acid Hydrolysis n.a. Increase toxicity In vivo Rat Health n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. PMID PMID: 30890566; PMID: 23408055 PMDBI42480 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42480 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1280 Mesalazines Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42481 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003379116] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42481 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1327 Oleic acid Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Acylation N-acyl synthase Metabolism In vitro High-throughput incubation assays n.a. n.a. Products are able to modulate GPCRs PMID PMID: 30890566; PMID: 25483337 PMDBI42482 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. Acute lymphocytic leukemia (ALL) n.a. n.a. PMID PMID: 29555994 PMDBI42482 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD1369 Polychemotherapy Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Increased chemotherapy induced HEM toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42483 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42483 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1450 Thioguanine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42484 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000275271] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42484 Microbes metabolize substances PMDBM199 1351 Enterococcus faecalis PMDBD1451 Thiopurines Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42485 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000295286] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42485 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1451 Thiopurines Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42486 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42486 Microbes metabolize substances PMDBM68 818 Bacteroides thetaiotaomicron PMDBD1451 Thiopurines Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42487 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42487 Microbes metabolize substances PMDBM379 498718 Slackia equolifaciens PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dihydroresveratrol n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 23283496; PMID: 31906281 PMDBI42488 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027457] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42488 Microbes metabolize substances PMDBM4 446660 Adlercreutzia equolifaciens PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dihydroresveratrol n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 23283496; PMID: 31906281 PMDBI42489 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.98E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42489 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 3,4'-dihydroxy-trans-stilbene n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 23283496; PMID: 31906281 PMDBI42490 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001915979] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42490 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 3,4'-dihydroxybibenzyl n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 23283496; PMID: 31906281 PMDBI42491 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002315632] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42491 Microbes metabolize substances PMDBM203 1547 Clostridium ramosum PMDBD455 Irinotecan Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial β-glucuronidases Metabolize prodrug to active form; Increase toxicity In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID PMID: 21789126; PMID: 21051639 PMDBI42492 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002376626] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42492 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial β-glucuronidases Metabolize prodrug to active form; Increase toxicity In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID PMID: 21789126; PMID: 21051639 PMDBI42493 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42493 Microbes metabolize substances PMDBM75 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial β-glucuronidases Metabolize prodrug to active form; Increase toxicity In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID PMID: 21789126; PMID: 21051639 PMDBI42494 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42494 Microbes metabolize substances PMDBM653 n.a. Beta-glucuronidase encoding species PMDBD455 Irinotecan Therapeutic Substance Approved Drug; Prodrug n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial β-glucuronidases Metabolize prodrug to active form; Increase toxicity In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial β-glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID PMID: 21789126; PMID: 21051639 PMDBI42495 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002306283] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42495 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD10 Abacavir Sulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42496 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009152734] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42496 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD112 Bicalutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42497 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003241472] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42497 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42498 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001134983] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42498 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD122 Bosentan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42499 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42499 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42500 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008783433] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42500 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD130 Bupropion Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42501 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006089512] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42501 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42502 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42502 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD16 Acetaminophen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42503 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00322275] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42503 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42504 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004949573] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42504 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42505 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.84E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42505 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42506 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.15E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42506 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42507 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149994] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42507 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42508 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001348701] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42508 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD223 Colchicine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42509 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD523 Mercaptopurine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002094487] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42509 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD234 Cyclobenzaprine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42510 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004225595] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42510 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42511 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD74 Asenapine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006518934] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42511 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42512 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD200 Cladribine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42512 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD26 Alfuzosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42513 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD196 Cinnarizine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001760582] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42513 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42514 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD591 Nilutamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001197623] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42514 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42515 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD743 Ribostamycin sulfate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002052349] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42515 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD276 Digoxin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42516 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD436 Ibutilide fumarate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005740186] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42516 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42517 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD703 Prilocaine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000109489] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42517 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42518 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD276 Digoxin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006949505] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42518 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42519 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD317 Estropipate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009514871] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42519 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD30 Altretamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42520 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD416 Guanadrel sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008720694] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42520 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD313 Erlotinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42521 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD593 Nimodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009606651] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42521 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD317 Estropipate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42522 Substances alter microbe abundance PMDBM167 74426 Collinsella aerofaciens PMDBD38 Amiprilose hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004929581] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42522 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42523 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42523 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42524 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42524 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42525 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42525 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42526 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42526 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42527 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42527 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD332 Famotidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42528 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42528 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42529 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.69E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42529 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42530 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42530 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42531 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42531 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42532 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42532 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42533 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42533 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD377 Galantamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42534 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.04E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42534 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42535 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42535 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD382 Gefitinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42536 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42536 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42537 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.78E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42537 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42538 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42538 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD41 Amoxapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42539 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42539 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD415 Griseofulvin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42540 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42540 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD418 Haloperidol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42541 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42541 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42542 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42542 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42543 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42543 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42544 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42544 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42545 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42545 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD46 Anastrozole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42546 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42546 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42547 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42547 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD467 Ketoconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42548 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42548 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD468 Ketoprofen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42549 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42549 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42550 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42550 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD473 Leflunomide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42551 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42551 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42552 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42552 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42553 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42553 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD490 Loperamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42554 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42554 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD494 Loratadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42555 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42555 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD496 Lovastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42556 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42556 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42557 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42557 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42558 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42558 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD521 Memantine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42559 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42559 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42560 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42560 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42561 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42561 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD537 Methoxsalen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42562 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42562 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42563 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42563 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42564 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42564 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD554 Mitotane Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42565 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42565 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42566 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42566 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42567 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42567 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42568 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42568 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42569 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42569 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42570 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42570 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD611 Ofloxacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42571 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.56E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42571 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42572 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42572 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42573 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42573 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42574 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42574 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD629 Oxcarbazepine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42575 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.88E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42575 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42576 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.95E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42576 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD642 Paroxetine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42577 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42577 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42578 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42578 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42579 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42579 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42580 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42580 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42581 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42581 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42582 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42582 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42583 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42583 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42584 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.84E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42584 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42585 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42585 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42586 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42586 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD739 Reserpine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42587 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42587 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42588 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42588 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42589 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42589 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42590 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42590 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42591 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42591 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD779 Sertraline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42592 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42592 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD783 Simvastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42593 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42593 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42594 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.67E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42594 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42595 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42595 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD808 Sulfadiazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42596 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42596 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42597 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42597 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42598 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42598 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42599 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42599 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42600 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42600 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42601 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42601 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42602 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42602 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42603 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42603 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42604 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42604 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD893 Verapamil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42605 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42605 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42606 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42606 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD900 Warfarin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42607 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42607 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42608 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42608 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42609 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42609 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD910 Zileuton Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42610 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42610 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42611 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42611 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1000 4-Aminosalicylic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42612 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42612 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1010 Acebutolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42613 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42613 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1012 Acetohexamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42614 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42614 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1013 Acitretin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42615 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42615 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1014 Acrivastine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42616 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42616 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1016 Acyclovir Zovirax Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42617 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42617 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1018 Adefovir Dipivoxil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42618 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004056104] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42618 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1022 Alosetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42619 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000849895] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42619 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1024 Ambrisentan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42620 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42620 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1025 Amiloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42621 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.56E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42621 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1027 Aminophylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42622 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42622 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1028 Amitriptyline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42623 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42623 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1037 Apomorphine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42624 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42624 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1042 Artemether Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42625 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42625 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD74 Asenapine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42626 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005069808] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42626 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42627 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42627 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1045 Atazanavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42628 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42628 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1046 Atorvastatin Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42629 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42629 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1053 Benztropine Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42630 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007454688] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42630 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1057 Bexarotene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42631 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000759868] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42631 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1059 Bisoprolol Fumarate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42632 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42632 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD125 Bromocriptine Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42633 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002866397] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42633 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1063 Brompheniramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42634 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42634 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1064 Bumetanide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42635 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42635 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1065 Buspirone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42636 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42636 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1066 Butorphanol-(+)-Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42637 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42637 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1067 Cabergoline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42638 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42638 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1069 Caffeine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42639 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42639 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1070 Calcitriol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42640 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000417653] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42640 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1073 Candesartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42641 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00343082] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42641 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1075 Carbamazepine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42642 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42642 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1077 Carbidopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42643 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42643 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1078 Carbinoxamine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42644 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42644 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1084 Cefditoren Pivoxil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42645 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42645 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42646 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00052388] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42646 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1106 Chloroquine Diphosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42647 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000769478] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42647 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1108 Chlorothiazide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42648 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002624633] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42648 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD184 Chlorpheniramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42649 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.19E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42649 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1110 Chlorpropamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42650 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42650 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1112 Chlorthalidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42651 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004828422] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42651 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1113 Chlorzoxazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42652 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42652 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1116 Cilostazol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42653 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165081] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42653 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1117 Cinacalcet Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42654 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001136075] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42654 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1118 Ciprofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42655 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283328] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42655 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1120 Citalopram Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42656 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42656 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42657 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42657 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1122 Clindamycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42658 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241584] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42658 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1123 Clobazam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42659 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42659 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1125 Clomiphene Citrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42660 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42660 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1126 Clomipramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42661 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944881] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42661 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1127 Clopidogrel Hydrogen Sulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42662 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000296205] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42662 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1128 Clozapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42663 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42663 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1131 Cromolyn Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42664 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003892562] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42664 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1134 Cyclosporine A Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42665 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42665 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1135 Cyproheptadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42666 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00112447] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42666 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1139 Dapsone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42667 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003489629] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42667 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1140 Darifenacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42668 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110866] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42668 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1141 Darunavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42669 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006347589] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42669 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1143 Deferasirox Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42670 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000493545] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42670 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1144 Delavirdine Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42671 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000199681] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42671 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1145 Demeclocycline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42672 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004739732] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42672 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1148 Desipramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42673 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005017795] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42673 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1149 Desloratadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42674 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207101] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42674 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1150 Desvenlafaxine Succinate Hydrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42675 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.04E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42675 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1151 Dexchlorpheniramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42676 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42676 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1152 Dextromethorphan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42677 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009519216] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42677 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1154 Diazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42678 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000234948] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42678 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1156 Diazoxide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42679 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233009] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42679 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1158 Dienogest Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42680 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003648773] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42680 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1160 Diflunisal Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42681 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000432177] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42681 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1161 Dimenhydrinate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42682 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42682 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1162 Diphenhydramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42683 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000508931] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42683 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1163 Disopyramide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42684 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000735586] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42684 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1165 Dofetilide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42685 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005921662] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42685 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1167 Donepezil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42686 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428591] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42686 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD289 Doxazosin Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42687 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009136971] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42687 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1169 Doxepin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42688 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42688 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1170 Doxycycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42689 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002051243] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42689 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1171 Dutasteride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42690 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004408996] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42690 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1172 Emtricitabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42691 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006625292] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42691 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1174 Enalapril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42692 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD523 Mercaptopurine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355458] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42692 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1175 Enalaprilat Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42693 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD450 Iohexol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.15E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42693 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1177 Eprosartan Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42694 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD444 Indatraline hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008151822] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42694 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD312 Ergotamine Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42695 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD332 Famotidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.96E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42695 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1180 Escitalopram Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42696 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005356222] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42696 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1181 Esomeprazole Potassium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42697 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD532 Methantheline bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008706801] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42697 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1183 Estrone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42698 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD912 Ziprasidone Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003648773] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42698 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1186 Ethinyl Estradiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42699 Substances alter microbe abundance PMDBM171 410072 Coprococcus comes PMDBD31 Alverine citrate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006749194] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42699 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1187 Ethionamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42700 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42700 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1188 Everolimus Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42701 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42701 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1190 Felbamate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42702 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42702 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1191 Fenoprofen Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42703 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.08E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42703 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1192 Fexofenadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42704 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42704 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1193 Fingolimod Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42705 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42705 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1195 Flavoxate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42706 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.40E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42706 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1196 Flecainide Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42707 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42707 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1201 Flurbiprofen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42708 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42708 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1203 Fluvastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42709 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42709 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD370 Fluvoxamine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42710 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42710 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1205 Formoterol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42711 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42711 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1207 Fosinopril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42712 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42712 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1209 Furosemide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42713 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42713 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1210 Gabapentin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42714 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42714 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1212 Gemfibrozil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42715 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42715 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1213 Gemifloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42716 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42716 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1215 Glimepiride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42717 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42717 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1217 Glyburide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42718 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42718 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1220 Granisetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42719 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150075] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42719 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1221 Guanabenz Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42720 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42720 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1222 Guanfacine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42721 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42721 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1225 Hydralazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42722 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42722 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1226 Hydrochlorothiazide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42723 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42723 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1228 Hydroflumethiazide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42724 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42724 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1229 Hydroxychloroquine Sulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42725 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.97E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42725 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1230 Hydroxyzine Dihydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42726 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42726 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1231 Ibuprofen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42727 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000227146] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42727 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1235 Imipramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42728 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.68E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42728 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1236 Indapamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42729 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42729 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1238 Indinavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42730 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42730 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1240 Isocarboxazid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42731 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42731 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1241 Isradipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42732 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42732 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD469 Ketorolac Tromethamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42733 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42733 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1243 Ketotifen Fumarate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42734 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42734 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1244 Labetalol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42735 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42735 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1245 Lacosamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42736 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42736 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1246 Lamivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42737 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42737 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1247 Lamotrigine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42738 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42738 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1248 Lapatinib Ditosylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42739 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42739 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1253 Lenalidomide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42740 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42740 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1255 Letrozole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42741 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42741 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1256 Levocetirizine Dihydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42742 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.05E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42742 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1257 Levofloxacin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42743 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42743 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1258 Lincomycin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42744 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42744 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1259 Lopinavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42745 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42745 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1261 Losartan Potassium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42746 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00821249] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42746 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD502 Loxapine Succinate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42747 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.63E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42747 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1266 Maprotiline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42748 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42748 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1267 Maraviroc Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42749 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42749 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1269 Meclizine Dihydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42750 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42750 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1270 Meclofenamate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42751 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00023782] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42751 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1271 Mefenamic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42752 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.35E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42752 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1274 Meloxicam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42753 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42753 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1276 Mepenzolate Bromide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42754 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42754 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1277 Meprobamate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42755 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42755 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1281 Mestranol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42756 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42756 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1282 Metaproterenol Hemisulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42757 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42757 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1283 Methazolamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42758 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42758 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1284 Methenamine Hippurate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42759 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42759 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1285 Methimazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42760 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42760 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1286 Methocarbamol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42761 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42761 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1287 Methylergonovine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42762 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42762 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1289 Metoclopramide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42763 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42763 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1290 Metolazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42764 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002419759] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42764 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD545 Metoprolol Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42765 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42765 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1292 Metyrapone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42766 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42766 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1293 Mexiletine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42767 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42767 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1295 Milnacipran Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42768 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.07E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42768 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1296 Minocycline Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42769 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42769 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1297 Mirtazapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42770 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42770 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1302 Modafinil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42771 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42771 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1303 Moexipril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42772 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42772 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1306 Mycophenolic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42773 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42773 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1307 Nadolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42774 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42774 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1309 Naltrexone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42775 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42775 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1310 Naproxen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42776 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42776 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1311 Naratriptan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42777 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.30E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42777 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1312 Nebivolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42778 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42778 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1313 Nefazodone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42779 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42779 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1315 Nelfinavir Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42780 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42780 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1321 Nisoldipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42781 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42781 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1323 Nortriptyline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42782 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42782 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1325 Nystatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42783 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42783 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1328 Olmesartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42784 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42784 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1329 Olopatadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42785 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42785 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1331 Ondansetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42786 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42786 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1334 Oseltamivir Phosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42787 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.09E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42787 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1337 Oxtriphylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42788 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42788 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD634 Oxybutynin Chloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42789 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42789 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1339 Oxytetracycline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42790 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42790 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1341 Palonosetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42791 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42791 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1344 Pazopanib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42792 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42792 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD647 Pemirolast Potassium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42793 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42793 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1355 Pentoxifylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42794 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42794 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1357 Perindopril Erbumine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42795 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006943422] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42795 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1361 Phenoxybenzamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42796 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.71E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42796 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1362 Phenylephrine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42797 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42797 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1363 Phenytoin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42798 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42798 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1364 Pilocarpine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42799 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.46E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42799 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1366 Piroxicam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42800 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42800 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1367 Pitavastatin Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42801 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42801 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1372 Posaconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42802 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42802 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1373 Pramipexole Dihydrochloride Monohydrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42803 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42803 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1375 Pravastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42804 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.46E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42804 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1376 Praziquantel Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42805 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.38E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42805 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1377 Prazosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42806 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42806 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD704 Primaquine Phosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42807 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.17E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42807 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1381 Primidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42808 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42808 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1383 Procainamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42809 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42809 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1385 Promethazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42810 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42810 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1386 Propafenone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42811 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004285355] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42811 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1388 Propranolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42812 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42812 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1389 Propylthiouracil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42813 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42813 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1391 Protriptyline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42814 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42814 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1392 Pyrazinamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42815 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42815 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1393 Quetiapine Fumarate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42816 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004498] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42816 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1394 Quinidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42817 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003450843] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42817 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1395 Quinine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42818 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0084923] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42818 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1397 Rabeprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42819 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000842546] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42819 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1398 Raloxifene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42820 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000121143] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42820 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1399 Raltegravir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42821 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42821 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1400 Ranolazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42822 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000387379] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42822 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1401 Rasagiline Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42823 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42823 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1403 Rimantadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42824 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42824 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1405 Rivastigmine Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42825 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42825 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1406 Ropinirole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42826 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42826 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1407 Rosiglitazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42827 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009131912] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42827 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1408 Rosuvastatin Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42828 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361304] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42828 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1409 Rufinamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42829 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00112447] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42829 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD764 Saquinavir Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42830 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42830 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1413 Scopolamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42831 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001634087] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42831 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1414 Selegiline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42832 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42832 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD781 Sildenafil Citrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42833 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0003577] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42833 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1418 Sitagliptin Phosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42834 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42834 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1420 Sorafenib Tosylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42835 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005395687] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42835 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD820 Sumatriptan Succinate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42836 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.27E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42836 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1431 Sunitinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42837 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42837 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1432 Tacrine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42838 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42838 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1433 Tamoxifen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42839 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.31E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42839 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1434 Tamsulosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42840 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42840 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1439 Telbivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42841 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003042737] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42841 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1440 Telithromycin Therapeutic Substance Approved Drug; Antibiotics n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42842 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42842 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1441 Temazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42843 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42843 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1442 Terazosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42844 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008706801] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42844 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1443 Terbinafine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42845 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.84E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42845 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1444 Terbutaline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42846 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003381699] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42846 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1445 Tetrabenazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42847 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000745054] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42847 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1447 Thalidomide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42848 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000758779] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42848 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1448 Theophylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42849 Substances alter microbe abundance PMDBM183 39486 Dorea formicigenerans PMDBD473 Leflunomide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002219157] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42849 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1450 Thioguanine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42850 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42850 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1452 Thioridazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42851 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42851 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1453 Tiagabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42852 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42852 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1456 Ticlopidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42853 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42853 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1458 Tizanidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42854 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42854 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1459 Tolbutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42855 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42855 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1461 Tolmetin sodium dihydrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42856 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42856 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1462 Tolterodine Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42857 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42857 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1463 Tolvaptan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42858 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42858 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1464 Topiramate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42859 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42859 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1465 Topotecan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42860 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.21E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42860 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1466 Toremifene Base Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42861 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42861 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1467 Torsemide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42862 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.67E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42862 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1469 Tramadol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42863 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42863 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1471 Tranylcypromine Hemisulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42864 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42864 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1472 Trazodone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42865 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42865 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1473 Triamcinolone Acetonide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42866 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.58E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42866 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1474 Triamterene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42867 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42867 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1475 Triazolam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42868 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42868 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1478 Trifluoperazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42869 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42869 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1479 Trimethobenzamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42870 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42870 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1481 Trimipramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42871 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42871 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1482 Trospium Chloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42872 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42872 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1488 Venlafaxine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42873 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.37E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42873 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1491 Vinorelbine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42874 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.87E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42874 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1494 Ziprasidone hydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42875 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42875 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1495 Zolmitriptan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42876 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42876 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42877 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42877 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42878 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42878 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD142 Capsaicin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42879 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42879 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD210 Clofazimine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42880 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42880 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42881 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.80E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42881 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42882 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42882 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42883 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42883 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42884 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42884 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD315 Estradiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42885 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42885 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42886 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001029457] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42886 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD366 Fluoxetine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42887 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003422085] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42887 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD546 Metronidazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42888 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42888 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD565 Nabumetone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42889 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.74E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42889 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD591 Nilutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42890 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.48E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42890 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD593 Nimodipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42891 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.37E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42891 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42892 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42892 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42893 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42893 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD639 Pantoprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42894 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42894 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD744 Rifabutin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42895 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.70E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42895 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42896 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42896 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42897 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42897 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42898 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42898 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42899 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42899 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42900 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42900 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42901 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.30E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42901 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1021 Allopurinol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42902 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001552307] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42902 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1056 Betamethasone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42903 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000290109] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42903 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1105 Chenodiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42904 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42904 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1130 Cortisone Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42905 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42905 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1138 Dantrolene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42906 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.39E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42906 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1166 Dolasetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42907 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.17E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42907 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD319 Ethacrynic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42908 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42908 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1189 Exemestane Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42909 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001088287] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42909 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1199 Fludrocortisone Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42910 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42910 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1202 Flutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42911 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42911 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1227 Hydrocortisone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42912 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006144696] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42912 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1227 Hydrocortisone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42913 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42913 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1233 Iloperidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42914 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42914 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1260 Lorazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42915 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000779058] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42915 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD519 Megestrol Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42916 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42916 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1288 Methylprednisolone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42917 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002482895] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42917 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1298 Misoprostol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42918 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001496762] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42918 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD563 Mycophenolate Mofetil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42919 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.64E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42919 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1318 Nicardipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42920 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.55E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42920 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1322 Nitisinone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42921 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42921 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1336 Oxazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42922 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.14E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42922 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1374 Prasugrel Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42923 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.89E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42923 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1378 Prednisolone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42924 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42924 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1379 Prednisone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42925 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42925 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1382 Probenecid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42926 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.72E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42926 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1384 Progesterone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42927 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019363] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42927 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1402 Rifampin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42928 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009392496] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42928 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1421 Spironolactone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42929 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110867] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42929 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1427 Sulfamethoxazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42930 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42930 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1460 Tolcapone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42931 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42931 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1484 Ursodiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42932 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000963399] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42932 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1493 Vorinostat Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42933 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001088834] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42933 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD16 Acetaminophen Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42934 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42934 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD476 Levodopa Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42935 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.87E-06] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42935 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD546 Metronidazole Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42936 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281578] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42936 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD619 Omeprazole Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42937 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42937 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD783 Simvastatin Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42938 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006630414] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42938 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD915 Zonisamide Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42939 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.64E-05] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42939 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1139 Dapsone Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42940 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006477672] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42940 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42941 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42941 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42942 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42942 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42943 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000136718] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42943 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42944 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42944 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42945 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42945 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42946 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000206272] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42946 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD829 Temozolomide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42947 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42947 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD829 Temozolomide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42948 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42948 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1005 5-fluoro-2'-deoxyuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42949 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001003844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42949 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1316 Neocarzinostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42950 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002535612] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42950 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1316 Neocarzinostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42951 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42951 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1431 Sunitinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42952 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207238] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42952 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1431 Sunitinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42953 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42953 Microbes metabolize substances PMDBM209 562 Escherichia coli PMDBD1433 Tamoxifen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42954 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000445674] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42954 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1433 Tamoxifen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID PMID: 30890566; PMID: 28431244 PMDBI42955 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001653916] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42955 Microbes metabolize substances PMDBM768 469008 Escherichia coli BL21(DE3) PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566; PMID: 29160065 PMDBI42956 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000320991] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42956 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD445 Indole Environmental Substance Metabolite n.a. n.a. n.a. n.a. indoxyl sulfate; indole-3-propionic acid; isatin; 5-hydroxyindole n.a. n.a. Metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26439294 PMDBI42957 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42958 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42959 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.25E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42960 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105176] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42961 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000483527] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42962 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001923619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42963 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002615896] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42964 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004328366] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42965 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42966 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42967 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42968 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42969 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006216034] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42970 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42971 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150815] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42972 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42973 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007574365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42974 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD418 Haloperidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00721154] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42975 Substances alter microbe abundance PMDBM186 n.a. Eggerthella lenta PMDBD129 Bufexamac Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00773707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42976 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42977 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42978 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42979 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42980 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42981 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42982 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42983 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42984 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42985 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42986 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42987 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42988 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42989 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42990 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42991 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42992 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42993 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42994 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002697598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42995 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42996 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42997 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42998 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42999 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43000 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00405416] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43001 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43002 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43003 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43004 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43005 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43006 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43007 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43008 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43009 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43010 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006329494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43011 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43012 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43013 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000154779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43014 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43015 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43016 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43017 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43018 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43019 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384468] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43020 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43021 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43022 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43023 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43024 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43025 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43026 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43027 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43028 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43029 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43030 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43031 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43032 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43033 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43034 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43035 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43036 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43037 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43038 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43039 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43040 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43041 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43042 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43043 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43044 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43045 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43046 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.38E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43047 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43048 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43049 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43050 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43051 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000843474] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43052 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001295934] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43053 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43054 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43055 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD675 Pipemidic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43056 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD842 Thioguanosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43057 Substances alter microbe abundance PMDBM212 585397 Escherichia coli ED1a PMDBD678 Pivmecillinam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43058 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.22E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43059 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43060 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43061 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43062 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43063 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43064 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43065 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43066 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43067 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43068 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43069 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43070 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43071 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43072 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000619485] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43073 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43074 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43075 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43076 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007723953] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43077 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43078 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43079 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43080 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.62E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43081 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43082 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43083 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43084 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43085 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43086 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43087 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43088 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000751721] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43089 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43090 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43091 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.90E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43092 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43093 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43094 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005361641] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43095 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43096 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43097 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43098 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43099 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43100 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43101 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43102 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43103 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43104 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43105 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43106 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43107 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43108 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43109 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43110 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43111 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43112 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43113 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43114 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43115 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43116 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43117 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43118 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43119 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43120 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43121 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43122 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002511467] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43123 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43124 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43125 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43126 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43127 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43128 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43129 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43130 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43131 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43132 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43133 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43134 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000480935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43135 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43136 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43137 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD675 Pipemidic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43138 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD200 Cladribine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43139 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD842 Thioguanosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43140 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD678 Pivmecillinam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43141 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD350 Fexofenadine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008281463] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43142 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD359 Fludarabine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00022021] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43143 Substances alter microbe abundance PMDBM213 585034 Escherichia coli IAI1 PMDBD364 Fluorometholone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005527231] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43144 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43145 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43146 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43147 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43148 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43149 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43150 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43151 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43152 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43153 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43154 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43155 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43156 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43157 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43158 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43159 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43160 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43161 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43162 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43163 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43164 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43165 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43166 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43167 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43168 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43169 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43170 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43171 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.04E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43172 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43173 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407513] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43174 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43175 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.49E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43176 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43177 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43178 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43179 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43180 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43181 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43182 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43183 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43184 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43185 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43186 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43187 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43188 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43189 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000200215] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43190 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43191 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43192 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43193 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43194 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43195 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43196 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43197 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43198 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43199 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43200 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43201 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43202 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43203 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43204 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43205 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.68E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43206 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43207 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43208 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43209 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002160053] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43210 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43211 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43212 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000949381] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43213 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43214 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.70E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43215 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43216 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43217 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43218 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43219 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43220 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43221 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43222 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43223 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43224 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43225 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003050721] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43226 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43227 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43228 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43229 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43230 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43231 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180873] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43232 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43233 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43234 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43235 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005040288] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43236 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43237 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43238 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43239 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009240568] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43240 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43241 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009959859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43242 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43243 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43244 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43245 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43246 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43247 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43248 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43249 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008468237] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43250 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43251 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43252 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003586475] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43253 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43254 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43255 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43256 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43257 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43258 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43259 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003395309] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43260 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43261 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43262 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43263 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43264 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43265 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43266 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006847773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43267 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43268 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43269 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43270 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003762061] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43271 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43272 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43273 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000354051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43274 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43275 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43276 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000409922] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43277 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001196707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43278 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00171391] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43279 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002062169] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43280 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003959654] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43281 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000919651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43282 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000587621] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43283 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000147452] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43284 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005291612] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43285 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003077566] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43286 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001858081] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43287 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009434026] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43288 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43289 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001303223] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43290 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001711794] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43291 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004276717] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43292 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005211733] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43293 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002639895] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43294 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000285174] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43295 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000767287] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43296 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001229724] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43297 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001383791] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43298 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007897794] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43299 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003200122] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43300 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00386463] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43301 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003952581] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43302 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD779 Sertraline Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008314918] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43303 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD381 GBR 12909 dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004498] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43304 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD847 Thyroxine (L) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001698405] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43305 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD606 Norcyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000421185] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43306 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD256 Deptropine citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002434065] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43307 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD267 Dicyclomine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002806708] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43308 Substances alter microbe abundance PMDBM219 39485 [Eubacterium] eligens PMDBD282 Dimethisoquin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004750396] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43309 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000378371] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43310 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000409003] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43311 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43312 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000306383] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43313 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43314 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214078] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43315 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000974908] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43316 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017063] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43317 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001033647] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43318 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338955] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43319 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43320 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000898138] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43321 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000262719] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43322 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00040424] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43323 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355776] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43324 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43325 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000935714] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43326 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43327 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273851] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43328 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001400586] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43329 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169166] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43330 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214299] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43331 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000399994] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43332 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000162753] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43333 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000265494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43334 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000221545] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43335 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209646] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43336 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001837541] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43337 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43338 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165922] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43339 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43340 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43341 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000353513] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43342 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43343 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43344 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000399703] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43345 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000988593] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43346 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43347 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168726] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43348 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43349 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164611] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43350 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43351 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43352 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43353 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0004071] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43354 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43355 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001492278] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43356 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002294069] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43357 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000163771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43358 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271581] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43359 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001038111] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43360 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000361878] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43361 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000362657] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43362 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384931] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43363 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000387318] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43364 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000382397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43365 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000402648] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43366 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43367 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008421756] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43368 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000167597] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43369 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001040151] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43370 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001923597] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43371 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168984] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43372 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000967328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43373 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000401702] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43374 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001080112] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43375 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000167548] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43376 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000976862] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43377 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271267] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43378 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000412089] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43379 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170885] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43380 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000346097] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43381 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169502] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43382 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001055051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43383 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43384 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164898] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43385 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170513] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43386 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43387 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034623] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43388 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407731] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43389 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168628] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43390 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168706] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43391 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168435] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43392 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168822] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43393 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43394 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216184] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43395 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271872] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43396 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271267] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43397 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000403341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43398 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016811] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43399 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017063] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43400 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001199846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43401 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000405409] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43402 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001689] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43403 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000163962] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43404 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000453083] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43405 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372795] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43406 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001039356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43407 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001718902] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43408 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000230873] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43409 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000350754] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43410 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43411 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000982525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43412 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407345] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43413 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171186] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43414 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43415 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005029022] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43416 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003862578] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43417 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43418 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003261408] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43419 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000991355] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43420 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000279971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43421 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000347934] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43422 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166653] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43423 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207066] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43424 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169425] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43425 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001026634] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43426 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000449161] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43427 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002922821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43428 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000168449] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43429 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000957735] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43430 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001224807] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43431 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165081] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43432 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002168721] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43433 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001593325] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43434 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00079504] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43435 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00028298] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43436 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00811522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43437 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003193652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43438 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001445676] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43439 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43440 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000905297] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43441 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166388] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43442 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000162663] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43443 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00166258] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43444 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002765864] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43445 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000195813] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43446 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003048825] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43447 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003451354] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43448 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001010013] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43449 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001928589] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43450 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001468787] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43451 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001557165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43452 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001929889] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43453 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000556732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43454 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003665325] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43455 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000569178] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43456 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002436407] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43457 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000755219] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43458 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005069808] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43459 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000965664] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43460 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00029395] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43461 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001925619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43462 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43463 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000439773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43464 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002310188] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43465 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000282724] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43466 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007492184] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43467 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000198323] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43468 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004664749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43469 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003364809] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43470 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009134219] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43471 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00073008] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43472 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00282026] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43473 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001843987] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43474 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000219214] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43475 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006471855] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43476 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005453684] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43477 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000769692] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43478 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD12 Acarbose Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000460108] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43479 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00183633] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43480 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003095836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43481 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006409321] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43482 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008337197] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43483 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD464 Ivermectin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00339554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43484 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002281473] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43485 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003104732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43486 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006182585] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43487 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004729501] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43488 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005696752] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43489 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003173408] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43490 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001757155] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43491 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0041032] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43492 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000301514] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43493 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000200168] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43494 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001454241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43495 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD779 Sertraline Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001553159] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43496 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD74 Asenapine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003655819] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43497 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD444 Indatraline hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005829803] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43498 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD491 Loperamide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002894824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43499 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD513 Mebhydroline 1,5-naphtalenedisulfonate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002495343] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43500 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD871 Triflupromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008014017] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43501 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD371 Folic acid Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001145843] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43502 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD369 Fluspirilen Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009483084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43503 Substances alter microbe abundance PMDBM224 39491 [Eubacterium] rectale PMDBD248 Darifenacin hydrobromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001015196] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43608 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43609 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43610 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43611 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43612 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43613 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43614 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43615 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.43E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43616 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43617 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43618 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.09E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43619 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43620 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43621 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43622 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43623 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43624 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43625 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.04E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43626 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43627 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43628 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43629 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43630 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43631 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43632 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43633 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43634 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43635 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.07E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43636 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43637 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.38E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43638 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43639 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000473102] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43640 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004079502] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43641 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43642 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43643 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43644 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43645 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43646 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43647 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43648 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43649 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43650 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43651 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43652 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43653 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43654 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43655 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.12E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43656 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000312424] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43657 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43658 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.83E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43659 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43660 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43661 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43662 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43663 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686529] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43664 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43665 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43666 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.23E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43667 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43668 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.81E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43669 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686521] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43670 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001427007] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43671 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43672 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43673 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000711793] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43674 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43675 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43676 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43677 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43678 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43679 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008164124] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43680 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43681 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000949493] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43682 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43683 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000198677] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43684 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43685 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003529462] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43686 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43687 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007174905] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43688 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43689 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001721254] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43690 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005573957] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43691 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43692 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002834728] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43693 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001049058] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43694 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149183] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43695 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003173959] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43696 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43697 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004700317] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43698 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43699 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43700 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43701 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004579591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43702 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008854011] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43703 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001957133] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43704 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43705 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43706 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43707 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003224539] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43708 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001227586] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43709 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003395954] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43710 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD464 Ivermectin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006102465] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43711 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD847 Thyroxine (L) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009357149] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43712 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007454192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43713 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004253894] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43714 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD330 Fadrozole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007672282] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43715 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD110 Betaxolol hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006477728] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43716 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD449 Iocetamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.86E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43717 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43718 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43719 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43720 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43721 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43722 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43723 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43724 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43725 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43726 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43727 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43728 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43729 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43730 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43731 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43732 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43733 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43734 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43735 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43736 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43737 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43738 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43739 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43740 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43741 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43742 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43743 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43744 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43745 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43746 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43747 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43748 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43749 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43750 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43751 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43752 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43753 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43754 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43755 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43756 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43757 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43758 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43759 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43760 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43761 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43762 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43763 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43764 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001166423] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43765 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43766 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43767 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43768 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43769 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43770 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43771 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43772 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43773 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43774 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000270398] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43775 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43776 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43777 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43778 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43779 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43780 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43781 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43782 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43783 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43784 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43785 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43786 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43787 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43788 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43789 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43790 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43791 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43792 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43793 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43794 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43795 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43796 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43797 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43798 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021442] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43799 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43800 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43801 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002400165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43802 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43803 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43804 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43805 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43806 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43807 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43808 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43809 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43810 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43811 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001063906] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43812 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43813 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43814 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43815 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43816 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43817 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43818 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43819 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43820 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43821 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43822 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004208369] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43823 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001074754] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43824 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43825 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43826 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000298156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43827 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43828 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43829 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43830 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43831 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43832 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43833 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43834 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43835 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002107446] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43836 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43837 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43838 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.38E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43839 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43840 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43841 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43842 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021713] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43843 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43844 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43845 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43846 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000732883] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43847 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43848 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43849 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43850 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006814855] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43851 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43852 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006094828] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43853 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001265417] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43854 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004225506] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43855 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000511457] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43856 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000994849] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43857 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43858 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002627508] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43859 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43860 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006969853] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43861 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003783935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43862 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001979002] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43863 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000154227] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43864 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001120241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43865 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43866 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003155935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43867 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838187] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43868 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD202 Clavulanate potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000334219] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43869 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD529 Metergoline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002160053] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43870 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD363 Flunixin meglumine Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691593] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43871 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD829 Temozolomide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008274591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43872 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD247 Dantrolene sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002634804] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43873 Substances alter microbe abundance PMDBM303 28118 Odoribacter splanchnicus PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008264925] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43874 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43875 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43876 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43877 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43878 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43879 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43880 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.59E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43881 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43882 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43883 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43884 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43885 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43886 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43887 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43888 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43889 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.62E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43890 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43891 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43892 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43893 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43894 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.78E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43895 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43896 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43897 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43898 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43899 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43900 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43901 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43902 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43903 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43904 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43905 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43906 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43907 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43908 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43909 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43910 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.33E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43911 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43912 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43913 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.09E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43914 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43915 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43916 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43917 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43918 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43919 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43920 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43921 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43922 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43923 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43924 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43925 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43926 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43927 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43928 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43929 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43930 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43931 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000453712] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43932 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43933 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43934 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43935 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43936 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43937 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43938 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43939 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.16E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43940 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.70E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43941 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43942 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43943 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43944 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43945 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.12E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43946 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.36E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43947 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43948 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43949 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43950 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43951 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43952 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43953 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646374] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43954 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43955 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43956 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43957 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000199681] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43958 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43959 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43960 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43961 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.35E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43962 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.22E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43963 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43964 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.78E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43965 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43966 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003167824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43967 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43968 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43969 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001800915] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43970 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000153415] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43971 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43972 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007636386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43973 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43974 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43975 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43976 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43977 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43978 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000192316] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43979 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43980 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43981 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43982 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43983 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43984 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000485641] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43985 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000213793] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43986 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.94E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43987 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000407345] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43988 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43989 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43990 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43991 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43992 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43993 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43994 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0023746] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43995 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43996 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43997 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008757232] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43998 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000112711] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43999 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44000 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44001 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001985399] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44002 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44003 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004049483] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44004 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000114306] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44005 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000479833] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44006 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44007 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44008 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000137683] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44009 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44010 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000776517] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44011 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44012 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44013 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003256341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44014 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009098165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44015 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.92E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44016 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44017 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44018 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000999474] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44019 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007677224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44020 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001621938] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44021 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008917598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44022 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003429568] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44023 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44024 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100254] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44025 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002695836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44026 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003019082] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44027 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005572399] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44028 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001361982] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44029 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004467722] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44030 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001149242] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44031 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD40 Amodiaquin dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44032 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018774] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44033 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003822923] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44034 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000762378] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44035 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD325 Etofenamate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338854] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44036 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD554 Mitotane Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003007578] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44037 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD726 Racepinephrine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000111392] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44038 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD647 Pemirolast potassium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006799706] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44039 Substances alter microbe abundance PMDBM309 823 Parabacteroides distasonis PMDBD723 R(-) Apomorphine hydrochloride hemihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00016442] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44040 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44041 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44042 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44043 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44044 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44045 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44046 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44047 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44048 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44049 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44050 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44051 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44052 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44053 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44054 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44055 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44056 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44057 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44058 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44059 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44060 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44061 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44062 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44063 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44064 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44065 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44066 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44067 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44068 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44069 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44070 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44071 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.49E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44072 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44073 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44074 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44075 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44076 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44077 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44078 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44079 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44080 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44081 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44082 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44083 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44084 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44085 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44086 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44087 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44088 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44089 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44090 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44091 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44092 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44093 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44094 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44095 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44096 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44097 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44098 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44099 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44100 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44101 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44102 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44103 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44104 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44105 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.90E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44106 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44107 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44108 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44109 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44110 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44111 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44112 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44113 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44114 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44115 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44116 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.21E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44117 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44118 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44119 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00034437] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44120 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44121 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44122 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44123 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44124 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44125 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000181202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44126 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44127 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44128 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44129 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44130 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44131 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.59E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44132 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44133 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005381005] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44134 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44135 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44136 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44137 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003097339] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44138 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.30E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44139 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44140 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000170427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44141 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002584087] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44142 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.90E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44143 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44144 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44145 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44146 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001809617] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44147 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44148 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44149 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44150 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003093329] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44151 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002866397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44152 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000970824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44153 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44154 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44155 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007133259] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44156 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44157 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000403341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44158 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44159 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44160 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001688439] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44161 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003190057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44162 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44163 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126222] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44164 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44165 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000997738] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44166 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44167 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44168 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44169 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141002] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44170 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006860033] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44171 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002065448] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44172 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44173 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44174 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00216403] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44175 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006955194] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44176 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44177 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44178 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44179 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44180 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0018713] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44181 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000120861] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44182 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003605615] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44183 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44184 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009525141] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44185 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000845062] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44186 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44187 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008821497] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44188 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44189 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD40 Amodiaquin dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44190 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003021836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44191 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44192 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD461 Isosorbide dinitrate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001898209] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44193 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD41 Amoxapine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008486101] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44194 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD726 Racepinephrine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005817496] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44195 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD647 Pemirolast potassium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003849058] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44196 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD584 Nicardipine hydrochloride Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005823836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44197 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004960818] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44198 Substances alter microbe abundance PMDBM313 46503 Parabacteroides merdae PMDBD564 N6-methyladenosine Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004484062] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44199 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000105362] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44200 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000337554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44201 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000204718] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44202 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44203 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44204 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44205 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44206 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000937349] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44207 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002795386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44208 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44209 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44210 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006006895] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44211 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44212 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333615] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44213 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44214 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44215 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44216 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44217 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44218 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000335395] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44219 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44220 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44221 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44222 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44223 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000101163] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44224 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44225 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002363748] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44226 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001576716] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44227 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44228 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44229 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44230 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44231 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44232 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005302486] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44233 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44234 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44235 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44236 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44237 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44238 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44239 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44240 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44241 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44242 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44243 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000862574] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44244 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44245 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44246 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44247 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44248 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44249 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000119098] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44250 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000102179] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44251 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103492] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44252 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000355466] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44253 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44254 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000338971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44255 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44256 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44257 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44258 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44259 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44260 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000312742] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44261 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000877737] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44262 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44263 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44264 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44265 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333376] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44266 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44267 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44268 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.38E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44269 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44270 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44271 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44272 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.04E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44273 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00193131] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44274 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44275 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00216796] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44276 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44277 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44278 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44279 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44280 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44281 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44282 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44283 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44284 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002799645] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44285 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44286 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44287 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00773707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44288 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000322932] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44289 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44290 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44291 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44292 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000129378] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44293 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000348442] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44294 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44295 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00048278] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44296 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005092649] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44297 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44298 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000334037] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44299 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44300 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008944356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44301 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002185392] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44302 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44303 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007296817] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44304 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44305 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44306 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000660736] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44307 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44308 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003414426] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44309 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44310 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002523703] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44311 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44312 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000187809] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44313 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003915281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44314 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44315 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0028704] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44316 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000188147] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44317 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000548876] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44318 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00027388] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44319 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003241269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44320 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002796885] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44321 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005071009] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44322 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44323 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44324 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00615387] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44325 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000180705] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44326 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44327 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000600373] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44328 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007431509] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44329 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001747188] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44330 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007611659] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44331 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000263044] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44332 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008678266] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44333 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003764233] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44334 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000955606] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44335 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.20E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44336 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008811167] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44337 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003321156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44338 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000688403] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44339 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004271679] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44340 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004270959] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44341 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171237] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44342 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002177626] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44343 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001053227] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44344 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000746972] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44345 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003039172] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44346 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006327976] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44347 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001603792] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44348 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000796508] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44349 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003972536] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44350 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000454427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44351 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD523 Mercaptopurine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214679] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44352 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD779 Sertraline Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002797396] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44353 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008493167] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44354 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD200 Cladribine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004324909] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44355 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD461 Isosorbide dinitrate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000673767] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44356 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000437895] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44357 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD451 Iopanoic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000901834] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44358 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD578 Nefazodone HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006634379] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44359 Substances alter microbe abundance PMDBM329 165179 Prevotella copri PMDBD213 Clomipramine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000642265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44360 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44361 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44362 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44363 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44364 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44365 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44366 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44367 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44368 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44369 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44370 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44371 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002785984] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44372 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44373 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44374 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44375 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44376 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44377 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44378 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44379 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00010614] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44380 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44381 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000258893] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44382 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44383 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44384 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44385 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44386 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00023389] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44387 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000114592] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44388 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.18E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44389 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44390 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44391 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44392 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44393 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44394 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232154] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44395 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44396 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44397 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44398 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44399 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44400 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44401 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44402 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232311] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44403 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44404 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44405 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002579406] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44406 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000626908] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44407 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.57E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44408 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44409 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44410 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44411 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44412 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44413 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.92E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44414 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44415 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44416 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44417 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001497261] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44418 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44419 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44420 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44421 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44422 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004555788] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44423 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44424 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44425 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44426 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44427 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44428 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44429 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44430 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44431 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44432 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44433 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44434 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44435 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142897] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44436 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44437 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44438 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44439 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44440 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44441 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002297368] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44442 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44443 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44444 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44445 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44446 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44447 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44448 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44449 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44450 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44451 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000964707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44452 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44453 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44454 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44455 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44456 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002911093] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44457 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44458 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44459 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44460 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44461 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44462 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44463 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009830868] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44464 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44465 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44466 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44467 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.90E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44468 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44469 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183536] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44470 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44471 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44472 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44473 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44474 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44475 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.83E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44476 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44477 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000165427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44478 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44479 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44480 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.59E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44481 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44482 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000341198] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44483 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44484 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44485 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005257452] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44486 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44487 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44488 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000103252] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44489 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000342803] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44490 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44491 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006374774] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44492 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001652559] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44493 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009074269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44494 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000281831] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44495 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44496 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001005864] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44497 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44498 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271321] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44499 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000130393] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44500 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44501 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003428481] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44502 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44503 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000251723] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44504 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404048] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44505 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000835203] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44506 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000688404] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44507 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000360067] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44508 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005482844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44509 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44510 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007614793] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44511 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000822814] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44512 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00250842] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44513 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44514 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000472372] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44515 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00602832] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44516 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44517 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000254099] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44518 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44519 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002679627] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44520 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00126153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44521 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD529 Metergoline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002585901] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44522 Substances alter microbe abundance PMDBM354 301301 Roseburia hominis PMDBD254 Demecarium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207856] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44523 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000225141] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44524 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000406033] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44525 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135092] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44526 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164879] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44527 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183586] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44528 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44529 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000477981] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44530 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000183647] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44531 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001195925] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44532 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133856] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44533 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151221] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44534 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000416305] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44535 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160919] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44536 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000342522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44537 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131781] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44538 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141125] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44539 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000468263] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44540 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44541 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000169425] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44542 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44543 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018783] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44544 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646073] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44545 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000325894] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44546 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000239345] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44547 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000179511] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44548 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44549 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00066158] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44550 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000345801] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44551 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000536192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44552 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001243714] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44553 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018963] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44554 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166377] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44555 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44556 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44557 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133484] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44558 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000691798] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44559 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000309554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44560 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000686521] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44561 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185636] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44562 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000209985] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44563 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159446] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44564 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000171847] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44565 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133498] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44566 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00021134] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44567 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000658811] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44568 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000323156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44569 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172121] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44570 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000190957] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44571 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44572 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000243363] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44573 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000179188] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44574 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000606965] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44575 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000138933] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44576 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131781] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44577 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000300773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44578 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000253591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44579 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233624] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44580 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000315934] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44581 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000128455] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44582 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000346874] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44583 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000126331] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44584 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00095505] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44585 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000602138] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44586 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000135328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44587 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000604897] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44588 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000320023] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44589 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001211448] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44590 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44591 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000925813] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44592 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172471] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44593 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00033814] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44594 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017552] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44595 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000144555] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44596 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000233624] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44597 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000687091] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44598 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133324] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44599 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000131961] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44600 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000202857] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44601 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00015911] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44602 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44603 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000324492] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44604 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00018563] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44605 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000148521] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44606 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132382] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44607 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000245651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44608 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166421] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44609 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000681488] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44610 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000175753] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44611 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000155772] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44612 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000362476] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44613 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44614 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000185438] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44615 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000422533] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44616 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000372124] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44617 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000140634] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44618 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000178834] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44619 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000250692] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44620 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000424954] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44621 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000833633] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44622 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004538411] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44623 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00015842] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44624 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44625 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000635361] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44626 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000508555] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44627 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000333791] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44628 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000216356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44629 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001943] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44630 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001979002] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44631 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0064412] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44632 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000152121] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44633 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007277845] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44634 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005828529] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44635 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000563638] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44636 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000177543] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44637 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44638 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00019455] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44639 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000665366] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44640 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000166653] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44641 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000175664] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44642 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001187417] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44643 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00022602] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44644 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000543699] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44645 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000899543] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44646 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160194] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44647 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132871] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44648 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004838187] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44649 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003185447] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44650 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003522489] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44651 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004038344] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44652 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000751703] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44653 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000215102] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44654 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000925335] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44655 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002287279] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44656 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000484892] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44657 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000800613] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44658 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000156512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44659 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426132] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44660 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000142009] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44661 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000246537] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44662 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008092593] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44663 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002131008] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44664 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00061337] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44665 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001020538] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44666 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00089262] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44667 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001194454] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44668 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000559087] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44669 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000236766] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44670 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000241562] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44671 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000336385] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44672 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000364452] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44673 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44674 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000930375] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44675 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000454054] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44676 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44677 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000672828] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44678 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002565] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44679 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000269858] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44680 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000158052] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44681 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000223961] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44682 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000673509] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44683 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000630469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44684 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003134602] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44685 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00082887] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44686 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001403155] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44687 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000428798] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44688 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001149386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44689 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001273328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44690 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44691 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006747685] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44692 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000841542] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44693 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005890941] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44694 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000580982] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44695 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000981846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44696 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006991061] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44697 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000854305] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44698 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002532969] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44699 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000311386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44700 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007521944] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44701 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD464 Ivermectin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00087023] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44702 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000894084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44703 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005479453] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44704 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004760197] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44705 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001686706] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44706 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00080764] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44707 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD278 Dihydrostreptomycin sulfate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000428843] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44708 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008448038] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44709 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004535848] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44710 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006525874] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44711 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000586538] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44712 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004885272] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44713 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008916378] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44714 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001487911] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44715 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD388 Gentamicine sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008614335] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44716 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD310 Epirizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003382732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44717 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD381 GBR 12909 dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007394277] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44718 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD450 Iohexol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004750711] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44719 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002620571] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44720 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD784 Sisomicin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005840765] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44721 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD554 Mitotane Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003977147] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44722 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD749 Riluzole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00913864] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44723 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD369 Fluspirilen Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000392987] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44724 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005430066] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44725 Substances alter microbe abundance PMDBM355 166486 Roseburia intestinalis PMDBD362 Flunarizine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004676065] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44726 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44727 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44728 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44729 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44730 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44731 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44732 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44733 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44734 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44735 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44736 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44737 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000283578] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44738 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44739 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44740 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44741 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44742 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44743 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44744 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44745 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.37E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44746 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44747 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44748 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44749 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44750 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44751 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44752 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44753 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44754 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44755 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000132773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44756 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44757 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44758 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44759 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44760 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44761 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44762 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00122221] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44763 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44764 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44765 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44766 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44767 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44768 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44769 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44770 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44771 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44772 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44773 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44774 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44775 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44776 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44777 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44778 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44779 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44780 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44781 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44782 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44783 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000651391] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44784 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44785 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44786 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44787 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44788 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44789 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44790 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44791 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44792 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44793 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44794 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44795 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44796 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44797 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44798 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44799 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000271654] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44800 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44801 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44802 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.09E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44803 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44804 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44805 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000217512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44806 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44807 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44808 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44809 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44810 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44811 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44812 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44813 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44814 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44815 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44816 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.12E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44817 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44818 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44819 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000159192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44820 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44821 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44822 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44823 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44824 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44825 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44826 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001070784] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44827 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44828 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44829 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44830 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44831 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44832 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44833 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.21E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44834 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44835 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44836 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44837 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44838 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44839 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44840 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44841 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44842 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44843 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004078377] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44844 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44845 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.23E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44846 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44847 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.83E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44848 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44849 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001808803] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44850 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44851 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44852 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44853 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44854 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44855 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0002032] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44856 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44857 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44858 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001950525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44859 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000152827] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44860 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000196508] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44861 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000238177] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44862 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44863 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001688439] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44864 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002425866] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44865 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002512885] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44866 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD461 Isosorbide dinitrate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44867 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD202 Clavulanate potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008071607] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44868 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD14 Acenocoumarol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006136303] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44869 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD313 Erlotinib Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005683558] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44870 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD505 Lynestrenol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000228354] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44871 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD280 Diloxanide furoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009077749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44872 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD587 Nicorandil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002266077] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44873 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD698 Pranlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007658516] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44874 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD398 Glafenine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44875 Substances alter microbe abundance PMDBM361 40518 Ruminococcus bromii PMDBD836 Testosterone propionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000556732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44876 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44877 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44878 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44879 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44880 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44881 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44882 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44883 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44884 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44885 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44886 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44887 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000314817] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44888 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44889 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44890 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44891 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44892 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44893 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44894 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44895 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44896 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44897 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44898 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44899 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44900 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44901 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44902 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44903 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44904 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000172471] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44905 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44906 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44907 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44908 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44909 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44910 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44911 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44912 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44913 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44914 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44915 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44916 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44917 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44918 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44919 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44920 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44921 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44922 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44923 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164947] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44924 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44925 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44926 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44927 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44928 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44929 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44930 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44931 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44932 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44933 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44934 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44935 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44936 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44937 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44938 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44939 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44940 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44941 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44942 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001636301] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44943 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44944 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000477981] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44945 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44946 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000798186] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44947 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44948 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44949 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44950 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44951 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44952 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44953 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44954 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44955 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44956 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44957 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000151975] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44958 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001363477] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44959 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44960 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44961 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44962 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44963 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44964 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44965 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44966 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44967 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000895076] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44968 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44969 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44970 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44971 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44972 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44973 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002313221] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44974 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44975 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44976 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44977 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44978 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44979 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44980 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44981 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44982 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003813771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44983 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44984 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44985 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44986 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44987 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44988 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44989 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009392496] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44990 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003780078] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44991 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44992 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44993 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44994 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44995 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44996 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44997 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000740599] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44998 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009586657] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44999 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009222294] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45000 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45001 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009425311] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45002 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45003 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45004 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45005 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45006 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45007 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007923075] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45008 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45009 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45010 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005475023] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45011 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000473573] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45012 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00446964] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45013 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45014 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005149904] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45015 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001596797] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45016 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000214389] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45017 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45018 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001543463] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45019 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000919651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45020 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001890094] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45021 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000958761] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45022 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006930773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45023 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000543623] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45024 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD381 GBR 12909 dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000891288] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45025 Substances alter microbe abundance PMDBM363 33038 [Ruminococcus] gnavus PMDBD450 Iohexol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002666464] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45026 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45027 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45028 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45029 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45030 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45031 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45032 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45033 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45034 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45035 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45036 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45037 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45038 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45039 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45040 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45041 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45042 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000150969] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45043 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45044 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45045 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006468553] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45046 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45047 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45048 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.51E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45049 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.74E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45050 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45051 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45052 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45053 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45054 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000778131] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45055 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45056 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45057 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000141893] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45058 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.68E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45059 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45060 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45061 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45062 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45063 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45064 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45065 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45066 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45067 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45068 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45069 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45070 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45071 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45072 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45073 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000404096] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45074 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000646322] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45075 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45076 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45077 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45078 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45079 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45080 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45081 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45082 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45083 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45084 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45085 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45086 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45087 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45088 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45089 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45090 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45091 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008930242] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45092 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45093 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45094 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.58E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45095 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45096 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45097 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45098 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45099 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004828422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45100 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45101 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45102 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.81E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45103 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45104 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45105 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45106 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45107 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45108 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45109 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45110 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45111 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45112 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000787021] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45113 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45114 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45115 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45116 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45117 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45118 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.98E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45119 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45120 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007772802] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45121 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.83E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45122 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001391235] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45123 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000207669] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45124 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.11E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45125 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.25E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45126 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45127 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45128 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.77E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45129 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45130 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45131 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45132 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45133 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45134 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45135 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45136 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000331598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45137 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45138 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45139 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00358652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45140 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000244933] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45141 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45142 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45143 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45144 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000118131] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45145 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000240309] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45146 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD268 Dienestrol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45147 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45148 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009028298] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45149 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000360321] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45150 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45151 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100649] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45152 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD494 Loratadine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000561844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45153 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000273281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45154 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45155 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001354778] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45156 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000110537] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45157 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45158 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45159 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45160 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000575241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45161 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD467 Ketoconazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45162 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000536906] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45163 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45164 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002561027] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45165 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45166 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD382 Gefitinib Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003385786] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45167 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001171004] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45168 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45169 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45170 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45171 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007511804] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45172 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160806] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45173 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.20E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45174 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45175 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001283709] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45176 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000374146] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45177 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD464 Ivermectin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45178 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45179 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45180 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD278 Dihydrostreptomycin sulfate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000776173] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45181 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45182 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000390662] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45183 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45184 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD388 Gentamicine sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001548607] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45185 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD310 Epirizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45186 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD783 Simvastatin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004017029] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45187 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD784 Sisomicin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001018] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45188 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD336 Fenbendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0001339] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45189 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001083172] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45190 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002191168] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45191 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD313 Erlotinib Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002028454] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45192 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD749 Riluzole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000384151] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45193 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD584 Nicardipine hydrochloride Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003157294] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45194 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD473 Leflunomide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45195 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD591 Nilutamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000442687] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45196 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD505 Lynestrenol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003709083] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45197 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD10 Abacavir Sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000584373] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45198 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD533 Methiazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000164286] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45199 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD592 Nimesulide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001019344] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45200 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD131 Butamben Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001622822] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45201 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD762 Salmeterol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002505954] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45202 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD134 Butylparaben Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000285497] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45203 Substances alter microbe abundance PMDBM369 33039 [Ruminococcus] torques PMDBD861 Tracazolate hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000232154] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45204 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45205 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45206 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45207 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45208 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45209 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45210 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45211 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45212 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.96E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45213 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45214 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45215 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45216 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45217 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45218 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45219 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45220 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45221 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45222 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45223 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45224 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45225 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45226 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45227 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45228 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45229 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45230 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45231 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.83E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45232 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45233 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.18E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45234 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45235 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45236 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45237 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45238 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45239 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45240 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45241 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45242 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45243 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45244 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45245 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45246 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45247 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45248 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45249 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.90E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45250 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45251 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.85E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45252 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45253 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.14E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45254 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45255 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.08E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45256 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45257 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45258 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45259 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45260 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45261 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00127379] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45262 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45263 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.11E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45264 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45265 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45266 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45267 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001734051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45268 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45269 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45270 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.88E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45271 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45272 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45273 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001708248] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45274 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45275 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45276 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45277 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.0005815] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45278 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45279 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45280 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45281 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45282 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45283 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45284 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45285 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45286 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45287 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45288 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.79E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45289 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45290 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45291 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00406747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45292 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000750268] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45293 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.08E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45294 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45295 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45296 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006240123] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45297 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45298 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45299 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001963582] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45300 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000100118] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45301 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45302 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45303 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45304 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45305 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45306 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001859804] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45307 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00012336] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45308 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45309 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45310 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45311 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000596883] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45312 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45313 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45314 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000240274] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45315 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008363427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45316 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45317 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009673022] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45318 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45319 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45320 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000160215] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45321 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=4.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45322 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45323 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008913545] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45324 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.005574865] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45325 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008830102] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45326 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000358033] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45327 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009376224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45328 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD278 Dihydrostreptomycin sulfate Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000349122] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45329 Substances alter microbe abundance PMDBM388 1318 Streptococcus parasanguinis PMDBD388 Gentamicine sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009968201] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45330 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.82E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45331 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45332 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45333 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45334 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45335 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45336 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45337 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.83E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45338 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45339 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45340 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45341 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.69E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45342 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45343 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45344 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45345 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45346 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45347 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45348 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45349 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45350 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45351 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45352 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45353 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45354 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45355 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001009145] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45356 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45357 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45358 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45359 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45360 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45361 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00357394] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45362 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45363 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45364 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45365 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45366 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45367 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45368 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.62E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45369 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45370 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45371 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45372 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45373 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45374 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45375 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45376 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.60E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45377 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45378 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45379 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45380 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45381 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45382 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45383 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45384 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45385 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45386 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45387 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=9.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45388 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45389 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45390 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45391 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45392 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45393 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45394 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45395 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45396 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45397 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45398 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45399 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45400 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45401 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45402 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45403 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45404 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000623909] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45405 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45406 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45407 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45408 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45409 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45410 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45411 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45412 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45413 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45414 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD869 Triclosan Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45415 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45416 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45417 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001329469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45418 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45419 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003205469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45420 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006108494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45421 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45422 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000279971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45423 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45424 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45425 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006471536] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45426 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45427 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45428 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD210 Clofazimine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004620385] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45429 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45430 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45431 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001995732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45432 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45433 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004177971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45434 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=2.25E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45435 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45436 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45437 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45438 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003427444] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45439 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45440 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45441 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45442 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001027956] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45443 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45444 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45445 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004629765] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45446 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001510749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45447 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD327 Etoposide Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45448 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.004139029] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45449 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45450 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008500296] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45451 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45452 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45453 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45454 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.009110665] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45455 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45456 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD853 Tobramycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45457 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007766915] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45458 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD265 Dicumarol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000465018] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45459 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45460 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002196121] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45461 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45462 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD62 Apramycin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00394427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45463 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.007635661] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45464 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45465 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD464 Ivermectin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00248147] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45466 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006928984] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45467 Substances alter microbe abundance PMDBM391 1304 Streptococcus salivarius PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.003156937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45468 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD744 Rifabutin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45469 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45470 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45471 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45472 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD178 Chloramphenicol Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45473 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45474 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45475 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45476 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45477 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD180 Chlorhexidine Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45478 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45479 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45480 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45481 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45482 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45483 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45484 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45485 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45486 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45487 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45488 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45489 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45490 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD745 Rifampicin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45491 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45492 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45493 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45494 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45495 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45496 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45497 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45498 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45499 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45500 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45501 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD314 Erythromycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45502 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD465 Josamycin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45503 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45504 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45505 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45506 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45507 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45508 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45509 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45510 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD881 Tylosin Therapeutic Substance; Herbal Substance Approved Drug (veterinary medicine); Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45511 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45512 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.36E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45513 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45514 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45515 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45516 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45517 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45518 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45519 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45520 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45521 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45522 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45523 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=3.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45524 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.80E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45525 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45526 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45527 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45528 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45529 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45530 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45531 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45532 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45533 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45534 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45535 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45536 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45537 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45538 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD546 Metronidazole Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45539 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45540 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45541 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45542 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45543 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45544 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45545 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45546 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45547 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45548 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45549 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45550 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45551 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45552 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45553 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45554 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45555 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45556 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45557 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45558 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45559 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45560 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45561 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45562 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45563 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45564 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45565 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD611 Ofloxacin Therapeutic Substance; Herbal Substance Approved Drug; Medicinal Herbal Compounds n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45566 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45567 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45568 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=6.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45569 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.006092327] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45570 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45571 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45572 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002974409] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45573 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45574 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000124422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45575 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45576 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45577 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45578 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45579 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45580 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45581 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008757071] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45582 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45583 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.001967198] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45584 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000149165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45585 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45586 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.002817096] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45587 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.00310105] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45588 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008100327] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45589 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD433 Hydrocortisone base Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.008929837] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45590 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD910 Zileuton Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000426281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45591 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD800 Spiperone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=0.000133269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45592 Substances alter microbe abundance PMDBM405 29466 Veillonella parvula PMDBD555 Mometasone furoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 μM [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994